

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 October 2004 (28.10.2004)

PCT

(10) International Publication Number
WO 2004/092210 A2

(51) International Patent Classification⁷: **C07K 14/37**

(21) International Application Number:
PCT/SG2004/000098

(22) International Filing Date: 16 April 2004 (16.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0308988.5 17 April 2003 (17.04.2003) GB

(71) Applicants (*for all designated States except US*): NATIONAL UNIVERSITY OF SYNGAPORE [SG/SG]; 10 Kent Ridge Crescent, Singapore 119260 (SG). AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH [SG/SG]; 20 Biopolis Way, #07-01 Centros, Singapore 138668 (SG).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): CHUA, Kaw, Yan [AU/SG]; Department of Paediatrics, Faculty of Medicine, National University of Syngapore, Lower Kent Ridge Road, Singapore 119074 (SG). SEOW, See, Voon [MY/SG]; Department of Paediatrics, Faculty of Medicine, National University of Singapore, Lower Kent Ridge Road, Singapore 119074 (SG). KOLATKAR, Prasanna, Ratnakar [US/SG]; Genome Institute of Syngapore, Genome #02-01, 60 Biopolis Steret, Singapore 138672 (SG).

(74) Agent: AXIS INTELLECTUAL CAPITAL PTE. LTD.; 21A Duxton Road, Singapore 089487 (SG).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,

[Continued on next page]

(54) Title: MOLECULE



(57) Abstract: We describe an Fve polypeptide being a fragment, homologue, variant or derivative of Fve protein, which comprises at least one biological activity of Fve protein. Uses of such a polypeptide, etc, and nucleic acids encoding these, in the treatment and prevention of allergy and cancer are also disclosed.

WO 2004/092210 A2



KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— without international search report and to be republished upon receipt of that report

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

MOLECULE

FIELD

The present invention relates to the fields of microbiology. It also relates to the fields of medicine, especially therapy and diagnosis.

5 BACKGROUND

Some microorganisms are capable of acting as immunomodulating agents, such as *Mycobacterium smegmatis* used in Freund's complete adjuvant and OK432 from *Streptococcus pygens* as the anti-tumor potentiator. Many polysaccharide immunomodulating agents have also been detected and isolated from *Basidiomycetes* class
10 of fungi, such as lentinan, schizophyllan, TML and SF A1. A novel family of fungal immunomodulatory proteins has been isolated from the edible mushrooms, such as Vvo from *Volvariella volvacea* (grass mushroom), LZ-S from *Ganoderma lucidum* (Ling-Zhi), Gts from *Ganoderma tsugae* (songshan lingzhi), and Fve from *Flammulina velutipes* (golden needle mushroom).

15 Although the therapeutic value of a number of mushrooms has been documented, the active components that confer such therapeutic effects are not well understood.

Ko et al (Eur. J. Biochem., 228, 244-2419) describes the isolation and purification of a protein known as FIP-fve from Golden Needle Mushroom extracts. The authors describe a method of extracting this protein, as well as some biochemical properties of
20 FIP-fve. The amino acid sequence of FIP-fve is presented. FIP-fve is shown to cause proliferation of human peripheral blood lymphocytes, and mice sensitised to BSA are protected against anaphylactic shock by periodic injections of FIP-fve. A hind-paw edema test shows that FIP-fve inhibits antibody production against antigen 48/80. Finally, the authors show that FIP-fve induces expression of IL-2 and IFN- γ in spleen cells from
25 mouse.

An amino acid sequence of FIP-*fve* is found as GenBank accession numbers: S69147 immunomodulatory protein FIP-*fve* - golden needle mushroom gi|7438667|pir|S69147[7438667] and P80412 IMMUNOMODULATORY PROTEIN FIP-FVE gi|729544|sp|P80412[FVE_FLAVE[729544]].

5 SUMMARY

According to a first aspect of the present invention, we provide an Fve polypeptide comprising at least one biological activity of native Fve protein, and being a fragment, homologue, variant or derivative thereof.

Preferably, the Fve polypeptide comprises an immunomodulatory activity.

- 10 Preferably, the biological activity is selected from the group consisting of: up-regulation of expression of Th1/Tc1 cytokines, preferably IFN- γ and TNF- α , down-regulation of expression of Th2/Tc2 cytokines, preferably IL-4 and IL-13, up-regulation of expression of T regulatory (Tr) cytokines IL-10 and TGF- β , hemagglutination activity, cell aggregation activity, lymphocyte aggregation activity, lymphoproliferation activity, up-regulation of
- 15 expression of IL-2, IFN- γ , TNF- α , but not IL-4 in CD3⁺ T cells, interaction with T and NK cells, adjuvant activity, stimulation of CD3⁺ CD16⁺ CD56⁺ natural killer (NK) T cells and CD3⁺ CD8⁺ CD18⁺ ^{bright} T cells, and up-regulation of allergen specific Th1 immune responses.

- 20 Preferably, the polypeptide comprises between 2 to 20 residues of amino acid sequence flanking the glycine residue corresponding to position 28 of Fve.

Preferably, the polypeptide comprises the sequence RGT or the sequence RGD.

Preferably, the polypeptide has a sequence as set out in **Appendix A** or **Appendix B**.

There is provided, according to a second aspect of the present invention, a Fve polypeptide comprising an sequence selected from the group consisting of: Fve R27A, Fve T29A, GST-Fve (wild type), GST-Fve R27A, and GST-Fve T29A, and fragments, homologues, variants and derivatives thereof.

5 We provide, according to a third aspect of the present invention, a polypeptide comprising a first portion comprising at least a portion of Fve and a second portion comprising at least a portion of an allergen.

Preferably, the allergen comprises an allergen from a mite, preferably from Family *Glycyphagidae* or Family *Pyroglyphidae*, preferably a group 1 allergen (Der p 1, Der f 1,
10 Blo t 1, Eur m1, Lep d 1), a group 2 allergen (Der p 2, Der f 2, Blo t 2, Eur m 2, Lep d 2), a group 5 allergen (Blo t 5, Der p 5, Der f 5, Eur m 5, Lep d 5) a group 15 allergen (Der p 15, Der f 15, Blo t 15, Eur m 15, Lep d 15).

Preferably, the Fve polypeptide or a polypeptide is selected from the group consisting of: Blo t 5-Fve, Blo t 5-FveR27A, Blo t 5-FveT29A, GST-Der p 2-FveR27A,
15 GST-Der p 2-FveT29A, Blo t 5-Der p 2-FveR27A, and Blo t 5-Der p 2-FveT29A. More preferably, it comprises Blo t 5-FveT29A, Der p 2-FveT29A, or Blo t 5-Der p 2-FveT29A.

Preferably, the allergen is selected from the group consisting of: tree pollen allergen, Bet v 1 and Bet v 2 from birch tree; grass pollen allergen, Phl p 1 and Phl p 2 from timothy grass; weed pollen allergen, antigen E from ragweed; major feline antigen,
20 Fel d; major fungal allergen, Asp f1, Asp f2, and Asp f3 from *Aspergillus fumigatus*.

As a fourth aspect of the present invention, there is provided a polypeptide comprising a first portion comprising at least a portion of Fve and a second portion comprising at least a portion of a viral antigen selected from the group consisting of: E6 and E7 from HPV; core Ag and E2 from HCV; core and surface antigens from HBV;
25 LMP-1, LMP-2, EBNA-2, EBNA-3 from EBV; and Tax from HTLV-1.

Preferably, it comprises HCV Core23-FveT29A, or HPV E7-FveT29A.

We also provide a polypeptide comprising a first portion comprising at least a portion of Fve and a second portion comprising at least a portion of a viral antigen selected from the group consisting of antigens from Adenovirus, Parainfluenza 3 virus, Human
5 Immunodeficiency Virus (HIV), Herpes simplex virus, HSV, Respiratory syncytial virus, RSV, and Influenza A, Flu A.

We provide, according to a fifth aspect of the present invention, a polypeptide comprising a first portion comprising at least a portion of Fve and a second portion comprising at least a portion of a tumour-associated antigen selected from the group
10 consisting of: MAGE-1, MAGE-2, MAGE-3, BAGE, GAGE, PRAME, SSX-2, Tyrosinase, MART-1, NY-ESO-1, gp100, TRP-1, TRP-2, A2 melanotope, BCR/ABL, Proteinase-3/Myeloblastin, HER2/neu, CEA, P1A, HK2, PAPA, PSA, PSCA, PSMA, pg75, MUM-1, MUC-1, BTA, GnT-V, β -catenin, CDK4, and P15.

Preferably, it comprises MAGE3-FveT29A, MART1-FveT29A or CEA-FveT29A.

15 The present invention, in a sixth aspect, provides a nucleic acid encoding a Fve polypeptide or a polypeptide according to any preceding statement of invention.

Preferably, the nucleic acid comprises CGT GGT ACC, or a sequence which differs from the above by virtue of the degeneracy of the genetic code and which encodes a sequence RGT.

20 In a seventh aspect of the present invention, there is provided a nucleic acid comprising a sequence encoding at least a portion of Fve and a sequence encoding at least a portion of an allergen.

Preferably, it comprises Blo t 5-FveT29A, Der p 2-FveT29A, or Blo t 5-Der p 2-FveT29A.

According to an eighth aspect of the present invention, we provide a nucleic acid comprising a sequence encoding at least a portion of Fve and a sequence encoding at least a portion of a viral antigen selected from the group consisting of: E6 and E7 from HPV; core Ag and E2 from HCV; core and surface antigens from HBV; LMP-1, LMP-2, EBNA-2, EBNA-3 from EBV; and Tax from HTLV-1.

Preferably, it comprises HCV Core23-FveT29A, or HPV E7-FveT29A.

We also provide a nucleic acid comprising a sequence encoding at least a portion of Fve and a sequence encoding at least a portion of a viral antigen selected from the group consisting of antigens from Adenovirus, Parainfluenza 3 virus, Human Immunodeficiency Virus (HIV), Herpes simplex virus, HSV, Respiratory syncytial virus, RSV, and Influenza A, Flu A.

We provide, according to a ninth aspect of the invention, a nucleic acid comprising a sequence encoding at least a portion of Fve and a sequence encoding at least a portion of a tumour associated antigen selected from the group consisting of: MAGE-1, MAGE-2, MAGE-3, BAGE, GAGE, PRAME, SSX-2, Tyrosinase, MART-1, NY-ESO-1, gp100, TRP-1, TRP-2, A2 melanotope, BCR/ABL, Proteinase-3/Myeloblastin, HER2/neu, CEA, P1A, HK2, PAPA, PSA, PSCA, PSMA, pg75, MUM-1, MUC-1, BTA, GnT-V, β -catenin, CDK4, and P15.

Preferably, it comprises MAGE3-FveT29A, MART1-FveT29A or CEA-FveT29A.

There is provided, in accordance with a tenth aspect of the present invention, a nucleic acid selected from the group consisting of: Fve R27A, Fve T29A, GST-Fve (wild type), GST-Fve R27A, GST-Fve T29A, Blo t 5-Fve, Blo t 5-FveR27A, Blo t 5-FveT29A, GST-Der p 2-FveR27A, GST-Der p 2-FveT29A, Blo t 5-Der p 2-FveR27A, Blo t 5-Der p 2-FveT29A, and fragments, homologues, variants and derivatives thereof.

As an eleventh aspect of the invention, we provide a vector, preferably an expression vector, comprising a nucleic acid sequence as set out above.

We provide, according to a twelfth aspect of the invention, there is provided DNA vaccine comprising a nucleic acid encoding Fve, a nucleic acid, or a vector as set out
5 above.

According to a thirteenth aspect of the present invention, we provide host cell comprising a nucleic acid encoding Fve, a nucleic acid, or a vector as set out above.

There is provided, according to a fourteenth aspect of the present invention, transgenic non-human organism comprising a nucleic acid encoding Fve, a nucleic acid, or
10 a vector as set out above.

Preferably, the transgenic non-human organism is a bacterium, a yeast, a fungus, a plant or an animal, preferably a mouse.

According to a sixteenth aspect of the present invention, we provide a pharmaceutical composition comprising a polypeptide, a nucleic acid, a vector, a DNA
15 vaccine, or a host cell as set out above, together with a pharmaceutically acceptable carrier or diluent.

According to a seventeenth aspect of the present invention, we provide the use of a native Fve polypeptide, or an Fve polypeptide, nucleic acid, vector, DNA vaccine, host
20 cell, transgenic organism, or a pharmaceutical composition as set out above as an immunomodulator.

According to an eighteenth aspect of the present invention, we provide the use of a native Fve polypeptide, or an Fve polypeptide, nucleic acid, vector, DNA vaccine, host
cell, transgenic organism, or a pharmaceutical composition as set out above to enhance an immune response in a mammal.

According to a nineteenth aspect of the present invention, we provide the use of a native Fve polypeptide, or an Fve polypeptide, nucleic acid, vector, DNA vaccine, host cell, transgenic organism, or a pharmaceutical composition as set out above to stimulate proliferation of $CD3^+ CD8^+ CD18^{+ \text{bright}}$ T cells.

- 5 According to a twentieth aspect of the present invention, we provide the use of a native Fve polypeptide, or an Fve polypeptide, nucleic acid, vector, DNA vaccine, host cell, transgenic organism, or a pharmaceutical composition as set out above to stimulate proliferation of $CD3^+ CD16^+ CD56^+$ natural killer (NK) T cells.

- 10 According to a twenty first aspect of the present invention, we provide the use of a native Fve polypeptide, or an Fve polypeptide, nucleic acid, vector, DNA vaccine, host cell, transgenic organism, or a pharmaceutical composition as set out above to stimulate production of IL-2, IL-10, TGF- β , IFN- γ or TNF- α in $CD3^+$ cells.

Preferably, production of IL-4 is not stimulated in the $CD3^+$ cells.

- 15 According to a twenty second aspect of the present invention, we provide the use of a native Fve polypeptide, or an Fve polypeptide, nucleic acid, vector, DNA vaccine, host cell, transgenic organism, or a pharmaceutical composition as set out above as an adjuvant for a vaccine.

- 20 According to a twenty third aspect of the present invention, we provide the use of a native Fve polypeptide, or an Fve polypeptide, nucleic acid, vector, DNA vaccine, host cell, transgenic organism, or a pharmaceutical composition as set out above in a method of treatment or prophylaxis of a disease.

According to a twenty fourth aspect of the present invention, we provide the use of a native Fve polypeptide, or an Fve polypeptide, nucleic acid, vector or host cell as set out above for the preparation of a pharmaceutical composition for the treatment of a disease.

According to a twenty fifth aspect of the present invention, we provide a method of treating an individual suffering from a disease or preventing the occurrence of a disease in an individual, the method comprising administering to the individual a therapeutically or prophylactically effective amount of a native Fve polypeptide, or an Fve polypeptide,
5 nucleic acid, vector, DNA vaccine, host cell, transgenic organism, or a pharmaceutical composition as set out above.

Preferably, the use or method is such that disease comprises an atopic disease or allergy.

Preferably, the allergy is selected from the group consisting of: allergic asthma, a
10 seasonal respiratory allergy, a perennial respiratory allergy, allergic rhinitis, hayfever, nonallergic rhinitis, vasomotor rhinitis, irritant rhinitis, an allergy against grass pollen, weed pollen, tree pollen or animal danders, an allergy associated with allergic asthma and a food allergy.

Preferably, the allergy is to a house dust mite from Family Glyphagidae, preferably
15 *Blomia tropicalis* or from Family Pyroglyphidae, preferably *Dermatophagoides pteronyssinus* or *Dermatophagoides farinae*, or to fungi or fungal spores, preferably *Aspergillus fumigatus*.

In an alternative embodiment, the disease comprises a cancer.

According to a twenty seventh aspect of the present invention, we provide the use
20 of a DNA vaccine as described, in a method of treatment or prevention of a cancer, or in a method of suppressing tumour progression.

Preferably, the cancer comprises a T cell lymphoma, melanoma, lung cancer, colon cancer, breast cancer or prostate cancer.

According to a twenty eighth aspect of the present invention, we provide a method of identifying a molecule capable of binding to Fve, the method comprising exposing a native Fve polypeptide, or an Fve polypeptide or nucleic acid, vector, host cell or transgenic organism according as set out above to a candidate molecule and detecting
5 whether the candidate molecule binds to the native Fve polypeptide, or an Fve polypeptide or nucleic acid, vector, host cell or transgenic organism.

According to a twenty ninth aspect of the present invention, we provide a method of identifying an agonist or antagonist of an Fve polypeptide, the method comprising: (a) providing a cell or organism; (b) exposing the cell or organism to a native Fve polypeptide,
10 or an Fve polypeptide or nucleic acid, vector, host cell or transgenic organism as set out above; (c) exposing the cell to a candidate molecule; and (d) detecting an Fve mediated effect.

Preferably, the Fve mediated effect is selected from the biological activities set out above.

15 Preferably, the method further comprises isolating or synthesising a selected or identified molecule.

According to a thirtieth aspect of the present invention, we provide a molecule identified or selected using such a method.

According to a thirty first aspect of the present invention, we provide a native Fve
20 polypeptide, or an Fve polypeptide in crystalline form.

Preferably, the crystal has the structural coordinates shown in **Appendix C**.

According to a thirty second aspect of the present invention, we provide a model for at least part of Fve made using such a crystal.

According to a thirty third aspect of the present invention, we provide a method of screening for a receptor capable of binding to Fve, or designing a ligand capable of modulating the interaction between Fve and an Fve receptor, comprising the use of such a model.

- 5 According to a thirty fourth aspect of the present invention, we provide a computer readable medium having stored thereon the structure of such a crystal or such a model.

According to a thirty fifth aspect of the present invention, we provide a ligand identified by the method set out above.

- 10 According to a thirty sixth aspect of the present invention, we provide a use of such a molecule or such a ligand for the treatment or prevention of a disease in an individual.

According to a thirty seventh aspect of the present invention, we provide a pharmaceutical composition comprising such a molecule or such a ligand and optionally a pharmaceutically acceptable carrier, diluent, excipient or adjuvant or any combination thereof.

- 15 According to a thirty eighth aspect of the present invention, we provide a method of treating and/or preventing a disease comprising administering such a molecule or such a ligand and/or such a pharmaceutical composition to a mammalian patient.

- 20 According to a thirty ninth aspect of the present invention, we provide a method of amplifying a sub-population of cells, the method comprising: (a) obtaining a population of cells from an individual; (b) amplifying CD3⁺ CD8⁺ and CD18⁺ ^{bright} T cells by exposing the population of cells to a native Fve polypeptide, or an Fve polypeptide or nucleic acid, vector, host cell or transgenic organism as set out above.

Preferably, the method further comprises the step of: (c) isolating the CD3⁺ CD8⁺ and CD18⁺ ^{bright} T cells.

According to a fortieth aspect of the present invention, we provide a method of treating an individual suffering from a disease or preventing the occurrence of a disease in an individual, the method comprising amplifying a CD3⁺ CD8⁺ and CD18⁺ bright T cell by such a method, and administering the amplified CD3⁺ CD8⁺ and CD18⁺ bright T cell to an individual.

According to a forty first aspect of the present invention, we provide a combination comprising a first component comprising an immunomodulator and a second component comprising at least a portion of an allergen, a viral antigen or a tumour associated antigen.

Preferably, the first component is separate from the second component.

Alternatively, or in addition, the first component may be associated with the second component. Preferably, the combination comprises a fusion protein.

The first component may comprise a native Fve polypeptide, or a polypeptide as set out above. The second component may comprise an allergen selected from the group consisting of: a mite allergen, an mite allergen from Family *Glycyphagidae* or Family *Pyroglyphidae*, a group 1 allergen (Der p 1, Der f 1, Blo t 1, Eur m1, Lep d 1), a group 2 allergen (Der p 2, Der f 2, Blo t 2, Eur m 2, Lep d 2), a group 5 allergen (Blo t 5, Der p 5, Der f 5, Eur m 5, Lep d 5), a group 15 allergen (Der p 15, Der f 15, Blo t 15, Eur m 15, Lep d 15), a tree pollen allergen, Bet v 1 and Bet v 2 from birch tree; grass pollen allergen, Phl p 1 and Phl p 2 from timothy grass; weed pollen allergen, antigen E from ragweed; major feline antigen, Fel d; major fungal allergen, Asp f1, Asp f2, and Asp f3 from *Aspergillus fumigatus*.

In preferred embodiments, the second component comprises a viral antigen selected from the group consisting of: E6 and E7 from HPV; core Ag and E2 from HCV; core and surface antigens from HBV; LMP-1, LMP-2, EBNA-2, EBNA-3 from EBV; and Tax from HTLV-1. Alternatively, or in addition, the second component may comprise a tumour-associated antigen selected from the group consisting of: MAGE-1, MAGE-2, MAGE-3, BAGE, GAGE, PRAME, SSX-2, Tyrosinase, MART-1, NY-ESO-1, gp100,

TRP-1, TRP-2, A2 melanotope, BCR/ABL, Proteinase-3/Myeloblastin, HER2/neu, CEA, P1A, HK2, PAPA, PSA, PSCA, PSMA, pg75, MUM-1, MUC-1, BTA, GnT-V, β -catenin, CDK4, and P15.

We further disclose an immunomodulator-antigen conjugate, preferably an immunomodulator-allergen conjugate, an immunomodulator-tumour associated antigen conjugate or a immunomodulator-viral antigen conjugate, in which the immunomodulator preferably comprises an Fve polypeptide.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Analysis of purified native Fve by SDS-PAGE and gel filtration chromatography. (a). The native Fve protein purified by cation and anion exchange chromatography is analyzed by Tricine SDS-PAGE. Fve protein gave a single band with an apparent molecular mass of 12.7 kDa. Lane M, molecular mass markers; lane 1, purified native Fve protein. (b) Elution profile of calibration proteins by Superdex 75 chromatography. Peaks, 1. bovine serum albumin (67 kDa); 2. ovalbumin (43 kDa); 3. chymotrypsinogen A (25 kDa); 4. ribonuclease A (13.7 kDa). (c) Purified native Fve formed homodimer at 25.5 kDa.

Figure 2 shows a profile of cytokines and iNOS produced by mouse splenocytes upon stimulation with Fve protein. Mouse spleen cells from Balb/cJ mice are stimulated with 20 μ g of Fve. The mRNAs of cytokines are analyzed by RT-PCR after culturing for 48 hours. A: A non-stimulated culture as negative controls, B: A culture stimulated with 20 μ g of Fve.

Figure 3 shows a profile of human cytokines, transcriptional factors, adhesion molecule and anti-apoptotic protein produced by human PBMC upon stimulation with Fve protein. Human PBMC from healthy donor are stimulated with 20 μ g of Fve. The mRNA expression is analyzed by RT-PCR after culturing for 48 hours. A: A non-stimulated culture as negative control, B: A culture stimulated with 20 μ g of Fve.

Figure 4. A schematic representation showing the principle of overlap extension PCR for the generation of single amino acid residue substitution (A) and deletion mutagenesis of DNA (B).

Figure 5. A schematic representation of the strategy used to generate mutants. On the basis of the structures predicted by PHD prediction program, eleven deletion mutants and three point mutants of Fve plasmid DNA are generated by PCR-based mutagenesis.

Figure 6. SDS-PAGE analysis of recombinant Fve mutant proteins.

Figure 7. *In vitro* proliferation assay of mouse splenocytes. Mouse splenocytes from Balb/cJ is stimulated with 2.5µg/ml, 5µg/ml, 10µg/ml, and 20µg/ml, respectively, with 13 of Fve mutant proteins for 48 hours. Recombinant GST-Fve is positive control. GST is negative control.

Figure 8. Lymphoproliferation activity of human PBMC at 48 hours. Human PBMC from a healthy donor is stimulated with 2.5µg/ml, 5µg/ml, 10µg /ml, and 20µg /ml, respectively, with eleven of Fve mutant proteins for 48 hours. Recombinant GST-Fve and native Fve are positive control. GST and Blo t 5 are negative control.

Figure 9. Recombinant GST-Fve (wild type) and GST-FveT29 mutant protein showed strong lymphoproliferative activity. Human PBMC from healthy donor are cultured with: (A) no antigen, (B) GST, (C) wild type GST-Fve, (D) GST-FveT29, each protein is used at 20µg /ml. The percentage of CD3⁺ T lymphocytes is analyzed at day 5 by using flow cytometry.

Figure 10. Increased production of TNF-α, IFN-γ, IL-2 but not IL-4 in CD3⁺ T lymphocytes after stimulation with native Fve protein. The production of (A) IL-4; (B) IL-2; (C) IFN-γ and (D) TNF-α by human PBMC after stimulation with 20µg /ml of native Fve protein for three days. The data are analyzed by flow cytometry.

Figure 11. Recombinant wild type GST-Fve and mutant GST-FveT29A, but not mutant GST-FveG28A, maintained IFN- γ cytokine production activity. Human PBMC from healthy donor are cultured with 20 μ g of GST (1); GST-Fve (2); GST-FveR27A (3); GST-FveG28A (4); GST-FveT29A (5). IFN- γ cytokine by T cells is detected at day 3 by staining with anti-CD3 PerCP and anti-IFN- γ FITC specific monoclonal antibody. IFN- γ secretion by small granular lymphocytes and large granular lymphocytes are shown in (a) and (b), respectively. The total amount of IFN- γ production by T cells is the sum of (a) and (b).

Figure 12. Recombinant wild type GST-Fve and mutant GST-FveT29A, but not mutant GST-FveG28A, maintained TNF- α production activity. Human PBMC from healthy donor are cultured with 20 μ g of GST (1); GST-Fve (2); GST-FveR27A (3); GST-FveG28A (4); GST-FveT29A (5). IFN- γ cytokine by T cells is detected at day 3 by staining with anti-CD3 PerCP and anti- TNF- α FITC specific monoclonal antibody. TNF- α secretion by small granular lymphocytes and large granular lymphocytes are shown in (a) and (b), respectively. The total amount of TNF- α production by T cells is the sum of (a) and (b).

Figure 13. Schematic representation of the experimental design of the *in vivo* study. Balb/cJ mice are immunized with Der p 2 in aluminum hydroxide at day 0 and boosted at day 21 by intraperitoneal injection. Treatment with Der p 2 alone or Der p 2 plus Fve is started at day 28 by given 6 subcutaneous injections over 12 days. Mice are challenged with Der p 2 at day 42.

Figure 14. Enhanced anti-Der p 2 IgG2a by adjuvanticity of Fve protein. IgG2a response in mice that are subcutaneously injected six times with Der p 2 alone (close circle), or Der p 2 plus Fve (close square) twenty-eight days after the initial sensitization with Der p 2 in alum. Mice received third intraperitoneal injection with Der p 2 in alum at day 42. Results are shown as mean titers and error bars indicate the standard deviations from the mean titers.

Figure 14B. Fungal immunomodulatory protein Fve increases allergen-specific IgG2a production in mice sensitized to house dust mite major allergen. All groups of female BALB/cJ (6 – 8 weeks old) are sensitized intraperitoneally on day 1 with 20 µg of recombinant mite allergen Blo t 5 and boosted at day 14 with same dose of allergen adsorbed to 64 µg/µl of aluminum hydroxide gel in a final volume of 200 µl. Mice treated with six subcutaneous injections of 50 µg of Blo t 5 plus 10 µg of Fve or 50 µg of Blo t 5 plus 50 µg of Fve in 200 µl of PBS at three days interval starting from day 21 - 35. The negative control mice receive six subcutaneous injections of 50 µg of Blo t 5 alone. All mice are bled weekly and sera were collected for analysis of Blo t 5-specific IgG2a by ELISA. These results show that fungal immunomodulatory protein Fve has the ability to induce Blo t 5-specific IgG2a antibody in allergen-sensitized mice.

Figure 15A and Figure 15B. Fve could reduce wheal and erythematic flare formation on skin prick test-positive human subject. Both the left and right hands of the house dust mite allergen sensitized human subject are challenged with saline, histamine, Der p 2, and mixture of Der p 2 and Fve at the separated sites on hands. The diameter sizes of wheel (A) and erythematic flare (B) are measured after 10 minutes incubation time

Figure 15C. Demonstration of immunomodulatory activity of Fve in allergic subject. Quantitative skin-prick tests were performed to evaluate the immunomodulatory function of Fve by co-administration with Der p 2 mite allergen in vivo. A positive reaction (56 - 130 mm wheel diameter) was shown when Der p 2 alone (20 ug/ml) was applied onto the skin of the fore arm of Dermatophagoides mite allergic subject. There was a Fve- dose-dependent reduction of skin reaction when different amount of Fve was used in combination with Der p2 allergen for skin tests.

Figure 16. A schematic representation of the seven fusion proteins of Bt5-Fve (wild type), Bt5-FveR27A, Bt5-FveT29A, Dp2-FveR27A, Dp2-FveT29A, Bt5-Dp2-FveR27A, and Bt5-Dp2-FveT29A.

Figure 17. Expression and purification of recombinant fusion protein Bt5-Fve, Bt5-FveR27A, and GST-Dp2-FveR27A. Lane 1 and 10 are protein marker. Lane 2 to 9 are GST; Blo t 5; Fve; Bt5-Fve; Bt5-FveR27A; Der p 2; Fve; and GST-Bt5, respectively.

Figure 18. Functional characterization of recombinant fusion proteins of Fve and allergen. The morphology of human lymphocytes upon stimulation with three different fusion proteins for three days. All photographs are taken at a magnification of $\times 10$ and $\times 40$ with a confocal microscope. 1(a) Control: Non-stimulated (10×10 magnification); 1(b) Control: Non-stimulated (40×10 magnification); 2(a): 20 μ g of GST 10×10 ; 2(b): 20 μ g of GST 40×10 ; 3(a): 20 μ g of Blo t 5 10×10 ; 3(b): 20 μ g of Blo t 5 40×10 ; 4(a): 20 μ g of native Fve 10×10 ; 4(b): 20 μ g of native Fve 40×10 ; 5(a): 20 μ g of Bt5-Fve 10×10 ; 5(b): 20 μ g of Bt5-Fve 40×10 ; 6(a): 40 μ g of Bt5-Fve 10×10 ; 6(b): 40 μ g of Bt5-Fve 40×10 ; 7(a) 40 μ g of Bt5-FveR27A 10×10 ; 7(b): 40 μ g of Bt5-FveR27A 40×10 ; 8(a): 20 μ g of Der p 2 10×10 ; 8(b): 20 μ g of Der p 2 40×10 ; 9(a): 40 μ g of GST-Dp2-FveR27A 10×10 ; 9(b): 40 μ g of GST-Dp2-FveR27A 40×10 . Human lymphocytes maintained aggregation ability upon stimulation with Bt5-Fve (5a, 5b, 6a, 6b) and Bt5-FveR27A (7a, 7b) for 3 days. Native Fve (4a, 4b) is a positive control. Non-stimulated cells (1a, 1b), GST (2a, 2b), Blo t 5 (3a, 3b), and Der p 2 (8a, 8b) are negative controls. The aggregation ability of GST-Dp2-FveR27A is not apparent at day 3 (9a, 9b).

Figure 19. Cell number comparison of human PBMC after 7 days cultured with tested antigens. Human PBMC are cultured with different doses of recombinant allergen and Fve fusion proteins. Non-stimulated cells and cells stimulated with either 20 μ g of Blo t 5; 20 μ g of Fve; 20 μ g of Bt5-Fve; 40 μ g of Bt5-Fve; 20 μ g of Bt5-FveR27A; and 40 μ g of Bt5-FveR27A are shown in Figure 19A. Cells stimulated with 20 μ g of Der p 2; 20 μ g of GST-Dp2-FveR27A; and 40 μ g of GST-Dp2-FveR27A are shown in Figure 19B. The cells are collected and counted at day 7.

Figure 20. The lymphoproliferation activity of human lymphocytes upon stimulation with recombinant fusion protein Bt5-Fve for 72 hours. Human PBMC from a healthy donor is co-cultured with 5 μ g /ml, 10 μ g /ml, 20 μ g /ml, and 40 μ g /ml, respectively,

with fusion protein Bt5-Fve (BFwt). Recombinant GST and Blo t 5 are used as negative controls. Fve is used a positive control.

Figure 21. Bt5Fve fusion protein maintained CD8 T cells polarization activity. Human PBMC are isolated from healthy donar and stimulated with 20µg of GST (b), 20µg of Blo t 5 allergen (c), 20µg of Fve (d), 20µg of Bt5Fve (e), 40µg of Bt5Fve (f), 20µg of Bt5FveR27 (g), and 40µg of Bt5FveR27 (h) for 5 days. Cells without any stimulation served as negative control (a). Cultured cells are stained with CD3-PerCP and CD8-FITC monoclonal antibodies and analyzed with FACSCalibur cytometry.

Figure 22. Fve and allergen-Fve fusion protein are able to induce T helper type 1 and T regulatory immune responses. (A). Fve induced IFN-γ and IL-10 production. Human PBMC from seven individuals are cultured with 20µg of Fve. The production of IFN-γ, IL-4 and IL-10 is assayed by ELISA at day 3. (B). Comparable levels of IFN-γ production are induced by Fve and allergen – Fve fusion protein. Human PBMC are stimulated with Fve, Blot5, Blot5-Fve (wild type) and Blot5-FveR27A (mutant), respectively. The production of IL-4 and IFN-γ is detected by ELISA at day 3 and day 7.

Figure 23. Competitive inhibition assay. Varying concentrations of inhibitors are used to inhibit the binding of human IgE to GST-Blot5 bound to the Elisa plate. The concentration of different inhibitors ranged from 0.01ng to 10000ng/ml. Results are obtained from serum of a representative allergic subject with high IgE reactivity to house dust mite allergens. GST: Glutathione S-transferase. GF: GST-Fve. GFB: GST-Fve-Blot5. GBF: GST-Blot5-Fve. BF: Blot5-Fve. B: Blo t 5.

Figure 23B. Polarized Th1 immune responses by recombinant fusion protein of allergen and fungal immunomodulatory protein Five mice per group of female BALB/cJ (6 - 8 weeks old) were subcutaneous immunized with 10 µg/ml of major house dust mite allergen Blo t 5 alone or fusion protein Blo t 5- FveT29A in tail at day 1. Mice were received similar antigen boosting in footpads at day 14 and day 28. All mice were bled weekly and sera were collected for analysis of Blo t 5 and Fve-specific IgG1, IgG2a and

IgE by ELISA. Results show that recombinant fusion protein of allergen and fungal immunomodulatory protein has the ability to induce Blo t 5-specific IgG2a (2a) and down-regulate IgE production (2c). The overall of Fve-specific IgG1 and IgG2a antibodies are lower than Blo t 5 and decrease gradually after day 42 (2d and 2e), and the induction of
 5 Fve-specific IgE is less than 1 ng/ml (2f). Therefore, fungal immunomodulatory protein Fve has the potential to be developed for the immunotherapeutic vaccine of allergy.

Figure 23C. Efficient induction of Th 1-mediated immune responses in mite allergen-induced mice by recombinant fusion protein Blo t 5-Fve. All groups of female BALB/cJ (6 – 8 weeks old) were sensitized intraperitoneally on day 1 with 5 µg of
 10 recombinant mite allergen Blo t 5 and boosted at day 14 with 1 µg of Blo t 5 adsorbed to 64 µg/µl of aluminum hydroxide gel in a final volume of 200 µl. Mice treated with six subcutaneous injections of 20 µg of Blo t 5-FveWT or Blo t 5-FveT29A fusion protein in 200 µl of PBS at three days interval started from day 21 - 35. The negative control mice received six subcutaneous injections of 20 µg of Blo t 5 alone. All mice were bled weekly
 15 and sera were collected for analysis of Blo t 5 and Fve-specific IgG1, IgG2a, and IgE by ELISA. Result show that recombinant fusion protein Blo t 5- FveT29A has the ability to induce Blo t 5-specific IgG2a antibody (3a) in allergensensitized mice.

Figure 24. Human PBMC stimulated with native Fve protein for five days showed a significant increase in CD16⁺ and CD56⁺ cells. The CD3⁺ cells and CD16⁺ + CD56⁺
 20 cells are analyzed by FACScan after staining with anti-CD3 FITC, anti-CD16 PE and anti-CD56 PE conjugated mouse anti-human specific monoclonal antibody. Cells stimulated with (a) no antigen; (b). 5µg of Der p 2 house dust mite allergen as negative control; (c). 5µg of PHA; (d). 5µg of Fve; (e). 25µg of Fve.

Figure 25. Human PBMC stimulated with Fve protein for ten days showed a
 25 significant increase in CD8⁺ cells. The proportion of CD4⁺ and CD8⁺ T cells are analyzed by FACScan after staining with anti-CD4 FITC and anti-CD8 PE conjugated mouse anti-human specific monoclonal antibody. Cells are stimulated with (a). no antigen; (b). 5µg of

Der p 2 house dust mite allergen as negative control; (c). 5µg of PHA; (d). 5µg of Fve; (e). 25µg of Fve.

Figure 26. Expanded human CD3⁺CD18^{+Bright} T cells subset in human PBMC after stimulation with Fve protein for five days. Human PBMC from healthy donor are cultured alone (a and c) or with 20µg of native Fve protein (b and d) for 5 days. Cells are then analyzed by flow cytometry after staining with anti-CD3 PerCP, anti-CD8 PE and anti-CD18 FITC.

Figure 27. Expanded CD3⁺CD8^{+Bright}CD18^{+Bright} T cells in human PBMC after cultured with Fve protein for five days. Human PBMC from healthy donor are cultured alone (a and c) or with 20µg of native Fve protein (b and d) for five days. Cells are analyzed by flow cytometry after staining with anti-CD3 PerCP, anti-CD8 PE and anti-CD18 FITC.

Figure 28. Proportion of *in vivo* BrdU incorporated natural killer (NK) cells from spleen of C57BL/6J naïve mice (a), or mouse received three consecutive subcutaneous injections with 10µg of Fve (b), 50µg of Fve (c), 250µg of Fve (d). Splenocytes are stained with anti-Pan NK PE and anti-BrdU FITC monoclonal antibodies and then analyzed with flow cytometry.

Figure 29. Proportion of *in vivo* BrdU incorporated CD8⁺ T cells from spleen of C57BL/6J naïve mice (a), or mouse received three consecutive subcutaneous injections with 10µg of Fve (b), 50µg of Fve (c), 250µg of Fve (d). Splenocytes are stained with anti-CD8 PE and anti-BrdU FITC monoclonal antibodies and then analyzed with flow cytometry.

Figure 30. Proportion of *in vivo* BrdU incorporated CD4⁺ T cells from spleen of C57BL/6J naïve mice (a), or mouse received three consecutive subcutaneous injections with 10µg of Fve (b), 50µg of Fve (c), 250µg of Fve (d). Splenocytes are stained with anti-

CD4 PE and anti-BrdU FITC monoclonal antibodies and then analyzed with flow cytometry.

Figure 31. Proportion of *in vivo* BrdU incorporated CD19⁺ B cells from spleen of C57BL/6J naïve mice (a), or mouse received three consecutive subcutaneous injections with 10µg of Fve (b), 50µg of Fve (c), 250µg of Fve (d). Splenocytes are stained with anti-CD19 PE and anti-BrdU FITC monoclonal antibodies and then analyzed with flow cytometry.

Figure 32. Proportion of *in vivo* BrdU incorporated CD8⁺ T cells from lymph nodes of C57BL/6J naïve mice (a), or mouse received three consecutive subcutaneous injections with 10µg of Fve (b), 50µg of Fve (c), 250µg of Fve (d). Lymph nodes are stained with anti-CD8 PE and anti-BrdU FITC monoclonal antibodies and then analyzed with flow cytometry.

Figure 33. Proportion of CD4⁺ and CD8⁺ T cell subsets from mouse peripheral blood mononuclear cells of Balb/cJ naïve mouse (a), or mouse received seven consecutive subcutaneous injections with 125µg of Fve. Panels (b), (c), (d) represent results for three respective individual mouse. Mouse peripheral blood mononuclear cells are collected in a tube with anti-coagulant. Cells are stained with anti-CD8 PE and anti-CD4 FITC monoclonal antibodies and then analyzed by flow cytometry.

Figure 34. Schematic representative of two mammalian eukaryotic expression vectors. (A) pCI-neo can constitutively express high level of recombinant protein in mammalian cells (Picture adopted from Promega, USA). (B) pDisplay can display recombinant protein to the surface of mammalian cells (Picture adopted from Invitrogen life technologies, USA).

Figure 35. Growth suppression of EL4 solid tumor. C57BL mice are inoculated with 8×10^6 EL4 cells have reduced tumor growing rate in the group treated with pCIneo-fve plasmid DNA and Fve protein (Square curve). The control group received pCIneo

DNA vector alone and 1xPBS (Diamond curve). EL4 tumor formation is observed at day 3. 100µg of pCIneo-fve DNA is intramuscularly injected into the tibialis muscle at days 0 and 7. 20µg of Fve protein is given by subcutaneous injection at days 5, 7, 9, 11, 13, 15, and 18, respectively.

- 5 Figure 36. C57BL/6J mice with EL4 solid tumor have extended mean survival time following treatment with the native Fve protein. Eight weeks old female C57BL mice are inoculated with EL4 tumor in the dorsal back. Tumor formation is observed 3 days after inoculation. Red line: 100µg of pCIneo-fve plasmid DNA is intramuscularly injected at the tribilis muscle at days 0 and 7. Mice are received 20µg of native Fve protein treatment by
10 subcutaneous injection surrounding the tumor site at days 5, 7, 9, 11, 13, 15, and 18, respectively. Blue line: Mice received 100µg of pCIneo vector alone and 1xPBS as control group.

- Figure 37. C57BL/6J mice with B16-F1 melanoma have extended mean survival time following treatment with native Fve protein. Mice are inoculated with B16-F1 tumor
15 cells in the dorsal back. Tumor formation is observed at day 3. Red line: 200µg of pCIneo-fve plasmid DNA is intramuscularly injected at the tribilis muscle at days -30 and day -1. 50µg of Fve protein is given by subcutaneous injection surrounding the tumor site at days 4, 7, 9, and 12, respectively. Blue line: Mice received 200µg of pCIneo vector and 1xPBS as control group.

- 20 Figure 38. B16-Fve transfectant has longer survival rate as comparing with B16-vec transfectant. Two groups of C56BL/6J female mice are inoculated either with 5×10^4 of B16-Fve (Red line) or 5×10^4 of B16-vec (Blue line) transfectants in the right flank. Transfectant melanoma solid tumor is established at days 5-7. The fatal rates of mice are recorded and presented as survival curve.

- 25 Figure 39. Combined DNA vaccination and Fve gene-transduced melanoma cells synergizes the extension of life span in solid tumor-established mice. C57BL/6J mice are separated into three groups and each group consisted of ten mice. Mice are inoculated with

5 5×10^4 of B16-F1 tumor transfectants in the dorsal back. Tumor formation is observed at day 5-7. 100 μ g of pCIneo-fve plasmid DNA is intramuscularly injected at the right and left tribilis muscle of C57BL/6J at day -77, day -35 and day -21. Mice are subcutaneously injected with 5×10^4 of B16-Fve transfectants (Red line) and B16-vec transfectant (Green Line) at day 0, respectively. 100 μ g of pCIneo plasmid DNA is operated as same experimental procedure and mice are subcutaneously injected with 5×10^4 of B16-vec transfectants as negative control (Blue line).

10 Figure 40. Strategy of oral primed with Fve protein and intramuscular boosted with plasmid DNA could extend the survival rate of mice with lung metastasis. Two groups of five C57BL/6J mice are given with 10mg/ml of Fve protein in the drinking water at day -35, -28 and -21, and each water providing is maintained consecutively for one week. Mice are intravenously injected with 2×10^4 of B16-F1 (wild type) melanoma cells at day 0. One week after, mice are intramuscularly injected with 100 μ g of pCIneo-fve plasmid DNA into the right and left tribilis muscle, respectively. The mixture of 5×10^4 of B16-Fve cells lysate plus 10 μ g of Fve protein (Red line) or 10 μ g of Fve protein alone (Green line) are subcutaneously injected to mice at the following three weeks. Negative control group of mice received same amount of 1xPBS in the drinking water, intravenously injected with 2×10^4 of B16-F1 melanoma cells, followed by intramuscularly injected with plasmid DNA vector pCIneo, and finally subcutaneously injected with B16-vec cells lysate plus 1xPBS (Blue line).

Figure 40B is a shematic representation of the protocol used in the experiments described in Example 25A.

Figure 40C is a graph showing the results of Example 25A.

25 Figure 41. Two representative crystals of Fve. Tetragonal crystal is grown in 2% PEG 400, 2.0 M Ammonium Sulfate; 0.1 M Tris-HCl pH 8.5. The crystal dimensions are approximately 1 mm \times 0.9 mm \times 0.5 mm.

Figure 42. 1° oscillation image of Fve crystal. The edge of the image corresponds to a resolution of 1.4Å. Image displayed with Mosflm/Scala.

Figure 43, 44A, 44B, 44C, 45A and 45B show structures of Fve.

SEQUENCES

5 **Appendix A** shows the nucleic acid and/or amino acid sequences of the deletion mutants Fve D6-18, Fve D19-33, Fve D34-46, Fve D47-60, Fve D61-72, Fve D73-84, Fve D85-97, Fve D98-106, Fve D107-115, Fve D61-97, Fve p55-100.

10 **Appendix A** also shows the nucleic acid and/or amino acid sequences of the substitution mutants Fve R27A, Fve G28A, Fve T29A, as well as the fusion proteins Blo t 5-Fve (two-in-one chimeric wild type), Blo t 5-Fve R27A (two-in-one chimeric mutant), Blo t 5-Fve T29A (two-in-one chimeric mutant), Der p 2-Fve R27A (two-in-one chimeric mutant), Der p 2-Fve T29A (two-in-one chimeric mutant), Blo t 5-Der p 2-Fve R27A (three-in-one chimeric mutant).

15 **Appendix A** also shows the nucleic acid and/or amino acid sequences of the Fusion Proteins of Viral Antigen and Fve, HPV E7-FveT29A and HCV Core23-FveT29A, as well as the nucleic acid and/or amino acid sequences of the Fusion Proteins of Tumor-Associated Antigen and Fve, MAGE3-FveT29A, MART1-FveT29A and CEA-FveT29A.

20 **Appendix A** also shows the sequences of the primers Fd6-18F (36 mer), Fd6-18R (36 mer), Fd19-33F(36 mer), Fd19-33R(36 mer), Fd34-46F(36 mer), Fd34-46R(36 mer), Fd47-60F(36 mer), Fd47-60R(36 mer), Fd61-72F(36 mer), Fd61-72R(36 mer), Fd73-84F(36 mer), Fd73-84R(36 mer), Fd85-97F(36 mer), Fd85-97R(36 mer), Fd98-106F (36 mer), Fd98-106R (36 mer), Fd107-115R(39 mer), d(61-97)-F(36mer), d(61-97)-R(36mer), [Fv55-100]-F(48mer), [Fv55-100]-R(42mer), F(R27A)-F (27 mer), F(R27A)-R (27 mer), F(G28A)-F (27 mer), F(G28A)-R (27 mer), F(T29A)-F (27 mer), F(T29A)-R (27 mer),

Bt5Fv-F (36mer), Bt5Fv-R (36mer), Dp2Fv-F (36mer), Dp2Fv-R (36mer), Bt5Dp2-F(36mer), Bt5Dp2-R(36mer).

Appendix B shows the sequences of fragments of Fve, which comprise all or part of the RGT motif.

5 **Appendix C** shows the crystal coordinates of Fve protein.

The methods and compositions described here may suitably employ any one or more of the sequences shown in the Appendices.

DETAILED DESCRIPTION

10 We have identified an immunoregulatory protein, designated as native Fve, from *Flammulina velutipes*. The cDNA encoding Fve protein has been isolated and biologically active recombinant Fve has been successfully produced in *E.coli*.

15 Our studies show that native Fve is capable of inducing high levels of expression of IFN- γ , TNF- α and ICAM-I gene expression in activated human T -and NK cells. It also up-regulates transcription factors IRF-I and NF- κ B (c-Rel), but down-regulates Il.-4. In allergic murine model, mice treated with Der p 2, a major house dust mite allergen from *Dermatophagoides pteronyssinus*, plus native Fve show a significant boost of Der p 2-specific IgG2a production. Native Fve also reduces wheel and erythematic flare formation on Der p 2 skin prick test-positive human subject. We also find that fragments, homologues, variants derivatives of native Fve disclosed here (termed "Fve polypeptides")
20 as well as nucleic acids encoding these, also have such activities.

Furthermore, we show in the Examples that Fve polypeptide and native Fve polypeptide is a potent adjuvant that can be codelivered with specific allergens for desensitization of allergic disorders such as asthma, rhinitis and atopic dermatitis. In addition, Fve selectively induces polarization of NK (natural killer) cells and cytotoxic

CD8⁺ T cells *in vitro* and *in vivo*. We therefore disclose anti-cancer therapies and methods which employ these immunostimulatory or immunomodulatory effects. We disclose *in vivo* animal studies which show that this protein prolongs survival rate in solid tumor-transplanted mice.

5 Fve and its polypeptides may therefore be used for any application where up-regulation of a immune response is desired or necessary. Fve polypeptides may in particular be used in therapy, for example for the treatment of diseases such as infections, cancer, etc.

10 We further disclose a combination of Fve polypeptide or native Fve, with an allergen, for example in the form of a fusion protein. Such a combination is able to counteract an established allergic reaction. Combinations of Fve polypeptide or native Fve with a tumour associated protein or viral oncogenic protein may be used to prevent or treat cancer, or specifically for preventing tumour progression.

15 We disclose immunotherapeutic methods and reagents for allergy and virus infections, which take advantage of these immunomodulatory effects of native Fve and Fve polypeptides. We also disclose methods of treatment or prevention of a cancer, tumour, neoplasm or cancerous cell, by use of the Fve polypeptides and nucleic acids described here. DNA vaccines, expression vectors, host cells and transgenic organisms comprising such Fve nucleic acids, or a fragment, homologue, variant or derivative
20 thereof, may also be used for such a purpose. In general, any use of a Fve polypeptide described here may employ a nucleic acid encoding such, or a DNA vaccine, expression vector, host cell and transgenic organism comprising such, and the disclosure should be read accordingly.

25 We also show that native Fve stimulates gene expression of human IFN- γ , TNF- α , IL-1 β , IL-2, IRF-1, c-Rel, Bcl-X_L, ICAM-1 and iNOS. In addition, we show that Fve up-regulates a novel subset of CD8⁺ T cells (CD3⁺ CD8⁺ CD18⁺ ^{bright}), and induces NK cell and CD8⁺ T cell proliferation *in vivo*. Animal studies show that Fve prolongs survival rate

of tumor-inoculated mice treated with Fve gene and protein. We disclose methods and reagents for cancer therapy using the Fve gene, protein and products, for example in the form of cell-based vaccines for cancers.

Fve may be used *in vitro* to stimulate the proliferation of CD3⁺ CD8⁺ CD18⁺ CD18⁺ populations, and the amplified populations may then be administered to the individual in need of treatment. Thus, while it is possible to stimulate CD3⁺ CD8⁺ CD18⁺ populations in the context of the body of the animal, it will be apparent that such amplification is also possible *in vitro*. We therefore disclose the use of Fve polypeptides to stimulate such cells *in vitro*. Such amplified populations may then be infused into or otherwise administered to the individual in need of treatment. The starting cell population may come from another individual, but preferably it is derived from the same individual who requires treatment.

We also disclose a crystal of FIP, which has been crystallised for the first time. Such a crystal may be used for modelling, or designing ligands which may interact with Fve. The crystal or model may be stored on a computer, or on a computer readable medium, and manipulated using methods known to the skilled person. A computer readable medium comprising a data representation of the crystal is therefore provided.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA and immunology, which are within the capabilities of a person of ordinary skill in the art. Such techniques are explained in the literature. See, for example, J. Sambrook, E. F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A Laboratory Manual*, Second Edition, Books 1-3, Cold Spring Harbor Laboratory Press; Ausubel, F. M. et al. (1995 and periodic supplements; *Current Protocols in Molecular Biology*, ch. 9, 13, and 16, John Wiley & Sons, New York, N.Y.); B. Roe, J. Crabtree, and A. Kahn, 1996, *DNA Isolation and Sequencing: Essential Techniques*, John Wiley & Sons; J. M. Polak and James O'D. McGee, 1990, *In Situ Hybridization: Principles and Practice*, Oxford University Press; M. J. Gait (Editor), 1984, *Oligonucleotide Synthesis: A Practical Approach*, Irl Press; and, D.

M. J. Lilley and J. E. Dahlberg, 1992, *Methods of Enzymology: DNA Structure Part A: Synthesis and Physical Analysis of DNA* Methods in Enzymology, Academic Press. Each of these general texts is herein incorporated by reference.

NATIVE FVE

5 The terms “native Fve polypeptide” or “native Fve protein”, as used in this document, should be taken to refer to the immunoregulatory protein Fve from *Flammulina velutipes*, preferably in isolated form. The term “wild type Fve” should be understood to be synonymous with “native” Fve; furthermore, the term “nFve” is sometimes used to refer to native Fve.

10 Preferably, “native” Fve has an amino acid sequence set out as as GenBank accession numbers: S69147 immunomodulatory protein FIP-fve - golden needle mushroom gi|7438667|pir||S69147[7438667] and P80412 IMMUNOMODULATORY PROTEIN FIP-FVE gi|729544|sp|P80412|FVE_FLAVE[729544]. A polypeptide and
15 the term “native FIP” preferably refers to a polypeptide or nucleic acid, as the case may be, having such sequence. Methods of isolating the “native” Fve gene and protein from *Flammulina velutipes* are known in the art, and are also set out in the Examples.

 A “native” Fve may comprise a methionine residue at the N terminus; however, a native Fve may include versions which lack the initial methionine. The nucleic acid
20 sequence which encodes such a native Fve may therefore comprise or not comprise an initial ATG codon.

 As noted above, we have identified certain previously unknown properties of native Fve, including immunomodulatory and stimulatory properties, and one aspect of the invention is directed to such new uses of native Fve nucleic acid and native Fve
25 polypeptide. These are disclosed in further detail below.

It should be understood, therefore, that the invention preferably does not include wild-type or native Fve protein; however, it does encompass the uses of this in immunomodulation, enhancing immune response and in allergy and cancer treatment. Furthermore, we disclose a fusion protein comprising glutathione S transferase (GST) and native Fve; such a fusion protein is shown in the Examples to have the beneficial properties of native Fve itself. The sequence of GST-Fve is shown in **Appendix A**. Therefore, the invention includes this GST-Fve fusion protein (also referred to as rGST-Fve and GST-Fve (wild type)), and nucleic acids encoding it.

We further disclose a nucleic acid sequence encoding native Fve, termed here a “native Fve nucleic acid sequence”. The Examples describe the cloning and isolation of a cDNA encoding native Fve protein. The sequence of this is set out as “Fve (Wild type)” in **Appendix A**. Preferably such a sequence is in isolated form.

FVE POLYPEPTIDES

Additionally, we have identified various fragments, homologues, variants and derivatives of “native Fve”, which are previously unknown. Such fragments, homologues, variants and derivatives are referred to here as “Fve polypeptides” (as contrasted with “native Fve polypeptides”). We disclose such Fve polypeptides, and their uses.

It will be apparent that the terms “Fve” and “Fve polypeptide”, as they are used in this document, preferably exclude the wild type or native Fve protein or gene encoding this, and includes only molecules derived from native Fve, being fragments, homologues, variants and derivatives of native Fve (i.e., Fve polypeptides).

The Fve polypeptides are preferably at least as biologically active as native Fve. However, they may have 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more of the biological activity of native Fve, for example as assayed by any of the tests set out below. As used herein “biologically active” refers to a sequence having a similar structural function (but not necessarily to the same degree), and/or similar regulatory function (but

not necessarily to the same degree), and/or similar biochemical function (but not necessarily to the same degree) of the naturally occurring sequence.

“Fve polypeptides” preferably comprise at least one biological activity of native Fve. By “biological activity” in relation to Fve, we refer to at least one of the following activities: up-regulation of expression of Th1 cytokines, preferably IFN- γ and TNF- α , down-regulation of expression of Th2 cytokines, preferably IL-4 and IL-13, hemagglutination activity, cell aggregation activity, lymphocyte aggregation activity, lymphoproliferation activity, up-regulation of expression of IL-2, IFN- γ , TNF- α , but not IL-4 in CD3⁺ T cells, interaction with T and NK cells, adjuvant activity, stimulation of CD3⁺ CD16⁺ CD56⁺ natural killer (NK) T cells, and up-regulation of expression of allergen specific IgG2a antibody. Further biological activities preferably comprised by Fve polypeptides as described here include prevention of systemic anaphylactic reactions and/or decreased footpad edema, preferably as assayed using the Arthus reaction (Ko et al, 1995). In particular, Fve polypeptides preferably comprise at least some of useful properties, preferably medically or therapeutically useful properties, of native Fve.

Assays for each of these activities are set out in the Examples, and preferably, whether a Fve polypeptide comprises a “biological activity” of Fve is to be assessed according to the relevant assay set out in the Examples.

Preferably, Fve polypeptides comprise at least one or more of the biological activities for the relevant use, preferably use as an immunomodulator, or for upregulating immune response. Preferably, they comprise at least one or more of the biological activities which enable use as a cancer therapy or allergy therapy.

Preferably, Fve polypeptides comprise two or more biological activities of native Fve, preferably substantially all the biological activities of native Fve.

We show in the Examples that the sequence RGT at positions 27-29 of the native Fve polypeptide sequence plays a crucial role in the biological activity of native Fve. In

particular, the RGT is shown to mediate the ability of native Fve to cause lymphocyte aggregation and adhesion. This sequence is also shown to mediate lymphoproliferation, and stimulation of IL-2, IFN- γ and TNF- γ secretion in T cells, preferably CD3⁺ T cells.

Accordingly, in preferred embodiments, the Fve polypeptides comprise at least
5 one, two or all three of the RGT residues (or a functional variant such as RGD) at or about a position corresponding to position 28 of the native Fve polypeptide. By functional variant of RGT, we mean any change in the residues of RGT (or a sequence surrounding it) which does not substantially abolish its function, preferably its function in mediating the activities set out above. Preferably, the Fve polypeptide comprises between 2 to 50,
10 more preferably between 2 to 40, more preferably between 2 to 30, most preferably between 2 to 20 residues of amino acid sequence flanking the glycine residue corresponding to position 28 of native Fve. More preferably, the Fve polypeptide comprises the sequence RGT or the sequence RGD.

However, we show that mutations of R at position 27, as well as mutations of T at
15 position 29, have advantageous effects, in that they independently increase activity of a Fve polypeptide comprising either or both of these mutations. Furthermore, each of the mutations, or in combination, have the potential to increase the solubility of the Fve polypeptide comprising it or them. One, each or both of R27 and T29 may therefore be independently mutated advantageously, by substitution or deletion.

20 In preferred embodiments, the or each of R27 and T29 are mutated by substitution. The R27 and / or T29 may be substituted by any other residue, but preferably a neutral residue such as G or A. We therefore disclose Fve polypeptides in which R at position 27 is changed to another residue, for example, Fve polypeptides in which R27 is mutated to A, i.e., a Fve polypeptide comprising R27A. We therefore disclose Fve polypeptides in
25 which T at position 29 is changed to another residue, for example, Fve polypeptides in which T29 is mutated to A, i.e., a Fve polypeptide comprising T29A.

Combinations are also possible; hence we disclose Fve polypeptides in which R at position 27 and T at position 29 are independently changed to one or more other residues. For example, we disclose Fve polypeptides in which R27 is mutated to A, and T29 is mutated to A, i.e., a Fve polypeptide comprising R27A and T29A. As noted above, the polypeptide may comprise between 2 to 50, 40, 30 or preferably 20 residues of amino acid flanking the glycine residue at position 28 of native Fve.

Fve polypeptides may comprise fragments of native Fve. For example, Fve D6-18, Fve D19-33, Fve D34-46, Fve D47-60, Fve D61-72, Fve D73-84, Fve D85-97, Fve D98-106, Fve D107-115, Fve D61-97, and Fvep55-100. Fusion proteins comprising these deletion fragments and GST are also disclosed. Fve polypeptides may comprise substitutions, including FveR27A, FveG28A and FveT29A. Further examples of Fve polypeptides are shown in **Appendix B**, each of which includes at least a portion of the RGT sequence (preferably the whole of the RGT sequence) discussed above. Preferably, the length of such a fragment is 9 amino acid residues or more, e.g., fragment numbers 34-403.

Fve polypeptides may comprise fusion proteins, particularly fusion proteins between an allergen and a Fve polypeptide as defined here. Such allergen-immunomodulator combinations include Blo t 5-Fve(two-in-one chimeric wild type), Blo t 5-FveR27A (two-in-one chimeric mutant), Blo t 5-FveT29A (two-in-one chimeric mutant), Der p 2-FveR27A (two-in-one chimeric mutant), Der p 2-FveT29A (two-in-one chimeric mutant) and Blo t 5-Der p 2-FveR27A (three-in-one chimeric mutant).

Fragments, homologues, variants and derivatives of each of these Fve polypeptides are also included.

The Fve polypeptides may be made by biochemical methods, for example, protein digestion of native Fve, or preferably by recombinant DNA methods as known in the art. Accordingly, it will be understood that Fve polypeptides specifically include recombinant

Fve polypeptides. For example, we disclose in the Examples successful production in *E.coli* of biologically active recombinant Fve polypeptide.

The Fve polypeptides disclosed also include homologous sequences obtained from any source, for example related viral/bacterial proteins, cellular homologues and synthetic peptides, as well as variants or derivatives thereof. Thus polypeptides also include those encoding homologues of Fve from other species including other microorganisms. Furthermore, homologues from higher animals such as mammals (e.g. mice, rats or rabbits), especially primates, more especially humans are also included.

Homologues

In the context of this document, a "homologous" sequence is taken to include an amino acid sequence which is at least 15, 20, 25, 30, 40, 50, 60, 70, 80 or 90% identical, preferably at least 95 or 98% identical at the amino acid level over at least 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 110 or 114 amino acids with the sequence of native Fve shown as "Fve (Wild type)" in Appendix A. In particular, homology should typically be considered with respect to those regions of the sequence known to be essential for protein function rather than non-essential neighbouring sequences. This is especially important when considering homologous sequences from distantly related organisms.

Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present document it is preferred to express homology in terms of sequence identity.

Homology comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These publicly and commercially available computer programs can calculate % homology between two or more sequences.

% homology may be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid in one sequence directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is

called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues (for example less than 50 contiguous amino acids).

Although this is a very simple and consistent method, it fails to take into
5 consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion will cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in % homology when a global alignment is performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into consideration possible insertions and deletions without
10 penalising unduly the overall homology score. This is achieved by inserting "gaps" in the sequence alignment to try to maximise local homology.

However, these more complex methods assign "gap penalties" to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence alignment with as few gaps as possible - reflecting higher relatedness between the two
15 compared sequences - will achieve a higher score than one with many gaps. "Affine gap costs" are typically used that charge a relatively high cost for the existence of a gap and a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties will of course produce optimised alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, it
20 is preferred to use the default values when using such software for sequence comparisons. For example when using the GCG Wisconsin Bestfit package (see below) the default gap penalty for amino acid sequences is -12 for a gap and -4 for each extension.

Calculation of maximum % homology therefore firstly requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer
25 program for carrying out such an alignment is the GCG Wisconsin Bestfit package (University of Wisconsin, U.S.A; Devereux *et al.*, 1984, Nucleic Acids Research 12:387). Examples of other software than can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel *et al.*, 1999 *ibid* - Chapter 18), FASTA

(Atschul *et al.*, 1990, J. Mol. Biol., 403-410) and the GENWORKS suite of comparison tools. Both BLAST and FASTA are available for offline and online searching (see Ausubel *et al.*, 1999 *ibid*, pages 7-58 to 7-60). However it is preferred to use the GCG Bestfit program.

5 Although the final % homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite of
10 programs. GCG Wisconsin programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for further details). It is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix, such as BLOSUM62.

 Advantageously, the BLAST algorithm is employed, with parameters set to default
15 values. The BLAST algorithm is described in detail at http://www.ncbi.nih.gov/BLAST/blast_help.html, which is incorporated herein by reference. The search parameters are defined as follows, can be advantageously set to the defined default parameters.

 Advantageously, "substantial identity" when assessed by BLAST equates to
20 sequences which match with an EXPECT value of at least about 7, preferably at least about 9 and most preferably 10 or more. The default threshold for EXPECT in BLAST searching is usually 10.

 BLAST (Basic Local Alignment Search Tool) is the heuristic search algorithm employed by the programs blastp, blastn, blastx, tblastn, and tblastx; these programs
25 ascribe significance to their findings using the statistical methods of Karlin and Altschul (Karlin and Altschul 1990, *Proc. Natl. Acad. Sci. USA* 87:2264-68; Karlin and Altschul, 1993, *Proc. Natl. Acad. Sci. USA* 90:5873-7; see

http://www.ncbi.nih.gov/BLAST/blast_help.html) with a few enhancements. The BLAST programs are tailored for sequence similarity searching, for example to identify homologues to a query sequence. For a discussion of basic issues in similarity searching of sequence databases, see Altschul *et al* (1994) Nature Genetics 6:119-129.

- 5 The five BLAST programs available at <http://www.ncbi.nlm.nih.gov> perform the following tasks: **blastp** - compares an amino acid query sequence against a protein sequence database; **blastn** - compares a nucleotide query sequence against a nucleotide sequence database; **blastx** - compares the six-frame conceptual translation products of a nucleotide query sequence (both strands) against a protein sequence database; **tblastn** -
10 compares a protein query sequence against a nucleotide sequence database dynamically translated in all six reading frames (both strands); **tblastx** - compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.

BLAST uses the following search parameters:

- 15 **HISTOGRAM** - Display a histogram of scores for each search; default is yes. (See parameter H in the BLAST Manual).

DESCRIPTIONS - Restricts the number of short descriptions of matching sequences reported to the number specified; default limit is 100 descriptions. (See parameter V in the manual page).

- 20 **EXPECT** - The statistical significance threshold for reporting matches against database sequences; the default value is 10, such that 10 matches are expected to be found merely by chance, according to the stochastic model of Karlin and Altschul (1990). If the statistical significance ascribed to a match is greater than the EXPECT threshold, the match will not be reported. Lower EXPECT thresholds are more stringent, leading to
25 fewer chance matches being reported. Fractional values are acceptable. (See parameter E in the BLAST Manual).

CUTOFF - Cutoff score for reporting high-scoring segment pairs. The default value is calculated from the EXPECT value (see above). HSPs are reported for a database sequence only if the statistical significance ascribed to them is at least as high as would be ascribed to a lone HSP having a score equal to the CUTOFF value. Higher CUTOFF values are more stringent, leading to fewer chance matches being reported. (See parameter S in the BLAST Manual). Typically, significance thresholds can be more intuitively managed using EXPECT.

ALIGNMENTS - Restricts database sequences to the number specified for which high-scoring segment pairs (HSPs) are reported; the default limit is 50. If more database sequences than this happen to satisfy the statistical significance threshold for reporting (see EXPECT and CUTOFF below), only the matches ascribed the greatest statistical significance are reported. (See parameter B in the BLAST Manual).

MATRIX - Specify an alternate scoring matrix for BLASTP, BLASTX, TBLASTN and TBLASTX. The default matrix is BLOSUM62 (Henikoff & Henikoff, 1992). The valid alternative choices include: PAM40, PAM120, PAM250 and IDENTITY. No alternate scoring matrices are available for BLASTN; specifying the MATRIX directive in BLASTN requests returns an error response.

STRAND - Restrict a TBLASTN search to just the top or bottom strand of the database sequences; or restrict a BLASTN, BLASTX or TBLASTX search to just reading frames on the top or bottom strand of the query sequence.

FILTER - Mask off segments of the query sequence that have low compositional complexity, as determined by the SEG program of Wootton & Federhen (1993) Computers and Chemistry 17:149-163, or segments consisting of short-periodicity internal repeats, as determined by the XNU program of Claverie & States (1993) Computers and Chemistry 17:191-201, or, for BLASTN, by the DUST program of Tatusov and Lipman (see <http://www.ncbi.nlm.nih.gov>). Filtering can eliminate statistically significant but biologically uninteresting reports from the blast output (e.g., hits against common acidic-

basic- or proline-rich regions), leaving the more biologically interesting regions of the query sequence available for specific matching against database sequences.

Low complexity sequence found by a filter program is substituted using the letter "N" in nucleotide sequence (e.g., "NNNNNNNNNNNNNN") and the letter "X" in protein sequences (e.g., "XXXXXXXXXX").

Filtering is only applied to the query sequence (or its translation products), not to database sequences. Default filtering is DUST for BLASTN, SEG for other programs.

It is not unusual for nothing at all to be masked by SEG, XNU, or both, when applied to sequences in SWISS-PROT, so filtering should not be expected to always yield an effect. Furthermore, in some cases, sequences are masked in their entirety, indicating that the statistical significance of any matches reported against the unfiltered query sequence should be suspect.

NCBI-gi - Causes NCBI gi identifiers to be shown in the output, in addition to the accession and/or locus name.

Most preferably, sequence comparisons are conducted using the simple BLAST search algorithm provided at <http://www.ncbi.nlm.nih.gov/BLAST>. In some embodiments, no gap penalties are used when determining sequence identity.

Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.

Variants and Derivatives

The terms "variant" or "derivative" in relation to the amino acid sequences disclosed here includes any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acids from or to the sequence providing the

resultant amino acid sequence retains substantially the same activity as the unmodified sequence. Preferably, the modified sequence has at least one biological activity as the unmodified sequence, preferably all the biological activities of the unmodified sequence. Preferably, the "variant" or "derivative" has at least one biological activity of native Fve,
5 as described above.

Polypeptides having the amino acid sequence shown in the description and Examples, or fragments or homologues thereof may be modified for use in the methods and compositions described here. Typically, modifications are made that maintain the biological activity of the sequence. Amino acid substitutions may be made, for example
10 from 1, 2 or 3 to 10, 20 or 30 substitutions provided that the modified sequence retains the biological activity of the unmodified sequence. Alternatively, modifications may be made to deliberately inactivate one or more functional domains of the polypeptides described here. Functional domains of native Fve include the α helix at the N terminus, any of the six β helices, as well as the "loop-like" structures at the N and C termini. Preferably, the
15 functional domain of native Fve comprises the N-terminus helix and the loop/strand, which are essential for protein dimerization.

Amino acid substitutions may include the use of non-naturally occurring analogues, for example to increase blood plasma half-life of a therapeutically administered polypeptide.

20 Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

ALIPHATIC	Non-polar	G A P
		I L V
	Polar - uncharged	C S T M
		N Q
	Polar - charged	D E
		K R
AROMATIC		H F W Y

Polypeptides also include fragments of the full length sequence of native Fve, or any of the Fve polypeptides disclosed here. Preferably fragments comprise at least one epitope. Methods of identifying epitopes are well known in the art. Fragments will typically comprise at least 6 amino acids, more preferably at least 10, 20, 30, 50 or 100 amino acids.

Fve polypeptides, fragments, homologues, variants and derivatives, are typically made by recombinant means, for example as described below in the Examples. However they may also be made by synthetic means using techniques well known to skilled persons such as solid phase synthesis. The proteins may also be produced as fusion proteins, for example to aid in extraction and purification. Examples of fusion protein partners include glutathione-S-transferase (GST), 6xHis, GAL4 (DNA binding and/or transcriptional activation domains) and β -galactosidase. It may also be convenient to include a proteolytic cleavage site between the fusion protein partner and the protein sequence of interest to allow removal of fusion protein sequences. Preferably the fusion protein will not hinder the function of the protein of interest sequence. Proteins may also be obtained by purification of cell extracts from animal cells.

The Fve polypeptides, variants, homologues, fragments and derivatives disclosed here may be in a substantially isolated form. It will be understood that such polypeptides may be mixed with carriers or diluents which will not interfere with the intended purpose of the protein and still be regarded as substantially isolated. A Fve variant, homologue, fragment or derivative may also be in a substantially purified form, in which case it will

generally comprise the protein in a preparation in which more than 90%, e.g. 95%, 98% or 99% of the protein in the preparation is a protein.

The Fve polypeptides, variants, homologues, fragments and derivatives disclosed here may be labelled with a revealing label. The revealing label may be any suitable label which allows the polypeptide, etc to be detected. Suitable labels include radioisotopes, e.g. ¹²⁵I, enzymes, antibodies, polynucleotides and linkers such as biotin. Labelled polypeptides may be used in diagnostic procedures such as immunoassays to determine the amount of a polypeptide in a sample. Polypeptides or labelled polypeptides may also be used in serological or cell-mediated immune assays for the detection of immune reactivity to said polypeptides in animals and humans using standard protocols.

A Fve polypeptide, variant, homologue, fragment or derivative disclosed here, optionally labelled, may also be fixed to a solid phase, for example the surface of an immunoassay well or dipstick. Such labelled and/or immobilised polypeptides may be packaged into kits in a suitable container along with suitable reagents, controls, instructions and the like. Such polypeptides and kits may be used in methods of detection of antibodies to the polypeptides or their allelic or species variants by immunoassay.

Immunoassay methods are well known in the art and will generally comprise: (a) providing a polypeptide comprising an epitope bindable by an antibody against said protein; (b) incubating a biological sample with said polypeptide under conditions which allow for the formation of an antibody-antigen complex; and (c) determining whether antibody-antigen complex comprising said polypeptide is formed.

The Fve polypeptides, variants, homologues, fragments and derivatives disclosed here may be used in *in vitro* or *in vivo* cell culture systems to study the role of their corresponding genes and homologues thereof in cell function, including their function in disease. For example, truncated or modified polypeptides may be introduced into a cell to disrupt the normal functions which occur in the cell. The polypeptides may be introduced into the cell by *in situ* expression of the polypeptide from a recombinant expression vector

(see below). The expression vector optionally carries an inducible promoter to control the expression of the polypeptide.

The use of appropriate host cells, such as insect cells or mammalian cells, is expected to provide for such post-translational modifications (e.g. myristolation, glycosylation, truncation, lapidation and tyrosine, serine or threonine phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products. Such cell culture systems in which the Fve polypeptides, variants, homologues, fragments and derivatives disclosed here are expressed may be used in assay systems to identify candidate substances which interfere with or enhance the functions of the polypeptides in the cell.

IMMUNOMODULATOR-ANTIGEN COMBINATIONS AND CONJUGATES

We show throughout this document (for the first time) that Fve has immunomodulatory properties, and in particular can act to potentiate an immune response. The adjuvant property of Fve may be exploited by administering Fve polypeptide or nucleic acid (or a fragment, homologue, variant or derivative thereof, or a host cell or vector comprising such) as described below, along with a molecule to which an immune response is desired.

The Fve polypeptide, etc may be administered to an individual either in combination, sequentially or simultaneously or in succession with the molecule to which an immune response is desired. We therefore provide for the first time a combination of a Fve polypeptide, etc with an antigenic molecule.

Where the Fve polypeptide, etc and the molecule are administered in combination, this may be achieved by administering a mixture of the Fve polypeptide, etc and the molecule. We therefore provide a simple combination of the Fve polypeptide, etc and the molecule, preferably as a kit. The kit may comprise the Fve polypeptide, etc and the

molecule to which an immune response is desired in separate containers, and may optionally comprise instructions to administer these simultaneously, sequentially, etc.

The molecule to which an immune response is desired may comprise an allergen. These are set out in further detail in the following section.

5 The molecule to which an immune response is desired may comprise a tumour associated antigen. In preferred embodiments, the tumour associated antigen comprises MAGE-1, MAGE-2, MAGE-3, BAGE, GAGE, PRAME, SSX-2, Tyrosinase, MART-1, NY-ESO-1, gp100, TRP-1, TRP-2, A2 melanotope, BCR/ABL, Proteinase-
3/Myeloblastin, HER2/neu, CEA, P1A, HK2, PAPA, PSA, PSCA, PSMA, pg75, MUM-1,
10 MUC-1, BTA, GnT-V, β -catenin, CDK4, or P15. Nucleic acid and amino acid sequences of these antigens are known in the art, and the skilled person will know how to produce tumour associated antigens, including those set out above. We therefore disclose combinations, preferably in the form of kits, comprising an Fve polypeptide or nucleic acid (or a fragment, homologue, variant or derivative thereof, or a host cell or vector
15 comprising such), together with a tumour associated antigen, for example as set out above.

 The molecule to which an immune response is desired may comprise a viral antigen. In preferred embodiments, the viral antigen comprises a protein from an oncogenic virus; such viruses are known in the art. Preferably the oncogenic viral antigen comprises E6 and E7 from HPV; core Ag and E2 from HCV; core and surface antigens
20 from HBV; LMP-1, LMP-2, EBNA-2, EBNA-3 from EBV; or Tax from HTLV-1.

 In a further embodiment, the viral antigen comprises an antigen, preferably a protein, more preferably an antigenic protein or fragment thereof from an infectious virus. Such immunomodulator-viral antigen conjugates may be used to treat or prevent a viral infectious disease, i.e., the cognate disease. For example, an immunomodulator-HSV
25 antigen conjugate, for example, a Fve polypeptide-HSV antigen conjugate, may be used to treat or prevent Herpes Simplex Virus infection. Other preferred viral antigens include those from Adenovirus, Parainfluenza 3 virus, Human Immunodeficiency Virus (HIV),

Herpes simplex virus, HSV, Respiratory syncytial virus, RSV, and Influenza A, Flu A. These viruses, and the diseases they cause, are well known in the art, and methods for making and purifying antigens from such viruses are also well known. For example, US Patent Number 4,313,927 (Fridlender) discloses detailed protocols for preparation of
5 rubella and Cytomegalovirus (CMV) antigen.

Nucleic acid and amino acid sequences of these viral antigens are known in the art, and the skilled person will know how to produce viral antigen antigens, including these set out above. We therefore disclose combinations, preferably in the form of kits, comprising an Fve polypeptide or nucleic acid (or a fragment, homologue, variant or derivative
10 thereof, or a host cell or vector comprising such), together with a viral antigen, for example as set out above.

In preferred embodiments, we provide administration of the Fve polypeptide, etc and the molecule to which an immune response is desired, in which there is some degree of association between the Fve polypeptide, etc and the molecule in question.

15 We therefore disclose for the first time an an agent which comprises an immunomodulator coupled, fused, mixed, combined, or otherwise joined to an allergen. Such a construct is referred to as a "immunomodulator-allergen conjugate" in this document. In particular, we disclose the use of Fve adjuvanted allergen vaccines, as explained in further detail in Examples 13 and 14.

20 The coupling, etc between the immunomodulator and the allergen may be permanent or transient, and may involve covalent or non-covalent interactions (including ionic interactions, hydrophobic forces, Van der Waals interactions, etc). The exact mode of coupling is not important, so long as the immunomodulator-allergen conjugate. Accordingly, where reference is made to "comprising", "conjugation", "coupling", etc,
25 these references should be taken to include any form of interaction between the immunomodulator and the allergen.

Thus, the immunomodulator may be a polypeptide which is provided as a fusion protein with the allergen, for example as shown in Example 13 for Fve/Allergen. An expression vector may be constructed by standard recombinant DNA technology to include a nucleotide sequence capable of expressing a immunomodulator, such that a fusion protein is expressed comprising the allergen of interest fused to the immunomodulator. The expression vector is transfected or transformed into a suitable host for large scale production of fusion protein, by means known in the art. Purification of the fusion protein may also be carried out by known means. Alternatively, or in addition, and as discussed above, the allergen may be physically associated with the immunomodulator, and attached to it by chemical conjugation. Thus, Example 14 below describes the use of allergen physically conjugated to Fve.

In preferred embodiments, the immunomodulator-allergen conjugate is capable of at least one of the following, preferably two or more, more preferably all: increase the number of human PBMC, to stimulate the proliferation of human lymphocytes, to polarize human CD8⁺ T cells, and to increase the production of IFN- γ (Th1 response) and IL-10 (Tr response). Preferably, the immunomodulator-allergen conjugate is capable of inducing both Th1 and Tr immune responses. Preferably, the Th1 response inhibits the development of Th2 cells via IFN- γ , more preferably it is capable of inducing a life-long (or substantially long lasting) protective Th1 memory immune response. Allergen specific Tr cells may in turn dampen the anti-allergic Th1 immune response, ensuring a well-balanced protective but nonpathological Th1 response. Allergen-Fve fusion proteins meet these criteria since they induce cytokine IL-10, and these are therefore preferred.

Where the conjugate comprises Fve, the Fve portion of the conjugate may comprise the whole molecule, or fragments of it. It may for example comprise the native Fve, or any Fve polypeptide as disclosed above. The allergen portion may comprise any allergen, whether proteinaceous or not. Advantageously, proteinaceous allergens are conjugated to the immunomodulator portion by means of covalent bonds, for example, amide bonds (for example, as a fusion protein).

The allergen may comprise for example the whole or a portion of Blo t 5 or Der p 2 allergen. In highly preferred embodiments, the immunomodulator-allergen conjugate comprises Bt5-Fve, Bt5-FveR27 or GST-Dp2-FveR27. Examples of other allergens suitable for use in the immunomodulator-allergen conjugate described here are provided
5 below.

Furthermore, protein-protein conjugation also provides a convenient and alternative choice to develop allergen vaccine. Any suitable means of conjugation, for example, chemical conjugation may be used to couple the immunomodulator and the allergen. Cross-linkers, for example, heterobifunctional cross linkers are known in the art,
10 and may be used. Furthermore, other conjugation agents, for example, poly-lactic acid (PLA) and polyethylene glycol (PEG) may also be employed.

ALLERGENS

In general, the allergen from which an immunomodulator-allergen conjugate may be constructed may come from any source, for example, a source known to induce
15 allergenic responses in humans. For example, the allergen may comprise a tree pollen allergen, a grass pollen allergen, a weed pollen allergen, a feline antigen, or a fungal allergen. Thus, the allergen may comprise a tree pollen allergen, for example Bet v 1 and Bet v 2 from birch tree. It may comprise a grass pollen allergen, for example, Phl p 1 and Phl p 2 from timothy grass. It may comprise a weed pollen allergen, for example, antigen
20 E from ragweed. It may comprise a major feline antigen, for example, Fel d 1. It may comprise a major fungal allergen, for example, Asp f1, Asp f2, and Asp f3 from *Aspergillus fumigatus*.

In preferred embodiments, the allergen comprises a dust mite allergen, preferably a house dust mite allergen. In particular, the allergen is preferably derived from a mite from
25 Family Glycyphagidae or Family Pyroglyphidae. Dust mites of Family Glycyphagidae include those in the genera Aeroglyphus, Austroglycyphagus, Blomia, Ctenoglyphus, Glycyphagus, Gohieria, Lepidoglyphus. Dust mites of Family Pyroglyphidae include those

in the genera Dermatophagoides, Euroglyphus, Pyroglyphus. In preferred embodiments, the allergen is preferably an allergen from a species in any of these genera.

In highly preferred embodiments, the allergen is a group 1 allergen (Der p 1, Der f 1, Blo t 1, Eur m 1, Lep d 1), a group 2 allergen (Der p 2, Der f 2, Blo t 2, Eur m 2, Lep d 2), a group 5 allergen (Blo t 5, Der p 5, Der f 5, Eur m 5, Lep d 5) or a group 15 allergen (Der p 15, Der f 15, Blo t 15, Eur m 15, Lep d 15) from dust mite. Nucleic acid and amino acid sequences of these allergens are known in the art, and the skilled person will know how to produce allergen-immunomodulator conjugates from any of these allergens using such sequences.

10 OTHER IMMUNOMODULATOR CONJUGATES

Immunomodulator-Tumour Associated Antigen Conjugates

We also disclose for the first time an agent which comprises an immunomodulator coupled, fused, mixed, combined, or otherwise joined to an tumour associated antigen. Such a construct is referred to as a "immunomodulator-tumour associated antigen conjugate" in this document.

As the term is used here, "tumour associated antigen" generally includes a cancer protein or a cancer antigen, i.e., a protein which is preferentially expressed in a tumour cell or a transformed cell, compared to a "normal" non-cancerous cell.

In highly preferred embodiments, the tumour associated antigen may comprise
20 MAGE-1, MAGE-2, MAGE-3, BAGE, GAGE, PRAME, SSX-2, Tyrosinase, MART-1, NY-ESO-1, gp100, TRP-1, TRP-2, A2 melanotope, BCR/ABL, Proteinase-3/Myeloblastin, HER2/neu, CEA, P1A, HK2, PAPA, PSA, PSCA, PSMA, pg75, MUM-1, MUC-1, BTA, GnT-V, β -catenin, CDK4, or P15. Nucleic acid and amino acid sequences of these antigens are known in the art, and the skilled person will know how to produce
25 tumour associated antigen-immunomodulator conjugates from any of these allergens using such sequences.

We present in **Appendix A** the sequences of MAGE3-FveT29A, MART1-FveT29A and CEA-FveT29A, which are preferred Immunomodulator-Tumour Associated Antigen Conjugates suitable for use in the methods and compositions described here.

Immunomodulator-Viral Antigen Conjugates

5 We further disclose an agent comprising an immunodulator coupled, etc to a viral antigen. In highly preferred embodiments, the viral antigen comprises a protein from an oncogenic virus; such viruses are known in the art. Preferably the oncogenic viral antigen comprises E6 and E7 from HPV; core Ag and E2 from HCV; core and surface antigens from HBV; LMP-1, LMP-2, EBNA-2, EBNA-3 from EBV; or Tax from HTLV-1. Nucleic
10 acid and amino acid sequences of these viral antigens are known in the art, and the skilled person will know how to produce viral antigen-immunomodulator conjugates from any of these allergens using such sequences.

 We also provide an agent (for example a polypeptide) comprising a first portion comprising at least a portion of Fve and a second portion comprising at least a portion of a
15 viral antigen, preferably coupled together. The viral antigen may be selected from the group consisting of antigens from Adenovirus, Parainfluenza 3 virus, Herpes simplex virus, HSV, Respiratory syncytial virus, RSV, and Influenza A, Flu A.

 The viral antigen may comprise any portion of the native viral antigen, for example, a portion of the HCV core antigen. We have established that a deletion of the
20 HCV core antigen, particularly a deletion of 23 amino acids from residues 141 to 163 of the core antigen leads to an increase in efficiency of protein production. Accordingly, we provide an agent comprising an immunodulator coupled, etc to a viral antigen, which viral antigen comprises such a deleted core antigen (here referred to as "Core23"), e.g., the fusion protein HCV Core23-FveT29A.

25 In particular, we find that the polypeptides HCV Core23-FveT29A and HPV E7-FveT29A (the sequences of which are shown in **Appendix A**) are particularly useful as Immunomodulator-Viral Antigen conjugates.

The coupling, etc between the immunomodulator and the tumour associated antigen, and the viral antigen, may be as described above for the immunomodulator-allergen conjugate.

FVE NUCLEIC ACIDS

5 We provide for a nucleic acid encoding a Fve polypeptide, which we refer to as a "Fve nucleic acid". We also provide nucleic acids encoding variants, homologues, derivatives and fragments of native Fve, as well as fragments, homologues, derivatives and variants of Fve nucleic acids.

10 Preferably, the Fve nucleic acid is derived from a natural or native Fve sequence, for example, the nucleic sequence shown as "Fve (Wild type)" in **Appendix A**. In a preferred embodiment, the Fve nucleic acid is a recombinant fragment of native Fve nucleic acid, or any fragment, homologue, variant or derivative thereof. Fragments, homologues, variants and derivatives of each of the above sequences are also included.

15 "Fve nucleic acids" preferably encode polypeptides which have at least one biological activity of native Fve, as described above. Preferably, Fve nucleic acids encode polypeptides which comprise two or more biological activities of native Fve, preferably substantially all the biological activities of native Fve.

20 In preferred embodiments, the Fve nucleic acids encode polypeptides which comprise at least one, two or all three of the RGT residues (or a functional variant as defined above, such as RGD) at or about a position corresponding to position 28 of the native Fve polypeptide. In particular, the Fve nucleic acid may comprise the sequence CGTGGTACC. Alternatively, the Fve nucleic acid may comprise the sequence CGTGGTGAT or the sequence CGTGGTGAC. The Fve nucleic acid may comprise a nucleotide sequence which encodes the same amino acids as a result of the redundancy of
25 the genetic code.

The Fve nucleic acid may comprise a sequence comprising three codons, with a first codon selected from the group consisting of: CGT, CGC, CGA, CGG, AGA and AGG, a second codon selected from the group consisting of: GGT, GGC, GGA and GGG, and a third codon selected from the group consisting of: ACT, ACC, ACA and ACG.

- 5 Alternatively, the third codon may be selected from the group consisting of: GAT and GAC,

Preferably, the Fve polypeptide comprises between 2 to 60 residues of nucleic acid sequence flanking the codon for the glycine residue corresponding to position 28 of native Fve.

- 10 In preferred embodiments, Fve nucleic acids may comprise nucleic acids encoding fragments of native Fve. For example, Fve nucleic acids may comprise the nucleic acid sequences depicted in **Appendix A** as Fve D6-18, Fve D19-33, Fve D34-46, Fve D47-60, Fve D61-72, Fve D73-84, Fve D85-97, Fve D98-106, Fve D107-115, Fve D61-97, and Fvep55-100. Nucleic acids encoding fusion proteins comprising these deletion fragments and GST are also disclosed. Fve nucleic acids may comprise those encoding substitutions, including FveR27A, FveG28A and FveT29A. Fve nucleic acids include those which encode the polypeptide sequences shown in **Appendix A**.
- 15

- We also disclose Fve nucleic acids which encode Fve polypeptides comprising fusion proteins, particularly fusion proteins between an allergen and a Fve polypeptide as defined here. We disclose in particular nucleic acid sequences of Blo t 5-Fve(two-in-one chimeric wild type), Blo t 5-FveR27A (two-in-one chimeric mutant), Blo t 5-FveT29A (two-in-one chimeric mutant), Der p 2-FveR27A (two-in-one chimeric mutant), Der p 2-FveT29A (two-in-one chimeric mutant) and Blo t 5-Der p 2-FveR27A (three-in-one chimeric mutant), and shown in **Appendix A**.
- 20

- 25 As used here in this document, the terms "polynucleotide", "nucleotide", and nucleic acid are intended to be synonymous with each other. "Polynucleotide" generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified

RNA or DNA or modified RNA or DNA. "Polynucleotides" include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications has been made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

It will be understood by a skilled person that numerous different polynucleotides and nucleic acids can encode the same polypeptide as a result of the degeneracy of the genetic code. In addition, it is to be understood that skilled persons may, using routine techniques, make nucleotide substitutions that do not affect the polypeptide sequence encoded by the polynucleotides described here to reflect the codon usage of any particular host organism in which the polypeptides are to be expressed.

Five nucleic acids, variants, fragments, derivatives and homologues may comprise DNA or RNA. They may be single-stranded or double-stranded. They may also be polynucleotides which include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of this document, it is to be understood that the polynucleotides may be modified by any method available in the art. Such modifications may be carried out in order to enhance the *in vivo* activity or life span of polynucleotides of interest.

The terms "variant", "homologue" or "derivative" in relation to a nucleotide sequence include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence. Preferably said variant, homologues or derivatives code for a polypeptide having biological activity.

5 As indicated above, with respect to sequence homology, preferably there is at least 50 or 75%, more preferably at least 85%, more preferably at least 90% homology to the sequences shown in the sequence listing herein. More preferably there is at least 95%, more preferably at least 98%, homology. Nucleotide homology comparisons may be conducted as described above. A preferred sequence comparison program is the GCG
10 Wisconsin Bestfit program described above. The default scoring matrix has a match value of 10 for each identical nucleotide and -9 for each mismatch. The default gap creation penalty is -50 and the default gap extension penalty is -3 for each nucleotide.

We further describe nucleotide sequences that are capable of hybridising selectively to the sequences presented herein, or any variant, fragment or derivative
15 thereof, or to the complement of any of the above. Nucleotide sequences are preferably at least 15 nucleotides in length, more preferably at least 20, 30, 40 or 50 nucleotides in length.

The term "hybridization" as used herein shall include "the process by which a strand of nucleic acid joins with a complementary strand through base pairing" as well as
20 the process of amplification as carried out in polymerase chain reaction technologies.

Polynucleotides capable of selectively hybridising to the nucleotide sequences presented herein, or to their complement, will be generally at least 70%, preferably at least 80 or 90% and more preferably at least 95% or 98% homologous to the corresponding nucleotide sequences presented herein over a region of at least 20, preferably at least 25 or
25 30, for instance at least 40, 60 or 100 or more contiguous nucleotides.

The term "selectively hybridizable" means that the polynucleotide used as a probe is used under conditions where a target polynucleotide is found to hybridize to the probe at a level significantly above background. The background hybridization may occur because of other polynucleotides present, for example, in the cDNA or genomic DNA library being
5 screening. In this event, background implies a level of signal generated by interaction between the probe and a non-specific DNA member of the library which is less than 10 fold, preferably less than 100 fold as intense as the specific interaction observed with the target DNA. The intensity of interaction may be measured, for example, by radiolabelling the probe, e.g. with ^{32}P .

10 Hybridization conditions are based on the melting temperature (T_m) of the nucleic acid binding complex, as taught in Berger and Kimmel (1987, Guide to Molecular Cloning Techniques, Methods in Enzymology, Vol 152, Academic Press, San Diego CA), and confer a defined "stringency" as explained below.

Maximum stringency typically occurs at about $T_m - 5^\circ\text{C}$ (5°C below the T_m of the
15 probe); high stringency at about 5°C to 10°C below T_m ; intermediate stringency at about 10°C to 20°C below T_m ; and low stringency at about 20°C to 25°C below T_m . As will be understood by those of skill in the art, a maximum stringency hybridization can be used to identify or detect identical polynucleotide sequences while an intermediate (or low) stringency hybridization can be used to identify or detect similar or related polynucleotide
20 sequences.

In a preferred aspect, we provide nucleotide sequences that can hybridise to the Fve nucleic acids, fragments, variants, homologues or derivatives disclosed here under stringent conditions (e.g. 65°C and $0.1\times\text{SSC}$ ($1\times\text{SSC} = 0.15\text{ M NaCl}, 0.015\text{ M Na}_3\text{ Citrate pH } 7.0$)).

Where the polynucleotide is double-stranded, both strands of the duplex, either
25 individually or in combination, are encompassed by the methods and compositions described here. Where the polynucleotide is single-stranded, it is to be understood that the complementary sequence of that polynucleotide is also included.

Polynucleotides which are not 100% homologous to the Fve sequences disclosed here but which are also included can be obtained in a number of ways. Other variants of the sequences may be obtained for example by probing DNA libraries made from a range of individuals, for example individuals from different populations. For example, Fve
5 homologues may be identified from other individuals, or other species. Further recombinant Fve nucleic acids and polypeptides may be produced by identifying corresponding positions in the homologues, and synthesising or producing the molecule as described elsewhere in this document. Furthermore, the collagen region, neck region and carbohydrate binding domain in such homologues may be identified, for example, by
10 sequence gazing or computer assisted comparisons, and selected for combination into or production of a recombinant Fve which has one or more biological activities of native Fve.

In addition, other viral/bacterial, or cellular homologues of Fve particularly cellular homologues found in mammalian cells (e.g. rat, mouse, bovine and primate cells), may be obtained and such homologues and fragments thereof in general will be capable of
15 selectively hybridising to Fve. Such homologues may be used to design non-human Fve nucleic acids, fragments, variants and homologues. Mutagenesis may be carried out by means known in the art to produce further variety.

Sequences of Fve homologues may be obtained by probing cDNA libraries made from or genomic DNA libraries from other animal or non-animal species, particularly
20 microbial or fungal species, and probing such libraries with probes comprising all or part of any of the Fve nucleic acids, fragments, variants and homologues, or other fragments of Fve under conditions of medium to high stringency.

Similar considerations apply to obtaining species homologues and allelic variants of the polypeptide or nucleotide sequences disclosed here.

25 Variants and strain/species homologues may also be obtained using degenerate PCR which will use primers designed to target sequences within the variants and homologues encoding conserved amino acid sequences within the sequences of the Fve

nucleic acids. Conserved sequences can be predicted, for example, by aligning the amino acid sequences from several variants/homologues. Sequence alignments can be performed using computer software known in the art. For example the GCG Wisconsin FileUp program is widely used.

- 5 The primers used in degenerate PCR will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences. It will be appreciated by the skilled person that overall nucleotide homology between sequences from distantly related organisms is likely to be very low and thus in these situations degenerate PCR may be the
10 method of choice rather than screening libraries with labelled fragments the Fve sequences.

In addition, homologous sequences may be identified by searching nucleotide and/or protein databases using search algorithms such as the BLAST suite of programs.

- Alternatively, such polynucleotides may be obtained by site directed mutagenesis
15 of characterised sequences, for example, Fve nucleic acids, or variants, homologues, derivatives or fragments thereof. This may be useful where for example silent codon changes are required to sequences to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequence changes may be desired in order to introduce restriction enzyme recognition sites, or to alter the property
20 or function of the polypeptides encoded by the polynucleotides.

- The polynucleotides described here may be used to produce a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labelled with a revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors. Such primers, probes and other fragments will
25 be at least 8, 9, 10, or 15, preferably at least 20, for example at least 25, 30 or 40 nucleotides in length, and are also encompassed by the term "polynucleotides" as used herein.

Polynucleotides such as a DNA polynucleotides and probes may be produced recombinantly, synthetically, or by any means available to those of skill in the art. They may also be cloned by standard techniques.

5 In general, primers will be produced by synthetic means, involving a step wise manufacture of the desired nucleic acid sequence one nucleotide at a time. Techniques for accomplishing this using automated techniques are readily available in the art.

10 Longer polynucleotides will generally be produced using recombinant means, for example using a PCR (polymerase chain reaction) cloning techniques. This will involve making a pair of primers (e.g. of about 15 to 30 nucleotides) flanking a region of the lipid targeting sequence which it is desired to clone, bringing the primers into contact with mRNA or cDNA obtained from an animal or human cell, performing a polymerase chain reaction under conditions which bring about amplification of the desired region, isolating the amplified fragment (e.g. by purifying the reaction mixture on an agarose gel) and recovering the amplified DNA. The primers may be designed to contain suitable restriction enzyme recognition sites so that the amplified DNA can be cloned into a suitable cloning vector

20 Polynucleotides or primers may carry a revealing label. Suitable labels include radioisotopes such as ^{32}P or ^{35}S , enzyme labels, or other protein labels such as biotin. Such labels may be added to polynucleotides or primers and may be detected using by techniques known *per se*. Polynucleotides or primers or fragments thereof labelled or unlabeled may be used by a person skilled in the art in nucleic acid-based tests for detecting or sequencing polynucleotides in the human or animal body.

25 Such tests for detecting generally comprise bringing a biological sample containing DNA or RNA into contact with a probe comprising a polynucleotide or primer under hybridising conditions and detecting any duplex formed between the probe and nucleic acid in the sample. Such detection may be achieved using techniques such as PCR or by immobilising the probe on a solid support, removing nucleic acid in the sample which is

not hybridised to the probe, and then detecting nucleic acid which has hybridised to the probe. Alternatively, the sample nucleic acid may be immobilised on a solid support, and the amount of probe bound to such a support can be detected. Suitable assay methods of this and other formats can be found in for example WO89/03891 and WO90/13667.

5 Tests for sequencing nucleotides, for example, the Fve nucleic acids, involve bringing a biological sample containing target DNA or RNA into contact with a probe comprising a polynucleotide or primer under hybridising conditions and determining the sequence by, for example the Sanger dideoxy chain termination method (see Sambrook *et al.*).

10 Such a method generally comprises elongating, in the presence of suitable reagents, the primer by synthesis of a strand complementary to the target DNA or RNA and selectively terminating the elongation reaction at one or more of an A, C, G or T/U residue; allowing strand elongation and termination reaction to occur; separating out according to size the elongated products to determine the sequence of the nucleotides at
15 which selective termination has occurred. Suitable reagents include a DNA polymerase enzyme, the deoxynucleotides dATP, dCTP, dGTP and dTTP, a buffer and ATP. Dideoxynucleotides are used for selective termination.

PROTEIN EXPRESSION AND PURIFICATION

Host cells comprising polynucleotides may be used to express polypeptides, such
20 as Fve polypeptides, fragments, homologues, variants or derivatives thereof. Host cells may be cultured under suitable conditions which allow expression of the proteins. Expression of the polypeptides may be constitutive such that they are continually produced, or inducible, requiring a stimulus to initiate expression. In the case of inducible expression, protein production can be initiated when required by, for example, addition of
25 an inducer substance to the culture medium, for example dexamethasone or IPTG.

Polypeptides can be extracted from host cells by a variety of techniques known in the art, including enzymatic, chemical and/or osmotic lysis and physical disruption.

Polypeptides may also be produced recombinantly in an *in vitro* cell-free system, such as the TnT™ (Promega) rabbit reticulocyte system.

5 FVE NUCLEIC ACID MOLECULES

We disclose a nucleic molecule that: a) has a strand that encodes an Fve polypeptide disclosed here, b) has a strand that is complementary with a strand as described in a) above; or c) has a strand that hybridises with a molecule as described in a) or b) above.

10 Unless the context indicates otherwise, such nucleic acid molecules, which are included within the term "Fve nucleic acid molecule" may have one or more of the following characteristics:

1) They may be DNA or RNA (including variants of naturally occurring DNA or RNA structures, which have non-naturally occurring bases and/or non-naturally occurring
15 backbones).

2) They may be single-stranded or double-stranded (or in some cases higher stranded, e.g. triple- stranded).

3) They may be provided in recombinant form i.e. covalently linked to a heterologous 5' and/or 3' flanking sequence to provide a chimeric molecule (e.g. a vector)
20 that does not occur in nature.

4) They may be provided with or without 5' and/or 3' flanking sequences that normally occur in nature.

5) They may be provided in substantially pure form, e.g. by using probes to isolate cloned molecules having a desired target sequence or by using chemical synthesis techniques. Thus they may be provided in a form that is substantially free from contaminating proteins and/or from other nucleic acids.

5 6) They may be provided with introns (e.g. as a full-length gene) or without introns (e.g. as DNA).

7) They may be provided in linear or non-linear (e.g. circular) form.

These Fve molecules include not only molecules with classical DNA or RNA structures, but also variants with modified (non-phosphodiester) backbones - e.g. morpholino derivatives and peptide nucleic acids (PNAs), which contain an N-(2-aminoethyl)glycine-based pseudopeptide backbone. (See Nielsen, P.E., Annual Review of Biophysics & Biomolecular Structure, 24:167-83 (1995)). Nucleic acid variants with modified backbones can have increased stability relative to unmodified nucleic acids and are particularly useful where hybridisation is desired over a relatively long period (e.g. in antisense therapy).

Nucleic acid molecules and uses thereof are discussed in further detail below:

a) Coding nucleic acid molecules

The Fve polypeptides can be coded for by a large variety of nucleic acid molecules, taking into account the well-known degeneracy of the genetic code. All of these coding nucleic acid molecules are within the scope of the present document.

The Fve nucleic acids may be administered to an individual and used to express polypeptides disclosed here. Thus, they may be used for the same treatments as the Fve polypeptides.

The Fve nucleic acid molecules may be provided in the form of vectors, although this is not essential. Preferred vectors for use in treatment include replication-deficient adenoviruses, retroviruses and adeno-associated viruses.

Fve nucleic acid molecules may be administered to a patient by physical methods. These methods include topical application of the nucleic acid in an appropriate vehicle, for example in solution in a pharmaceutically acceptable excipient, such as phosphate buffered saline (PBS). They also include particle bombardment (which is sometimes known as “gene gun” technology and is described in US Patent No. 5371015). Here inert particles, such as gold beads coated with a nucleic acid, can be accelerated at speeds sufficient to enable them to penetrate cells. They can be used for example to penetrate the skin of a patient and may be administered by means of discharge under high pressure from a projecting device. Other physical methods of administering the Fve nucleic acid directly to a recipient include ultrasound, electrical stimulation (including iontophoresis) and microseeding (see e.g. US Patent No. 5697901). Alternatively, the Fve nucleic acid molecules may simply be injected at appropriate site (e.g. muscle). They may be incorporated in or on a carrier (which may be a lipid-based carrier, such as a liposome).

Fve nucleic acid molecules may be introduced into host cells (optionally in the form of vectors) to enable the expression of polypeptides. Alternatively, cell-free expression systems may be used. By using an appropriate expression system the Fve polypeptides can be produced in a desired form. For example, the Fve polypeptides can be produced by micro-organisms such as bacteria or yeast, by cultured insect cells (which may be baculovirus-infected), by mammalian cells (such as CHO cells) or by transgenic animals that, for instance, secrete the Fve proteins in milk (see e.g. international patent application WO88/00239). Where glycosylation is desired, eukaryotic (e.g. mammalian or insect) expression systems are preferred.

Whatever means is used to obtain expression, transcriptional and translational control sequences will normally be present and will be operatively linked to a sequence encoding a polypeptide to be expressed. These control sequences may be heterologous to

the sequence encoding the Fve polypeptide or may be found associated with it *in vivo*. Promoter, operator and /or enhancer sequences may, for example, be provided, as may polyadenylation sites, splice sites, stop and start codons, upstream and downstream regulatory regions, etc. If desired, a constitutive promoter may be provided. Alternatively,
5 a regulatable promoter may be provided to enable transcription to be controlled by administration of a regulator. The promoter (if present) may be tissue-specific or non tissue-specific.

Polypeptides comprising N-terminal methionine may be produced using certain expression systems, whilst in others the mature polypeptide may lack this residue. Fve
10 polypeptides may initially be expressed so as to include signal sequences. Different signal sequences may be provided for different expression systems. Alternatively, signal sequences may be absent, if not needed.

Once expressed, Fve polypeptides may be purified by a wide variety of techniques. Purification techniques may be used under reducing conditions (in order prevent
15 disulphide bond formation) or non-reducing conditions. Available purification techniques include, for example, electrophoretic techniques, such as SDS PAGE (see e.g. Hunkapiller *et al*, *Methods Enzymol.* 91:227 (1983), which discloses "Isolation of microgram quantities of proteins from polyacrylamide gels for amino acid sequence analysis."); affinity techniques (e.g. immunoaffinity chromatography); HPLC; gel filtration; ion-exchange
20 chromatography; isoelectric focussing; etc. If desired, combinations of different purification steps may be used and/or individual purification steps may be repeated.

In summary, techniques for cloning, expressing and purifying polypeptides are well known to the skilled person. Various such techniques are disclosed in standard text-books, such as in Sambrook *et al* [*Molecular Cloning* 2nd Edition, Cold Spring Harbor
25 Laboratory Press (1989)]; in Old & Primrose [*Principles of Gene Manipulation* 5th Edition, Blackwell Scientific Publications (1994)]; and in Stryer [*Biochemistry* 4th Edition, W H Freeman and Company (1995)].

b) Complementary nucleic acid molecules

We also describe nucleic acid strands complementary thereto, whether or not the coding and complementary strands are associated in a duplex. Thus, for example, mRNA and cDNA molecules are included.

5 *c) Hybridising nucleic acid molecules*

Nucleic acid molecules that can hybridise to one or more of the Fve nucleic acid molecules discussed above are also disclosed. Such nucleic acid molecules are referred to herein as "hybridising" nucleic acid molecules. Desirably hybridising molecules are at least 10 nucleotides in length and preferably are at least 20, at least 50, at least 100, or at
10 least 200 nucleotides in length.

A hybridising nucleic acid molecule may have a high degree of sequence identity along its length with a nucleic acid molecule within the scope of b) or a) above (e.g. at least 50%, at least 75% or at least 90% sequence identity), although this is not essential. The greater the degree of sequence identity that a given single stranded nucleic acid
15 molecule has with a strand of a nucleic acid molecule, the greater the likelihood that it will hybridise to the complement of said strand.

Most preferably, hybridising nucleic acid molecules hybridise to either DNA strand of a Fve nucleic acid, for example a sequence shown in **Appendix A**, or to an RNA equivalent thereof, or to a strand that is complementary to either of the aforesaid strands.

20 Hybridising nucleic acid molecules can be useful as probes or primers, for example.

Probes can be used to purify and/or to identify Fve nucleic acids. They may be used in diagnosis. For example, probes may be used to determine whether or not an organism such as a fungus has a wild-type gene encoding a Fve polypeptide described here, or
25 whether or not one or more deletions, insertions and/or replacements of bases relative to

the wild-type sequence are present. It may therefore be used to identify organisms that do not express Fve polypeptides or that express Fve polypeptides having reduced activity (including inactive polypeptides).

5 Primers are useful in synthesising nucleic acids or parts thereof based upon a template to which a probe hybridises. They can be used in techniques such as PCR to provide large numbers of nucleic acid molecules.

10 Hybridising molecules also include antisense strands. These hybridise with "sense" strands so as to inhibit transcription and /or translation. An antisense strand can be synthesised based upon knowledge of a sense strand and base pairing rules. It may be exactly complementary with a sense strand, although it should be noted that exact complementarity is not always essential. It may also be produced by genetic engineering, whereby a part of a DNA molecule is provided in an antisense orientation relative to a promoter and is then used to transcribe RNA molecules. Large numbers of antisense molecules can be provided (e.g. by cloning, by transcription, by PCR, by reverse PCR, etc.

15 Hybridising molecules include ribozymes. Ribozymes can also be used to regulate expression by binding to and cleaving RNA molecules that include particular target sequences recognised by the ribozymes. Ribozymes can be regarded as special types of antisense molecule. They are discussed, for example, by Haselhoff and Gerlach (Nature (1988) 334:585 – 91).

20 Antisense molecules may be DNA or RNA molecules. They may be used in antisense therapy to prevent or reduce undesired expression or activity. Antisense molecules may be administered directly to a patient (e.g. by injection). Alternatively, they may be synthesised *in situ* via a vector that has been administered to a patient.

25 In addition to the uses described above, the Fve nucleic acid molecules disclosed here (of whatever nature) may be used in screening. Screening can be done to identify moieties that bind to said nucleic acid molecules (e.g. to identify hybridising molecules). It

can also be done to identify moieties that affect transcription or translation from said nucleic acid molecules.

It can be used to analyse expression, including analysing expression levels or expression patterns (e.g. by analysing mRNA or cDNA), etc. It can be used to identify particular nucleic acid molecules in a sample. This is useful for in identifying biological material from a given source (e.g. from a human or non-human animal). For example, a reference nucleic acid molecule (or part of it) can be digested with restriction enzymes and the resultant nucleic acid fragments can be run on a gel. This can provide a restriction fragment pattern or "fingerprint" that can be compared with a sample. If the comparison provides a match that is unlikely to have occurred by chance, a conclusion can be reached that the sample and the reference molecule are likely to have originated from a common source. By performing statistical analysis a specific degree of confidence that such a conclusion is correct can be provided.

We also describe a library having a Fve nucleic acid molecule described here, as well as an array comprising such an Fve nucleic acid molecule (which may be a library). Preferably the array is a regular array. The array may have a predetermined pattern. It may have a grid-like pattern. The discussion provided herein in respect of libraries and arrays comprising a polypeptide described here applies *mutatis mutandis* to libraries and arrays comprising the corresponding nucleic acid molecule.

One or more Fve nucleic acid molecules may be immobilised upon a surface (e.g. the surface of a bead or a chip). The surface may, for example, be silicon surface, glass, quartz, a membrane, etc. Techniques for immobilising nucleic acid molecules upon a surface are known and are disclosed, for example, in EP-A-0487104, WO96/04404, WO90/02205, WO96/12014, WO98/44151. In some cases they may include a step of nucleic acid amplification, which may involve PCR. Immobilisation is not however essential. For example nucleic acids may be provided in wells or other containment means (e.g. in a fluid environment).

The Five nucleic acids may be used in various ways. For example, sequence information can be used in predicting structure and/or function, in homology or identity studies, etc.

VECTORS

- 5 As indicated above the nucleic acid molecules described here may be provided in the form of vectors.

- 10 Vectors comprising such nucleic acid include plasmids, phasmids, cosmids, viruses (including bacteriophages), YACs, PACs, etc. They will usually include an origin of replication and may include one or more selectable markers e.g. drug resistance markers and/or markers enabling growth on a particular medium. A vector may include a marker that is inactivated when a nucleic acid molecule, such as the ones described here, is inserted into the vector. Here a further marker may be provided that is different from the marker that is inactivated (e.g. it encodes a different type of drug resistance).

- 15 Vectors may include one or more regions necessary for transcription of RNA encoding a polypeptide. Such vectors are often referred to as expression vectors. They will usually contain a promoter and may contain additional regulatory regions – e.g. operator sequences, enhancer sequences, etc. Translation can be provided by a host cell or by a cell free expression system.

- 20 Vectors need not be used for expression. They may be provided for maintaining a given nucleic acid sequence, for replicating that sequence, for manipulating, it or for transferring it between different locations (e.g. between different organisms).

Large nucleic acid molecules may be incorporated into high capacity vectors (e.g. cosmids, phasmids, YACs or PACs). Smaller nucleic acid molecules may be incorporated into a wide variety of vectors.

Five polynucleotides, for example those described here, can be incorporated into a recombinant replicable vector. The vector may be used to replicate the nucleic acid in a compatible host cell. Thus in a further embodiment, we provide a method of making polynucleotides by introducing a polynucleotide into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector. The vector may be recovered from the host cell. Suitable host cells include bacteria such as *E. coli*, yeast, mammalian cell lines and other eukaryotic cell lines, for example insect Sf9 cells.

Preferably, a polynucleotide in a vector is operably linked to a control sequence that is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector. The term "operably linked" means that the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under condition compatible with the control sequences.

The control sequences may be modified, for example by the addition of further transcriptional regulatory elements to make the level of transcription directed by the control sequences more responsive to transcriptional modulators.

Vectors may be transformed or transfected into a suitable host cell as described below to provide for expression of a protein. This process may comprise culturing a host cell transformed with an expression vector as described above under conditions to provide for expression by the vector of a coding sequence encoding the protein, and optionally recovering the expressed protein. Vectors will be chosen that are compatible with the host cell used.

The vectors may be for example, plasmid or virus vectors provided with an origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter. The vectors may contain one or more selectable

marker genes, for example an ampicillin resistance gene in the case of a bacterial plasmid or a neomycin resistance gene for a mammalian vector. Vectors may be used, for example, to transfect or transform a host cell.

Control sequences operably linked to sequences encoding the polypeptide include
5 promoters/enhancers and other expression regulation signals. These control sequences may be selected to be compatible with the host cell for which the expression vector is designed to be used in. The term promoter is well-known in the art and encompasses nucleic acid regions ranging in size and complexity from minimal promoters to promoters including upstream elements and enhancers.

10 The promoter is typically selected from promoters which are functional in mammalian cells, although prokaryotic promoters and promoters functional in other eukaryotic cells, such as insect cells, may be used. The promoter is typically derived from promoter sequences of viral or eukaryotic genes. For example, it may be a promoter derived from the genome of a cell in which expression is to occur. With respect to
15 eukaryotic promoters, they may be promoters that function in a ubiquitous manner (such as promoters of α -actin, β -actin, tubulin) or, alternatively, a tissue-specific manner (such as promoters of the genes for pyruvate kinase). They may also be promoters that respond to specific stimuli, for example promoters that bind steroid hormone receptors. Viral promoters may also be used, for example the Moloney murine leukaemia virus long
20 terminal repeat (MMLV LTR) promoter, the rous sarcoma virus (RSV) LTR promoter or the human cytomegalovirus (CMV) IE promoter.

It may also be advantageous for the promoters to be inducible so that the levels of expression of the heterologous gene can be regulated during the life-time of the cell. Inducible means that the levels of expression obtained using the promoter can be
25 regulated.

In addition, any of these promoters may be modified by the addition of further regulatory sequences, for example enhancer sequences. Chimeric promoters may also be

used comprising sequence elements from two or more different promoters described above.

Polynucleotides may also be inserted into the vectors described above in an antisense orientation to provide for the production of antisense RNA. Antisense RNA or
5 other antisense polynucleotides may also be produced by synthetic means. Such antisense polynucleotides may be used in a method of controlling the levels of RNAs transcribed from genes comprising any one of the polynucleotides described here.

HOST CELLS

Vectors and polynucleotides or nucleic acids comprising or encoding Fve nucleic
10 acids, fragments, homologues, variants or derivatives thereof may be introduced into host cells for the purpose of replicating the vectors/polynucleotides and/or expressing the polypeptides encoded by the polynucleotides. Although the polypeptides may be produced using prokaryotic cells as host cells, it is preferred to use eukaryotic cells, for example yeast, insect or mammalian cells, in particular mammalian cells.

15 Vectors/polynucleotides may be introduced into suitable host cells using a variety of techniques known in the art, such as transfection, transformation and electroporation. Where vectors/polynucleotides are to be administered to animals, several techniques are known in the art, for example infection with recombinant viral vectors such as retroviruses, herpes simplex viruses and adenoviruses, direct injection of nucleic acids and
20 biolistic transformation.

We therefore further disclose cells comprising Fve nucleic acid molecules or vectors. These may for example be used for expression, as described herein.

A cell capable of expressing a Fve polypeptide described here can be cultured and used to provide the Fve polypeptide, which can then be purified.

Alternatively, the cell may be used in therapy for the same purposes as the Fve polypeptide. For example, cells may be provided from a patient (e.g. via a biopsy), transfected with a nucleic acid molecule or vector and, if desired, cultured *in vitro*, prior to being returned to the patient (e.g. by injection). The cells can then produce the Fve polypeptide *in vivo*. Preferably the cells comprise a regulatable promoter enabling transcription to be controlled via administration of one or more regulator molecules. If desired, the promoter may be tissue specific.

Expression is not however essential since the cells may be provided simply for maintaining a given nucleic acid sequence, for replicating the sequence, for manipulating it, etc.

Such cells may be provided in any appropriate form. For example, they may be provided in isolated form, in culture, in stored form, etc. Storage may, for example, involve cryopreservation, buffering, sterile conditions, etc. Such cells may be provided by gene cloning techniques, by stem cell technology or by any other means. They may be part of a tissue or an organ, which may itself be provided in any of the forms discussed above. The cell, tissue or organ may be stored and used later for implantation, if desired. Techniques for providing tissues or organs, include stem cell technology, the provision of cells tissues or organs from transgenic animals, retroviral and non-retroviral techniques for introducing nucleic acids, etc.

In some case cells may be provided together with other material to aid the structure or function of an implant. For example scaffolds may be provided to hold cells in position, to provide mechanical strength, etc. These may be in the form of matrixes of biodegradable or non-biodegradable material. WO95/01810 describes various materials that can be used for this purpose.

ANIMALS

We also disclose transgenic animals, preferably non-human transgenic animals. Such animals may be useful for producing the particular Fve polypeptides described here (e.g. via secretion in milk, as described herein). Alternatively, they may be useful as test
5 animals for analysing the effect(s) of such Fve polypeptides.

Techniques for producing transgenic animals are well known and are described e.g. in US patents 4870009 and 4873191. For example, a nucleic acid encoding a Fve polypeptide of interest may be microinjected into a pronucleus of a fertilised oocyte. The oocyte may then be allowed to develop in a pseudopregnant female foster animal. The
10 animal resulting from development of the oocyte can be tested (e.g. with antibodies) to determine whether or not it expresses the particular polypeptide. Alternatively, it can be tested with a probe to determine if it has a transgene (even if there is no expression).

A transgenic animal can be used as a founder animal, which may be bred from in order to produce further transgenic animals. Two transgenic animals may be crossed. For
15 example, in some cases transgenic animals may be haploid for a given gene and it may be desired to try to provide a diploid offspring via crossing.

A transgenic animal may be cloned, e.g. by using the procedures set out in WO97/07668 and WO97/07699 (see also Nature 385:810-813 (1997)). Thus a quiescent cell can be provided and combined with an oocyte from which the nucleus has been
20 removed combined. This can be achieved using electrical discharges. The resultant cell can be allowed to develop in culture and can then be transferred to a pseudopregnant female.

ANALYTICAL TOOLS AND SYSTEMS

We disclose a moiety comprising a Fve polypeptide, a Fve nucleic acid, a vector comprising Fve, a cell expressing Fve, an Fve binding agent, a moiety

identified/identifiable by a screen as described here, when used as an analytical tool or when present in a system suitable for analysis, especially high throughput analysis.

Such an analytical tool or system is useful for a plethora of different purposes. These include diagnosis, forensic science, screening, the identification or characterisation of individuals or populations, preventative medicine, etc.

Libraries comprising such a Fve moiety may be used for the above purposes. A library will generally comprise a plurality of heterologous moieties. Preferred libraries comprise at least 100, at least 10,000, at least 1,000,000, or at least 1,000,000,000 heterologous moieties. Desirably a moiety is provided at a predetermined position within a library. In some cases a plurality of moieties may be present within a library at predetermined positions. A predetermined position may be assigned spatial co-ordinates. These may be stored or processed in a computer in order to assist in analysis.

We further disclose an array comprising such a Fve moiety (whether or not the array is also a library). Preferably the array is a regular array. The array may have a predetermined pattern. It may have a grid-like pattern. Preferred arrays comprise at least 100, at least 10,000, at least 1,000,000, or at least 1,000,000,000 components.

A library or array may include naturally occurring moieties, non-naturally occurring moieties, or a mixture of naturally occurring and non-naturally occurring moieties. The moieties may be provided in solution, on beads, on chips (see e.g. Fodor (1993) Nature 364:555-556), on bacteria (see e.g. US Patent 5223409), on spores (see e.g. US Patent 5223409), on phage (see e.g. Scott and Smith (1990) Science 249:386-90 and US Patent 5223409), etc.

Such Fve moieties may be immobilised upon a surface, if desired. For example, one or more nucleic acid molecules may be immobilised upon a surface (e.g. the surface of a bead or a chip). The surface may, for example, be silicon, glass, quartz, a membrane, etc. Techniques for immobilising nucleic acid molecules upon a surface are known and are

disclosed, for example, in EP-A-0487104, WO96/04404, WO90/02205, WO96/12014, WO98/44151. In some cases they may include a step of nucleic acid amplification, and may involve PCR.

Immobilisation is not however essential, even if moieties are to be used in high throughput analysis. For example, they may be provided in wells, channels, grooves or other containment means.

Whether or not present in a library, an array or in immobilised or non-immobilised form, it is often desirable to locate the position of one or more moieties being analysed or being used in analysis. This can be done by assigning it spatial co-ordinates, which may be provided, stored or processed or provided by a computer. In some cases the location may be determined by a sensor (e.g. a CCD device), which may be operatively linked with a computer.

DNA VACCINES

Any of the Fve nucleic acids disclosed here may be administered to an individual in the form of a DNA vaccine. DNA vaccines are known in the art, and are described in detail in, for example, WO03012117, WO03007986, etc.

The Fve may be administered to an individual in the form of a DNA vaccine. A DNA encoding the Fve, for example, a Fve nucleic acid as disclosed here, may be in any form, for example in the form of a cloned plasmid DNA or a synthetic oligonucleotide. The DNA may be delivered together with a cytokine, for example, IL-2, and / or other co-stimulatory molecules. The cytokines and / or co-stimulatory molecules may themselves be delivered in the form of plasmid or oligonucleotide DNA.

The response to a DNA vaccine has been shown to be increased by the presence of immunostimulatory DNA sequences (ISS). These can take the form of hexameric motifs containing methylated CpG, according to the formula: 5' purine-purine-CG-pyrimidine-

pyrimidine-3'. The DNA vaccines may incorporate these or other ISSs, in the DNA encoding the Fve, in the DNA encoding the cytokine or other co-stimulatory molecules, or in both. A review of the advantages of DNA vaccination is provided by Tighe et al (1998, Immunology Today, 19(2), 89-97).

5 ANTIBODIES

We also provide monoclonal or polyclonal antibodies to polypeptides or fragments thereof. Thus, we further provide a process for the production of monoclonal or polyclonal antibodies to an Fve polypeptide, fragment, homologue, variant or derivative thereof

10 If polyclonal antibodies are desired, a selected mammal (e.g., mouse, rabbit, goat, horse, etc.) is immunised with an immunogenic polypeptide bearing an epitope(s) from a polypeptide. Serum from the immunised animal is collected and treated according to known procedures. If serum containing polyclonal antibodies to an epitope from a polypeptide contains antibodies to other antigens, the polyclonal antibodies can be purified by immunoaffinity chromatography. Techniques for producing and processing polyclonal
15 antisera are known in the art. In order that such antibodies may be made, we also provide polypeptides or fragments thereof haptenised to another polypeptide for use as immunogens in animals or humans.

Monoclonal antibodies directed against epitopes in the polypeptides can also be readily produced by one skilled in the art. The general methodology for making
20 monoclonal antibodies by hybridomas is well known. Immortal antibody-producing cell lines can be created by cell fusion, and also by other techniques such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. Panels of monoclonal antibodies produced against epitopes in the polypeptides can be screened for various properties; i.e., for isotype and epitope affinity.

An alternative technique involves screening phage display libraries where, for example the phage express scFv fragments on the surface of their coat with a large variety of complementarity determining regions (CDRs). This technique is well known in the art.

Antibodies, both monoclonal and polyclonal, which are directed against epitopes
5 from polypeptides are particularly useful in diagnosis, and those which are neutralising are useful in passive immunotherapy. Monoclonal antibodies, in particular, may be used to raise anti-idiotypic antibodies. Anti-idiotypic antibodies are immunoglobulins which carry an "internal image" of the antigen of the agent against which protection is desired.

Techniques for raising anti-idiotypic antibodies are known in the art. These anti-
10 idiotypic antibodies may also be useful in therapy.

For the purposes of this document, the term "antibody", unless specified to the contrary, includes fragments of whole antibodies which retain their binding activity for a target antigen. Such fragments include Fv, F(ab') and F(ab')₂ fragments, as well as single chain antibodies (scFv). Furthermore, the antibodies and fragments thereof may be
15 humanised antibodies, for example as described in EP-A-239400.

Antibodies may be used in method of detecting polypeptides present in biological samples by a method which comprises: (a) providing an antibody; (b) incubating a biological sample with said antibody under conditions which allow for the formation of an antibody-antigen complex; and (c) determining whether antibody-antigen complex
20 comprising said antibody is formed.

Suitable samples include extracts tissues such as brain, breast, ovary, lung, colon, pancreas, testes, liver, muscle and bone tissues or from neoplastic growths derived from such tissues.

Antibodies may be bound to a solid support and/or packaged into kits in a suitable
25 container along with suitable reagents, controls, instructions and the like.

ASSAYS

We disclose assays that are suitable for identifying substances which bind to Fve polypeptides, or fragments, homologues, variants or derivatives thereof

5 In general, such binding assays involve exposing a Fve polypeptide, nucleic acid, or a fragment, homologue, variant or derivative thereof to a candidate molecule and detecting an interaction or binding between the Fve polypeptide, nucleic acid, or a fragment, homologue, variant or derivative thereof and the candidate molecule. The binding assay may be conducted *in vitro*, or *in vivo*.

10 We disclose assays for identifying substances which are capable of potentiating the activities of Fve polypeptide. Activities of Fve have been described in detail above. Such compounds may be employed as agonists of Fve polypeptide, and may for example be co-administered to an individual to enhance any desired effect.

15 In general, an assay to identify such substances or compounds involves providing a cell or organism, exposing the cell or organism to a Fve polypeptide, nucleic acid, or a fragment, homologue, variant or derivative thereof, exposing the cell to a candidate molecule, and detecting an effect associated with Fve. Any Fve polypeptide mediated effect or function, as disclosed in this document, particularly the Examples, may be detected.

20 In particular, the Fve polypeptide mediated effect is preferably chosen from the group consisting of: up-regulation of expression of Th1 cytokines, preferably IFN- γ and TNF- α , down-regulation of expression of Th2 cytokines, preferably IL-4 and IL-13, hemagglutination activity, cell aggregation activity, lymphocyte aggregation activity, lymphoproliferation activity, up-regulation of expression of IL-2, IFN- γ , TNF- α , but not IL-4 in CD3⁺ T cells, interaction with T and NK cells, adjuvant activity, stimulation of
25 CD3⁺ CD16⁺ CD56⁺ natural killer (NK) T cells, up-regulation of expression of allergen

specific IgG2a antibody, prevention of systemic anaphylactic reactions and/or decreased footpad edema, preferably as assayed using the Arthus reaction (Ko et al, 1995).

In order to identify agonists, an additive or preferably synergistic effect is detected. Thus, while Fve polypeptide on its own is, for example, capable of reducing a level or number, or down-regulation of expression of a molecule, the assays identify molecules which further reduce the level, number or further down-regulate the expression of a molecule. Thus, preferably, the candidate molecule in conjunction with the Fve polypeptide, nucleic acid, or a fragment, homologue, variant or derivative thereof, down-regulates the expression of, or reduces the level or number, by more than 10%, more than 20%, more than 30%, more than 40%, more than 50%, more than 60%, more than 70%, more than 80%, more than 90%, or more compared to an Fve polypeptide on its own. Thus, for example, a candidate molecule suitable for use as an agonist is one which is capable of enhancing by 10% more the up-regulation of expression of Th1 cytokines, preferably IFN- γ and TNF- α , achieved by Fve polypeptide on its own.

Conversely, assays to identify antagonists involve the detection of a reduction in Fve polypeptide mediated effect. Preferably, the down-regulation of expression or reduction in number or level achieved by Fve polypeptide is reduced in the presence of a suitable candidate molecule. Preferably, the reduction is at least 10%, preferably at least 20%, preferably at least 30%, preferably at least 40%, preferably at least 50%, preferably at least 60%, preferably at least 70%, preferably at least 80%, preferably at least 90%, or more compared to an Fve polypeptide on its own. Thus, for example, a candidate molecule suitable for use as an antagonist is one which is capable of reducing by 10% more the up-regulation of expression of Th1 cytokines, preferably IFN- γ and TNF- α , achieved by Fve polypeptide on its own.

As an illustration, if N1 is the expression of Th1 cytokines, in an untreated organism or cell, and N2 the expression in an organism or cell exposed to Fve polypeptide, nucleic acid, or a fragment, homologue, variant or derivative thereof, the expression of Th1 cytokines is increased by $R = (N2-N1)/N1 \times 100\%$. Agonists increase R, by a factor x,

where x is greater than 1 (e.g., $x = 1, 1.1, 1.2, 1.3, 1.4, 1.5, 2, 3, 4, 5, 10, 20, 50, 100$ etc); while antagonists decrease R , by a factor x , where x is less than 1 (e.g., $x = 0.9, 0.9, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1$ etc).

For example, an organism may be exposed to a Fve polypeptide, nucleic acid, or a fragment, homologue, variant or derivative thereof and a candidate molecule, and any of the biological activities as set out above, or any combination, detected. Preferred candidate molecules are those which provide an additive or synergistic effect in combination with Fve.

Also disclosed are assays to identify antagonists of Fve polypeptide. Such assays involve detecting a reduced effect on exposure of a cell or organism to an Fve polypeptide, nucleic acid, or a fragment, homologue, variant or derivative thereof in conjunction with a candidate molecule.

In a preferred embodiment, the assays are conducted on whole organisms rather than cells. Preferably, the organism is one which suffers from a disease as disclosed in this document, or exhibits one or more symptoms of such a disease.

CANDIDATE MOLECULES

Suitable candidate molecules for use in the above assays include peptides, especially of from about 5 to 30 or 10 to 25 amino acids in size. Peptides from panels of peptides comprising random sequences or sequences which have been varied consistently to provide a maximally diverse panel of peptides may be used.

Suitable candidate molecules also include antibody products (for example, monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies and CDR-grafted antibodies). Furthermore, combinatorial libraries, peptide and peptide mimetics, defined chemical entities, oligonucleotides, and natural product libraries may be screened for activity. The candidate molecules may be used in an initial screen in batches

of, for example 10 types of molecules per reaction, and the molecules of those batches which show enhancement or reduction of a Fve polypeptide mediated effect tested individually.

LIBRARIES

- 5 Libraries of candidate molecules, such as libraries of polypeptides or nucleic acids, may be employed in the methods and compositions described here. Such libraries are exposed a cell or organism in the presence of a Fve polypeptide, nucleic acid, or a fragment, homologue, variant or derivative thereof, and an Fve polypeptide mediated effect detected and assayed as described above.
- 10 Selection protocols for isolating desired members of large libraries are known in the art, as typified by phage display techniques. Such systems, in which diverse peptide sequences are displayed on the surface of filamentous bacteriophage (Scott and Smith (1990 *supra*), have proven useful for creating libraries of antibody fragments (and the nucleotide sequences that encoding them) for the *in vitro* selection and amplification of
- 15 specific antibody fragments that bind a target antigen. The nucleotide sequences encoding the V_H and V_L regions are linked to gene fragments which encode leader signals that direct them to the periplasmic space of *E. coli* and as a result the resultant antibody fragments are displayed on the surface of the bacteriophage, typically as fusions to bacteriophage coat proteins (e.g., pIII or pVIII). Alternatively, antibody fragments are displayed externally on
- 20 lambda phage capsids (phagebodies). An advantage of phage-based display systems is that, because they are biological systems, selected library members can be amplified simply by growing the phage containing the selected library member in bacterial cells. Furthermore, since the nucleotide sequence that encodes the polypeptide library member is contained on a phage or phagemid vector, sequencing, expression and subsequent genetic manipulation
- 25 is relatively straightforward.

Methods for the construction of bacteriophage antibody display libraries and lambda phage expression libraries are well known in the art (McCafferty *et al.* (1990)

supra; Kang *et al.* (1991) *Proc. Natl. Acad. Sci. U.S.A.*, 88: 4363; Clackson *et al.* (1991) *Nature*, 352: 624; Lowman *et al.* (1991) *Biochemistry*, 30: 10832; Burton *et al.* (1991) *Proc. Natl. Acad. Sci. U.S.A.*, 88: 10134; Hoogenboom *et al.* (1991) *Nucleic Acids Res.*, 19: 4133; Chang *et al.* (1991) *J. Immunol.*, 147: 3610; Breitling *et al.* (1991) *Gene*, 104: 147; Marks *et al.* (1991) supra; Barbas *et al.* (1992) supra; Hawkins and Winter (1992) *J. Immunol.*, 22: 867; Marks *et al.*, 1992, *J. Biol. Chem.*, 267: 16007; Lerner *et al.* (1992) *Science*, 258: 1313, incorporated herein by reference). Such techniques may be modified if necessary for the expression generally of polypeptide libraries.

One particularly advantageous approach has been the use of scFv phage-libraries (Bird, R.E., *et al.* (1988) *Science* 242: 423-6, Huston *et al.*, 1988, *Proc. Natl. Acad. Sci. U.S.A.*, 85: 5879-5883; Chaudhary *et al.* (1990) *Proc. Natl. Acad. Sci. U.S.A.*, 87: 1066-1070; McCafferty *et al.* (1990) supra; Clackson *et al.* (1991) supra; Marks *et al.* (1991) supra; Chiswell *et al.* (1992) *Trends Biotech.*, 10: 80; Marks *et al.* (1992) supra). Various embodiments of scFv libraries displayed on bacteriophage coat proteins have been described. Refinements of phage display approaches are also known, for example as described in WO96/06213 and WO92/01047 (Medical Research Council *et al.*) and WO97/08320 (Morphosys, supra), which are incorporated herein by reference.

Alternative library selection technologies include bacteriophage lambda expression systems, which may be screened directly as bacteriophage plaques or as colonies of lysogens, both as previously described (Huse *et al.* (1989) *Science*, 246: 1275; Caton and Koprowski (1990) *Proc. Natl. Acad. Sci. U.S.A.*, 87; Mullinax *et al.* (1990) *Proc. Natl. Acad. Sci. U.S.A.*, 87: 8095; Persson *et al.* (1991) *Proc. Natl. Acad. Sci. U.S.A.*, 88: 2432) and are of use. These expression systems may be used to screen a large number of different members of a library, in the order of about 10^6 or even more. Other screening systems rely, for example, on direct chemical synthesis of library members. One early method involves the synthesis of peptides on a set of pins or rods, such as described in WO84/03564. A similar method involving peptide synthesis on beads, which forms a peptide library in which each bead is an individual library member, is described in U.S. Patent No. 4,631,211 and a related method is described in WO92/00091. A significant improvement

of the bead-based methods involves tagging each bead with a unique identifier tag, such as an oligonucleotide, so as to facilitate identification of the amino acid sequence of each library member. These improved bead-based methods are described in WO93/06121.

Another chemical synthesis method involves the synthesis of arrays of peptides (or
5 peptidomimetics) on a surface in a manner that places each distinct library member (e.g.,
unique peptide sequence) at a discrete, predefined location in the array. The identity of
each library member is determined by its spatial location in the array. The locations in the
array where binding interactions between a predetermined molecule (e.g., a receptor) and
reactive library members occur is determined, thereby identifying the sequences of the
10 reactive library members on the basis of spatial location. These methods are described in
U.S. Patent No. 5,143,854; WO90/15070 and WO92/10092; Fodor *et al.* (1991) *Science*,
251: 767; Dower and Fodor (1991) *Ann. Rep. Med. Chem.*, 26: 271.

Other systems for generating libraries of polypeptides or nucleotides involve the
use of cell-free enzymatic machinery for the *in vitro* synthesis of the library members. In
15 one method, RNA molecules are selected by alternate rounds of selection against a target
ligand and PCR amplification (Tuerk and Gold (1990) *Science*, 249: 505; Ellington and
Szostak (1990) *Nature*, 346: 818). A similar technique may be used to identify DNA
sequences which bind a predetermined human transcription factor (Thiesen and Bach
(1990) *Nucleic Acids Res.*, 18: 3203; Beaudry and Joyce (1992) *Science*, 257: 635;
20 WO92/05258 and WO92/14843). In a similar way, *in vitro* translation can be used to
synthesise polypeptides as a method for generating large libraries. These methods which
generally comprise stabilised polysome complexes, are described further in WO88/08453,
WO90/05785, WO90/07003, WO91/02076, WO91/05058, and WO92/02536. Alternative
display systems which are not phage-based, such as those disclosed in WO95/22625 and
25 WO95/11922 (Affymax) use the polysomes to display polypeptides for selection. These
and all the foregoing documents also are incorporated herein by reference.

COMBINATORIAL LIBRARIES

Libraries, in particular, libraries of candidate molecules, may suitably be in the form of combinatorial libraries (also known as combinatorial chemical libraries).

5 A "combinatorial library", as the term is used in this document, is a collection of multiple species of chemical compounds that consist of randomly selected subunits. Combinatorial libraries may be screened for molecules which are capable of potentiating, enhancing, reducing or minimising the a Fve polypeptide mediated effect when exposed to a cell or organism.

10 Various combinatorial libraries of chemical compounds are currently available, including libraries active against proteolytic and non-proteolytic enzymes, libraries of agonists and antagonists of G-protein coupled receptors (GPCRs), libraries active against non-GPCR targets (e.g., integrins, ion channels, domain interactions, nuclear receptors, and transcription factors) and libraries of whole-cell oncology and anti-infective targets, among others. A comprehensive review of combinatorial libraries, in particular their
15 construction and uses is provided in Dolle and Nelson (1999), *Journal of Combinatorial Chemistry*, Vol 1 No 4, 235-282. Reference is also made to *Combinatorial peptide library protocols* (edited by Shmuel Cabilly, Totowa, N.J.: Humana Press, c1998. *Methods in Molecular Biology*; v. 87).

20 Further references describing chemical combinatorial libraries, their production and use include those available from the URL <http://www.netsci.org/Science/Combichem/>, including The Chemical Generation of Molecular Diversity. Michael R. Pavia, Sphinx Pharmaceuticals, A Division of Eli Lilly (Published July, 1995); Combinatorial Chemistry: A Strategy for the Future - MDL Information Systems discusses the role its Project Library plays in managing diversity libraries (Published July, 1995); Solid Support Combinatorial
25 Chemistry in Lead Discovery and SAR Optimization, Adnan M: M. Mjalli and Barry E. Toyonaga, Ontogen Corporation (Published July, 1995); Non-Peptidic Bradykinin Receptor Antagonists From a Structurally Directed Non-Peptide Library. Sarvajit

- Chakravarty, Babu J. Mavunkel, Robin Andy, Donald J. Kyle*, Scios Nova Inc.
(Published July, 1995); Combinatorial Chemistry Library Design using Pharmacophore
Diversity Keith Davies and Clive Briant, Chemical Design Ltd. (Published July, 1995); A
Database System for Combinatorial Synthesis Experiments - Craig James and David
5 Weininger, Daylight Chemical Information Systems, Inc. (Published July, 1995); An
Information Management Architecture for Combinatorial Chemistry, Keith Davies and
Catherine White, Chemical Design Ltd. (Published July, 1995); Novel Software Tools for
Addressing Chemical Diversity, R. S. Pearlman, Laboratory for Molecular Graphics and
Theoretical Modeling, College of Pharmacy, University of Texas (Published June/July,
10 1996); Opportunities for Computational Chemists Afforded by the New Strategies in Drug
Discovery: An Opinion, Yvonne Connolly Martin, Computer Assisted Molecular Design
Project, Abbott Laboratories (Published June/July, 1996); Combinatorial Chemistry and
Molecular Diversity Course at the University of Louisville: A Description, Arno F.
Spatola, Department of Chemistry, University of Louisville (Published June/July, 1996);
15 Chemically Generated Screening Libraries: Present and Future. Michael R. Pavia, Sphinx
Pharmaceuticals, A Division of Eli Lilly (Published June/July, 1996); Chemical Strategies
For Introducing Carbohydrate Molecular Diversity Into The Drug Discovery Process..
Michael J. Sofia, Transcell Technologies Inc. (Published June/July, 1996); Data
Management for Combinatorial Chemistry. Maryjo Zaborowski, Chiron Corporation and
20 Sheila H. DeWitt, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert
Company (Published November, 1995); and The Impact of High Throughput Organic
Synthesis on R&D in Bio-Based Industries, John P. Devlin (Published March, 1996).

- Techniques in combinatorial chemistry are gaining wide acceptance among modern
methods for the generation of new pharmaceutical leads (Gallop, M. A. et al., 1994, J.
25 Med. Chem. 37:1233-1251; Gordon, E. M. et al., 1994, J. Med. Chem. 37:1385-1401.).
One combinatorial approach in use is based on a strategy involving the synthesis of
libraries containing a different structure on each particle of the solid phase support,
interaction of the library with a soluble receptor, identification of the 'bead' which
interacts with the macromolecular target, and determination of the structure carried by the
30 identified 'bead' (Lam, K. S. et al., 1991, Nature 354:82-84). An alternative to this

approach is the sequential release of defined aliquots of the compounds from the solid support, with subsequent determination of activity in solution, identification of the particle from which the active compound was released, and elucidation of its structure by direct sequencing (Salmon, S. E. et al., 1993, Proc.Natl.Acad.Sci.USA 90:11708-11712), or by
5 reading its code (Kerr, J. M. et al., 1993, J.Am.Chem.Soc. 115:2529-2531; Nikolaiev, V. et al., 1993, Pept. Res. 6:161-170; Ohlmeyer, M. H. J. et al., 1993, Proc.Natl.Acad.Sci.USA 90:10922-10926).

Soluble random combinatorial libraries may be synthesized using a simple principle for the generation of equimolar mixtures of peptides which was first described by
10 Furka (Furka, A. et al., 1988, Xth International Symposium on Medicinal Chemistry, Budapest 1988; Furka, A. et al., 1988, 14th International Congress of Biochemistry, Prague 1988; Furka, A. et al., 1991, Int. J. Peptide Protein Res. 37:487-493). The construction of soluble libraries for iterative screening has also been described (Houghten, R. A. et al.1991, Nature 354:84-86). K. S. Lam disclosed the novel and unexpectedly
15 powerful technique of using insoluble random combinatorial libraries. Lam synthesized random combinatorial libraries on solid phase supports, so that each support had a test compound of uniform molecular structure, and screened the libraries without prior removal of the test compounds from the support by solid phase binding protocols (Lam, K. S. et al., 1991, Nature 354:82-84).

20 Thus, a library of candidate molecules may be a synthetic combinatorial library (e.g., a combinatorial chemical library), a cellular extract, a bodily fluid (e.g., urine, blood, tears, sweat, or saliva), or other mixture of synthetic or natural products (e.g., a library of small molecules or a fermentation mixture).

A library of molecules may include, for example, amino acids, oligopeptides,
25 polypeptides, proteins, or fragments of peptides or proteins; nucleic acids (e.g., antisense; DNA; RNA; or peptide nucleic acids, PNA); aptamers; or carbohydrates or polysaccharides. Each member of the library can be singular or can be a part of a mixture (e.g., a compressed library). The library may contain purified compounds or can be "dirty"

(i.e., containing a significant quantity of impurities). Commercially available libraries (e.g., from Affymetrix, ArQule, Neose Technologies, Sarco, Ciddco, Oxford Asymmetry, Maybridge, Aldrich, Panlabs, Pharmacopoeia, Sigma, or Tripose) may also be used with the methods described here.

- 5 In addition to libraries as described above, special libraries called diversity files can be used to assess the specificity, reliability, or reproducibility of the new methods. Diversity files contain a large number of compounds (e.g., 1000 or more small molecules) representative of many classes of compounds that could potentially result in nonspecific detection in an assay. Diversity files are commercially available or can also be assembled
10 from individual compounds commercially available from the vendors listed above.

CANDIDATE SUBSTANCES

- Suitable candidate substances include peptides, especially of from about 5 to 30 or 10 to 25 amino acids in size, based on the sequence of the polypeptides described in the Examples, or variants of such peptides in which one or more residues have been
15 substituted. Peptides from panels of peptides comprising random sequences or sequences which have been varied consistently to provide a maximally diverse panel of peptides may be used.

- Suitable candidate substances also include antibody products (for example, monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies and
20 CDR-grafted antibodies) which are specific for a polypeptide. Furthermore, combinatorial libraries, peptide and peptide mimetics, defined chemical entities, oligonucleotides, and natural product libraries may be screened for activity as inhibitors of binding of a polypeptide to the cell division cycle machinery, for example mitotic/meiotic apparatus (such as microtubules). The candidate substances may be used in an initial screen in
25 batches of, for example 10 substances per reaction, and the substances of those batches which show inhibition tested individually. Candidate substances which show activity in *in vitro* screens such as those described below can then be tested in whole cell systems, such

as mammalian cells which will be exposed to the inhibitor and tested for inhibition of any of the stages of the cell cycle.

POLYPEPTIDE BINDING ASSAYS

One type of assay for identifying substances that bind to a polypeptide involves
5 contacting a polypeptide, which is immobilised on a solid support, with a non-immobilised
candidate substance determining whether and/or to what extent the polypeptide and
candidate substance bind to each other. Alternatively, the candidate substance may be
immobilised and the polypeptide non-immobilised. This may be used to detect substances
capable of binding to Fve polypeptides, or fragments, homologues, variants or derivatives
10 thereof.

In a preferred assay method, the polypeptide is immobilised on beads such as
agarose beads. Typically this is achieved by expressing the Fve polypeptide, or a fragment,
homologue, variant or derivative thereof as a GST-fusion protein in bacteria, yeast or
higher eukaryotic cell lines and purifying the GST-fusion protein from crude cell extracts
15 using glutathione-agarose beads (Smith and Johnson, 1988). As a control, binding of the
candidate substance, which is not a GST-fusion protein, to the immobilised polypeptide is
determined in the absence of the polypeptide. The binding of the candidate substance to
the immobilised polypeptide is then determined. This type of assay is known in the art as a
GST pulldown assay. Again, the candidate substance may be immobilised and the
20 polypeptide non-immobilised.

It is also possible to perform this type of assay using different affinity purification
systems for immobilising one of the components, for example Ni-NTA agarose and
histidine-tagged components.

Binding of the Fve polypeptide, or a fragment, homologue, variant or derivative
25 thereof to the candidate substance may be determined by a variety of methods well-known
in the art. For example, the non-immobilised component may be labeled (with for

example, a radioactive label, an epitope tag or an enzyme-antibody conjugate).

Alternatively, binding may be determined by immunological detection techniques. For example, the reaction mixture can be Western blotted and the blot probed with an antibody that detects the non-immobilised component. ELISA techniques may also be used.

- 5 Candidate substances are typically added to a final concentration of from 1 to 1000 nmol/ml, more preferably from 1 to 100 nmol/ml. In the case of antibodies, the final concentration used is typically from 100 to 500 µg/ml, more preferably from 200 to 300 µg/ml.

FVE DISEASES

- 10 As disclosed elsewhere in this document, Fve polypeptides, nucleic acids, and fragments, homologues, variants and derivatives thereof, host cells, vectors, DNA vaccines, etc, are suitable for treating or preventing various diseases (here referred to as "Fve diseases"). They may be administered in an amount in the range of 1 microgram to 1 gramme to an average human patient or individual to be vaccinated. It is preferred to use
15 a smaller dose in the range of 1 microgram to 1 milligram for each administration, however.

- The Fve polypeptides, etc may be administered together, either simultaneously or, separately with compounds such as cytokines and / or growth factors, such as interleukin-2 (IL-2), Interleukin 12 (IL-12), GM-CSF or the like in order to strengthen the
20 immune response. The Fve polypeptides, etc can be used in a vaccine or a therapeutic composition either alone or in combination with other materials, for example, in the form of a lipopeptide conjugate which is known to induce a high-affinity cytotoxic T cell responses (Deres, 1989, Nature 342).

- In particular, Fve diseases include allergies and cancer, described in further detail
25 below.

Cancer

Fve polypeptides, nucleic acids, and fragments, homologues, variants and derivatives thereof, are suitable for treating or preventing cancer.

The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia. More particular examples of such cancers include squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastric cancer, pancreatic cancer, glial cell tumors such as glioblastoma and neurofibromatosis, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial carcinoma, salivary gland carcinoma, kidney cancer, renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer. Further examples are solid tumor cancer including colon cancer, breast cancer, lung cancer and prostate cancer, hematopoietic malignancies including leukemias and lymphomas, Hodgkin's disease, aplastic anemia, skin cancer and familial adenomatous polyposis. Further examples include brain neoplasms, colorectal neoplasms, breast neoplasms, cervix neoplasms, eye neoplasms, liver neoplasms, lung neoplasms, pancreatic neoplasms, ovarian neoplasms, prostatic neoplasms, skin neoplasms, testicular neoplasms, neoplasms, bone neoplasms, yellow fever trophoblastic neoplasms, fallopian tube neoplasms, rectal neoplasms, colonic neoplasms, kidney neoplasms, stomach neoplasms, and parathyroid neoplasms. Breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, lung cancer, malignant melanoma, leukaemia, lymphoma, ovarian cancer, cervical cancer and biliary tract carcinoma are also included.

In preferred embodiments, Fve polypeptide, nucleic acid, and fragments, homologues, variants and derivatives thereof are used to treat T cell lymphoma, melanoma or lung cancer.

The Fve polypeptides and nucleic acids, etc, as described here, may also be used in combination with anticancer agents such as endostatin and angiostatin or cytotoxic agents

- or chemotherapeutic agent. For example, drugs such as such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and alkaloids, such as vincristine, and antimetabolites such as methotrexate. The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells.
- 5 The term is intended to include radioactive isotopes (e.g. I, Y, Pr), chemotherapeutic agents, and toxins such as enzymatically active toxins of bacterial, fungal, plant or animal origin, or fragments thereof.

Also, the term includes oncogene product/tyrosine kinase inhibitors, such as the bicyclic ansamycins disclosed in WO 94/22867; 1,2-bis(arylamino) benzoic acid derivatives disclosed in EP 600832; 6,7-diamino-phthalazin-1-one derivatives disclosed in EP 600831; 4,5-bis(arylamino)-phthalimide derivatives as disclosed in EP 516598; or
5 peptides which inhibit binding of a tyrosine kinase to a SH2-containing substrate protein (see WO 94/07913, for example). A "chemotherapeutic agent" is a chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include Adriamycin, Doxorubicin, 5-Fluorouracil (5-FU), Cytosine arabinoside (Ara-C), Cyclophosphamide, Thiotepa, Busulfan, Cytosin, Taxol, Methotrexate, Cisplatin,
10 Melphalan, Vinblastine, Bleomycin, Etoposide, Ifosfamide, Mitomycin C, Mitoxantrone, Vincristine, VP-16, Vinorelbine, Carboplatin, Teniposide, Daunomycin, Carminomycin, Aminopterin, Dactinomycin, Mitomycins, Nicotinamide, Esperamicins (see U.S. Pat. No. 4,675,187), Melphalan and other related nitrogen mustards, and endocrine therapies (such as diethylstilbestrol (DES), Tamoxifen, LHRH antagonizing drugs, progestins, anti-
15 progestins etc).

Allergies

Existing treatments for allergies typically involve the long-term use of steroids to depress the immune system. There are undesirable side effects with long-term steroid therapy. We demonstrate that Fve polypeptide, nucleic acid, or a fragment, homologue,
20 variant or derivative thereof (as well as DNA vaccines, host cells and transgenic organisms comprising any of these) may be used to alleviate the symptoms of allergy, or to treat allergy. The term "allergy" as used here, refers to any allergic reactions such as allergic contact hypersensitivity.

In general, the allergy may be to an allergen from any source, for example, a source
25 known to induce allergenic responses in humans. For example, the allergy may be to a tree pollen allergen, a grass pollen allergen, a weed pollen allergen, a feline antigen, or a fungal allergen. Thus, the allergy may be to a tree pollen allergen, for example Bet v 1 and Bet v 2 from birch tree. The allergy may be to a grass pollen allergen, for example, Phl p 1 and

Phl p 2 from timothy grass. It may be to a weed pollen allergen, for example, antigen E from ragweed. It may be to an animal allergen, for example, a canine or feline antigen. Specifically, it may be to a major feline antigen, for example, Fel d 1. The allergy may be to a fungal allergen, for example a major fungal allergen, for example, Asp f1, Asp f2, and
5 Asp f3 from *Aspergillus fumigatus*.

In preferred embodiments, the allergy is to a dust mite allergen, preferably a house dust mite allergen. In particular, the allergen is preferably derived from a mite from Family Glycyphagidae or Family Pyroglyphidae. Dust mites of Family Glycyphagidae include those in the genera Aeroglyphus, Austroglyphus, Blomia, Ctenoglyphus,
10 Glycyphagus, Gohieria, Lepidoglyphus. Dust mites of Family Pyroglyphidae include those in the genera Dermatophagoides, Euroglyphus, Pyroglyphus. In preferred embodiments, the allergy is preferably to an allergen from a species in any of these genera.

In highly preferred embodiments, the allergy is to an allergen which is a group 1 allergen (Der p 1, Der f 1, Blo t 1, Eur m1, Lep d 1), a group 2 allergen (Der p 2, Der f 2,
15 Blo t 2, Eur m 2, Lep d 2), a group 5 allergen (Blo t 5, Der p 5, Der f 5, Eur m 5, Lep d 5) or a group 15 allergen (Der p 15, Der f 15, Blo t 15, Eur m 15, Lep d 15) from dust mite.

Allergies suitable for treatment with Fve polypeptide, nucleic acid, or a fragment, homologue, variant or derivative thereof may therefore include a seasonal respiratory allergy, allergic rhinitis, hayfever, nonallergic rhinitis, vasomotor rhinitis, irritant rhinitis,
20 an allergy against grass pollens, tree pollens or animal danders, an allergy associated with allergic asthma, and food allergies. In particular, and as described elsewhere, Fve polypeptide, nucleic acid, or a fragment, homologue, variant or derivative thereof may be used to treat allergies to house dust mite (*Dermatophagoides* spp), preferably
Dermatophagoides pteronyssinus or *Dermatophagoides farinae*, or to fungi or fungal
25 spores, preferably *Aspergillus fumigatus*. Preferably, the allergens are comprised in faeces of *Dermatophagoides* spp.

Viral Infections

The immunomodulator-viral infectious antigen combinations, preferably conjugates, may be used to treat or prevent any of a number of viral infectious diseases. The virus concerned may be an RNA virus or a DNA virus. Preferably, the virus is an integrating virus. Preferably, the virus is selected from a lentivirus and a herpesvirus. More preferably, the virus is an HIV virus or a HSV virus.

The methods described here can therefore be used to prevent the development and establishment of diseases caused by or associated with any of the above viruses, including human immunodeficiency virus, such as HIV-1 and HIV-2, and herpesvirus, for example HSV-1, HSV-2, HSV-7 and HSV-8, as well as human cytomegalovirus, varicella-zoster virus, Epstein-Barr virus and human herpesvirus 6 in humans. Human papillomavirus (HPV) is also included, and the immunomodulator as described may be administered in combination (simultaneously or sequentially, etc) together with a viral infectious antigen comprising for example E7 antigen from HPV, as shown in the Examples.

Examples of viruses which may be targeted using the methods and compositions described here are given in the tables below.

DNA VIRUSÉS			
Family	Genus or [Subfamily]	Example	Diseases
Herpesviridae	[Alphaherpesvirinae]	Herpes simplex virus type 1 (aka HHV-1)	Encephalitis, cold sores, gingivostomatitis
		Herpes simplex virus type 2 (aka HHV-2)	Genital herpes, encephalitis
		Varicella zoster virus (aka HHV-3)	Chickenpox, shingles
	[Gammaherpesvirinae]	Epstein Barr virus (aka HHV-4)	Mononucleosis, hepatitis, tumors (BL, NPC)
		Kaposi's sarcoma associated herpesvirus, KSHV (aka Human herpesvirus 8)	?Probably: tumors, inc. Kaposi's sarcoma (KS) and some B cell lymphomas
	[Betaherpesvirinae]	Human cytomegalovirus (aka HHV-5)	Mononucleosis, hepatitis, pneumonitis, congenital
Adenoviridae	Mastadenovirus	Human herpesvirus 6	Roseola (aka E. subitum), pneumonitis
Papovaviridae		Human herpesvirus 7	Some cases of roseola?
Hepadnaviridae	Papillomavirus	Human adenoviruses	50 serotypes (species); respiratory infections
	Polyomavirus	Human papillomaviruses	80 species; warts and tumors
Poxviridae	Orthohepadnavirus	JC, BK viruses	Mild usually; JC causes PML in AIDS
		Hepatitis B virus (HBV)	Hepatitis (chronic), cirrhosis, liver tumors
		Hepatitis C virus (HCV)	Hepatitis (chronic), cirrhosis, liver tumors
	Orthopoxvirus	Vaccinia virus	Smallpox vaccine virus

Parvoviridae	Parapoxvirus	Monkeypox virus	Smallpox-like disease; a rare zoonosis (recent outbreak in Congo; 92 cases from 2/96 - 2/97)
	Erythrovirus	Orf virus	Skin lesions ("pocks")
		B19 parvovirus	E. infectiousum (aka Fifth disease), aplastic crisis, fetal loss
Circoviridae	Dependovirus	Adeno-associated virus	Useful for gene therapy; integrates into chromosome
	Circovirus	TT virus (TTV)	Linked to hepatitis of unknown etiology

RNA VIRUSES

Family	Genus or [Subfamily]	Example	Diseases
Picornaviridae	Enterovirus	Polioviruses	3 types; Aseptic meningitis, paralytic poliomyelitis
		Echoviruses	30 types; Aseptic meningitis, rashes
Caliciviridae	Hepatovirus Rhinovirus Calicivirus	Coxsackieviruses	30 types; Aseptic meningitis, myopericarditis
		Hepatitis A virus	Acute hepatitis (fecal-oral spread)
		Human rhinoviruses	115 types; Common cold
		Norwalk virus	Gastrointestinal illness
Paramyxoviridae	Paramyxovirus	Parainfluenza viruses	4 types; Common cold, bronchiolitis, pneumonia
		Rubulavirus	Mumps: parotitis, aseptic meningitis (rare: orchitis, encephalitis)
		Morbillivirus	Measles: fever, rash (rare: encephalitis, SSPE)
		Pneumovirus	Common cold (adults), bronchiolitis, pneumonia (infants)
Orthomyxoviridae	Influenzavirus A	Influenza virus A	Flu: fever, myalgia, malaise, cough, pneumonia
	Influenzavirus B	Influenza virus B	Flu: fever, myalgia, malaise, cough, pneumonia
Rhabdoviridae	Lyssavirus	Rabies virus	Rabies: long incubation, then CNS disease, death
Filoviridae	Filovirus	Ebola and Marburg viruses	Hemorrhagic fever, death
Bornaviridae	Bornavirus	Borna disease virus	Uncertain; linked to schizophrenia-like disease in some animals
Retroviridae	Deltaretrovirus	Human T-lymphotropic virus type-1	Adult T-cell leukemia (ATL), tropical spastic paraparesis (TSP)
	Spumavirus	Human foamy viruses	No disease known
	Lentivirus	Human immunodeficiency virus type-1 and -2	AIDS, CNS disease
Togaviridae	Rubivirus	Rubella virus	Mild exanthem; congenital fetal defects
	Alphavirus	Equine encephalitis viruses (EEE, EEE, VEE)	Mosquito-borne, encephalitis
Flaviviridae	Flavivirus	Yellow fever virus	Mosquito-borne; fever, hepatitis (yellow fever!)
		Dengue virus	Mosquito-borne; hemorrhagic fever
		St. Louis Encephalitis virus	Mosquito-borne; encephalitis
Reoviridae	Hepacivirus	Hepatitis C virus	Hepatitis (often chronic), liver cancer
		Hepatitis G virus	Hepatitis???
		Human rotaviruses	Numerous serotypes; Diarrhea
		Colorado Tick Fever virus	Tick-borne; fever
Bunyaviridae	Hantavirus	Human reoviruses	Minimal disease
		Pulmonary Syndrome	Rodent spread; pulmonary illness (can be lethal, "Four Corners" outbreak)
		Hantavirus	Rodent spread; hemorrhagic fever with renal syndrome
		Hantaan virus	Rodent spread; hemorrhagic fever with renal syndrome
Arenaviridae	Arenavirus	Rift Valley Fever virus	Mosquito-borne; hemorrhagic fever
		Crimean-Congo Hemorrhagic Fever virus	Mosquito-borne; hemorrhagic fever
		Lymphocytic Choriomeningitis virus	Rodent-borne; fever, aseptic meningitis

		Lassa virus	Rodent-born; severe hemorrhagic fever (BL4 agents; also: Machupo, Junin)
	Deltavirus	Hepatitis Delta virus	Requires HBV to grow; hepatitis, liver cancer
Coronaviridae	Coronavirus	Human coronaviruses	Mild common cold-like illness
Astroviridae	Astrovirus	Human astroviruses	Gastroenteritis
Unclassified	"Hepatitis E-like viruses"	Hepatitis E virus	Hepatitis (acute); fecal-oral spread

Human Immunodeficiency Virus-1 (HIV-1)

The combinations and conjugates described here, including Fve polypeptide combinations and conjugates, may be used to treat or prevent Human Immunodeficiency Virus (HIV) infection. The methods described here can therefore be used to prevent the development and establishment of diseases caused by or associated with human immunodeficiency virus, such as HIV-1 and HIV-2.

Human Immunodeficiency Virus (HIV) is a retrovirus which infects cells of the immune system, most importantly CD4⁺ T lymphocytes. CD4⁺ T lymphocytes are important, not only in terms of their direct role in immune function, but also in stimulating normal function in other components of the immune system, including CD8⁺ T-lymphocytes. These HIV infected cells have their function disturbed by several mechanisms and/or are rapidly killed by viral replication. The end result of chronic HIV infection is gradual depletion of CD4⁺ T lymphocytes, reduced immune capacity, and ultimately the development of AIDS, leading to death.

The regulation of HIV gene expression is accomplished by a combination of both cellular and viral factors. HIV gene expression is regulated at both the transcriptional and post-transcriptional levels. The HIV genes can be divided into the early genes and the late genes. The early genes, Tat, Rev, and Nef, are expressed in a Rev-independent manner. The mRNAs encoding the late genes, Gag, Pol, Env, Vpr, Vpu, and Vif require Rev to be cytoplasmically localized and expressed. HIV transcription is mediated by a single promoter in the 5' LTR. Expression from the 5' LTR generates a 9-kb primary transcript that has the potential to encode all nine HIV genes. The primary transcript is roughly 600 bases shorter than the provirus. The primary transcript can be spliced into one of more than

30 mRNA species or packaged without further modification into virion particles (to serve as the viral RNA genome).

Any of the HIV proteins disclosed here may be used as a viral infectious antigen for productions of conjugates and combinations as described above.

5 *Herpes Virus*

The combinations and conjugates described here, including Fve polypeptide combinations and conjugates, may be used to treat or prevent Herpesvirus infection. The methods described here can therefore be used to prevent the development and establishment of diseases caused by or associated with herpesvirus, for example HSV-1,
10 HSV-2, HSV-7 and HSV-8.

Particular examples of herpesvirus include: herpes simplex virus 1 ("HSV-1"), herpes simplex virus 2 ("HSV-2"), human cytomegalovirus ("HCMV"), varicella-zoster virus ("VZV"), Epstein-Barr virus ("EBV"), human herpesvirus 6 ("HHV6"), herpes simplex virus 7 ("HSV-7") and herpes simplex virus 8 ("HSV-8").

15 Herpesviruses have also been isolated from horses, cattle, pigs (pseudorabies virus ("PSV") and porcine cytomegalovirus), chickens (infectious laryngotracheitis), chimpanzees, birds (Marck's disease herpesvirus 1 and 2), turkeys and fish (see "Herpesviridae: A Brief Introduction", Virology, Second Edition, edited by B. N. Fields, Chapter 64, 1787 (1990)).

20 Herpes simplex viral ("HSV") infection is generally a recurrent viral infection characterized by the appearance on the skin or mucous membranes of single or multiple clusters of small vesicles, filled with clear fluid, on slightly raised inflammatory bases. The herpes simplex virus is a relatively large-sized virus. HSV-2 commonly causes herpes labialis. HSV-2 is usually, though not always, recoverable from genital lesions. Ordinarily,
25 HSV-2 is transmitted venereally.

Diseases caused by varicella-zoster virus (human herpesvirus 3) include varicella (chickenpox) and zoster (shingles). Cytomegalovirus (human herpesvirus 5) is responsible for cytomegalic inclusion disease in infants. There is presently no specific treatment for treating patients infected with cytomegalovirus. Epstein-Barr virus (human herpesvirus 4) is the causative agent of infectious mononucleosis and has been associated with Burkitt's lymphoma and nasopharyngeal carcinoma. Animal herpesviruses which may pose a problem for humans include B virus (herpesvirus of Old World Monkeys) and Marmoset herpesvirus (herpesvirus of New World Monkeys).

Herpes simplex virus 1 (HSV-1) is a human pathogen capable of becoming latent in nerve cells. Like all the other members of *Herpesviridae* it has a complex architecture and double-stranded linear DNA genome which encodes for variety of viral proteins including DNA pol. and TK.

HSV gene expression proceeds in a sequential and strictly regulated manner and can be divided into at least three phases, termed immediate-early (IE or α), early (β) and late (γ). The cascade of HSV-1 gene expression starts from IE genes, which are expressed immediately after lytic infection begins. The IE proteins regulate the expression of later classes of genes (early and late) as well as their own expression. The product of IE175k (ICP4) gene is critical for HSV-1 gene regulation and ts mutants in this gene are blocked at IE stage of infection.

The IE genes themselves are activated by a virion structural protein VP16 (expressed late in the replicative cycle and incorporated into HSV particle). All 5 IE genes of HSV-1 (IE110k - 2 copies/HSV genome, IE175 - 2 copies/HSV genome, IE68k, IE63k and IE12k) have at least one copy of a conserved promoter/enhancer sequence - TAATGARAT. This sequence is recognized by the transactivation complex which consists of; Oct-1, HCF and VP16. The GARAT element is required for efficient transactivation by VP16. This mechanism of gene activation is unique for HSV and despite Oct-1 being a common transcription factor, the Oct-1/HCF/VP16 complex activates specifically only HSV IE genes.

Any of the herpesvirus proteins disclosed here may be used as a viral infectious antigen for productions of conjugates and combinations as described above.

CYTOKINES

In a further embodiment, the Fve polypeptide, nucleic acid, fragment, homologue, variant or derivative thereof is used to modulate cytokine levels in an individual. Preferably, the level of inflammatory cytokines is down-regulated. Examples of inflammatory cytokines include Granulocyte-Macrophage-Colony stimulating factor (GM-CSF), as well as any cytokine that mediates migration of alveolar macrophages into the lung and act to increase cell proliferation.

The term "cytokine" may be used to refer to any of a number of soluble molecules (e.g., glycoproteins) released by cells of the immune system, which act nonenzymatically through specific receptors to regulate immune responses. Cytokines resemble hormones in that they act at low concentrations bound with high affinity to a specific receptor. Preferably, the term "cytokine" refers to a diverse group of soluble proteins and peptides which act as humoral regulators at nano- to picomolar concentrations and which, either under normal or pathological conditions, modulate the functional activities of individual cells and tissues.

Particular examples of cytokines which are suitable for use in the methods and compositions described include interleukins, lymphokine, interferon, Colony Stimulating Factors (CSFs) such as Granulocyte-Colony Stimulating Factor (G-CSF), Macrophage-Colony stimulating factor (M-CSF) and Granulocyte-Macrophage-Colony stimulating factor (GM-CSF), GSF, Platelet-Activating Factors (PAF), Tumor Necrosis Factor (TNF).

Thus, interleukins such as IL1, IL2 and IL4, as well as interferons such as IFN- α , IFN- β and IFN- γ are included. Tumour necrosis factors TNF- α (cachetin), TNF- β (lymphotoxin) may also be suitably employed.

Preferred cytokines are those which are capable of recruiting immune responses, for example, stimulation of dendritic cell or cytotoxic T cell activity, or which are capable of recruiting macrophages to the target site. In a highly preferred embodiment, the cytokine comprises IL-2, GM-CSF or GSF.

5 CHEMICAL COUPLING

As noted above, the immunomodulator may be coupled to the allergen by a number of methods. Crosslinkers are divided into homobifunctional crosslinkers, containing two identical reactive groups, or heterobifunctional crosslinkers, with two different reactive groups. Heterobifunctional crosslinkers allow sequential conjugations, minimizing
10 polymerization.

Any of the homobifunctional or heterobifunctional crosslinkers presented in the table below may be used to couple the allergen with the immunomodulator to produce an immunomodulator-allergen conjugate.

Homobifunctional

Reagent	Cat. No.	Modified Group	Solubility	Comments	Refs
BMME	442635-Y	-SH	DMF, Acetone	Homobifunctional crosslinker useful for formation of conjugates via thiol groups.	Weston, P.D., et al. 1980. Biochem. Biophys Acta. 612, 40.
BSOCE S	203851-Y	-NH ₂	Water	Base cleavable crosslinker useful for studying receptors and mapping surface polypeptide antigens on lymphocytes.	Howard, A.D., et al. 1985. J. Biol. Chem. 260, 10833.
DSP	322133-Y	-NH ₂	Water	Thiol cleavable crosslinker used to immobilize proteins on supports containing amino groups.	Lee, W.T., and Conrad, D.H. 1985. J. Immunol. 134, 518.
DSS	322131-Y	-NH ₂	Water	Non-cleavable, membrane impermeable crosslinker widely used for conjugating radiolabeled ligands to cell surface receptors and for detecting conformational changes in membrane proteins.	D'Souza, S.E., et al. 1988. J. Biol. Chem. 263, 3943.
EGS	324550-Y	-NH ₂	DMSO	Hydroxylamine cleavable reagent for crosslinking and reversible immobilization of proteins through their primary amine groups.	Geisler, N., et al. 1992. Eur. J. Biochem. 206, 841. 14. Moenner, M., et al. 1986. Proc. Natl.

				Useful for studying structure-function relationships.	Acad. Sci. USA83, 5024.
EGS, Water Soluble	324551-Y	-NH ₂	Water	Water soluble version of EGS that reacts rapidly with dilute proteins at neutral pH. Crosslinked proteins are readily cleaved with hydroxylamine at pH 8.5 for 3-6 hours, 37°C.	Yanagi, T., et al. 1989. Agric. Biol. Chem.53, 525.
Glutaraldehyde	354400-Y	-OH	Water	Used for crosslinking proteins and polyhydroxy materials. Conjugates haptens to carrier proteins; also used as a tissue fixative.	Harlow, E., and Lane, D. 1988. Antibodies: A Laboratory Manual, Cold Spring Harbor Publications, N.Y., p. 349.
SATA	573100-Y	-NH ₂	DMSO	Introduces protected thiols via primary amines. When treated with hydroxylamine, yields a free sulhydryl group that can be conjugated to maleimide-modified proteins.	Duncan, R.J.S., et al. 1983. Anal. Biochem.132, 68.
<i>Heterobifunctional</i>					
Reagent	Cat. No.	Modified Group	Solubility	Comments	Refs
GMBS	442630-Y	-NH ₂ , -SH	DMSO	Heterobifunctional crosslinker useful for preparing enzyme-antibody conjugates (e.g. -gal-IgG) and for immobilizing enzymes on solid supports.	Kitagawa, T., et al. 1983. J. Biochem.94, 1160.19. Rusin, K.M., et al. 1992. Biosens. Bioelectron.7, 367.
MBS	442625-Y 442626-Y	-NH ₂ , -SH -NH ₂ , -SH	DMSO, Water	Thiol cleavable, heterobifunctional reagent especially useful for preparing peptide-carrier conjugates and conjugating toxins to antibodies.	Green, N., et al. 1982. Cell 28, 477.
PMPI	528250-Y	-SH ₂ , -OH	DMSO, DMF	Used in the preparation of alkaline phosphatase conjugates of estradiol, progesterone, serine-enriched peptides, and vitamin B12.	Aithal, H.N., et al. 1988. J. Immunol. Methods112, 63.
SMCC	573114-Y 573115-Y	-NH ₂ , -SH -NH ₂ , -SH	DMF, AN Acetonitrile Water	Heterobifunctional reagent for enzyme labeling of antibodies and antibody fragments. The cyclohexane bridge provides extra stability to the maleimide group. Ideal reagent for preserving enzyme activity and antibody specificity after coupling.	Annunziato, M.E., et al. 1993. Bioconjugate Chem.4, 212.
SPDP	573112-Y	-NH ₂ , -SH	DMF, AN Acetonitrile	Introduces protected thiol groups to amine groups. Thiolated proteins can be coupled to a second	Caruelle, D., et al. 1988. Anal. Biochem.173, 328.

				molecule via an iodoacetamide or maleimide group, or to a second pyridyldisulfide containing molecule.	
--	--	--	--	--	--

Each of these reagents may be obtained from a number of manufacturers, for example, from Calbiochem (catalogue number in column 2), or Piece Chemical Company.

PHARMACEUTICAL COMPOSITIONS

Fve polypeptides may be produced in large amounts at low cost in a bioactive form, allowing the development of Fve containing formulations by aerosolisation, nebulisation, intranasal or intratracheal administration.

While it is possible for the composition comprising the Fve polypeptide or nucleic acid to be administered alone, it is preferable to formulate the active ingredient as a pharmaceutical formulation. We therefore also disclose pharmaceutical compositions comprising Fve polypeptide or nucleic acid, or a fragment, homologue, variant or derivative thereof. Such pharmaceutical compositions are useful for delivery of Fve polypeptide, nucleic acid, fragment, homologue, variant or derivative thereof to an individual for the treatment or alleviation of symptoms as described.

The composition may include the Fve polypeptide, nucleic acid, fragment, homologue, variant or derivative thereof, a structurally related compound, or an acidic salt thereof. The pharmaceutical formulations comprise an effective amount of Fve polypeptide, nucleic acid, fragment, homologue, variant or derivative thereof, together with one or more pharmaceutically-acceptable carriers. An "effective amount" of an Fve polypeptide, nucleic acid fragment, homologue, variant or derivative thereof is the amount sufficient to alleviate at least one symptom of a disease as described.

The effective amount will vary depending upon the particular disease or syndrome to be treated or alleviated, as well as other factors including the age and weight of the

patient, how advanced the disease etc state is, the general health of the patient, the severity of the symptoms, and whether the Fve polypeptide, nucleic acid, fragment, homologue, variant or derivative thereof is being administered alone or in combination with other therapies.

- 5 Suitable pharmaceutically acceptable carriers are well known in the art and vary with the desired form and mode of administration of the pharmaceutical formulation. For example, they can include diluents or excipients such as fillers, binders, wetting agents, disintegrators, surface-active agents, lubricants and the like. Typically, the carrier is a solid, a liquid or a vaporizable carrier, or a combination thereof. Each carrier should be
- 10 “acceptable” in the sense of being compatible with the other ingredients in the formulation and not injurious to the patient. The carrier should be biologically acceptable without eliciting an adverse reaction (e.g. immune response) when administered to the host.

- The pharmaceutical compositions disclosed here include those suitable for topical and oral administration, with topical formulations being preferred where the tissue affected
- 15 is primarily the skin or epidermis (for example, psoriasis, eczema and other epidermal diseases). The topical formulations include those pharmaceutical forms in which the composition is applied externally by direct contact with the skin surface to be treated. A conventional pharmaceutical form for topical application includes a soak, an ointment, a cream, a lotion, a paste, a gel, a stick, a spray, an aerosol, a bath oil, a solution and the like.
- 20 Topical therapy is delivered by various vehicles, the choice of vehicle can be important and generally is related to whether an acute or chronic disease is to be treated. Other formulations for topical application include shampoos, soaps, shake lotions, and the like, particularly those formulated to leave a residue on the underlying skin, such as the scalp (Arndt et al, in *Dermatology In General Medicine* 2:2838 (1993)).

- 25 In general, the concentration of the Fve polypeptide, nucleic acid, fragment, homologue, variant or derivative thereof composition in the topical formulation is in an amount of about 0.5 to 50% by weight of the composition, preferably about 1 to 30%, more preferably about 2-20%, and most preferably about 5-10%. The concentration used

can be in the upper portion of the range initially, as treatment continues, the concentration can be lowered or the application of the formulation may be less frequent. Topical applications are often applied twice daily. However, once-daily application of a larger dose or more frequent applications of a smaller dose may be effective. The stratum corneum
5 may act as a reservoir and allow gradual penetration of a drug into the viable skin layers over a prolonged period of time.

In a topical application, a sufficient amount of active ingredient must penetrate a patient's skin in order to obtain a desired pharmacological effect. It is generally understood that the absorption of drug into the skin is a function of the nature of the drug, the
10 behaviour of the vehicle, and the skin. Three major variables account for differences in the rate of absorption or flux of different topical drugs or the same drug in different vehicles; the concentration of drug in the vehicle, the partition coefficient of drug between the stratum corneum and the vehicle and the diffusion coefficient of drug in the stratum corneum. To be effective for treatment, a drug must cross the stratum corneum which is
15 responsible for the barrier function of the skin. In general, a topical formulation which exerts a high *in vitro* skin penetration is effective *in vivo*. Ostrénga et al (J. Pharm. Sci., 60:1175-1179 (1971) demonstrated that *in vivo* efficacy of topically applied steroids was proportional to the steroid penetration rate into dermatomed human skin *in vitro*.

A skin penetration enhancer which is dermatologically acceptable and compatible
20 with the agent can be incorporated into the formulation to increase the penetration of the active compound(s) from the skin surface into epidermal keratinocytes. A skin enhancer which increases the absorption of the active compound(s) into the skin reduces the amount of agent needed for an effective treatment and provides for a longer lasting effect of the formulation. Skin penetration enhancers are well known in the art. For example, dimethyl
25 sulfoxide (U.S. Pat. No. 3,711,602); oleic acid, 1,2-butanediol surfactant (Cooper, J. Pharm. Sci., 73:1153-1156 (1984)); a combination of ethanol and oleic acid or oleyl alcohol (EP 267,617), 2-ethyl-1,3-hexanediol (WO 87/03490); decyl methyl sulphoxide and Azone.RTM. (Hadgraft, Eur. J. Drug. Metab. Pharmacokinet, 21:165-173 (1996));

alcohols, sulphoxides, fatty acids, esters, Azone.RTM., pyrrolidones, urea and polyols (Kalbitz et al, Pharmazie, 51:619-637 (1996));

Terpenes such as 1,8-cineole, menthone, limonene and nerolidol (Yamane, J. Pharmacy & Pharmacology, 47:978-989 (1995)); Azone.RTM. and Transcutol (Harrison et al, Pharmaceutical Res. 13:542-546 (1996)); and oleic acid, polyethylene glycol and propylene glycol (Singh et al, Pharmazie, 51:741-744 (1996)) are known to improve skin penetration of an active ingredient.

Levels of penetration of an agent or composition can be determined by techniques known to those of skill in the art. For example, radiolabeling of the active compound, followed by measurement of the amount of radiolabeled compound absorbed by the skin enables one of skill in the art to determine levels of the composition absorbed using any of several methods of determining skin penetration of the test compound. Publications relating to skin penetration studies include Reinfenrath, W G and G S Hawkins. The Weaning Yorkshire Pig as an Animal Model for Measuring Percutaneous Penetration. In: Swine in Biomedical Research (M. E. Tumbleson, Ed.) Plenum, New York, 1986, and Hawkins, G. S. Methodology for the Execution of *In Vitro* Skin Penetration Determinations. In: Methods for Skin Absorption, B W Kemppainen and W G Reifenrath, Eds., CRC Press, Boca Raton, 1990, pp.67-80; and W. G. Reifenrath, Cosmetics & Toiletries, 110:3-9 (1995).

For some applications, it is preferable to administer a long acting form of agent or composition using formulations known in the arts, such as polymers. The agent can be incorporated into a dermal patch (Junginger, H. E., in Acta Pharmaceutica Nordica 4:117 (1992); Thacharodi et al, in Biomaterials 16:145-148 (1995); Niedner R., in Hautarzt 39:761-766 (1988)) or a bandage according to methods known in the arts, to increase the efficiency of delivery of the drug to the areas to be treated.

Optionally, the topical formulations can have additional excipients for example; preservatives such as methylparaben, benzyl alcohol, sorbic acid or quaternary ammonium

compound; stabilizers such as EDTA, antioxidants such as butylated hydroxytoluene or butylated hydroxanisole, and buffers such as citrate and phosphate.

The pharmaceutical composition can be administered in an oral formulation in the form of tablets, capsules or solutions. An effective amount of the oral formulation is administered to patients 1 to 3 times daily until the symptoms of the disease alleviated. The effective amount of agent depends on the age, weight and condition of a patient. In general, the daily oral dose of agent is less than 1200 mg, and more than 100 mg. The preferred daily oral dose is about 300-600 mg. Oral formulations are conveniently presented in a unit dosage form and may be prepared by any method known in the art of pharmacy. The composition may be formulated together with a suitable pharmaceutically acceptable carrier into any desired dosage form. Typical unit dosage forms include tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, suppositories. In general, the formulations are prepared by uniformly and intimately bringing into association the agent composition with liquid carriers or finely divided solid carriers or both, and as necessary, shaping the product. The active ingredient can be incorporated into a variety of basic materials in the form of a liquid, powder, tablets or capsules to give an effective amount of active ingredient to treat the disease.

Other therapeutic agents suitable for use herein are any compatible drugs that are effective for the intended purpose, or drugs that are complementary to the agent formulation. The formulation utilized in a combination therapy may be administered simultaneously, or sequentially with other treatment, such that a combined effect is achieved.

The invention is described further, for the purpose of illustration only, in the following examples.

EXAMPLES

In each of the Examples presented below, where an activity is described for a Fve polypeptide comprising a GST (glutathione S transferase) portion (for example, as a GST-FIP fusion protein), we find that the polypeptide itself, without the GST portion, has substantially the same activity. This is to be expected, as the GST domain does not have any relevant biological activity as far as FIP is concerned.

Example 1. Isolation and Purification of Native Fve Protein from Golden Needle Mushroom*Methods and materials*

Two kilograms of the fruit bodies of *Flammulina velutipes* are homogenized with 2L ice-cold 5% acetic acid in the presence of 0.05 M 2-mercaptoethanol and 0.3 M sodium chloride. The proteins in the supernatant are precipitated by 95% saturated ammonium sulfate.

The precipitate is re-dissolved and dialyzed against 10 mM Tris-HCl pH 8.5 (buffer A) at 4°C for 48 hours with six to eight changes of dialysis buffer. The protein solution is applied to the Q Sepharose FF column (2.6 × 10 cm, Pharmacia) that has been previously equilibrated with buffer A. The unbound fraction is collected and dialyzed against 10 mM sodium acetate pH 5.0 (buffer B) at 4°C for 48 hours with six to eight changes of dialysis buffer and then further purified by applying to the SP Sepharose FF column (2.6 × 10 cm, Pharmacia) that has been previously equilibrated with buffer B.

The protein is eluted with a gradient of 0-0.5 M NaCl in buffer B. Fractions containing Fve protein are collected and analyzed by a 7.5% Tris-Tricine SDS-PAGE.

Results

High yield of native Fve protein is purified from Flammulina velutipes

The native Fve protein has an apparent molecular weight of 12.7 kDa as determined by SDS-PAGE (Figure 1A). However, it appears to be a homodimer with a
5 molecular weight of 25.5 kDa as determined by Superdex 75 (26 × 60 cm, Pharmacia) gel filtration chromatography (Figure 1B and 1C). The running buffer for gel filtration is 10 mM Tris-HCl pH 7.5, 0.2 M sodium chloride.

Fve protein is the major component in the crude extract from the mushroom fruit
bodies. By removing the cap of the mushroom, we managed to reduce the amount of
10 polysaccharides that cause undesirable interference in the process of protein purification.

The yield of native Fve protein is 40 mg from 1 kg wet-weight of starting material.

Example 2. Measurement of gene expression profile at mRNA level after Fve stimulation

Methods and Materials

15 Two subsets of effector Th cells have been defined on the basis of their distinct cytokine secretion patterns and immunomodulatory effects (Mosmann et al., 1989; Paul and Seder, 1994; Abbas et al., 1996). Th1 cells produce inflammatory cytokines, such as IFN- γ , TNF- α , IL-12, IL-15 and IL-18, and enhance cellular immunity mediated by macrophages. In contrast, Th2 cells produce a different group of cytokines, such as IL-4,
20 IL-5, IL-6 and IL-13. The differentiation of precursor T cells into Th1 or Th2 cells has important biologic implication in terms of susceptibility or resistance to a particular disease.

In order to characterize the cytokines expression pattern induced by Fve, human
PBMC from healthy donor and splenocytes from 8 week-old BALB/cJ mice are collected
25 and cultured with 20 μ g of native Fve. The mRNA is extracted at 48 hours using RNeasy

Mini mRNA Purification Kit (QIAGEN). First-strand cDNA is then generated from the mRNA template using oligo-dT primers and MMLV reverse transcriptase (Promega).

5 PCR reactions are performed with Taq polymerase (Promega) with standard conditions and optimized annealing temperatures. The amplified products are analysed by electrophoresis in 1.5% agarose gel containing ethidium bromide (0.5µg /ml) and photographed with UV exposure. Messenger RNA for various cytokines and transcription factors are measured. House keeping genes mRNA for hypoxanthine ribosyl-transferase (HPRT) and cyclophilin are used as internal controls.

Results

10 *Enhanced expression of IFN-γ, TNF-α, IL-1β, IL-2, IRF-1, c-Rel, Bcl-X_L, ICAM-1, and iNOS mRNA*

Human PBMC and spleen cells from BALB/cJ mice are cultured with 20µg of Fve and analyzed for cytokine mRNA expression at 48hr. The results indicated that there is an increase in IFN-γ, TNF-α, iNOS mRNA production by spleen cells cultured with Fve
15 protein. Mouse IL-12 remains unchanged. This phenomenon occurred in a dose dependent manner.

Similar results are seen in human PBMC. The mRNA for human cytokines IL-1β, IL-2, IFN-γ and TNF-α; transcription factor IRF-1 and c-Rel; adhesion molecule ICAM-1 and anti-apoptotic protein Bcl-X_L is up regulated after Fve stimulation. Figure 2 and
20 Figure 3 show the patterns of mRNA expression for transcription factors, cytokines and adhesion molecules of the splenocytes and PBMC stimulated by Fve.

Example 3. Generation of Fve Mutants By PCR-Based Mutagenesis

Materials and Methods

A cDNA encoding for the Fve protein is cloned into the BamHI and EcoRI site of
25 pGEX-4T1. This DNA template is used to generate a panel of mutants by recombinant-

PCR method (Figure 4). A schematic representation of the strategy used to generate mutants is shown in Figure 5.

As predicted by PHD prediction program, Fve contains one α -helix, six β -strands and two β -turns. Each of these predicted secondary structures is serially deleted by recombinant-PCR method. In addition, we also examined the potential function of the R27, G28, T29 residues, which resembles the cell aggregating RGD motif, located in the N-terminal β -turn of Fve protein by point mutation. Each of the amino acid residues of RGT is substituted by alanine residue.

A partial list of fragments of Fve is shown in **Appendix B**.

10 **Example 4. Production of the Fve-Derived Mutant Proteins**

Materials and methods

Eleven deletion mutants and three point mutants of Fve DNA are generated. Each of the polypeptides is expressed in TG1 *E.coli* cells as fusion protein with GST carrier protein and purified by glutathione affinity column. All the mutants could express protein except insoluble mutant D6-18, in which α -helix has been deleted.

Figure 6 shows the panel of the affinity purified mutant proteins on a SDS-PAGE. These purified proteins are used for the cell aggregation, hemagglutination and lymphocytes proliferation assay.

Example 5. Comparison of Hemagglutination Activity of Fve Mutants

20 *Materials and methods*

5ml of whole human blood obtained from a healthy volunteer is centrifuged at 2500Xg for 10min. The plasma is removed and 2ml of packed red blood cells are collected from the bottom of the tube.

The red blood cells (RBC) are diluted 5X with 1xPBS buffer and centrifuged at 1200Xg for 10min. RBC pellet is resuspended in 1.5%(v/v) of 1xPBS. 50ul of 2x serial dilutions (from 64µg /ml to 0.25µg /ml) of each Fve mutant protein is added into 50ul of 0.2% gelatin in 1xPBS (pH 7.4) and then mixed with 100ul of 1.5% RBC in each well of the 96-well round bottom microtiter plates. Cells are incubated at room temperature and examined for hemagglutination after 2 hours and over night, respectively (Table 1).

Example 6. Lymphocytes Aggregation Activity of Fve and Its Mutants

Materials and methods

Human peripheral blood mononuclear cells (PBMC) from a healthy donor are isolated and cells are then cultured with 20µg /ml of various Fve mutants in 24-well plates. Cells aggregation is observed by inverted light microscopy after 24 hours (Table 1).

Results

Mutant GST-FveG28A lost the hemagglutination and lymphocytes aggregation activity

Native Fve, GST-Fve (wild type) and two point mutants, GST-FveR27A and GST-FveT29A, show positive aggregation and hemagglutination activity. These properties are not seen in all the deletion mutants and a point mutant GST-FveG28A. PHA and ConA are used as positive controls; GST and Blo t 5 are used as negative controls. These results are summarized in Table 1.

The Arg-Gly-Asp (RGD) tripeptide sequence is the most common molecular recognition site implicated in several immunological reactions. Normally RGD motif is located in the β -turn structure. According to the PHD prediction, residue 19 to 33 is a β -turn structure. Therefore, we propose that glycine residue of RGT (RGD-like motif) tripeptide sequence at position 28 plays an important role on lymphocyte aggregation/adhesion. The potentially interaction between Fve and the proteins of integrin family will be addressed.

	Cell aggregation	Hemagglutination
--	------------------	------------------

D19-33	-	-
D34-46	-	-
D47-60	-	-
D61-72	-	-
D73-84	-	-
D85-97	-	-
D98-106	-	-
D107-115	-	-
P55-100	-	-
D61-97	-	-
*R27A	+	+
**G28A	-	-
***T29A	+	+
rGST-Fve	+	+
nFve	+	+
GST	-	-
Blo t 5	-	-
ConA	+	+
PHA	+	+

Table 1. Lymphocytes aggregation and RBC hemagglutination activities of Fve mutants

Example 7. Lymphoproliferation Activity of Fve Mutants

5 *Materials and methods*

Splenocytes from Balb/cJ mice and peripheral blood mononuclear cells (PBMC) from a healthy donor are stimulated with 2.5µg /ml, 5µg /ml, 10µg /ml or 20µg /ml respectively of Fve mutant proteins for 24 hours. Then 1 µCi [³H]-thymidine is added to the culture and further incubated for 18 hours. [³H]-thymidine incorporation is measured in
10 triplicates by a β counter (Beckman).

Results

Figure 7 and 8 show the results of the proliferation assay for the panel of proteins tested. Deletion mutants D19-33, D73-84, P55-100, and mutant with single amino acid substitution G28A showed significant reduction in lymphoproliferation activity in mouse splenocytes, whereas, such reduction is less pronounced for the rest of the mutants tested (Figure 7).

Interestingly, some mutants such as D34-46, D47-60 and D61-72, which show negative hemagglutination and cell aggregation, retain similar lymphoproliferative activity as the wild type protein. For the result of human PBMC, deletion mutant D61-72 and mutant with single amino acid substitution G28A show more than 50% reduction in lymphoproliferation activity (Figure 8). Taken together the proliferation results from mouse splenocytes and human PBMC demonstrate that glycine at position 28 plays a key role in lymphocyte proliferation.

Example 8. Recombinant GST-Fve (Wild Type) and GST-FveT29A (Mutant) Show Similar Proliferative Activity of CD3⁺ T Cells as the Native Fve

Materials and methods

Human peripheral blood mononuclear cells (PBMC) from a healthy donor are isolated according to the standard protocol (Coligan et al., 1998). The cells are then cultured with 20 µg /ml of recombinant wild type GST-Fve and mutant GST-FveT29A for 5 days. Cells are stained with anti-CD3⁺ PerCP monoclonal antibody (Becton Dickinson), and analyzed by FACScan flow cytometry (Becton Dickinson).

Results

A histogram shows that 8% and 17% enrichment of T cells are detected after stimulation with recombinant wild type GST-Fve and mutant GST-FveT29A for 5 days (Figure 9). Results showed that both recombinant wild type GST-Fve and mutant GST-

FveT29A showed comparable lymphoproliferative activity of T lymphocytes as well as the native Fve protein.

These data suggest that Fve-mediated T cell polarization and enrichment is detectable at day 5.

5 Example 9. Detection of IFN- γ and TNF- α by Intracellular Cytokine Staining After Stimulation with Recombinant GST-Fve Protein

Methods and Materials

Intracellular cytokine staining is done by modification of a standard method from PharMingen. Briefly, human PBMC are stimulated *in vitro* with 20 μ g of native Fve
10 protein, GST, recombinant GST-Fve, GST-R27A, GST-G28A, or with GST-T29A. GlogiPlugTM (PharMingen) is added 48hr after the cultures are initiated, cells are collected 14 hr later and then stained for T cells surface marker (CD3) in FACS buffer containing GlogiPlugTM. Cells are then treated with Cytofix/Cytoperm (PharMingen) for 30min. Cells
15 are incubated with cytokine antibodies for 30min after washing with Perm Wash buffer (PharMingen). Finally, cells are washed with PBS containing 1% paraformaldehyde and then analyzed by FACSCalibur flow cytometry (BD Biosciences). CellQuest software (BD Biosciences) is used for data analysis.

Results

The results show that native Fve protein is able to stimulate production of IL-2,
20 IFN- γ , TNF- α , but not IL-4 in CD3⁺ T cells (Figure 10). Similar results are seen for the recombinant wild type GST-Fve and two mutants GST-FveR27A, GST-FveT29A. Strikingly, recombinant mutant GST-FveG28A failed to stimulate the production of such cytokines (Figure 11 and 12).

The percentages of IFN- γ production induced by GST, GST-Fve, GST-FveR27A,
25 GST-FveG28A, GST-FveT29A are 0.8%, 12.3%, 14.3%, 1.8%, 17.6%, respectively. In contrast, the percentages of TNF- α production which induced by GST, GST-Fve, GST-

FveR27A, GST-FveG28A, GST-FveT29A are 1.2%, 21.5%, 18.7%, 1.5%, 14.4%, respectively (Table 2). This data provides further evidence that the glycine residue at position 28 of Fve protein plays an important role in the biological function such as aggregation/adhesion, cytokines production, proliferation, and differentiation of lymphocytes. Further examination of the physiological role of RGT sequence in Fve protein by using blocking monoclonal antibodies and peptide inhibition assay are carried out to confirm this function. The possibility of integrin-mediated T/NK-cell adhesion is also investigated.

In summary, mutants FveR27A and FveT29A show enhanced mitogenic activities as compared to that of wild type Fve. In addition, the solubility of both mutant proteins is significantly increased in comparison with that of wild type Fve. This improved solubility will greatly facilitate the large scale production of such recombinant protein.

Recombinant proteins	Intracellular IFN- γ	Intracellular TNF- α
GST	0.8%	1.2%
GST-FveWT	12.3%	21.5%
GST-FveR27A	14.3%	18.7%
GST-FveG28A	1.8%	1.5%
GST-FveT29A	17.6%	14.4%

Table 2: The percentage of intracellular cytokines production in CD3⁺ T lymphocytes during stimulation with three different Fve mutants with single amino acid substitution

Example 10. Applications of Fve in Allergy

The increasing prevalence of atopic diseases such as hayfever or allergic asthma is a major problem in most developing and developed countries. Accumulating evidence indicates that appropriate immunotherapy prevents the onset of new sensitization and the progress of allergic rhinitis to asthma.

The central role of allergen-specific Th2 cells in the regulation of allergic inflammation has been highlighted. Exploration of novel and effective treatment for atopic

diseases is active area of allergy research. Induction of allergen-specific T regulatory immune response, suppression of the effects of IL-4, IL-5 and IL-13 cytokines, and redirecting/balancing Th2 immune response in allergy is an attractive and promising approach to pursue (Akbari et al., 2002; Scanga and Le Gros, 2000; Zuany-Amorim et al.,
5 2002).

Our *in vitro* and *in vivo* studies reveal that Fve interacts with T and NK cells.

Fve-activated T cells produce Th1-skewed cytokines in high levels, and suppress Th2 cytokines (IL-4 and IL-13) production. Thus these biological activities of Fve can be exploited to treat Th2-associated diseases such as allergic asthma and rhinitis. The use of the
10 immunomodulatory properties of Fve to treat allergic diseases is novel because there are a number of differences between Fve approach and other existing methods such as hexameric motifs, called CpG motifs or DNA immunostimulatory sequences (ISS).

The function of ISS is act as a danger signal to stimulate non-specific innate immune response (Krieg 2000). It is known that ISS is recognized by the toll-like receptor
15 9 on B cells and CD123⁺ dendritic cells. It is unexpected that TLR9 is also involved in autoimmunity (Leadbetter et al., 2002; Krieg 2002; Vinuesa and Goodnow, 2002). Upon the detection of CpG motifs or ISS element, B cells are induced to proliferate and secrete immunoglobulin (Ig), and dendritic cells (DCs) secrete a wide array of cytokines, interferons and chemokines that promote T helper type 1 (Th1) cells. Both B and DCs up-
20 regulate costimulatory molecules and have enhanced abilities to induce Th1 cell immune responses. In contrast, Fve is directly target on T and NK cells to involve in the acquire immunity.

Example 11. Co-Administration of Fve with Allergens: *In vivo* Study of the Adjuvant Effect of Fve Using a Murine Allergic Asthma Model

25 Immunotherapy with recombinant allergen in combination with certain immunomodulator enhancing Th1 but suppressing Th2 immune response is a novel

approach to achieve higher efficacies in immunotherapy. Since Fve protein is an activator of Th1/Tc1 immune response, it may be used as such an immunomodulator to provide the adjuvant effects to enhance Th1-skewed immunity.

We investigated the adjuvant effects of Fve for allergy immunotherapy with a combination of a recombinant house dust mite major allergen, Der p 2 and Fve using an animal model.

Methods and Materials

A schematic representation of the experimental design is shown in Figure 13.

8 to 10 week old male BALB/cJ mice obtained from the Sembawang Laboratory Animal Center of Singapore are divided into two groups for each experiment. Mice are sensitized by intraperitoneal injection of 10µg of recombinant Der p 2 in aluminum hydroxide at day 0 and day 21. Twenty-eight days after the sensitization, each group of mice is subcutaneously injected with 50µg of Der p 2 and 50µg of Der p 2 plus 40µg of Fve, respectively. A total of six injections are performed at every alternative day over a period of 12 days. Mice are then challenged with the third intraperitoneal injection of 10µg of Der p 2 plus aluminum hydroxide at day 42. Der p 2-specific IgG1 and IgG2a are determined weekly starting at day 14 by ELISA. Since IgG2a is the hallmark of Th1 immunity in mouse, titer of IgG2a is used as a measure of Th1 immunity.

Results

Increased allergen-specific IgG2a production in the treatment group with combination of Fve and allergen Der p 2

As shown in Figure 13, mice that are subcutaneously treated with 50µg of Der p 2 alone produced relatively lower titers of Der p 2-specific IgG2a, whereas mice treated with 50µg of Der p 2 plus 40µg of Fve showed a significant boost of Der p 2-specific IgG2a production (Figure 14).

Upon challenge with intraperitoneal immunization of Der p 2 in alum at day 42, the Der p 2-specific IgG2a in Fve administered mice is further increased at day 49. It is interesting to note that the Fve-specific IgG1 and IgG2a remained low (data not shown).

5 *Increased allergen-specific IgG2a production in the treatment group with combination of Fve and allergen Blo t 5*

Similar results are observed in similar experiments performed with another house dust mite major allergen, Blo t 5, from *Bromia tropicalis*. These results are shown in Figure 14B.

10 Thus we demonstrate modulation of allergen-specific antibodies responses to the major house dust mite allergen, Blo t 5, by combining treatment with a fungal immunomodulatory protein,

Taken together, the data suggested that Fve protein may act as a potent adjuvant/immunomodulator to boost antigen-specific Th1-skewed immune response, therefore it may serves as a useful reagent to improve the efficacies of immunotherapeutic treatment of allergy in humans. The adjuvanticity and immunomodulatory property of Fve protein may be improved by biomolecular engineering.

20 While not wishing to be bound by theory, it is postulated that this molecule may activate NK cells and CD8⁺ T cells and thus result in production of IFN- γ . These may induce a strong cellular-mediated immune response and promote isotype switching to specific IgG2a predominantly.

Example 12. Assessment of Erythema Flare and Wheal Diameter Formation Induced by Skin Prick Tests in Human Allergic Subject

Materials and methods

25 The skin prick test is a convenient diagnostic method test for allergy in the clinics. The aim of this study is to evaluate the suppression effect of Fve protein to allergen

hypersensitivity. As an *in vivo* topical challenge method, the skin prick test is administered to a human subject with history of sensitization to house dust mite *Dermatophagoides pteronyssinus*.

25µg /ml of purified recombinant Der p 2 allergen mixed with same concentration
5 of native Fve protein or Der p 2 allergen alone, is applied to the skin of left and right hand of human subject for 10 minutes. Histamine is used as a positive control. The size of the wheel and erythematic flare diameter is measured manually.

Results

10 *Fve reduces wheal and erythematic flare formation on Der p 2 skin prick test-positive human subject*

The formation of wheal and erythematic flare could be detected in the challenged site of histamine, Der p 2, and Der p 2 combined with Fve. The diameter of the wheals in both left and right hand induced by Der p 2 is 22mm and 24mm, respectively. Interestingly, the mixture of Der p 2 and Fve reduces the wheal's diameter in both hands to
15 15mm and 18mm, respectively (Figure 15A). A similar reduction is also seen in the size of erythematic flare (Figure 15B, Table 3A and 3B).

The data indicates that there is a suppression of allergic reaction mediated by immunomodulatory effects of Fve protein. The results provide additional evidence that Fve could be used as an adjuvant for allergens immunotherapy.

20 Besides indoor allergens, outdoor allergens are also important triggering factors that lead to allergic diseases. Hay fever and allergic asthma triggered by grass pollen allergens affect approximately 20% of the population in cool temperate climates. Worldwide more than 200 million individuals are allergic to group 1 grass pollen allergens, and over 100 million individuals exhibit IgE-mediated allergic reactions against
25 Phl p 2, a major allergen from timothy grass (*Phleum pratense*) pollen.

Therefore, we propose that recombinant Fve as well as the native Fve may also be applied in the treatment of other allergies that induced by tree pollen allergen (Bet v 1 and Bet v 2 from birch), grass pollen allergen (Phl p 1 and Phl p 2 from timothy grass), weed pollen allergen (antigen E from ragweed), major feline antigen (Fel d 1), major canine allergen (Der f 15), etc. Other allergens will be known to the person skilled in the art.

Another useful application of Fve protein in allergy is to conjugate or co-deliver with allergenic crude extracts such as mite extracts, pollen extracts, cat and dog extracts, cockroach extracts, fungal and mold extracts for desensitization by immunotherapy.

	Wheal Diameter (mm)	
	Left hand	Right hand
Saline (negative control)	0	0
Histamine	7	5
Der p 2	22	24
Der p 2 + Fve (1:1 w/w)	15	18

Table 3A: Wheal formation on skin after challenged with Der p 2

	Erythematic Flare Diameter (mm)	
	Left hand	Right hand
Saline (negative control)	0	0
Histamine	30x25	35x30
Der p 2	55x40	50x43
Der p 2 + Fve (1:1 w/w)	45x35	45x35

Table 3B: Erythematic flare formation on skin after challenge with Der p 2

Reference is also made to Figure 15C, which shows a demonstration of immomodulatory activity of Fve in an allergic subject. Thus, quantitative skin-prick tests are performed to evaluate the immunomodulatory function of Fve by co-administration with Der p 2 mite allergen *in vivo*.

A positive reaction (56 - 130 mm wheel diameter) is shown when Der p 2 alone (20 ug/ml) is applied onto the skin of the fore arm of *Dermatophagoides* mite allergic subject. There is a Fve- dose-dependent reduction of skin reaction when different amount of Fve are used in combination with Der p2 allergen for skin tests.

FVE ADJUVANTED ALLERGEN VACCINES**Example 13. Fusion Proteins of Fve and Allergen***Materials and methods*

5 Treatment of recombinant allergen or vaccination with naked DNA encoding a specific allergen has been shown previously to elevate allergen-specific Th1 immune response against Th2 immune reaction (Maecker et al., 2001). To enhance the effectiveness of immunotherapy or DNA vaccine therapy, we generate several fusion proteins consisting of the complete Fve molecule and the mature form of Blo t 5 or Der p 2 allergen.

10 Figure 16 shows the construction of seven fusion proteins of Fve and major house dust mite allergen from *Dermatophagoides ptenyssinus* and *Blomia tropicalis*

The fused cDNAs are successfully expressed in E coli (Figure 17) and the biological properties of the recombinant proteins are examined.

Results

15 The morphology of lymphocyte culture upon stimulation with three recombinant fusion proteins is photographed with inverted microscope (Figure 18A-C). Each of Bt5-Fve, Bt5-FveR27, GST-Dp2-FveR27 are able to increase the number of human PBMC (Figure 19A and 19B), to stimulate the proliferation of human lymphocytes (Figure 20), to polarize human CD8⁺ T cells (Figure 21), and to increase the production of IFN- γ (Th1 response) and IL-10 (Tr response) (Figure 22).

A well-balanced vaccine that induces both Th1 and Tr immune response may be the most valuable and desirable. The Th1 response may very efficiently inhibit the development of Th2 cells via IFN- γ , leading to a life-long protective Th1 memory immune response. Allergen specific Tr cells may in turn dampen the anti-allergic Th1 immune

response, ensuring a well-balanced protective but nonpathological Th1 response. Allergen-Fve fusion proteins meet these criteria since they induce cytokine IL-10.

Thus, combining Fve protein with allergen in the form of a fusion protein may be used effectively to induce antigen-specific adjuvant effect that augment the Th1 and Tr responses, which in turn down-regulate the Th2 allergic responses.

To test the antigenicity of a Blo t 5-Fve fusion protein, competitive inhibition ELISA is performed using varying concentrations of proteins (GST, GST-Blo t5, GST-Fve, GST-Blo t5-Fve, GST-Fve-Blo t5, Blo t5-Fve). The results show that fusion protein Blo t 5-Fve, un-cleaved GST-Blo t5-Fve and GST-Fve-Blo t5 have lower IgE binding affinity compared to Blo t5 alone and un-cleaved GST-Blo t5 (Figure 23). The fusion protein Blo t5-Fve inhibited IgE binding to a maximum of 70% whereas Blo t5 is able to inhibit the binding of antibody to GST-Bt5 to 100% at inhibitor concentration of 10 µg/ml. Control GST and GST-Fve are not able to inhibit the binding of IgE to GST-Blo t5 (background levels). In summary, there is a reduction in the IgE binding affinity of Blo t5 when it is in the fusion forms of Blo t5-Fve, GST-Blo t5-Fve and GST-Fve-Blo t5 indicating that the antigenicity of Blo t5 with Fve in fusion forms is lowered.

Experiment B

Five mice per group of female BALB/cJ (6 - 8 weeks old) are subcutaneous immunized with 10 µg/ml of major house dust mite allergen Blo t 5 alone or fusion protein Blo t 5-FveT29A in tail at day 1. Mice are received similar antigen boosting in footpads at day14 and day 28. All mice were bled weekly and sera were collected for analysis of Blo t 5 and Fve-specific IgG1, IgG2a and IgE by ELISA.

The results are presented in Figure 23B, which shows the concentrations of Blo t 5-specific antibodies (left hand column: top Blo t 5-specific IgG2a, middle: Blo t 5-specific IgG1, bottom: Blo t 5-specific IgE) as well as Fve-specific antibodies (right hand column: top Fve-specific IgG2a, middle: Fve-specific IgG1, bottom: Fve-specific IgE).

The results show that recombinant fusion protein of allergen and fungal immunomodulatory protein has the ability to induce Blo t 5-specific IgG2a (2a) and down-regulate IgE production (2c). The overall of Fve-specific IgG1 and IgG2a antibodies are lower than Blo t 5 and decrease gradually after day 42 (2d and 2e), and the induction of
5 Fve-specific IgE is less than 1 ng/ml (2f).

Therefore, fungal immunomodulatory protein Fve has the potential to be developed for the immunotherapeutic vaccine of allergy.

Experiment C

All groups of female BALB/cJ (6 – 8 weeks old) are sensitized intraperitoneally on
10 day 1 with 5 µg of recombinant mite allergen Blo t 5 and boosted at day 14 with 1 µg of Blo t 5 adsorbed to 64 µg/µl of aluminum hydroxide gel in a final volume of 200 µl. Mice treated with six subcutaneous injections of 20 µg of Blo t 5-FveWT or Blo t 5-FveT29A fusion protein in 200 µl of PBS at three days interval started from day 21 - 35. The negative control mice receive six subcutaneous injections of 20 µg of Blo t 5 alone. All
15 mice are bled weekly and sera were collected for analysis of Blo t 5 and Fve-specific IgG1, IgG2a, and IgE by ELISA.

The results are presented in Figure 23C which shows the concentrations of Blo t 5-specific antibodies (left hand column: top Blo t 5-specific IgG2a, middle: Blo t 5-specific IgG1, bottom: Blo t 5-specific IgE) as well as Fve-specific antibodies (right hand column:
20 top Fve-specific IgG2a, middle: Fve-specific IgG1, bottom: Fve -specific IgE).

These results show that recombinant fusion protein Blo t 5- FveT29A has the ability to induce Blo t 5-specific IgG2a antibody (3a) in allergensensitized mice.

Discussion

It is well recognized that a vaccine that induces both Th1 and Tr immune response
25 is highly desirable for treatment of allergy, and the allergen-Fve fusion proteins seem to meet these criteria since it could induce both cytokines IFN-γ (Th1) and IL-10 (Tr). It is

anticipated that Fve protein with allergen in the form of a fusion protein could be an effective way to induce antigen-specific adjuvant effect that augment the Th1 and Tr responses, which in turns can down-regulate the Th2 allergic responses. Besides, it is known that in the inductive phase of allergen sensitization, Th1 cytokines can inhibit the development of Th2 cells via IFN- γ , leading to a life-long protective Th1 memory immune response. Allergen specific Tr cells may in turn dampen the anti-allergic Th1 immune response, ensuring a well-balanced protective but nonpathological Th1 response.

Therefore, Fve-allergen fusion proteins can be exploited to develop vaccine for prophylactic of allergic disorders.

10 Example 14. Allergen Conjugated to Fve

Beside the use of gene fusions to produce fusion proteins, protein-protein conjugation also provides a convenient and alternative choice to develop allergen vaccine.

To date, allergen conjugated adjuvants which have been reported include crystalline bacteria cell surface layer (S-layers) (Jahn-Schmid et al., 1996), CpG oligodeoxynucleotides (CpG motifs) (Shirota et al., 2000), cholera toxin B subunit (CTB) (Rask et al., 2000), and Brucella abortus (Scharf et al., 2001).

Here we disclose Fve protein which is isolated from edible mushroom can also be an ideal adjuvant coupling to allergen vaccine. Poly-lactic acid (PLA) and polyethylene glycol (PEG) are two materials which may be used to couple Fve and house dust mite allergen (Der p 2 or Blo t 5), although other materials will be evident to the skilled reader.

Particular cross-linking reagents which may be used to conjugate an allergen and immunomodulator, such as Fve, include N,N'-dicyclohexylcarbodiimide (DCC), N-succinimidyl-S-acetyl-thioacetate (SATA), N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), ortho-phenylenedimaleimide (o-PDM), and sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (sulfo-SMCC). A chemical conjugation

protocol which may be used is that provided in the Protein-Protein Crosslinking Kit (P6305) from Molecular Probes, Eugene, USA. Protocols for conjugation using SPDP are disclosed in Clinical Experimental Allergy 30: 1024-1032, 2000 and European Journal of Immunology 28: 424-432, 1998.

- 5 For example, native Fve or recombinant Fve from *E coli* is conjugated with N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP, Molecular Probes) as a bifunctional coupling reagent. The resulting Allergen-Fve conjugates are purified by gel filtration and characterized for their allergenicity and adjuvanicity by *in vitro* and *in vivo* assays.

Example 15. Human Cytokine Assay in Purified CD4⁺ and CD8⁺ T Cell Subsets

10 *Materials and Methods*

- To elucidate and identify subsets of human T lymphocytes responding to Fve stimulation, purified CD4⁺ T cells and CD8⁺ T cells from four human tonsillectomy patients (subject 1, 6 yrs-old Chinese; subject 2, 16 yrs-old Indian; subject 3, 17 yrs-old Malay; subject 4, 27 yrs-old Malay) are stimulated with 20µg of Fve after AutoMACS
15 seperation. AutoMACS is an automated magnetic cell sorter from Miltenyi-Biotec, Germany. The differential cytokine production profiles of these subsets are determined by intracellular cytokines staining after 48 hours *in vitro* culture.

Results

Fve Triggers Th1/Tc1 Cytokine Production in Human T Cells

- 20 The human cytokines induction studies show that Fve stimulates the production of IL-2, IFN-γ, TNF-α, whereas IL-4 and IL-10 are nearly undetectable. In addition, purified CD4⁺ T cells produce higher levels of TNF-α than purified CD8⁺ T cells (CD4⁺ vs CD8⁺: 11.4% vs 2.5%), whereas purified CD8⁺ T cells produce higher levels of IFN-γ than purified CD4⁺ T cells (CD4⁺ vs CD8⁺: 3.6% vs 8.5%) upon Fve stimulation (Table 4).
25 Therefore, the enrichment of CD8⁺ T cells seems to derive from a protein-cell direct interaction. Taken together, this data supported that Fve could trigger Th1/TC1 cytokines production in human T lymphocytes.

Intracellular Cytokines Secretion	Purified CD8 ⁺ T cells from human tonsil		Purified CD4 ⁺ T cells from human tonsil	
	None	Fve	None	Fve
IL-2	0.1%	0.6%	0.2%	6.8%
IL-4	0.1%	0.3%	0.1%	0.9%
IL-10	0.6%	0.5%	2.3%	0.9%
IFN- γ	0.1%	8.5%	0.6%	3.6%
TNF- α	0.2%	2.5%	0.4%	11.4%

Table 4. Cytokines profile of purified human T cells subsets

Example 16. Lymphocyte Aggregation Activity of Fve*Materials and Methods*

Human CD4⁺ and CD8⁺ T cells subset are purified from AutoMACS (an
 5 automated magnetic cell sorter from Miltenyi-Biotec, Germany). The morphology of the
 cells is observed by light microscope at day 3.

Six human cell lines are also used for the cell aggregation study. Promyelocytic
 HL-60 cells, Jurkat-T cells, monocytic leukemia U937 cells, myeloid leukemia K562 cells,
 Raji B cells, natural killer NK-92 cells are cultured with native Fve protein with 2.5 μ g/ml,
 10 5 μ g/ml, 10 μ g/ml, 20 μ g /ml and 40 μ g/ml, respectively. Cells aggregation is observed by
 inverted light microscopy after 24 hours.

Results

Fve induced aggregation of human CD4⁺ and CD8⁺ T cells subsets, HL-60, Jurkat-T cells, and NK-92 Cells

Human CD4⁺ and CD8⁺ T cells subset are purified from the tonsil of human
 5 subject. The aggregation of CD4⁺ and CD8⁺ T cells upon stimulation with 20µg of Fve
 protein is observed by confocal microscope at day 3 (photographed data not shown).

From the human cell line study, we found that Fve could induce HL-60 aggregation
 at low concentration of 2.5µg /ml. Jurkats-T cells and NK-92 also induced aggregation by
 Fve at concentration of 10µg /ml and 20µg /ml, respectively, where as U937, K562 and
 10 Raji didn't induce cell aggregation (Table 5). From the result, it seems that the level of cell
 aggregation correlates with the level of certain surface protein(s) expression in different
 cell lines. Promyelocytic cell line HL-60 seems to be an idea cell line to identify Fve
 receptor.

Human Cell Lines	Fve				
	2.5µg /ml	5µg /ml	10µg /ml	20µg /ml	40µg /ml
HL-60	+	+	+	+	+
Jurkat T	+/-	+/-	+	+	+
U937	-	-	-	-	+/-
K562	-	-	-	-	+/-
Raji	-	-	-	-	-
NK-92	-	-	+/-	+	+

Table 5. Cell aggregation activity of human cell lines

Example 17. *In vitro* Polarization of Human NK cells and CD8⁺ T Cells*Materials and Methods*

Human peripheral blood mononuclear cells (PBMC) from a healthy donor are isolated as standard protocol (Coligan et al., 1998). The cells are then cultured in 24-well
5 plates with native Fve (5µg /ml or 25µg /ml). At days 5 and 10, cell culture are stained with anti-CD4⁺ FITC, anti-CD8⁺ PE, anti-CD16⁺ PE plus anti-CD56⁺ PE monoclonal antibodies (Becton Dickinson), and analyzed by FACScan flow cytometry (Becton Dickinson).

Results

10 *Sequential polarization of cells by Fve, NK cells and NKT cells are proportionally increased at day 5 whereas CD8⁺ T cells are increased at day 10*

The results show a 10% increase of CD16⁺ and CD56⁺ double positive cells (Natural Killer cells) after stimulation with Fve protein for 5 days (Figure 24). In addition, CD8⁺ T cells but not CD4⁺ cells are increased up to 35% after culturing for 10 days
15 (Figure 25). This result showed that native Fve protein could stimulate both natural killer cells and CD8⁺ T cells and the stimulation of these cells occurred sequentially with polarization of NK cells and CD8⁺ T cells peaked at day 5 and day 10, respectively.

The data also showed that cell culture consisted of 10% of CD3⁺CD16⁺CD56⁺ NKT cells after stimulation with 25µg /ml of native Fve protein (Figure 24E). This subset
20 of cytotoxic NKT cells has a unique feature in that they mediate non-MHC-restricted cytotoxicity (Lanier et al., 1986).

Example 18. Up-Regulation of a Novel Subset of CD8⁺ T Cells (CD3⁺ CD8⁺ CD18⁺ bright)*Materials and Methods*

25 Repeated subcutaneous injection of IL-12 in patients with cancer resulted in the selective expansion of a unique subset of peripheral blood CD8⁺ T cells. This subset

expressed high levels of CD18⁺ and up-regulated IL-12 receptor expression after IL-12 treatment in vivo. They appeared morphologically as large granular lymphocytes, increased high IFN- γ production and enhanced non-MHC-restricted cytolytic activity. Thus, these T cells may play an important role in innate as well as acquired immunity to tumors and infectious pathogens.

To determine whether CD3⁺ CD8⁺ CD18⁺ bright T cells can be enriched by native Fve protein, human peripheral blood mononuclear cells (PBMC) from a healthy donor are isolated and cultured with 20µg /ml of native Fve protein. Cell culture are stained with anti-CD18 FITC, anti-CD8 PE, anti-CD3 PerCP monoclonal antibodies (Becton Dickinson) at day 5, and then analyzed by FACSCalibur flow cytometry (Becton Dickinson).

Results

Result showed that $CD3^{+}CD18^{+bright}$ T cells are increased from 8% to 31% of total cell population (Figure 26), and $CD3^{+}CD8^{+bright}CD18^{+bright}$ T cells are increased nearly three times, from 3.5% to 9% of the total cell population (Figure 27) after stimulation with 20 μ g /ml of native Fve protein. Furthermore, some $CD18^{+}CD8^{-}$ cells started to differentiate into $CD18^{+}CD8^{+dim}$ cells after stimulated with native Fve protein (Figure 27B). This data suggested that Fve protein from the golden needle mushroom has a potential ability to stimulate cellular immune responses directed against malignancies in human.

Example 19. *In vivo* Lymphocyte Proliferation Assays

Materials and Methods

Since Fve protein can activate human NK cells and CD8⁺ T cells *in vitro*, we sought to determine whether Fve would enhance activation of these cells *in vivo*. Mouse provides a good model system for such a study.

A group of three C57BL/6J mice are subcutaneously injected with 10 μ g, 50 μ g or 250 μ g Fve protein consecutively for three days, respectively. Another three BALB/cJ mice are treated with 125 μ g of Fve protein each for seven days by subcutaneous injection. For continuous BrdU labeling, mice are given 0.5mg/ml BrdU (Sigma) in the drinking water, which is changed every 3 days and then each mouse received one intraperitoneal injection of 1mg of BrdU in PBS at 6 hours before being sacrificed. PBMC, lymph node and spleen are isolated and resuspended in 200ul of washing buffer (1xPBS containing 1% bovine calf serum), then stained with anti CD4⁺-FITC, anti CD8⁺-PE, anti CD19⁺-PE or anti PanNK-PE monoclonal antibody (Pharmingen) for 30 minutes on ice. After two washings with washing buffer, the samples are fixed with FACS Permeabilizing Solution (Becton Dickinson) for 16 hours. After that samples are treated with 50U DNase I (Sigma) for 1hr at room temperature. The cells are washed and stained with anti BrdU-FITC mAb (Becton Dickinson) in PBS for 30 minutes. 1-5 x 10⁵ viable (forward and side scatter gated) PBMC, lymphocytes in lymph nodes or splenocytes per sample are analyzed with FACSscan (Becton Dickinson) and data are processed using the CellQuest software (Becton Dickinson).

Results

Fve induced NK cells and CD8⁺ T cells proliferation in vivo

FACSscan analysis data showed that Fve could induce increased proliferation of NK cells and CD8⁺ T cells in a dose-dependent manner in C57BL/6J mice (Figure 28 and Figure 29). In contrast, CD4⁺ T cells and CD19⁺ B cells showed no significant increase (Figure 30 and Figure 31). Similar CD8⁺ T cell polarization is also seen in lymph nodes of C57BL/6J mice (Figure 32) and so the peripheral blood mononuclear cells (PBMC) of Balb/cJ mice that are subcutaneous injected for seven consecutive days with 125 μ g of Fve protein. The CD8⁺ versus CD4⁺ T cells ratio is significantly increased in each of the Fve-treated BALB/cJ mouse as compared to the naïve control (Figure 33). Data from the experiment are presented in Table 6 below.

Naïve Balb/cJ mouse	PBMC		
	CD4 ⁺ T cells	CD8 ⁺ T cells	CD8 ⁺ /CD4 ⁺ ratio

#1 None	40.3 %	15.7 %	0.389
#2 125µg nFve	40.2 %	26.2 %	0.651
#3 125µg nFve	40.7 %	21.8 %	0.535
#4 125µg nFve	33.3 %	19.6 %	0.588

Table 6. Data showing results of Figure 33.

In summary, for NK cells in spleen, 10µg Fve caused one fold increase proliferation. The proliferation increased to 5-6 fold when 50µg and 250µg of Fve protein is added. Similar finding is observed in CD8 positive T cells in spleen and lymph nodes.

- 5 250µg Fve protein caused 2-3 fold increase proliferation as compared to non-treated mouse. By contrast, Fve failed to stimulate CD4 positive T cells and has very mild stimulation to CD19 B cells (Table 7). Similar phenomenon is also seen in the peripheral blood mononuclear cells. The proportional of CD8 T cells increased up to 6-10% after 125µg of Fve protein are subcutaneous injected to Balb/cJ mice for seven days (Table 8).

- 10 These *in vivo* data are in concordance with those derived from *in vitro* studies, which clearly indicate that Fve induces selective polarization of NK cells and CD8⁺ T cells. Furthermore, these immunostimulatory effects of Fve are independent of the genetic background of mouse strains. Thus, Fve appears to be a potent immunostimulator for cellular mediated immune response. Purified NK cells and CD8⁺ T cells will be used for
- 15 future studies to examine the molecular and cellular basis for the polarization of cell subsets.

Naïve C57BL/6J mouse	Spleen				Lymph nodes
	BrdU incorporated NK cells	BrdU incorporated CD4 ⁺ T cells	BrdU incorporated CD8 ⁺ T cells	BrdU incorporated CD19 ⁺ B cells	BrdU incorporated CD8 ⁺ T cells
#1 None	0.63%	3.49 %	2.22 %	3.48 %	5.83 %
#2 10µg Fve	1.20 %	3.32 %	2.81 %	3.43 %	5.72 %
#3 50µg Fve	3.53 %	3.47 %	3.34 %	4.11 %	9.19 %
#4 250µg Fve	4.00 %	2.55 %	7.31 %	4.55 %	12.05 %

Table 7. *In vivo* stimulation of C57BL/6J mouse lymphocytes

Naïve Balb/cJ mouse	PBMC		
	CD4 ⁺ T cells	CD8 ⁺ T cells	CD8 ⁺ /CD4 ⁺ ratio
#1 None	40.3 %	15.7 %	0.389
#2 125µg Fve	40.2 %	26.2 %	0.651
#3 125µg Fve	40.7 %	21.8 %	0.535
#4 125µg Fve	33.3 %	19.6 %	0.588

Table 8. *In vivo* stimulation of Balb/cJ mouse lymphocytes

Example 20. *In vivo* Evaluation of the Potential Use of Fve for Immunotherapy of Solid Tumors

- 5 There are several approaches to treat cancer such as surgery; radiation therapy; given tumor cell arrested drugs; induced apoptosis in cancerous cells; inhibited angiogenesis; elevated tumor recognition and specific killing ability of immune system to eliminate cancerous cells.

Previous data have indicated that Fve protein stimulate enhanced production of various cytokines, particularly IFN- γ , TNF- α and IL-2; induced polarization of natural killer cells and CD8⁺ T lymphocytes; and triggered a Th1/Tc1-like cellular-mediated immune response. Each of these biological properties may contribute to suppression of tumor growth and to prevent the risk of cancer recurrence by inducing various forms of nonspecific or even specific immunity after surgery.

Malignant melanoma is a very common cancer in the western world. A subset of patient with metastatic melanoma can be successfully treated by the administration of recombinant IL-2, sometimes given together with autologous melanoma-reactive lymphocytes that have been expanded ex vivo. Since melanocyte differentiation antigens, including MART-1/Melan-A, gp100, tyrosinase, TRP-1, and TRP-2, and cancer-testis antigens, including MAGE-3, BAGE, GAGE, NY-ESO-1, are recognized by human T lymphocytes, therefore they become the attractive targets for melanoma vaccines. However, from an immunological point of view, these melanocytes differentiation antigens and cancer-testis antigens are "self" antigens. It may induce central or peripheral tolerance, and thus potentially hampering the induction of powerful anti-melanoma immune responses. Therefore, induction of a strong tumor specific immunity with an immunopotentiator or novel adjuvant could be a useful treatment strategy to overcome immune ignorance and tolerance.

In order to investigate the anti-tumor effect of Fve, C57BL/6J mice are subcutaneously inoculated either with T cell lymphoma EL4 or melanoma B16-F1, the later is a well established and widely used tumor model for which treatment is notoriously difficult. The tumor growth and survival rate of mice are monitored.

Materials and Methods

Construction of pCIneo-fve and pDisplay-fve recombinant plasmid DNA

The pCIneo vector is designed for high level and constitutive expression of cloned DNA inserts in mammalian cells (Figure 34A). Fve DNA is amplified from pGEX-fve and

subcloned into the Xho I and EcoR I restriction enzyme cutting sites of pCIneo vector. The pCIneo-fve is used for priming the immune response by intramuscular injection.

The pDisplay vector is a mammalian expression vector that is designed to target and to display recombinant proteins to the surface of mammalian cells (Figure 34B).

- 5 Fusion DNA of Fve and murine Ig kappa chain V-J2-C signal peptide without hemagglutinin A epitope is generated by recombinant PCR and subcloned into the EcoR I and Pst I restriction enzyme cutting sites of pDisplay vector. The Fve protein expressed from the pDisplay-fve acts as triggering signal for immune system and recruiting T lymphocytes to recognize tumor cells.

10 *Transfection of B16-F1 cells with pDisplay-fve*

- The murine melanoma cells B16-F1 is purchased from ATCC, USA. Tumor cells are grown in DMEM supplemented with 10% FBS in 5% CO₂. Cells in the exponential growth phase within four passages are used in this investigation. To obtain stable transfectants, endotoxin free plasmid pDisplay-fve is mixed with polyfect transfection reagent (QIAGEN, Germany) and transfected into B16-F1 cells. Colonies resistant to G418 (Geneticin, GIBCO BRL) at 1000µg/ml for 25-30 days are isolated and designated as B16-Fve. The control B16-F1 cells which are transfected with pDisplay vector alone are designated as B16-vec.
- 15

EL4 protection assay

- 20 Six to eight weeks old C57BL/6J mice are inoculated with 8x10⁶ EL4 cells. Tumor formation is observed at day 3. 100µg of pCIneo-fve recombinant plasmid DNA is intramuscularly injected into the tibialis muscle at day 0 and day 7. 20µg of Fve protein is given by subcutaneous injection surrounding the tumor site at day 5, 7, 9, 11, 13, 15, and 18, respectively. The diameters of tumors are measured with a caliper and tumor volume is calculated by long diameter time short diameter. Finally the survival rate is recorded.
- 25

DNA vaccination and B16-F1 tumor protection experiments

Endotoxin free pCIneo and pCIneo-fve are purified from the QIAGEN plasmid DNA extraction and purification kits. 100µg of pCIneo-fve is intramuscularly injected into the tibialis muscle of C57BL/6 mice at day -30 and day -1. Muscles are pulsed with
5 Electro Square Porator ECM830 (BTX, Genetronics, USA) equipped with a two needle array electrode after DNA injection. Mice are inoculated with 5×10^5 B16-F1 cells. Small tumor nodule developed at day 3. 50µg of Fve protein is given by subcutaneous injection surrounding the tumor site at day 4, 7, 9, and 12, respectively.

Experimental lung metastasis

10 B16-F1 cells are trypsinized from monolayer cultures, counted and spun down at 1,200 rpm for 5 min and resuspended with DMEM. Five C57BL/6 syngenic 6-week-old female mice are intravenously injected with 2×10^4 of B16-F1 melanoma cells in a final volume of 120 µl. About 4 weeks after injection, tumor nodules are established in lung. Mice are kept until they died to assess survival.

15 **Example 21. Prolonged Survival Rate of Tumor-Inoculated Mice Receiving with Fve Gene and Protein**

Our results show that tumor established mice that received pCIneo-fve DNA and Fve protein had shown a reduction of T cell lymphoma growth rate (Figure 35) and an extension of survival time (Figure 36). Similar results are also seen in melanoma B16-F1
20 inoculated C57BL/6J mice (Figure 37).

These data indicate that Fve induces some protection against the solid EL4 tumor and B16-F1 melanoma, suggesting that Fve could be a potential candidate molecule for the development of the immunotherapeutic reagents for treatment of some cancers. The results also show that DNA vaccine-mediated treatment using the gene of Fve can be further
25 exploited for effective cancer treatment. Nowadays, DNA vaccination is being explored as a potential strategy for combating cancer. However, tumor antigens are often weak and the

immune system of patients may be compromised. Like the concept of allergen-Fve fusion protein, fusion of Fve to specific tumor antigen may an effective way to activate protective anti-tumor immune response. Genetic immunization with chimeric gene encoding Fve and tumor antigen may augment and direct immune attack on a range of target tumor antigens.

5 **Example 22. Life Span in Solid Tumor Model is Extended in Fve Transfectant**

In previous study, we have proved that using Fve plasmid DNA primed in muscle and Fve protein boosted in tumor region could initiate anti-tumor immune response and thus prolong the survival time of tumor-inoculated mice. Instead of injection Fve surrounding the tumor, we specifically targeted Fve gene into tumor cells and tried to
10 create an inducible-antigenic tumor for cancer therapy. This genetically modified tumor cells may provide signals for antigen presenting cells and both helper and cytotoxic T cells.

To determine whether introduction of the Fve gene into malignant cells would result in enhanced tumor recognition ability via Fve display and lead to extended survival
15 rate in solid tumor experiment. Recombinant plasmid DNA pDisplay-fve is transfected into wild type B16-F1 mouse melanoma and then G418 resistant colonies are selected. Five female of C57BL/6J mice are inoculated with 5×10^4 of B16-Fve transfectant. The antigenicity of B16-vec and B16-Fve transfectants are compared through the life span of two groups of tumor-inoculated mice.

20 Result demonstrated that artificially expressed Fve on the surface of B16-F1 mouse melanoma extended survival rate as compared to B16-vec inoculated mice (Figure 38). We propose that the characteristics of highly antigenecity and lymphocytes mitogenecity of Fve may elevate immune function to fight against tumor when it displayed on the surface of melanoma. Therefore, Fve may use as immune response activator and enhancer
25 especially for those poorly recognized and low immunogenic tumor, which escaped from cancer surveillance and immune clearance by altering immune recognition and modulating cytotoxic response.

Example 23. Fve DNA Vaccination Retards Tumor Progression

Cancer vaccines are designed to prevent and treat cancer. In general, research has shown that the most effective anti-tumor immune responses are achieved by stimulating T cells, which can recognize and kill tumor cells directly. Most current cancer vaccines try to activate T cells directly, try to enlist APCs to activate T cells, or both. Some novel ways in which researchers are attempting to better activate T cells are: (1) Altering tumor cells so molecules that are normally only express on APCs are now express on the tumor cell. These molecules are capable of giving T cells a stronger activating signal than the original tumor cells. (2) Testing more cytokines and adjuvants to determine which are best candidates for recruiting APCs to areas where they are needed. (3) Using dendritic cells and other APCs fused with tumor cells as the cancer vaccines. These cells go into the body carrying tumor antigen and ready to activate T cells. Early cancer vaccine clinical trials involved mainly patients with melanoma. Currently, cancer vaccines are also being tested in the treatment of many other types of cancer, including prostate cancer, breast cancer, colon cancer, and lymphoma.

Here, we assessed tumor immunity that stimulated by recombinant Fve DNA vaccination alone and the combination of Fve DNA vaccination and Fve-transduced tumor cells. C57BL/6J mice are separated into three groups and each group consisted of ten mice. Mice are inoculated either with 5×10^4 of B16-Fve or B16-vec tumor transfectants in the dorsal back. Tumor formation is observed at day 5-7. 100 μ g of pCIneo-fve plasmid DNA is intramuscularly injected at the right and left tribilis muscle of C57BL/6J at day -77, day -35 and day -21. Mice are subcutaneously injected with 5×10^4 of B16-Fve transfectant and B16-vec transfectant at day 0, respectively. 100 μ g of pCIneo plasmid DNA is administered following similar experimental procedure and mice are subcutaneously injected with 5×10^4 of B16-vec transfectant as negative control. The fatal rate of mice are recorded and data are presented as survival curves.

Result showed that Fve DNA vaccination contained certain degree of tumor protection (Green line in Figure 39) as compared with vector DNA vaccination (Blue line

in Figure 39). In addition, the combination of Fve DNA vaccination and B16-Fve transfectant exerted a stronger tumor protection effect (Red line in Figure 39). Based on the result, we propose Fve is a novel protein to activate T cells directly. This protein is capable of giving T cells a strong activating signal when it is displayed on the surface of
5 poorly immunogenic tumor cells. Therefore, the phenomenon of extended survival rate is observed in the experimental tumor-inoculated mice.

In future, the adjuvant effect of fusion proteins between Fve and tumor antigens to enhance tumor immunity will be determined. In particular, DNA fusion vaccine strategy, whereby target tumor antigen is genetically linked to immunostimulatory molecules such
10 as Fve, is currently being explored. The introduction of fusion gene encoding tumor-associated antigen with Fve into antigen-presenting cells hold considerable promise for the treatment of patients with cancer. The ease of DNA manipulation has allowed incorporation of a wide variety of molecules able to promote antigen uptake, processing and presentation by professional antigen-presenting cells, to provide critical CD4⁺ T-cell
15 help and to activate more effective immune effector pathways (Zhu and Stevenson 2002). The concept of DNA fusion vaccine strategy is particularly important for cancer vaccines to increase their immunogenicity and to overcome tolerance.

Example 24. Fve Extends the Survival Rate of Lung Metastatic Mice

2x10⁴ of B16-F1 melanoma cells is delivered to C57BL/6J via tail vein injection.
20 The effect of combination of distill water and DNA vector pCIneo versus Fve protein and plasmid DNA pCIneo-fve administration on survival after the establishment of lung metastasis is determined. Survival extended in both metastatic experimental groups undergoing Fve protein orally primed and DNA intramuscularly boosted strategy.

Two groups of five C57BL/6J mice are given with 10mg/ml of Fve protein in the
25 drinking water at days -35, -28 and -21, and each water providing is maintained consecutively for one week. Mice are intravenously injected with 2x10⁴ of B16-F1 (wild type) melanoma cells at day 0. One week after, mice are intramuscularly injected with

100 μ g of pCIneo-fve plasmid DNA into the right and left tribilis muscle, respectively. The mixture of 5×10^4 of B16-Fve cells lysate plus 10 μ g of Fve protein (Red line in Figure 40) or 10 μ g of Fve protein alone (Green line in Figure 40) are subcutaneously injected into mice at the following three weeks. Negative control group of mice received same amount of 1xPBS in the drinking water, intravenously injected with 2×10^4 of B16-F1 melanoma cells, followed by intramuscularly injected with plasmid DNA vector pCIneo, and finally subcutaneously injected with B16-vec cells lysate plus 1xPBS (Blue line in Figure 40).

Results showed that the strategy of orally primed with Fve protein before tumor introduced into the lung and intramuscularly boosted the immune response with the plasmid DNA pCIneo-fve after tumor established in lung could extend the survival rate of mice as compared with the control group (Figure 40). This data provided another evidence suggesting Fve could augment anti-tumor immune response against developing or metastatic tumor cells. The inhibition of B16-F1 melanoma experimental lung metastasis by Fve may go through induction of IFN- γ , TNF- α and activation of anti-tumor host mechanisms. IFN- $\gamma^{-/-}$ and TNF- $\alpha^{-/-}$ gene knockout mice and in vivo depletions of CD4 $^{+}$, CD8 $^{+}$, or NK1.1 $^{+}$ cells may provide supportive evidence to this phenomenon.

Example 25. Global Gene Expression Profiling of Human T Cells and NK Cells After Activation with Fve

The invention of microarray technology allows the simultaneous monitoring of the transcriptional behavior of thousands of genes. This technology has been repeatedly shown to be useful in the analysis of the response of a variety of cellular systems to stimuli, in the classification of human cancer, and in the analysis of animal models of human disease (Churchill 2002; Slonim 2002; van Berkum and Holstege, 2001). To characterize the transcriptional profile of Fve, we analyzed gene expression patterns in T and NK cells from either healthy donor or human cell lines stimulation with Fve by using oligonucleotide microarrays and compared them with gene expression patterns in non-stimulation cells. In future, protein microarray assays would also be used to study protein-protein interactions on a genome-wide scale (Templin et al., 2002; Zhu et al., 2001).

*Materials and Methods**Cells collection and total RNA purification*

- Peripheral blood mononuclear cells (PBMC) are collected from healthy donors. CD8-positive T lymphocytes and natural killer cells isolation are performed by
- 5 immunomagnetic bead selection with monoclonal mouse anti-human CD8 antibodies and monoclonal mouse anti-human CD56 antibodies using the AutoMACS automated separation system (Miltenyi-Biotec, Germany). CD8-positive T cells and CD56-positive natural killer cells purity of more than 94% and 88% homogeneity are confirmed by two-color flow cytometry using CD3⁺/CD8⁺ and CD56⁺ criteria (Becton Dickinson, USA).
- 10 Human T cell lines (Jurkat T cell, MOLT-4) and NK cell line (NK-92) are grown as recommended (ATCC, USA). Cells are stimulated with Fve and total RNA is isolated with RNeasy Mini Kit (Qiagen, Germany) after 2 and 48 hours, respectively.

Preparation of labeled complementary RNA and hybridization to high-density microarray

- 15 Double-stranded complementary DNA (cDNA) and biotinylated complementary RNA (cRNA) are synthesized from total RNA and hybridized to human GeneChip microarray (Affymetrix, USA), which are washed and scanned according to procedures developed by the manufacturer. The arrays are scanned using laser scanner and visualized using Affymetrix 3.3 software (Affymetrix).

- 20 *GeneChip data analysis*

Differentially expressed genes are analysed by functional assays

Example 25A. Th1 Adjuvant Effect of Fve on HPV E7 Antigen**Th1 adjuvant effect of Fve on HPV E7 antigen**

Introduction

Fve protein, which is isolated from the fruit bodies of edible mushroom *Flammulina velutipes*, belongs to a new family of fungal immunomodulatory protein. Previous studies showed that Fve could stimulate gene expression of human IFN- γ , TNF- α , IL-1 β , IL-2. In 5 allergic murine model, mice treated with Der p 2 plus Fve showed a significant Der p 2-specific IgG2a production. Taken together, Fve may act as a strong adjuvant to drive immune responses toward Th1-type responses. Human papillomavirus (HPV) infection is a major cause of cervical cancer worldwide. The HPV oncogenic proteins, E6 and E7 are required for tumorigenesis and maintenance of tumor state. Clinical study found that E7- 10 specific immune responses are detected in cervical cancer patient, suggesting that E7 could be a specific target for immunotherapy against HPV- derived cervical cancer. In this animal study, we demonstrated that the production of HPV E7-specific IgG1 and IgG2a is greatly enhanced when E7 is co-administrated injection with the fungal immunomodulatory protein Fve. Result suggests that Fve can be used as a potent 15 adjuvant for viral vaccines development

Materials And Methods

1. Construction of Plasmid DNA pGEX-4T1-E7

The DNA fragment encoding E7 of HPV type 16 is subcloned into pGEX-4T1 protein expression vector. E7 DNA fragment is amplified by polymerase chain reaction 20 (PCR) using a set of primers: 5'-TTGTTGGATCCCATGGAGATACACCTACATTG-3' and 5'-TTACTGAATTCTTATGGTTTCTGAGAACAGATG-3'. The amplified DNA is digested with BamH1 and EcoR1, and the resulting fragment is then cloned into the BamH1 and EcoR1 sites of pGEX- 4T1 vector. The presence of the inserted E7 is confirmed by and restriction enzyme digestion and gel electrophoresis. The accuracy of the 25 constructs is further confirmed by DNA sequencing. The plasmid construct is transformed into *Escherichia coli* TG-1 for protein expression.

2. Expression and Purification of Recombinant GST-E7 Protein

E7 is expressed as GST-fusions protein from pEGX-4T1 (Invitrogen, CA, USA). Small scale of pGEX-4T1-E7 transformed TG1 bacteria is seeded in LB medium. The overnight culture is transferred to 1L of LB medium containing ampicillin (100µg/ml) in 1 in 40 proportion and grown at 37.C with 250 rpm vigorous shaking until the OD₆₀₀ reach to 0.6-0.8 (approximately 2-3 hours). The recombinant protein is induced by 0.1mM isopropyl-β-D-thiogalactopyranoside (Gold Biotechnology, MO, USA) at final concentration and further incubation of 4-6 hours at 35.C with 200 rpm shaking. Cells are harvested by centrifugation at 6000 rpm for 10 minutes and the pellets are used for protein extraction. The pellets of E7 transformed bacteria are resuspended in 250 ml ice-cold lysis buffer (1 x TBS pH 7.5, 1mM PMSF (Sigma, MO, USA), 20 µg/ml DNase I and 1 % Tween 20). The cell suspension is then sonicated at 4.C for 50 seconds, 18cycles with 30seconds intervals. Total cell lysate is centrifuged at 16 000rpm for 25min, 4.C and the supernatant is collected for further affinity purification on glutathione agarose beads. Glutathione agarose beads (Sigma, MO, USA) is dispensed into a chromatography column and then washed with 1 x TBS (pH 7.5). Supernatant from the total cell lysate is then loaded onto the column and subsequently washed with 1 x TBS. GST-E7 is eluted with elution buffer (Glutathione 0.15 g, Tris-base in a total volume of 50 ml dH₂O) and then analyzed by SDS-PAGE. Pure fractions of GST-E7 protein are pooled together and cleaved with thrombin. Purified E7 is dialyzed against 1 x PBS (pH 7.4) and used in further studies.

3. Isolation and Purification of Fve Protein from *Flammulina velutipes*

Two kilo grams of *Flammulina velutipes* (Golden needle mushroom) is purchased from Taiwan. The fresh fruit bodies of mushroom are homogenized with 2 L 5% acetic acid (v/v) in the presence of 0.1% (v/v) 2-mercaptoethanol. The homogenate are centrifuged for 20 min and soluble proteins in the supernatant are precipitated by addition of ammonium sulphate to 95% saturation. After stirring for an overnight, the precipitates are collected by centrifuge for 20min again. The pellets are dialyzed against 4.5L of 10mM Tris/HCl (PH 8.0) at 4 °C for 4 days with 9 changes of dialysis solution. The dialysate is

firstly applied to Q column which is previously equilibrated with 10mM Tris/HCl (PH 8.0). The flowthrough fractions are then further purified by application to SP column which is previously equilibrated with 10mM sodium acetate (PH 5.0). The column is first washed with 10mM equilibration buffer and then eluted with a linear gradient of 0-1M NaCl in 5 10mM sodium acetate (PH 5.0). The fractions are then further purified on a Q column (PH 8.0) and SP column (PH5.0). After purification, we combined them and dialyzed with 2L 10mM PBS (PH 7.4), then stores Fve protein at -20°C.

4. SDS-PAGE and Western Blot

Purified Fve and E7 are run in a 7.5 % Tricine SDS-PAGE. After electrophoresis 10 has completed, the proteins in the gel are stained with Coomassie plus Reagent (Pierce, IL, USA). For western blotting, the proteins are transfer from the gel to a bio-blot nitrocellulose membrane and probed with either Fve polyclonal antibody or E7 monoclonal antibody (Southern Biotechnology, USA).

5. Mice

15 Female C57BL/6 mice are purchased from the Laboratory Animal Center (Sembawang, Singapore) and kept in the National University of Singapore (NUS) Animal Holding Unit. All animal procedures are performed according to approved protocols and in accordance with the Institutional Guidelines for Animal Care and Handling, NUS.

6. Protein Immunization of Mice

20 Two groups of eight- to ten-week-old female C57BL/6 mice (5 mice per group) are injected subcutaneously at the tail base with 10 µg of E7 alone or combination with 10 µg of Fve in a final volume of 100 µl of PBS at day 1. Mice are boosted with 20 µg of E7 alone or mixture with 20 µg of Fve at day 14 and day 28. Blood are collected weekly from the orbital sinus of the immunized mice and the collect sera are used for antibodies 25 analysis using ELISA.

7. ELISA

In all ELISA experiments, samples are assayed in duplicates and 50 µl per well of reagents and samples are used. 96-well plates (Costar 9018, Corning, NY, USA) are incubated overnight at 4 °C with 5 µg/ml of purified E7 proteins in 0.1 M NaHCO₃, pH 8.3 coating buffer. Wells are washed three times with washing buffer TBST (0.05 % Tween 20 (Sigma) in 1X (0.01 M) TBS, pH 7.4) using the automated Columbus washer (TECAN, Austria) and blocked with 100 µl/ well of blocking buffer (1 % BSA; bovine serum albumin in TBST) for 2 hours at room temperature. Plates are washed three times and diluted sera appropriately and incubated overnight at 4 °C. For quantification and internal control purposes, known serial dilutions of purified mouse IgG1, IgG2a and κ light chain isotype standard (Pharmingen, CA, USA) is used on wells coated with anti-mouse κ light chain (Pharmingen, CA, USA).

Plates are again washed 6 times before adding biotin-conjugated anti-mouse isotypic antibodies IgG1, IgG2a (Southern Biotech, AL, USA) at 1:1000 dilution are added. The plates are then incubated for 1 hour at room temperature, followed by 6 times washing and 1 hour incubation at room temperature with ExtrAvidin alkaline-phosphatase conjugate (Sigma, MO, USA). The plates are then washed 6 times and developed in paranitrophenyl phosphate (pNPP) substrate (Sigma, MO, USA) at room temperature in the dark. The binding of specific antibodies is measured as absorbance at 405 nm with the Spectra (Shell) reader (TECAN, Austria). The antibody production units of antigen-specific antibodies are determined from the OD₄₀₅ using the plot of absorbance versus concentration of the standard.

Two groups of female BALB/cJ mice aged 6 to 8 weeks are given subcutaneous injection of either 10 µg of HPV E7 antigen alone (group 1) or mixture of 10 µg of E7 with 10 µg of Fve (group 2) at day 1. Mice are boosted with 20 µg of same antigen at day 14 and 28. Sera are collected weekly and E7-specific IgG1 and IgG2a antibodies are analyzed using Elisa.

A schematic protocol of the animal study is shown in Figure 40B.

Results

Combinations of E7 and Fve enhance E7-specific immune response

The results are shown in Figure 40C. These results show that the production of E7-specific IgG1 and IgG2a are dramatically increased when E7 is co-administrated injection with Fve, as compared with E7 alone. The induction of IgG2a is 17-fold higher in the experimental mice as compare with the control group. This demonstrates that Fve displays an adjuvant effect and therefore enhance specific immune response to viral antigen. Co-administration of fungal immunomodulatory protein Fve and viral antigen HPV E7 increases the production of neutralizing antibodies.

Example 26. X-Ray Crystallographic Study of Fve: Materials and Methods

The three dimensional structural of Fve provides a good basis for the understanding of protein functions, immunomodulations and therapeutic applications in allergy and other diseases. We have crystallized the well-diffracting crystals of Fve and show that it diffracts to 1.4 Å resolution when exposed to synchrotron radiation.

This and the follwing Examples describe a 1.6 Å° x-ray structure of Fve, determined by Single Anomalous Diffraction (SAD) using the anomalous signal of bromide ions present in the crystal for phasing. Fve represents a novel structure, wherein each monomer consists of an N-terminal α-helix followed by an immunoglobulin fold (beta-sandwich). The structure strongly suggests that dimerization, critical for the activity of FIP proteins, occurs by 3-D domain swapping of these helices and is stabilized predominantly by strong hydrophobic interactions between them.

Crystallization

Fve protein is obtained as described above. It is concentrated to 4 mg/ml in 10 mM Tris-HCl pH 7.5. Initial crystallization screening is done by the sparse matrix crystallization screening kit 1 & 2 from Hampton Research (Jancarik and Kim, 1991;

Cudney, *et al.*, 1994). All the screening and crystals growth are accomplished by hanging drops vapor diffusion method at 21°C in VDX multi-well plates with 650 µl reservoir solutions. Drops consisting of 4 µl precipitant buffer from reservoirs and 4 µl protein sample (4 mg/ml) are equilibrated over the well solution for one week.

- 5 After extensive screening, plates-like crystals are obtained at two different low salt conditions: (1) 30% PEG 4000, 0.1 M Tris-HCl pH 8.5, 0.2 M MgCl₂; (2) 30% PEG 4000, 0.1 M Tris-HCl pH 8.5, 0.2 M NaOAc. 3D cubic-shaped and octahedral crystals also appeared after 3 days at two different high salt conditions: (1) 2.0 M (NH₄)₂SO₄, 0.1 M Tris-HCl pH 8.5; (2) 2% PEG 400; 0.1 M Na HEPES pH 7.5, 2.0 M (NH₄)₂SO₄. To
10 optimize the crystallization condition, combinations of varied protein and salt concentrations, different molecular weights of PEG, and different pH are screened.

- The best crystals formed at the high salt condition is optimized to 2.5% PEG 400, 2.0 M (NH₄)₂SO₄, 0.1 M Tris-HCl pH 8.5 at 21°C. They grew to the approximate dimensions of 1.0 × 0.9 × 0.5 mm within five days. The micrographs of five crystals are
15 captured by inverted light microscope (Figure 41).

- High resolution protein crystals are therefore grown by vapor diffusion from hanging drop at 2.0% PEG 400, 2.0 M (NH₄)₂SO₄, 0.1 M Tris-Base, pH 8.5 for 1-2 weeks. Heavy atom derivatives are prepared by soaking the crystals in mother liquor containing 25% glycerol and 1M NaBr. The crystals are flash-frozen at 100 K after a 1-min soak in
20 the heavy atom (Br) solution. SAD data from a derivatized crystal are collected at the National Synchrotron Light Source (NSLS) beam line X12C) at one wavelength (***) around the Br absorption edge. The crystal diffracted to 1.7 Å.

X-ray analysis

- The X-ray diffraction intensities from five crystals are measured at 100 K on
25 beamline BL9-2 from the Stanford Synchrotron Radiation Laboratory facility with ADSC Quantum-315 CCD detector. Data are collected at a wavelength of 1.07Å. All the data are processed by MOSFLM (Leslie, 1992) and X-ray intensities are scaled with SCALA

(CCP4, 1994). Well-ordered diffraction data at 1.4 Å resolution are collected from larger crystals (Figure 42).

Analysis of the collected data (Table 9) indicated that Fve crystals belong to the tetragonal space group $P4_32_12$ with unit cell dimensions of $a = b = 96.92$ Å, $c = 61.42$ Å.

- 5 The Matthews parameter (V_M) of these crystals is 2.84 Å³ per Da and thus the solvent content is 56.37% assuming two molecules of Fve per asymmetric unit (Matthews, 1968). A total of 344079 observations are obtained at 1.4 Å resolution giving approximate 56993 unique reflections (99.7% complete, $R_{\text{merge}} = 0.047$).

X-ray source, beamline	SSRL, BL9-2
Wavelength	1.07Å
Detector distance	99.97mm, Q-315 CCD Detector
Cell angles (°)	90.00, 90.00, 90.00
Unit cell dimensions (Å)	96.92, 96.92, 61.42
Space group	$P4_32_12$
Number of molecules per ASU	2
Number of observed reflections	344079
Number of unique reflections	56993
Solvent (%)	56.37
V_M (Å ³ Da ⁻¹)	2.84
Resolution range (Å)	33.5-1.4
Average $I/\sigma(I)$	10.1
R_{merge} ^a	0.047
Completeness (%)	99.7

- 10 ^a $R_{\text{merge}} = \sum |I_i - \langle I \rangle| / \sum I_i$, where I_i is the mean intensity of symmetry-related measurements of this reflection.

Table 9. Data Collection and Statistics of Fve Crystal

Data Processing

The SAD data are processed and scaled using DENZO and SCALEPACK from the HKL2000 suite of programs (Otwinowski and Minor, 1997).

- 15 The crystal of Fve belongs to the tetragonal space group $P43212$ and has unit cell dimensions $a = b = 97.12$, $c = 61.41$ and $\alpha = \beta = \gamma = 90.0$. All of the bromine heavy atom positions are located and refined by the program SOLVE at 1.7 Å (Terwilliger and

Berendzen, 1999) and solvent flattened map is calculated using RESOLVE (Terwilliger, 2001). The resulting electron density map reveals secondary structure elements and side chains. In principle, it is possible to build an initial model by standard protein map-tracing methods. However, the phases obtained from RESOLVE are directly used in ARP/wARP (Morris et al., 2001) for automated main chains tracing, result in 4 continuous fragments that contained 97% of model. The rest of the model and side chains are fitted manually using XtalView (McRae, 1999). The refinement is carried out in REFMAC 5 (Murshudov et al., 1999) using resolution range 30.02 - 1.7 and water molecules are picked up by ARP/WARP later in the refinement.

10 In chain A, C-terminal residue 114 is modeled as Ala residue, whereas in chain B, C-terminal residue 113 and 114 are omitted from the final model, due to the poor interpretable density. The quality of the final model is verified with PROCHECK (Laskowski et al., 1993). However, the Ramachandran plot shows that Lys 14 in both A and B chains is in the disallowed region, although this residue fits very well in the 2fo-fc map.

Example 27. X-Ray Crystallographic Study of Fve: Results

The crystal structure is solved by single anomalous scattering using Br as the heavy-atom, and is refined to a resolution of 1.7 . The atomic coordinates are presented in Appendix C.

20 In total, two chains with a total of 226 residues, 16 bromine atoms and 136 solvent molecules are built into a high quality electron density map. Fve comprises almost exclusively of β -sheet structure with an Ig-like fold, which is formed by seven major antiparallel β -strands arranged into two sheets of four (D, E, H and I) and three (B, C and F) strands packed against each other. The N-terminal domain is composed of a α -helix which spans a length of 12 residues from Ala2 to Val13 and a β -sheet (A). The N-terminal serine residue is blocked by an acetyl group the density of which is also observed. Six loops connect the two main β -sheets and one loop connects the N-terminal domain with

β -sheet structure. The loop between the β -sheets F and H contains a short β -strand and a 3_{10} helix.

The structure of Fve (Figure 43) reveals that exists as a dimer. This is corroborated experimentally by running Fve on a gel filtration column against standard molecular weight markers (data not shown). From the structure, there are two extended regions of subunit-subunit interactions: between the two N-terminal α -helical regions (residues 2 to 13) and the β -stranded region (A and A').

The buried side chains of the α -helical regions form a hydrophobic core (Figure 44A), containing residues Ala 2, Leu 5, Leu 9 and Val 13 whereas the side chains of β -strand (A and A') make inter-subunit hydrogen bonds (Figure 44B). These hydrophobic interactions and hydrogen bonds are responsible for dimer formation. The two monomers, A and B chains, of Fve can be closely superimposed: the RMSD between corresponding C_{α} positions of 112 residues is 0.29 Å (Figure 44C).

Domain Swapping

Domain swapping is a very efficient method of forming oligomers since the interactions within the monomer are reused in the dimer. There is thus no need to evolve a new site on the surface which in one monomer mutually recognizes the corresponding site on the other monomer, since in the domain swapped dimer the recognition requirement has already largely been accounted for (Bennett et al., 1995).

Domain-swapped proteins have a C-interface generally with many specifics interaction, formed between domains linked by a hinge loop (Bennett et al., 1995). In p13suc1, two proline residues, located in the hinge region, have been shown to be essential and control the domain-swapping process (Rousseau et al., 2001).

As shown in Figure 45A, half of the dimer of Fve contains one N-terminal helix, forming a C-interface with hydrophobic core, which is linked to rest of its subunit by a hinge loop, stretching from residue Val 13 to Pro 22. Furthermore, Fve contains a proline

residue at the end of the hinge region, which could adopt alternative conformation in the dimer by releasing the tension in the monomer. These observations suggest that domain-swapping could be the mechanism for forming dimer protein from its monomer. The monomer is modeled (Figure 45B).

5 *Structural Similarity with Other Proteins*

Fve has no sequence homology to any other non-FIP proteins. However, a search for similar structure in the DALI database (Holm and Sander, 1993) reveals that the protein has a significantly similar fold to 140 proteins but none with the significant sequence similarity to Fve. Among 140 similar fold protein, fibronectin type III family emerged with less topology diversity to Fve β -sandwich fold: the heparin and integrin binding segment of human fibronectin (FN12-15; PDB entry 1FNH), the fragment of human fibronectin type III repeat (FN7-10; 1FNF), The p40 domain of human interleukin-12 (p40; 1F42) and the antibody a6 fragment interferon-gamma receptor alpha chain (IFN γ R1-108; 1JRH). An alignment of FN12-15, FN7-10, p40, IFN γ R1-108 and Fve on the basis of structural similarity shows topology diversity in the range 11-17, calculated by Topp program (Lu, 1996) (Table 10).

	Name	PDB ID	Z-Score	RM SD	Length of aligned segment	Topological Diversity	Superfamily (Family)	Species
1	interleukin-4 receptor alpha chain fragment: b:1-96	1iar-B	5.8	3	78	8.5	Fn III (FNIII)	<i>Homo sapiens</i>
2	mhc class II I-ak: a:82-181	1lak-A	5.8	4.7	83	18.6	Ig (C1)	<i>Mus musculus</i>
3	mhc class II I-ak: b:93-190	1lak-B	5.6	3.5	74	17.8	Ig (C1)	<i>Mus musculus</i>
4	igg2a intact antibody - mab23, kappa L chain: a:1-108	1igt-B	5.5	3.8	86	18.4	Ig (V)	<i>Mus musculus</i>
5	class II histocompatibility antigen, HLA-DM: a:94-196	1hdm-B	5.3	4.7	82	18.4	Ig (C1)	<i>Homo sapiens</i>
6	fibronectin fragment, heparin & integrin binding segment: a:93-182	1fnh-A	5.3	3	73	11.1	Fn III (FNIII)	<i>Homo sapiens</i>
7	ch3 domain of mak33 antibody fragment:chain a	1cqk-A	5.3	3.3	76	18.5	Ig (C1)	<i>Mus musculus</i>
8	CD1, beta2-microglobulin and alpha-3 domain: d	1cid	5.3	2.8	76	17.8	Ig (V)	<i>Rattus rattus</i>
9	fibronectin fragment, ED-B domain:chain a	2fnb-A	5.2	3.9	72	17	Fn III (FNIII)	<i>Homo sapiens</i>
10	hiv-1 gag peptide: a:182-276	1agd-A	5.2	3.8	84	20.1	Ig (C1)	<i>Homo sapiens</i>
11	igg1 antibody 32c2 fragment: a:1-110	32c2-A	5.1	5.6	80	19.4	Ig (V)	<i>Mus musculus</i>

12	fibronectin repeat 7: 1142-1235	1fnf	5.1	2.7	71	10.8	Fn III (FNIII)	<i>Homo sapiens</i>
13	interleukin-12 beta chain fragment: a:88-211	1f42-A	5.1	2.8	70	12.8	Fn III (FNIII)	<i>Homo sapiens</i>
14	Mutant growth hormone receptor fragment: b:131-236	1axl-B	5.1	3.2	72	14.7	Fn III (FNIII)	<i>Homo sapiens</i>

Table 10

REFERENCES

- Akbari O, Freeman GJ, Meyer EH, Greenfield EA, Chang TT, Sharpe AH, Berry
5 G, DeKruyff RH, and Umetsu DT. (2002) Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. *Nat. Med.* 8:1024-1032.
- Arkwright PD and David TJ. (2001) Intradermal administration of a killed
10 *Mycobacterium vaccae* suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. *J. Allergy Clin. Immunol.* 107:531-534.
- Banos, V., Gomez, J., Garcia, A., Ruiz, J., Alvarez, R., Lorenzo, M., Canteras, M., and Valdes, M. (1997) Effectiveness of immunomodulating treatment (thymostimulin) in chronic obstructive pulmonary disease. *Respiration.* 64, 220-223.
- 15 Bennett, M.J., Schlunegger, M.P. & Eisenberg, D. 3D domain swapping - a mechanism for oligomer assembly, *Protein Science*, 4, 2455-2468, (1995).
- Bonde, J., Dahl, R., Edelstein, R., Kok-Jensen, A., Lazer, L., Punakivi, L., Seppala, A., Soes-Petersen, U., and Viskum, K. (1986) The effect of RU 41.740, an immune
20 modulating compound, in the prevention of acute exacerbations in patients with chronic bronchitis. *Eur. J. Respir. Dis.* 69, 235-241.

Braga, P.C., Dal Sasso, M., Maci, S., Piatti, G., Palmieri, R., Bruno, L., and Albanese, C. (1994) Restoration of polymorphonuclear leukocyte function in elderly subjects by thymomodulin. *J. Chemother.* 6, 354-359.

5 Chihara, G., Maeda, Y., Hamuro, J., Sasaki, T., and Fukuoka, F. (1969) Inhibition of mouse sarcoma 180 by polysaccharide from *Lentinus edodes*(Berk) sing. *Nature.* 222, 687-688.

Churchill GA. (2002) Fundamentals of experimental design for cDNA microarrays. *Nat. Genet.* 32 Suppl 2:490-495. Collaborative Computational Computer Project 4. (1994) The CCP4 suite: programs for protein crystallography. *Acta Crystallogr.* D50, 760-763.

10 Cross ML and Gill HS. (2001) Can immunoregulatory Lactic acid bacteria be used as dietary supplements to Limit Allergies? *Int. Arch. Allergy Immunol.* 125:112-119.

Cudney, B., Patel, S., Weisgraber, K., and Newhouse, Y. (1994) Screening and optimization strategies for macromolecular crystal growth. *Acta Crystallogr.* D50, 414-423.

15 Daniell H, Streatfield SJ, and Wycoff K. (2001) Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants. *Trends Plant Sci.* 6:219-226.

Darji A, Guzman CA, Gerstel B, Wachholz P, Timmis KN, Wehland J, Chakraborty T, and Weiss S. (1997) Oral somatic transgene vaccination using attenuated
20 *S. typhimurium*. *Cell* 91:765-775.

Donnelly JJ, Ulmer JB, Shiver JW, and Liu MA. (1997) DNA vaccines. *Annu. Rev. Immunol.* 15:617-648.

During MJ, Symes CW, Lawlor PA, Lin J, Dunning J, Fitzsimons HL, Poulsen D, Leone P, Xu R, Dicker BL, Lipski J, and Young D. (2000) An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. *Science* 287:1453-1460.

5 Erbacher, P., Zou, S., Bettinger, T., Steffan, A.M. & Remy, J.S. Chitosan-based vector/DNA complexes for gene delivery: biophysical characteristics and transfection ability. *Pharm. Res.* 15: 1332-1339, 1998.

Eriksson K and Holmgren J. (2002) Recent advances in mucosal vaccines and adjuvants. *Curr. Opin. Immunol.* 14:666-672.

10 Federico, M., Gobbi, P.G., Moretti, G., Avanzini, P., Di Renzo, N., Cavanna, L., Ascari, E., and Silingardi, V. (1995) Effects of thymostimulin with combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma. A report from the Italian Lymphoma Study Group (GISL). *Am. J. Clin. Oncol.* 18, 8-14.

Fenske DB, MacLachlan I, and Cullis PR. (2002) Stabilized plasmid-lipid particles: a systemic gene therapy vector. *Methods Enzymol.* 346:36-71.

15 Fischer R and Emans N. (2000) Molecular farming of pharmaceutical proteins. *Transgenic Res.* 9:279-99.

Fisher, M., and Yang, L. X. (2002) Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. *Anticancer Res.* 22, 1737-1754.

20 Fujimiya, Y., Suzuki, Y., Katakura, R., and Ebina, T. (1999) Tumor-specific cytotoxic and immunopotentiating effects of relatively low molecular weight products derived from the basidiomycete, *Agaricus blazei* Murill. *Anticancer Res.* 19, 113-118.

Giddings G, Allison G, Brooks D, and Carter A. (2000) Transgenic plants as factories for biopharmaceuticals. *Nat. Biotechnol.* 18:1151-1155.

- 5 Hirasawa, M., Shouji, N., Neta, T., Fukushima, K., and Takada, K. (1999) Three kinds of antibacterial substances from *Lentinus edodes* (Berk.) Sing. (Shiitake, an edible mushroom). *Int. J. Antimicrobial Agents.* 11, 151-157.

Holm, L & Sander, C. Protein structure comparison by alignment of distance matrices. *J.Mol.Biol.* 233, 123-138 (1993).

Holm, L & Sander, C. Protein structure comparison by alignment of distance matrices. *J.Mol.Biol.* 233, 123-138 (1993).

- 10 Hsu CH, Chua KY, Tao MH, Lai YL, Wu HD, Huang SK, and Hsieh KH. (1996) Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness *in vivo* by genetic immunization. *Nat. Med.* 2:540-544.

- 15 Hsu, H.C., Hsu, C.I., Lin, R.H., Kao, C.L., and Lin, J.Y. (1997) Fip-vvo, a new fungal immunomodulatory protein isolated from *Volvariella volvacea*. *Biochem. J.* 323, 557-565.

Iguchi, C., Nio, Y., Takeda, H., Yamasawa, K., Hirahara, N., Toga, T., Itakura, M., and Tamura, K. (2001) Plant polysaccharide PSK: cytostatic effects on growth and invasion; modulating effect on the expression of HLA and adhesion molecules on human gastric and colonic tumor cell surface. *Anticancer Res.* 21, 1007-1013.

- 20 Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, and Davis SS. (2001) Chitosan as a novel nasal delivery system for vaccines. *Adv. Drug Deliv. Rev.* 51:81-96.

Jahn-Schmid B, Graninger M, Glozik M, Kupcu S, Ebner C, Unger FM, Sleytr UB, and Messner P. (1996) Immunoreactivity of allergen (Bet v 1) conjugated to crystalline bacterial cell surface layers (S-layers). *Immunotechnology* 1996 2:103-113.

Jancarik, J., and Kim, S.H. (1991) Sparse matrix sampling: a screening method for
5 crystallization of proteins. *J. Appl. Crystallogr.* 24, 409-411.

Johnson-Saliba M, and Jans DA. (2001) Gene therapy: optimising DNA delivery to the nucleus. *Curr. Drug Targets* 2:371-399.

Jones DH, Corris S, McDonald S, Clegg JC, and Farrar GH. (1997) Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody
10 responses to encoded protein after oral administration. *Vaccine* 15:814-817.

Jong, et al. Immunomodulatory Substances of Fungal Origin, *J. Immunol. Immunopharmacol.*, Vol.XI, No.3, 1991. pp.115-122.

Kakuta S, Tagawa Y, Shibata S, Nanno M, and Iwakura Y. (2002) Inhibition of B16 melanoma experimental metastasis by interferon-gamma through direct inhibition of
15 cell proliferation and activation of antitumour host mechanisms. *Immunology* 105:92-100.

Kamat, A.M., and Lamm, D.L. (2001) Immunotherapy for bladder cancer. *Curr. Urol. Rep.* 2, 62-69.

Kas, H.S. Chitosan: properties, preparations and application to microparticulate systems. *J. Microencapsul.* 14: 689-711, 1997.

20 Kino, K., Yamashita, A., Yamaoka, K., Watanabe, J., Tanaka, S., Ko, K., Shimizu, K., and Tsunoo, H. (1989) Isolation and characterization of a new immunomodulatory protein, Ling Zhi-8 (LZ-8), from *Ganoderma lucidium*. *J. Biol. Chem.* 264, 472-478.

Klaenhammer TR. (1995) Genetics of intestinal lactobacilli. *Int. Dairy J.* 5:1019-1058.

Ko JL, Hsu CI, Lin RH, Kao CL, Lin JY, A new fungal immunomodulatory protein, FIP-fve isolated from the edible mushroom, *Flammulina velutipes* and its
5 complete amino acid sequence. *Eur. J Biochem* 228(2):244-9 (1995)

Ko, J.L., Lin, S.J., Hsu, C.I., Kao, C.L & Lin, J.Y. Molecular cloning and expression of a fungal immunomodulatory protein, FIP-fve, from *flammulina velutipes*. *J Forms Med Assoc.* 96, 517-524, (1997).

Komatsu, N., Okuto, S., Kikumoto, S., Kimura, K., Saito, G., and Sakai, S. (1969)
10 Host mediated antitumor action of Schizophyllan, a glucan produced by *Schizophyllum commune*. *Gann.* 60, 137-144.

Kong Q, Richter L, Yang YF, Arntzen CJ, Mason HS, and Thanavala Y. (2001) Oral immunization with hepatitis B surface antigen expressed in transgenic plants. *Proc. Natl. Acad. Sci. USA* 98:11539-11544.

Kraulis, P.J. A program to produce both detailed and schematic plots of protein. *J. Appl. Crystallogr.* 24, 946-950 (1991).
15

Krieg AM. (2000) The role of CpG motifs in innate immunity. *Curr. Opin. Immunol.* 12:35-43.

Krieg AM. (2002) A role for toll in autoimmunity. *Nat. Immunol.* 3: 423-424.

Kruger C, Hu Y, Pan Q, Marcotte H, Hultberg A, Delwar D, Van Dalen PJ, Pouwels PH, Leer RJ, Kelly CG, Van Dollenweerd C, Ma JK, and Hammarstrom L.
20 (2002) In situ delivery of passive immunity by lactobacilli producing single-chain antibodies. *Nat. Biotechnol.* 20:702-706.

- La Mantia, I., Grillo, C., Mattina, T., Zacccone, P., Xiang, M., Di Mauro, M., Meroni, P.L., and Nicoletti, F. (1999) Prophylaxis with the novel immunomodulator pidotimod reduces the frequency and severity of upper respiratory tract infections in children with Down's syndrome. *J. Chemother.* 11, 126-130.
- 5 Laskowski, R.A., MacArthur, M.W., Moss, D.S. & Thornton, J.M. PROCHECK: a program to check the stereochemical quality of protein structures. *J. Appl. Crystallogr.* 26, 283-290 (1993).
- Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. (2002) Chromatin-IgG complexes activate B cells by dual
10 engagement of IgM and Toll-like receptors. *Nature* 416:603-607.
- Leslie, A.G.W. (1992) Recent changes to the Mosfilm package for processing film and image plate data. *Joint CCP4 and ESF-EACBM Newsletter on Protein Crystallography*. No. 26. SERC Daresbury Laboratory, Warrington, UK.
- Liao, H.F., Chou, C.J., Wu, S.H., Khoo, K.H., Chen, C.F., and Wang, S.Y. (2001)
15 Isolation and characterization of an active compound from black soybean [Glycine max (L.) Merr.] and its effect on proliferation and differentiation of human leukemic U937 cells. *Anticancer Drugs*. 12, 841-846.
- Lin, W.H., Hung, C.H., Hsu, C.I., and Lin, J.Y. (1997) Dimerization of the N-terminal amphipathic α -helix domain of the fungal immunomodulatory protein from
20 *Ganoderma tsugae* (Fip-gts) defined by a yeast two-hybrid system and site-directed mutagenesis. *J. Biol. Chem.* 272, 20044-20048.
- Lu G., A WWW service system for automatic comparison of protein structures. *Protein Data Bank Quarterly Newsletter*. 78, 10-11 (1996).

- Maassen CB. A rapid and safe plasmid isolation method for efficient engineering of recombinant lactobacilli expressing immunogenic or tolerogenic epitopes for oral administration. *J. Immunol. Methods* 223: 131-136, 1999.
- 5 MacLaughlin, F.C., Mumper, R.J., Wang, J., Tagliaferri, J.M., Gill, I., Hinchcliffe, M. & Rolland, A.P. Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. *J. Controlled Release* 56: 259-272, 1998.
- Maecker HT, Hansen G, Walter DM, DeKruyff RH, Levy S, and Umetsu DT. (2001) Vaccination with allergen-IL-18 fusion DNA protects against, and reverses established, airway hyperreactivity in a murine asthma model. *J. Immunol.* 166:959-965.
- 10 Maeda, Y.Y. and Chihara, G. (1971) Lentinan, a new immuno-accelerator of cell-mediated responses. *Nature.* 229, 634.
- Matthews, B.W. (1968) Solvent content of protein crystals. *J. Mol. Biol.* 33, 491-497.
- McRee, D.E. XtalView/Xfit - A Versatile Program for Manipulating Atomic
15 Coordinates and Electron Density. *Journal Structural Biology*, 125, 156-165 (1999)
- Meneses, G., Delgado, M.A., Perez-Machado, M.A., Prieto, A., Alonso, R., Carrion, F., Lanzos, E., and Alvarez-Mon, M. (1997) Thymostimulin increases natural cytotoxic activity in patients with breast cancer. *Int. J. Immunopharmacol.* 19, 187-193.
- 20 Mercenier A, Muller-Alouf H, and Grangette C. (2000) Lactic acid bacteria as live vaccines. *Curr. Issues Mol. Biol.* 2:17-25.
- Meritt, E.A. & Bacon, D.J. RASTER3D. *Methods Enzymol.* 277, 505-524 (1997).

- Morales, A. (1984) Long term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer. *J. Urol.* **132**, 457-459.
- Morris, R. J., Perrakis, A. & Lamzin, V. S. Arp/warp's model-building algorithms. i. the main chain. *Acta Crystallogr. D* **58**, 968-975 (2002)
- 5 Murshudov, G.N., Lebedev, A., Vagin, A.A., Wilson, K.S. & Dodson, E.J
Efficient anisotropic refinement of Macromolecular structures using FFT *Acta Crystallogr. D* **55**, 247-255 (1999)
- 10 Nakamura, K., Yamaguchi, Y., Kagota, S., Kwon, Y.M., Shinozuka, K., and Kunitomo, M. (1999) Inhibitory effect of Cordyceps sinensis on spontaneous liver metastasis of Lewis lung carcinoma and B16 melanoma cells in syngeneic mice. *Jpn. J. Pharmacol.* **79**, 335-341.
- 15 Namba, K., Yamamura, E., Nitani, H., Otani, T., and Azuma, I. (1997)
Romurtide, a synthetic muramyl dipeptide derivative, promotes megakaryocytopoiesis through stimulation of cytokine production in nonhuman primates with myelosuppression. *Vaccine*. **15**, 405-413.
- Okamoto, M., Kaji, R., Kasetani, H., Yoshida, H., Moriya, Y., Saito, M., and Sato, M. (1993) Purification and characterization of interferon-gamma-inducing molecule of OK-432, a penicillin-killed streptococcal preparation, by monoclonal antibody neutralizing interferon-gamma-inducing activity of OK-432. *J. Immunother.* **13**, 232-242.
- 20 Otwinowski, Z. M. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. *Methods Enzymol.* **276**, 307-326 (1997).
- Piraino, F. and Brandt, C.R. (1999) Isolation and partial characterization of an antiviral, RC-183, from the edible mushroom *Rozites caperata*. *Antiviral Res.* **43**, 67-78.

Pochard P, Gosset P, Grangette C, Andre C, Tonnel AB, Pestel J, and Mercenier A. (2002) Lactic acid bacteria inhibit TH2 cytokine production by mononuclear cells from allergic patients. *J. Allergy Clin. Immunol.* 110:617-623.

- 5 Rask C, Holmgren J, Fredriksson M, Lindblad M, Nordstrom I, Sun JB, and Czerkinsky C. (2000) Prolonged oral treatment with low doses of allergen conjugated to cholera toxin B subunit suppresses immunoglobulin E antibody responses in sensitized mice. *Clin. Exp. Allergy* 30:1024-32.

Rost, B. (2001) Review: protein secondary structure prediction continues to rise. *J. Struct. Biol.* 134, 204-218.

- 10 Rousseau, F., Schymkowitz, J.W.H., Wilkinson, H.R., & Itzhaki, L.S. Three-dimensional domain swapping in p13suc1 occurs in the unfolded and controlled by conserved proline residues. *Proc.Natl Acad.Sci.USA.* 98, 5596-5601, (2001).

- Roy, K., Mao, H.Q., Huang, S.K. & Leong, K.W. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. 15 *Nat. Med.* 5: 387-391, 1999.

Scanga CB and Le Gros G. (2000) Development of an asthma vaccine: research into BCG. *Drugs* 59:1217-1221.

- Scharf O, Agranovich I, Lee K, Eller NL, Levy L, Inman J, Scott DE, and Golding B. (2001) Ontogeny of Th1 memory responses against a *Brucella abortus* conjugate. 20 *Infect Immun* 69:5417-5422.

Scheppler L, Vogel M, Zuercher AW, Zuercher M, Germond JE, Miescher SM, and Stadler BM. (2002) Recombinant *Lactobacillus johnsonii* as a mucosal vaccine delivery vehicle. *Vaccine* 20:2913-2920.

Shea LD, Smiley E, Bonadio J, and Mooney DJ. (1999) DNA delivery from polymer matrices for tissue engineering. *Nat. Biotechnol.* 17:551-554.

Shimizu, Y., Hasumi, K., and Masubuchi, K. (1992) Augmenting effect of sizofiran on the immunofunction of regional lymph nodes in cervical cancer. *Cancer*. 69,
5 1184-1194.

Shirota H, Sano K, Kikuchi T, Tamura G, and Shirato K. (2000) Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator. *J. Immunol.* 2000 164:5575-5582.

10 Singh, V.K., Biswas, S., Mathur, K.B., Haq, W., Garg, S.K., and Agarwal, S.S. (1998) Thymopentin and splenopentin as immunomodulators. Current status. *Immunol Res.* 17, 345-368.

Slonim DK. (2002) From patterns to pathways: gene expression data analysis comes of age. *Nat. Genet.* 32 Suppl 2:502-508.

15 Solomon, P., Wasser & Alexander, L.W. Therapeutic effect of substance occurring in higher Basidiomycetes Mushroom: A modern perspective. Critical Review in Immunology.19, 65-96 (1999).

Taal, B.G., Van Tinteren, H., Zoetmulder, F.A., and NACCP group. (2001) Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II
20 and III. *Br. J. Cancer.* 85, 1437-1443.

Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, and Arntzen CJ. (1998) Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. *Nat. Med.* 4:607-609.

- Templin MF, Stoll D, Schrenk M, Traub PC, Vohringer CF, and Joos TO. (2002) Protein microarray technology. *Trends Biotechnol.* 20:160-166.
- Terwilliger, T.C. & Berendzen, J. *Acta Crystallogr. D* 55, 849-861 (1999).
- Terwilliger. Map-likelihood phasing *Acta Crystallogr. D* 57, 1763-1775 (2001)
- 5 van Berkum NL and Holstege FC. (2001) DNA microarrays: raising the profile. *Curr. Opin. Biotechnol.* 12:48-52.
- Viland, H. and Blomgren, H. (1987) Augmentation of spontaneous cytotoxicity of human lymphocytes by RU 41.740, a glucoprotein extract of *Klebsiella pneumoniae*. *Anticancer Res.* 7, 17-22.
- 10 Vinuesa CG and Goodnow CC. (2002) Immunology: DNA drives autoimmunity. *Nature* 416:595-598.
- Wasson, V.P & Wasson, R.G. *Mushroom, Russia and History*, Pantheon Books, New York, 433, 1957.
- Wohlleben G and Erb KJ. (2001) Atopic disorders: a vaccine around the corner?
- 15 *Trends Immunol.* 22:618-626.
- Yoshino, S., Tabata, T., Hazama, S., Iizuka, N., Yamamoto, K., Hirayama, M., Tangoku, A., and Oka, M. (2000) Immunoregulatory effects of the antitumor polysaccharide lentinan on Th1/Th2 balance in patients with digestive cancers. *Anticancer Res.* 20, 4707-4711.
- 20 Zhu D and Stevenson FK. (2002) DNA gene fusion vaccines against cancer. *Curr. Opin. Mol. Ther.* 4:41-48.

Zhu H, Bilgin M, Bangham R, Hall D, Casamayor A, Bertone P, Lan N, Jansen R, Bidlingmaier S, Houfek T, Mitchell T, Miller P, Dean RA, Gerstein M, and Snyder M. (2001) Global analysis of protein activities using proteome chips. *Science* 293: 2101-2105.

- Zuany-Amorim C, Sawicka E, Manlius C, Le Moine A, Brunet LR, Kemeny DM, Bowen G, Rook G, and Walker C. (2002) Suppression of airway eosinophilia by killed *Mycobacterium vaccae*-induced allergen-specific regulatory T-cells. *Nat. Med.* 8:625-629.

Each of the applications and patents mentioned in this document, and each document cited or referenced in each of the above applications and patents, including during the prosecution of each of the applications and patents ("application cited documents") and any manufacturer's instructions or catalogues for any products cited or mentioned in each of the applications and patents and in any of the application cited documents, are hereby incorporated herein by reference. Furthermore, all documents cited in this text, and all documents cited or referenced in documents cited in this text, and any manufacturer's instructions or catalogues for any products cited or mentioned in this text, are hereby incorporated herein by reference.

Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the claims.

APPENDIX A: SEQUENCES

Fve is isolated from Golden Needle Mushroom (*Flammulina velutipes*).

ORGANISM: *Flammulina velutipes*. Eukaryota; Fungi; Basidiomycota; Hymenomycetes; Agaricales; Tricholomataceae; *Flammulina*.

5 *Fve (Wild type)*

ATGTCCGCCACGTCGCTCACCTTCCAGCTTGCCCTACTTGGTGAAGAAGATCGACTTCGAC
TACACCCCCAACTGGGGCCGTGGTACCCCAAGCAGCTACATCGACAACCTTACCTTCCCC
AAGGTTCTCACCGACAAAAAATACTCGTACCGCGTCGTGGTCAATGGCTCTGACCTTGGC
GTCGAGTCCAACCTTCGAGTGACACCGTCCGGTGGGCAGACCATCAACTTCCTCCAGTAC
10 AACAAGGGGTATGGTGTGCGGGACACAAAACGATTCAAGTTTTCGTTGTCATTCCAGAT
ACCGGCAACTCGGAGGAGTACATCATCGCTGAGTGGAAGAAGACTTGA
msatsltfqlaylvkkidfdytpnwgrgtpssyidnltfpkvltddkysyrvvngsdlg
vesnfavtppsggqtnflqynkgygvadtktiqvfvipdtgnseeyiaewkkt
ATG/TCC/GCC/ACG/TCG/CTC/ACC/TTC/CAG/CTT/GCC/TAC/TTG/GTG/AAG/
15 AAG/ATC/GAC/TTC/GAC/TAC/ACC/CCC/AAC/TGG/GGC/CGT/GGT/ACC/CCA/
AGC/AGC/TAC/ATC/GAC/AAC/CTT/ACC/TTC/CCC/AAG/GTT/CTC/ACC/GAC/
AAA/AAA/TAC/TCG/TAC/CGC/GTC/GTG/GTC/AAT/GGC/TCT/GAC/CTT/GGC/
GTC/GAG/TCC/AAC/TTC/GCA/GTG/ACA/CCG/TCC/GGT/GGG/CAG/ACC/ATC/
AAC/TTC/CTC/CAG/TAC/AAC/AAG/GGG/TAT/GGT/GTC/GCG/GAC/ACC/AAA/
20 ACG/ATT/CAA/GTT/TTC/GTT/GTC/ATT/CCA/GAT/ACC/GGC/AAC/TCG/GAG/
GAG/TAC/ATC/ATC/GCT/GAG/TGG/AAG/AAG/ACT/TGA

A *Fve* (Wild type) sequence may also comprise a sequence as set out above, but lacking the initial methionine (M) in the amino acid sequence, or lacking the initial ATG in the nucleic acid sequence.

25 *GST-Fve (Wild type) Nucleotide Sequence*

ATGTCCCCTATACTAGGTTATTGGAAAATTAAGGGCCTTGTGCAACCCACTCGACTTCTT
TTGGAATATCTTGAAGAAAAATATGAAGAGCATTGTATGAGCGCGATGAAGGTGATAAA
TGGCGAAACAAAAAGTTTGAATTGGGTTTGGAGTTTCCCAATCTTCCTTATTATATGAT
GGTGATGTTAAATTAACACAGTCTATGGCCATCATACGTTATATAGCTGACAAGCACAAC
30 ATGTTGGGTGGTTGTCCAAAAGAGCGTGACAGATTTCAATGCTTGAAGGAGCGGTTTTG
GATATTAGATACGGTGTTCGAGAATTGCATATAGTAAAGACTTTGAACTCTCAAAGTT
GATTTTCTTAGCAAGCTACCTGAAATGCTGAAAATGTTTGAAGATCGTTTATGTCATAAA
ACATATTTAAATGGTGATCATGTAACCCATCCTGACTTCATGTTGTATGACGCTCTTGAT
GTTGTTTTATACATGGACCCAATGTGCCTGGATGCGTTCCCAAATTAGTTTGTTTTAAA
35 AAACGTATTGAAGCTATCCCAAAATTGATAAGTACTTGAAATCCAGCAAGTATATAGCA
TGGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTGGTGGCGACCATCCTCCAAAATCGGAT
CTGGAAGTTCTGTTCCAGGGGCCCTGGGATCCTCCGCCACGTCGCTCACCTTCCAGCTT
GCCTACTTGGTGAAGAAGATCGACTTCGACTACACCCCCAACTGGGGCCGTGGTACCCCA
AGCAGCTACATCGACAACCTTACCTTCCCCAAGGTTCTACCGACAAAAAATACTCGTAC
40 CGCGTCGTGGTCAATGGCTCTGACCTTGGCGTCGAGTCCAACCTTCGAGTGACACCGTCC

GGTGGGCAGACCATCAACTTCCTCCAGTACAACAAGGGGTATGGTGTGCGGGACACCAAA
ACGATTCAAGTTTTCTGTGTCATTCCAGATACCGGCAACTCGGAGGAGTACATCATCGCT
GAGTGGAAGAAGACTTGA

5 *GST-Fve (Wild type) Amino Acid Sequence*

MSPILGYWKIKGLVQPTRLLLEYLEEKYEHELYERDEGDKWRNKKFELGLEFPNLPYYID
GDVKLTQSMAIIRYIADKHNMLGGCPKERAISMLEGAVLDIRYGVSR IAYSKDFETLKV
DFLSKLP EMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFK
KRIEAIPIQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLEVLFGGPLGSSATSLTFQL
10 AYLVKKIDFDYTPNWGRGTPSSYIDNLTFFPKVLTDDKYSYRVVNGSDLGVESNFAVTPS
GGQTINFLQYNKGYGVADTKTIQVFVVIPTDGNSEYIIAEWKKT

FVE DELETION MUTANTS

Fve D6-18

15 ATG/TCC/GCC/ACG/TCG/TTC/GAC/TAC/ACC/CCC/AAC/TGG/GGC/CGT/GGT/ACC/CC
A/AGC/AGC/TAC/ATC/GAC/AAC/CTT/ACC/TTC/CCC/AAG/GTT/CTC/ACC/GAC/AAA/
AAA/TAC/TCG/TAC/CGC/GTC/GTG/GTC/AAT/GGC/TCT/GAC/CTT/GGC/GTC/GAG/TC
C/AAC/TTC/GCA/GTG/ACA/CCG/TCC/GGT/GGG/CAG/ACC/ATC/AAC/TTC/CTC/CAG/
TAC/AAC/AAG/GGG/TAT/GGT/GTC/GCG/GAC/ACC/AAA/ACG/ATT/CAA/GTT/TTC/GT
20 T/GTC/ATT/CCA/GAT/ACC/GGC/AAC/TCG/GAG/GAG/TAC/ATC/ATC/GCT/GAG/TGG/
AAG/AAG/ACT/TGA
msats/fdytpnwgrgtpssyidnltfpkvltddkysyrvvvngsdlgvesnfavtppsggqtinfl
qynkgygvadtktiqvfviptdgnseeyiiaewkkt

Fve D19-33

25 ATG/TCC/GCC/ACG/TCG/CTC/ACC/TTC/CAG/CTT/GCC/TAC/TTG/GTG/AAG/AAG/AT
C/GAC/ATC/GAC/AAC/CTT/ACC/TTC/CCC/AAG/GTT/CTC/ACC/GAC/AAA/AAA/TAC/
TCG/TAC/CGC/GTC/GTG/GTC/AAT/GGC/TCT/GAC/CTT/GGC/GTC/GAG/TCC/AAC/TT
C/GCA/GTG/ACA/CCG/TCC/GGT/GGG/CAG/ACC/ATC/AAC/TTC/CTC/CAG/TAC/AAC/
AAG/GGG/TAT/GGT/GTC/GCG/GAC/ACC/AAA/ACG/ATT/CAA/GTT/TTC/GTT/GTC/AT
30 T/CCA/GAT/ACC/GGC/AAC/TCG/GAG/GAG/TAC/ATC/ATC/GCT/GAG/TGG/AAG/AAG/
ACT/TGA
msatsltfqlaylvkkid/idnltfpkvltddkysyrvvvngsdlgvesnfavtppsggqtinflqy
nkgygvadtktiqvfviptdgnseeyiiaewkkt

Fve D34-46

35 ATG/TCC/GCC/ACG/TCG/CTC/ACC/TTC/CAG/CTT/GCC/TAC/TTG/GTG/AAG/AAG/AT
C/GAC/TTC/GAC/TAC/ACC/CCC/AAC/TGG/GGC/CGT/GGT/ACC/CCA/AGC/AGC/TAC/
AAA/TAC/TCG/TAC/CGC/GTC/GTG/GTC/AAT/GGC/TCT/GAC/CTT/GGC/GTC/GAG/TC
C/AAC/TTC/GCA/GTG/ACA/CCG/TCC/GGT/GGG/CAG/ACC/ATC/AAC/TTC/CTC/CAG/
TAC/AAC/AAG/GGG/TAT/GGT/GTC/GCG/GAC/ACC/AAA/ACG/ATT/CAA/GTT/TTC/GT
40 T/GTC/ATT/CCA/GAT/ACC/GGC/AAC/TCG/GAG/GAG/TAC/ATC/ATC/GCT/GAG/TGG/
AAG/AAG/ACT/TGA
msatsltfqlaylvkkidfdytpnwgrgtpssy/kysyrvvvngsdlgvesnfavtppsggqtinfl
qynkgygvadtktiqvfviptdgnseeyiiaewkkt

Fve D47-60

45 ATG/TCC/GCC/ACG/TCG/CTC/ACC/TTC/CAG/CTT/GCC/TAC/TTG/GTG/AAG/AAG/AT
C/GAC/TTC/GAC/TAC/ACC/CCC/AAC/TGG/GGC/CGT/GGT/ACC/CCA/AGC/AGC/TAC/
ATC/GAC/AAC/CTT/ACC/TTC/CCC/AAG/GTT/CTC/ACC/GAC/AAA/GTC/GAG/TCC/AA

C/TTC/GCA/GTG/ACA/CCG/TCC/GGT/GGG/CAG/ACC/ATC/AAC/TTC/CTC/CAG/TAC/
 AAC/AAG/GGG/TAT/GGT/GTC/GCG/GAC/ACC/AAA/ACG/ATT/CAA/GTT/TTC/GTT/GT
 C/ATT/CCA/GAT/ACC/GGC/AAC/TCG/GAG/GAG/TAC/ATC/ATC/GCT/GAG/TGG/AAG/
 AAG/ACT/TGA
 5 msatsltfqlaylvkkidfdytpnwgrgtpssyidnltfpkvltldk/vesnfavtpsgggtinflq
 ynkgygvadtktiqvfvvipdtgnseeyiaewkkt

Fve D61-72

ATG/TCC/GCC/ACG/TCG/CTC/ACC/TTC/CAG/CTT/GCC/TAC/TTG/GTG/AAG/AAG/AT
 C/GAC/TTC/GAC/TAC/ACC/CCC/AAC/TGG/GGC/CGT/GGT/ACC/CCA/AGC/AGC/TAC/
 10 ATC/GAC/AAC/CTT/ACC/TTC/CCC/AAG/GTT/CTC/ACC/GAC/AAA/AAA/TAC/TCG/TA
 C/CGC/GTC/GTG/GTC/AAT/GGC/TCT/GAC/CTT/GGC/CAG/ACC/ATC/AAC/TTC/CTC/
 CAG/TAC/AAC/AAG/GGG/TAT/GGT/GTC/GCG/GAC/ACC/AAA/ACG/ATT/CAA/GTT/TT
 C/GTT/GTC/ATT/CCA/GAT/ACC/GGC/AAC/TCG/GAG/GAG/TAC/ATC/ATC/GCT/GAG/
 TGG/AAG/AAG/ACT/TGA
 15 msatsltfqlaylvkkidfdytpnwgrgtpssyidnltfpkvltddkysyrvvngsdlg/qtinf
 lqynkgygvadtktiqvfvvipdtgnseeyiaewkkt

Fve D73-84

ATG/TCC/GCC/ACG/TCG/CTC/ACC/TTC/CAG/CTT/GCC/TAC/TTG/GTG/AAG/AAG/AT
 C/GAC/TTC/GAC/TAC/ACC/CCC/AAC/TGG/GGC/CGT/GGT/ACC/CCA/AGC/AGC/TAC/
 20 ATC/GAC/AAC/CTT/ACC/TTC/CCC/AAG/GTT/CTC/ACC/GAC/AAA/AAA/TAC/TCG/TA
 C/CGC/GTC/GTG/GTC/AAT/GGC/TCT/GAC/CTT/GGC/GTC/GAG/TCC/AAC/TTC/GCA/
 GTG/ACA/CCG/TCC/GGT/GGG/GGT/GTC/GCG/GAC/ACC/AAA/ACG/ATT/CAA/GTT/TT
 C/GTT/GTC/ATT/CCA/GAT/ACC/GGC/AAC/TCG/GAG/GAG/TAC/ATC/ATC/GCT/GAG/
 TGG/AAG/AAG/ACT/TGA
 25 msatsltfqlaylvkkidfdytpnwgrgtpssyidnltfpkvltddkysyrvvngsdlgvesnfa
 vtpsgg/gvadtktiqvfvvipdtgnseeyiaewkkt

Fve D85-97

ATG/TCC/GCC/ACG/TCG/CTC/ACC/TTC/CAG/CTT/GCC/TAC/TTG/GTG/AAG/AAG/AT
 C/GAC/TTC/GAC/TAC/ACC/CCC/AAC/TGG/GGC/CGT/GGT/ACC/CCA/AGC/AGC/TAC/
 30 ATC/GAC/AAC/CTT/ACC/TTC/CCC/AAG/GTT/CTC/ACC/GAC/AAA/AAA/TAC/TCG/TA
 C/CGC/GTC/GTG/GTC/AAT/GGC/TCT/GAC/CTT/GGC/GTC/GAG/TCC/AAC/TTC/GCA/
 GTG/ACA/CCG/TCC/GGT/GGG/CAG/ACC/ATC/AAC/TTC/CTC/CAG/TAC/AAC/AAG/GG
 G/TAT/GTC/ATT/CCA/GAT/ACC/GGC/AAC/TCG/GAG/GAG/TAC/ATC/ATC/GCT/GAG/
 TGG/AAG/AAG/ACT/TGA
 35 msatsltfqlaylvkkidfdytpnwgrgtpssyidnltfpkvltddkysyrvvngsdlgvesnfa
 vtpsgggtinflqynkgy/ipdtgnseeyiaewkkt

Fve D98-106

ATG/TCC/GCC/ACG/TCG/CTC/ACC/TTC/CAG/CTT/GCC/TAC/TTG/GTG/AAG/AAG/AT
 C/GAC/TTC/GAC/TAC/ACC/CCC/AAC/TGG/GGC/CGT/GGT/ACC/CCA/AGC/AGC/TAC/
 40 ATC/GAC/AAC/CTT/ACC/TTC/CCC/AAG/GTT/CTC/ACC/GAC/AAA/AAA/TAC/TCG/TA
 C/CGC/GTC/GTG/GTC/AAT/GGC/TCT/GAC/CTT/GGC/GTC/GAG/TCC/AAC/TTC/GCA/
 GTG/ACA/CCG/TCC/GGT/GGG/CAG/ACC/ATC/AAC/TTC/CTC/CAG/TAC/AAC/AAG/GG
 G/TAT/GGT/GTC/GCG/GAC/ACC/AAA/ACG/ATT/CAA/GTT/TTC/GTT/GTC/TAC/ATC/
 ATC/GCT/GAG/TGG/AAG/AAG/ACT/TGA
 45 msatsltfqlaylvkkidfdytpnwgrgtpssyidnltfpkvltddkysyrvvngsdlgvesnfa
 vtpsgggtinflqynkgygvadtktiqvfv/yiaewkkt

Fve D107-115

ATG/TCC/GCC/ACG/TCG/CTC/ACC/TTC/CAG/CTT/GCC/TAC/TTG/GTG/AAG/AAG/AT
 C/GAC/TTC/GAC/TAC/ACC/CCC/AAC/TGG/GGC/CGT/GGT/ACC/CCA/AGC/AGC/TAC/

163

ATC/GAC/AAC/CTT/ACC/TTC/CCC/AAG/GTT/CTC/ACC/GAC/AAA/AAA/TAC/TCG/TA
 C/CGC/GTC/GTG/GTC/AAT/GGC/TCT/GAC/CTT/GGC/GTC/GAG/TCC/AAC/TTC/GCA/
 GTG/ACA/CCG/TCC/GGT/GGG/CAG/ACC/ATC/AAC/TTC/CTC/CAG/TAC/AAC/AAG/GG
 5 G/TAT/GGT/GTC/GCG/GAC/ACC/AAA/ACG/ATT/CAA/GTT/TTC/GTT/GTC/ATT/CCA/
 GAT/ACC/GGC/AAC/TCG/GAG/GAG/TGA
 msatsltfqlaylvkkidfdytpnwgrgtppssyidnltfpkvltddkysyrvvvngsdlgvesnfa
 vtpsgggtinflqynkgygvadtktiqfvvipdtgnsee/

Fve D61-97

ATG/TCC/GCC/ACG/TCG/CTC/ACC/TTC/CAG/CTT/GCC/TAC/TTG/GTG/AAG/AAG/AT
 10 C/GAC/TTC/GAC/TAC/ACC/CCC/AAC/TGG/GGC/CGT/GGT/ACC/CCA/AGC/AGC/TAC/
 ATC/GAC/AAC/CTT/ACC/TTC/CCC/AAG/GTT/CTC/ACC/GAC/AAA/AAA/TAC/TCG/TA
 C/CGC/GTC/GTG/GTC/AAT/GGC/TCT/GAC/CTT/GGC/ATT/CCA/GAT/ACC/GGC/AAC/
 TCG/GAG/GAG/TAC/ATC/ATC/GCT/GAG/TGG/AAG/AAG/ACT/TGA
 msatsltfqlaylvkkidfdytpnwgrgtppssyidnltfpkvltddkysyrvvvngsdlg/ipdtg
 15 nseeyiaewkkt

Fve p55-100

AAT/GGC/TCT/GAC/CTT/GGC/GTC/GAG/TCC/AAC/TTC/GCA/GTG/ACA/CCG/TCC/GG
 T/GGG/CAG/ACC/ATC/AAC/TTC/CTC/CAG/TAC/AAC/AAG/GGG/TAT/GGT/GTC/GCG/
 GAC/ACC/AAA/ACG/ATT/CAA/GTT/TTC/GTT/GTC/ATT/CCA/GAT/
 20 Ngsdlgvesnfavtpsgggtinflqynkgygvadtktiqfvvipd

FVE MUTANTS WITH SINGLE AMINO ACID SUBSTITUTIONS*FveR27A*

ATG/TCC/GCC/ACG/TCG/CTC/ACC/TTC/CAG/CTT/GCC/TAC/TTG/GTG/AAG/AAG/AT
 C/GAC/TTC/GAC/TAC/ACC/CCC/AAC/TGG/GGC/GCA/GGT/ACC/CCA/AGC/AGC/TAC/
 25 ATC/GAC/AAC/CTT/ACC/TTC/CCC/AAG/GTT/CTC/ACC/GAC/AAA/AAA/TAC/TCG/TA
 C/CGC/GTC/GTG/GTC/AAT/GGC/TCT/GAC/CTT/GGC/GTC/GAG/TCC/AAC/TTC/GCA/
 GTG/ACA/CCG/TCC/GGT/GGG/CAG/ACC/ATC/AAC/TTC/CTC/CAG/TAC/AAC/AAG/GG
 G/TAT/GGT/GTC/GCG/GAC/ACC/AAA/ACG/ATT/CAA/GTT/TTC/GTT/GTC/ATT/CCA/
 GAT/ACC/GGC/AAC/TCG/GAG/GAG/TAC/ATC/ATC/GCT/GAG/TGG/AAG/AAG/ACT/TG
 30 A
 msatsltfqlaylvkkidfdytpnwgaatpssyidnltfpkvltddkysyrvvvngsdlgvesnf
 avtpsgggtinflqynkgygvadtktiqfvvipdtgnseeyiaewkkt

FveG28A

ATG/TCC/GCC/ACG/TCG/CTC/ACC/TTC/CAG/CTT/GCC/TAC/TTG/GTG/AAG/AAG/AT
 35 C/GAC/TTC/GAC/TAC/ACC/CCC/AAC/TGG/GGC/CGT/GCA/ACC/CCA/AGC/AGC/TAC/
 ATC/GAC/AAC/CTT/ACC/TTC/CCC/AAG/GTT/CTC/ACC/GAC/AAA/AAA/TAC/TCG/TA
 C/CGC/GTC/GTG/GTC/AAT/GGC/TCT/GAC/CTT/GGC/GTC/GAG/TCC/AAC/TTC/GCA/
 GTG/ACA/CCG/TCC/GGT/GGG/CAG/ACC/ATC/AAC/TTC/CTC/CAG/TAC/AAC/AAG/GG
 G/TAT/GGT/GTC/GCG/GAC/ACC/AAA/ACG/ATT/CAA/GTT/TTC/GTT/GTC/ATT/CCA/
 40 GAT/ACC/GGC/AAC/TCG/GAG/GAG/TAC/ATC/ATC/GCT/GAG/TGG/AAG/AAG/ACT/TG
 A
 msatsltfqlaylvkkidfdytpnwgratpssyidnltfpkvltddkysyrvvvngsdlgvesnf
 avtpsgggtinflqynkgygvadtktiqfvvipdtgnseeyiaewkkt

FveT29A

ATG/TCC/GCC/ACG/TCG/CTC/ACC/TTC/CAG/CTT/GCC/TAC/TTG/GTG/AAG/AAG/AT
 45 C/GAC/TTC/GAC/TAC/ACC/CCC/AAC/TGG/GGC/CGT/GGT/GCA/CCA/AGC/AGC/TAC/

164

ATC/GAC/AAC/CTT/ACC/TTC/CCC/AAG/GTT/CTC/ACC/GAC/AAA/AAA/TAC/TCG/TAC/CGC/GTC/GTG/GTC/AAT/GGC/TCT/GAC/CTT/GGC/GTC/GAG/TCC/AAC/TTC/GCA/GTG/ACA/CCG/TCC/GGT/GGG/CAG/ACC/ATC/AAC/TTC/CTC/CAG/TAC/AAC/AAG/GG
 5 G/TAT/GGT/GTC/GCG/GAC/ACC/AAA/ACG/ATT/CAA/GTT/TTC/GTT/GTC/ATT/CCA/GAT/ACC/GGC/AAC/TCG/GAG/GAG/TAC/ATC/ATC/GCT/GAG/TGG/AAG/AAG/ACT/TGA
 A
 msatsltfqlaylvkkidfdytpnwgrgapsyidnltfpkvltddkysyrvvvngsdlgvesnf
 avtpsggqtnflqynkgygvadtktiqvfvvipdtgnseeyiaewkkt

FUSION PROTEINS OF MAJOR HOUSE DUST MITE ALLERGEN (BLO T 5 OR DER P 2) AND

10 FUNGAL IMMUNOMODULATORY PROTEIN FVE

Blo t 5-Fve (two-in-one chimeric wild type)

caagagcacaagccaaagaaggatgatttccgaaacgaattcgatcacttggtgatcgaaacaggca
 aaccatgctatcgaaaagggagaaacatcaattgctttacttgcaacaccaactcgacgaattgaat
 gaaaacaagagcaaggaattgcaagagaaaatcattcgagaacttgatggtggttgcccatgatc
 15 gaaggagcccaaggagctttggaacgtgaattgaagcgaactgatcttaacattttggaacgattc
 aactacgaagaggctcaaactctcagcaagatcttgcttaaggatttgaaggaaaccgaacaaaaa
 gtgaaggatattcaaacccaaTCCGCCACGTCGCTCACCTTCCAGCTTGCTTACTTGGTGAAGAAG
 ATCGACTTCGACTACACCCCCAACTGGGGCCGTGGTACCCCAAGCAGCTACATCGACAACCTTACC
 TTCCCCAAGGTTCTCACCGACAAAAAATACTCGTACCGCGTCGTGGTCAATGGCTCTGACCTTGGC
 20 GTCGAGTCCAACTTCGCAGTGACACCGTCCGGTGGGCAGACCATCAACTTCTCCAGTACACAAG
 GGGTATGGTGTGCGCGACACCAAAACGATTCAAGTTTTCGTTGTTCATTCCAGATACCGGCAACTCG
 GAGGAGTACATCATCGCTGAGTGGAAGAAGACTTGA
 QEHKPKKDDFRNEFDHLLIEQANHAIEKGEHQLLYLQHLDELNENKSKELQEKIIRELDVVCAMI
 EGAQGALERELKRTDLNILERFNIEEAQTLKILLKDLKETEQKVVDIQTQsatsltfqlaylvkk
 25 idfdytpnwgrgtptpsyidnltfpkvltddkysyrvvvngsdlgvesnfavtpsggqtnflqynk
 gygvadtktiqvfvvipdtgnseeyiaewkkt

Blo t 5-FveR27A (two-in-one chimeric mutant)

caagagcacaagccaaagaaggatgatttccgaaacgaattcgatcacttggtgatcgaaacaggca
 aaccatgctatcgaaaagggagaaacatcaattgctttacttgcaacaccaactcgacgaattgaat
 30 gaaaacaagagcaaggaattgcaagagaaaatcattcgagaacttgatggtggttgcccatgatc
 gaaggagcccaaggagctttggaacgtgaattgaagcgaactgatcttaacattttggaacgattc
 aactacgaagaggctcaaactctcagcaagatcttgcttaaggatttgaaggaaaccgaacaaaaa
 gtgaaggatattcaaacccaaTCCGCCACGTCGCTCACCTTCCAGCTTGCTTACTTGGTGAAGAAG
 ATCGACTTCGACTACACCCCCAACTGGGGC**G**CAGGTACCCCAAGCAGCTACATCGACAACCTTAC
 35 CTTCCCCAAGGTTCTCACCGACAAAAAATACTCGTACCGCGTCGTGGTCAATGGCTCTGACCTTGG
 CGTCGAGTCCAACTTCGCAGTGACACCGTCCGGTGGGCAGACCATCAACTTCTCCAGTACACAAG
 GGGTATGGTGTGCGCGACACCAAAACGATTCAAGTTTTCGTTGTTCATTCCAGATACCGGCAACTC
 GGAGGAGTACATCATCGCTGAGTGGAAGAAGACTTGA
 QEHKPKKDDFRNEFDHLLIEQANHAIEKGEHQLLYLQHLDELNENKSKELQEKIIRELDVVCAMI
 40 EGAQGALERELKRTDLNILERFNIEEAQTLKILLKDLKETEQKVVDIQTQsatsltfqlaylvkk
 idfdytpnwgragtptpsyidnltfpkvltddkysyrvvvngsdlgvesnfavtpsggqtnflqyn
 kgygvadtktiqvfvvipdtgnseeyiaewkkt

Blo t 5-FveT29A (two-in-one chimeric mutant)

caagagcacaagccaaagaaggatgatttccgaaacgaattcgatcacttggtgatcgaaacaggca
 45 aaccatgctatcgaaaagggagaaacatcaattgctttacttgcaacaccaactcgacgaattgaat
 gaaaacaagagcaaggaattgcaagagaaaatcattcgagaacttgatggtggttgcccatgatc
 gaaggagcccaaggagctttggaacgtgaattgaagcgaactgatcttaacattttggaacgattc
 aactacgaagaggctcaaactctcagcaagatcttgcttaaggatttgaaggaaaccgaacaaaaa

gtgaaggatattcaaacccaaTCCGCCACGTCGCTCACCTTCCAGCTTGCTTACTTGGTGAAGAAG
 ATCGACTTCGACTACACCCCCAACTGGGGCCGTGGT**GCA**CCAAGCAGCTACATCGACAACCTTAC
 CTTCCCAAGGTTCTCACCGACAAAAATACTCGTACCGCGTCGTGGTCAATGGCTCTGACCTTGG
 CGTCGAGTCCAACCTTCGAGTGACACCGTCCGGTGGGCAGACCATCAACTTCTCCAGTACAACAA
 5 GGGGTATGGTGTGCGCGGACACCAAAACGATTCAAGTTTTCGTTGTATTCCAGATACCGGCAACTC
 GGAGGAGTACATCATCGCTGAGTGGAAGAAGACTTGA
 QEHPKPKDDFRNEFDHLLIEQANHAIKGEHQLLYLQHLDELNENKSKELQEKIIRELDVVCAMI
 EGAQGALERELKRTDLNILERFNYEEAQTLSKILLKDLKETEQKVVDIQTQsatsltfqlaylvkk
 idfdytpnwgrgapsyidnltfpkvltddkysyrvvvngsdlgvesnfavtppsggqinlqyn
 10 kgygvadtktiqvfvvipdtgnseeyiaaewkkt

Der p 2-FveR27A (two-in-one chimeric mutant)

gatcaagtcgatgtcaaagattgtgccaatcatgaaatcaaaaaagttttggtaccaggatgccat
 ggttcagaacatgtatcattcatcggtgtaaacattccaattggaagccgttttcgaagccaac
 caaaacacaaaaacggctaaaattgaaatcaaagcctcaatcgatgggttagaagttgatgttccc
 15 ggtatcgatccaaatgcatgccattacatgaaatgccattgggttaaaggacaacaatatgatatt
 aaatatacatggaatgttccgaaaattgcacccaaatctgaaaatgttgctcgtcactgttaaagtt
 atgggtgatgatgggtgttttggcctgtgctattgctactcatgctaaaatccgcgatTCCGCCACG
 TCGCTCACCTTCCAGCTTGCTTACTTGGTGAAGAAGATCGACTTCGACTACACCCCCAACTGGGGC
GCAGGTACCCCCAAGCAGCTACATCGACAACCTTACCTTCCCCAAGGTTCTCACCGACAAAAATA
 20 CTCGTACCGCGTCGTGGTCAATGGCTCTGACCTTGGCGTCGAGTCCAACCTTCGAGTGACACCGTC
 CGGTGGGCAGACCATCAACTTCTCCAGTACAACAAGGGGTATGGTGTGCGCGGACACCAAAACGAT
 TCAAGTTTTCGTTGTATTCCAGATACCGGCAACTCGGAGGAGTACATCATCGCTGAGTGGAAGAA
 GACTTGA
 DQVDVKDCANHEIKKVLVPGCHGSEPCIIHRGKPFQLEAVFEANQNTKTAKIEIKASIDGLEVDVP
 25 GIDPNACHYMKCPLVKGQQYDIKYTNVVKIAPKSENVVVTVKVMGDDGVLACAIATHAKIRdsat
 sltfqlaylvkkidfdytpnwgaqtpssyidnltfpkvltddkysyrvvvngsdlgvesnfavtp
 sggqinlqynkgygvadtktiqvfvvipdtgnseeyiaaewkkt

Der p 2-FveT29A (two-in-one chimeric mutant)

gatcaagtcgatgtcaaagattgtgccaatcatgaaatcaaaaaagttttggtaccaggatgccat
 ggttcagaacatgtatcattcatcggtgtaaacattccaattggaagccgttttcgaagccaac
 caaaacacaaaaacggctaaaattgaaatcaaagcctcaatcgatgggttagaagttgatgttccc
 30 ggtatcgatccaaatgcatgccattacatgaaatgccattgggttaaaggacaacaatatgatatt
 aaatatacatggaatgttccgaaaattgcacccaaatctgaaaatgttgctcgtcactgttaaagtt
 atgggtgatgatgggtgttttggcctgtgctattgctactcatgctaaaatccgcgatTCCGCCACG
 35 TCGCTCACCTTCCAGCTTGCTTACTTGGTGAAGAAGATCGACTTCGACTACACCCCCAACTGGGGC
 CGTGGT**GCA**CCAAGCAGCTACATCGACAACCTTACCTTCCCCAAGGTTCTCACCGACAAAAATA
 CTCGTACCGCGTCGTGGTCAATGGCTCTGACCTTGGCGTCGAGTCCAACCTTCGAGTGACACCGTC
 CGGTGGGCAGACCATCAACTTCTCCAGTACAACAAGGGGTATGGTGTGCGCGGACACCAAAACGAT
 TCAAGTTTTCGTTGTATTCCAGATACCGGCAACTCGGAGGAGTACATCATCGCTGAGTGGAAGAA
 40 GACTTGA
 DQVDVKDCANHEIKKVLVPGCHGSEPCIIHRGKPFQLEAVFEANQNTKTAKIEIKASIDGLEVDVP
 GIDPNACHYMKCPLVKGQQYDIKYTNVVKIAPKSENVVVTVKVMGDDGVLACAIATHAKIRdsat
 sltfqlaylvkkidfdytpnwrgapsyidnltfpkvltddkysyrvvvngsdlgvesnfavtp
 sggqinlqynkgygvadtktiqvfvvipdtgnseeyiaaewkkt

45 *Blo t 5-Der p 2-FveR27A (three-in-one chimeric mutant)*

caagagcacaagccaaagaaggatgatttccgaaacgaattcgatcacttggtgatcgaacaggca
 aaccatgctatcgaaaagggaacatcaattgctttacttgcaacaccaactcgacgaattgaat
 gaaaacaaagagcaaggaattgcaagagaaaatcattcgagaacttgatgttgttgcgccatgatc
 gaaggagcccaaggagcttggaaacgtgaattgaagcgaactgatcttaacatttggaaacgattc
 50 aactacgaagaggctcaaaactctcagcaagatcttgcttaaggatttgaaggaaacgaacaaaaa

20 *HPV E7-FveT29A*

35

Deletion of the 23 amino acids of core antigen from 141-163 amino acid residues to increased protein production efficiency

40 MSTNPKPQRKTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATRKTSERSQPRGRRQPIPI
KARQPEGRAWAQPGYPWPPLYGNEGLGWAGWLLSPRGRSPSWGPTDPRRRSRNLGKVIDTLTCGFAD
LMGYLPLVYATGNLPGCSFSIFLLALLSCLTIPASAsatsltfqlaylvkkidfdytpnwgrgaps
syidltfpkvltdkkysyrvvngsdlgvesnfavtppsgggtinflqynkgygvadtktiqvfvv
ipdtgnseeiyiaewkkt
45 atgagcacgaatcctaaacctcaaagaaaaaccaaacgtaacaccaaacgcgcgccacaggacgctc
aagttcccgggcggttggtcagatcgtcggtaggattttacctgttgcgcgcgcagggggcccgaggttg
gggtgtgcgcgcgcataggaagacttccgagcggctcgcaacctcgtggaagcgcaaacctatcccc
aaggctcgccagcccgagggttagggctgggctcagcccggttaccctggccctctatggcaat

gagggccttgggggtgggcaggatggctcctgtcaccctgggtctcggcctagttggggccccacg
gacccccggcgtaggtcgcgcaatttgggtaaggtcatcgataccctcacgtgcggcttcgccgat
ctcatggggtagccttcgctcgtcggcgcaacagggaatctgccgggtgctccttttctatcttc
cttttggctttgctgtcctgtttgaccatcccagcttcgcttatgaagTCCGCCACGTCGCTCAC
5 CTTCAGCTTGCCTACTTGGTGAAGAAGATCGACTTCGACTACACCCCAACTGGGGCCGTGGTGC
ACCAAGCAGCTACATCGACAACCTTACCTTCCCAAGGTTCTACCGACAAAAAATACTCGTACCG
CGTCGTGGTCAATGGCTCTGACCTTGGCGTCGAGTCCAACCTTCGAGTGACACCCGTCCGGTGGGCA
GACCATCAACTTCCTCCAGTACAACAAGGGGTATGGTGTGCGGGACACCAAAACGATTCAAGTTTT
CGTTGTCAATCCAGATACCGGCAACTCGGAGGAGTACATCATCGCTGAGTGGAAGAAGACTTGA

10 FUSION PROTEINS OF TUMOR-ASSOCIATED ANTIGEN AND FVE

MAGE3-FveT29A

mpleqrsqhkpeegleargealglvgaqapateegeaasssstlvevtlgevpaaesdpdpqspq
gasslpttmnyplwsqsyedssnqeeegpstfpdlesefqaalsrkvaelvhllykrarepvtk
aemlgsvvgnwqyffpvijskassslglvfgielmevdpighlyifatclglsydgllgdnqimpk
15 agllliivlaiiaregdcapeekiweelsvlevfegredsildgpklltqhfvqenyleyrqvpqs
dpacyeflwppralvetsyvkvlhmvkissgpphisypplhewvlregeesatstfqlaylvkki
dfdytpnwgrgapssyidnltfpkvltddkysyrvvngsdlgvesnfavtppsqqtinflqynkg
ygvadtktiqvfvvipdtgnseeyiaewkkt
atgcctcttgagcagaggagtgcagcactgcaagcctgaagaaggccttgaggcccgaggagaggcc
20 ctgggcctgggtgggtgagcaggctcctgctactgaggagcaggaggctgcctcctcctcttact
ctagttgaagtcaccctgggggaggtgctgctgcccagtcaccagatcctccccagagtcctcag
ggagcctccagcctccccactaccatgaactaccctctctggagccaatcctatgaggactccagc
aaccaagaaggaggaggggccaagcacttcctgacctggagtcagagttccaagcagcactcagt
aggaaggtggccgagttgggtcattttctgctcctcaagatcgagccaggaggagccggtcacaaag
25 gcagaaatgctggggagtgtcgtcggaattggcagttatttcttctgtgatcttcagcaaaagt
tccagttccttgagcgtgggtccttggcatcgagctgatggaagtggaccccatcgccacttgtag
atctttgcccactgctgggcctctcctacgatggcctgctgggtgacaatcagatcatgcccag
gcaggcctcctgataatcgtcctggccataatcgcaagagaggcgactgtgcccctgaggagaaa
atctggggaggagctgagtggttagaggtgtttgaggggagggaagacagtatcttgggggatccc
30 aagaagctgctcacccaacatttcgtgcaggaaaactacctggagtagccggcaggtccccggcag
gatcctgcatgttatgaattcctgtgggtccaagggccctcgttgaaaccagctatgtgaaagtc
ctgcaccatattggtaaagatcagtgaggagcctcacatttcctacccacccctgcatgagtggtt
ttgagagaggggggaagagTCCGCCACGTCGCTACCTTCCAGCTTGCTACTTGGTGAAGAAGATC
GACTTCGACTACACCCCAACTGGGGCCGTGGTGCACCAAGCAGCTACATCGACAACCTTACCTTC
35 CCCAAGGTTCTACCGACAAAAAATACTCGTACCGCGTCGTGGTCAATGGCTCTGACCTTGGCGTC
GAGTCCAACCTTCGAGTGACACCGTCCGGTGGGCAGACCATCAACTTCCTCCAGTACAACAAGGGG
TATGGTGTGCGGGACACCAAAACGATTCAAGTTTTCTGTTGTCAATCCAGATACCGGCAACTCGGAG
GAGTACATCATCGCTGAGTGGAAGAAGACTTGA

MART1-FveT29A

mpredahfiygyppkkgghsyttaeaaagigiltvilgvliligcwycrrrngyralmdkslhvgt
qcaltrrcpqegfdhrskvslqekncepvvpnapayeklsaeqspypspatsltfqlaylvk
kidfdytpnwgrgapssyidnltfpkvltddkysyrvvngsdlgvesnfavtppsqqtinflqyn
kgygvadtktiqvfvvipdtgnseeyiaewkkt
atgccaaagagaagatgctcacttcatctatggttaccccaagaaggggcagggccactcttacacc
45 acggctgaagaggccgctgggatcgcatcctgacagtgatcctgggagtcctactgctcatcggc
tggttggtattgtagaagacgaaatggatacagagccttgatggataaaagtcttcatgttgccact
caatgtgccttaacaagaagatgcccacaagaagggttgatcatcgggacagcaaagtgtctctt
caagagaaaaactgtgaacctgtggttcccaatgctccacctgcttatgagaaactctctgcagaa
cagtcaccaccacctattcacctTCCGCCACGTCGCTACCTTCCAGCTTGCTACTTGGTGAAGA
50 AAGATCGACTTCGACTACACCCCAACTGGGGCCGTGGTGCACCAAGCAGCTACATCGACAACCTT
ACCTTCCCAAGGTTCTACCGACAAAAAATACTCGTACCGCGTCGTGGTCAATGGCTCTGACCTT

GGCGTCGAGTCCAACTTCGCAGTGACACCGTCCGGTGGGCAGACCATCAACTTCCTCCAGTACAAC
AAGGGGTATGGTGTGCGGGACACCAAAACGATTCAAGTTTTTCGTTGTATTCCAGATACCGGCAAC
TCGGAGGAGTACATCATCGCTGAGTGGAAGAAGACTTGA

5 *CEA-FveT29A*

kltiestpfvnaegkevl11lvhnlpqhlfgywykgervdgnrqiigyvigttqatpgpaysgrei
iypnaslliqniiqndtgfytlhviksdlvneeatggfrvypelpkpsissnnskpvedkdavaf
cepetqdatylwvwnqslpvsprlqlsngnrtltlfnvtrndtasykcetqnpvsarrdsviln
10 vlygpdaptisplntsyrgenlnlschaasnppaqyswfvngtfqgstqelfipnitvnnsgsy
cqahnsdtglnrttvttitvyaepkpfitsnnsnpvededavaltcepeiqttylwvwnqslp
vsprlqlsndnrtltlsvtrndvgpyecgimelsvdhsdpvilnvlygpdptispsyttyrpg
vnlslschaasnppaqyswlvldgniqhtqelfisniteknsglytcqannsasghsrttvtktitv
saelpkpsissnnskpvedkdavafcepeaqttylwvwnqslpvsprlqlsngnrtltlfnv
rndarayvcgiqnsvsanrsdpvltldvlygpdtpiisppdssylsganlnlschaasnppqysw
15 ingipqghtqvlfiakitpnngntyacfvsnlatgrnnsivksitvsasgtspglsagatvgimig
vlvgvalisatstfqlaylvkkidfdytpnwrgapssyidnltfpkvltddkysyrvvngsdl
gvesnfavtpeggqtinflqynkgygvadtktiqvfvvfpdtnseeyiaewkkt
aagctcactattgaatccacgccgttcaatgtcgcagaggggaaggaggtgcttctacttgtccac
aatctgccccagcatctttttggctacagctggtacaaagggtgaaagagtggtggcaaccgtcaa
20 attataggatattgaataggaactcaacaagctacccagggccgcatacagtggtcgagagata
atataccccaatgcacccctgctgatccagaacatcatccagaatgacacaggattctacacccta
cacgtcataaagtcagatcttgtgaatgaagaagcaactggccagttccgggtataccggagctg
cccaagccctccatctccagcaacaactccaacccgtggaggacaaggatgctgtggccttcacc
tgtgaacctgagactcaggacgcaacctacctgtggtgggtaaacatcagagcctcccggtcagt
25 ccaggctgcagctgtccaatggcaacaggaccctcactctattcaatgtcacaagaaatgacaca
gcaagctacaaatgtgaaaccagaaccagtgagtgccaggcgagtgattcagtcacatcctgaat
gtcctctatggcccggtgccccaccatttccctctaaacacatcttacagatcaggggaaaat
ctgaacctctcctgccatgcagcctctaaccacactgcacagtaactcttggtttgtcaatgggact
ttccagcaatccaccaagagctctttatccccaacatcactgtgaataatagtggtacctatacg
30 tgccaagcccataactcagacactggcctcaataggaccacagtcacgacgatcacagtcctatgca
gaccaacccaacccttcacaccagcaacaactccaacccgtggaggatgaggatgctgtagcc
ttaacctgtgaacctgagattcagaacacaacctacctgtggtgggtaaatatcagagcctcccg
gtcagtcacaggctgcagctgtccaatgacaacaggaccctcactctactcagtgtcacaaggaat
gatgtaggaccctatgagtggtgaatccagaacgaattaaagtgttgaccacagcgaccagtcac
35 ctgaatgtcctctatggcccagacgacccaccatttccctctatacacctattaccgtccaggg
gtgaacctcagcctctcctgccatgcagcctctaaccacactgcacagtaattcttggtgattgat
gggaacatccagcaacacacacaagagctctttatctccaacatcactgagaagaacagcgactc
tatactgccaggccaataactcagccagtgccacagcaggactacagtcaggaacatcacagtc
ctcgccggagctgcccgaagccctccatctccagcaacaactccaacccgtggaggacaaggatgct
40 gtggccttcacctgtgaacctgaggctcagaacacaaactacctgtggtgggtaaatggtcagagc
ctccagtcagtcacaggctgcagctgtccaatggcaacaggaccctcactctattcaatgtcaca
agaaatgacgcaagagcctatgtatgtggaatccagaactcagtgagtgcaaacccgagtgacca
gtcacctggatgtcctctatgggcccgaacccccatcatttccccccagactcgtcttacctt
tcgggagcgaaacctcaacctctcctgccactcggcctctaaccatccccgcagtaattcttggcgt
45 atcaatgggataaccgcagcaacacacacaagttctctttatcgccaaaatcacgccaataataac
gggacctatgctgttttgtctctaacttggtactggccgcaataattccatagtcagagcatc
acagtcctctgcatctggaacttctcctggtctctcagctggggccactgtcggcacatgattgga
gtgctggttgggggtgtctctgataTCCGCCACGTCGCTCACCTTCAGCTTGCCTACTTGGTGAAG
AAGATCGACTTCGACTACACCCCAACTGGGGCCGTGGTGACCAAGCAGCTACATCGACAACCTT
50 ACCTTCCCAAGGTTCTCACCGACAAAAATACTCGTACCGCGTCTGGTCAATGGCTCTGACCTT
GGCGTCGAGTCCAACTTCGCAGTGACACCGTCCGGTGGGCAGACCATCAACTTCCTCCAGTACAAC
AAGGGGTATGGTGTGCGGGACACCAAAACGATTCAAGTTTTTCGTTGTATTCCAGATACCGGCAAC
TCGGAGGAGTACATCATCGCTGAGTGGAAGAAGACTTGA

PRIMERS FOR CONSTRUCTION OF FIVE DELETION MUTANTS

Fd6-18F (36 mer)

5' -ggA/TCC/TCC/gCC/ACg/TCg/TTC/gAC/TAC/ACC/CCC/AAC- 3'

Fd6-18R (36 mer)

5 5' -gTT/ggg/ggT/gTA/gTC/gAA/CgA/CgT/ggC/ggA/ggA/TCC- 3'

Fd19-33F (36 mer)

5' -TTg/gTg/AAg/AAg/ATC/gAC/ATC/gAC/AAC/CTT/ACC/TTC- 3'

Fd19-33R (36 mer)

5' -gAA/ggT/AAg/gTT/gTC/gAT/gTC/gAT/CTT/CTT/CAC/CAA- 3'

10 *Fd34-46F (36 mer)*

5' -ggT/ACC/CCA/AgC/AgC/TAC/AAA/TAC/TCg/TAC/CgC/gTC- 3'

Fd34-46R (36 mer)

5' -gAC/gCg/gTA/CgA/gTA/TTT/gTA/gCT/gCT/Tgg/ggT/ACC- 3'

Fd47-60F (36 mer)

15 5' -AAg/gTT/CTC/ACC/gAC/AAA/gTC/gAg/TCC/AAC/TTC/gCA- 3'

Fd47-60R (36 mer)

5' -TgC/gAA/gTT/ggA/CTC/gAC/TTT/gTC/ggT/gAg/AAC/CTT- 3'

Fd61-72F (36 mer)

5' -AAT/ggC/TCT/gAC/CTT/ggC/CAG/ACC/ATC/AAC/TTC/CTC- 3'

20 *Fd61-72R (36 mer)*

5' -gAg/gAA/gTT/gAT/ggT/CTg/gCC/AAg/gTC/AgA/gCC/ATT- 3'

Fd73-84F (36 mer)

5' -gTg/ACA/CCg/TCC/ggT/ggg/ggT/gTC/gCg/gAC/ACC/AAA- 3'

Fd73-84R (36 mer)

25 5' -TTT/ggT/gTC/CgC/gAC/ACC/CCC/ACC/ggA/Cgg/TgT/CAC- 3'

Fd85-97F (36 mer)

5' -CAG/TAC/AAC/AAg/ggg/TAT/ATT/CCA/gAT/ACC/ggC/AAC- 3'

Fd85-97R (36 mer)

5' -gTT/gCC/ggT/ATC/Tgg/AAT/ATA/CCC/CTT/gTT/gTA/CTg- 3'

30 *Fd98-106F (36 mer)*

5' -ATT/CAA/gTT/TTC/gTT/gTC/TAC/ATC/ATC/gCT/gAg/Tgg- 3'

Fd98-106R (36 mer)

5' -CCA/CTC/AgC/gAT/gAT/gTA/gAC/AAC/gAA/AAC/TTg/AAT- 3'

Fd107-115R (39 mer)

5' -gAT/gCA/ACT/gAA/TTC/TTA/TTA/CTC/CTC/CgA/gTT/gCC/ggT- 3'

PRIMERS FOR CONSTRUCTION OF LARGE FRAGMENT DELETION OF FVE*d(61-97)-F (36mer)*

5 5' -/AAT/ggC/TCT/gAC/CTT/ggC/ATT/CCA/gAT/ACC/ggC/AAC/-3'

d(61-97)-R (36mer)

5' -/gTT/gCC/ggT/ATC/Tgg/AAT/gCC/AAg/gTC/AgA/gCC/ATT/-3'

PRIMERS FOR CONSTRUCTION OF SMALL FRAGMENT OF FVE (FROM 55AA TO 100AA)*[Fv55-100]-F (48mer)*10 5' -
/gTT/CCg/CgT/ggA/TCC/ATC/gAA/ggT/CgT/AAT/ggC/TCT/gAC/CTT/ggC/gTC/-
3'*[Fv55-100]-R (42mer)*

5' -/gAT/gCA/ACT/gAA/TTC/TTA/TCA/ATC/Tgg/AAT/gAC/AAC/gAA/AAC/-3'

15 **PRIMERS FOR CONSTRUCTION OF POINT MUTANTS OF FVE***F(R27A)-F (27 mer)*

5' - CCC/AAC/Tgg/ggC/gCA/ggT/ACC/CCA/AgC - 3'

F(R27A)-R (27 mer)

5' - gCT/Tgg/ggT/ACC/TgC/gCC/CCA/gTT/ggg - 3'

20 *F(G28A)-F (27 mer)*

5' - AAC/Tgg/ggC/CgT/gCA/ACC/CCA/AgC/AgC - 3'

F(G28A)-R (27 mer)

5' - gCT/gCT/Tgg/ggT/TgC/ACg/gCC/CCA/gTT - 3'

F(T29A)-F (27 mer)

25 5' - Tgg/ggC/CgT/ggT/gCA/CCA/AgC/AgC/TAC - 3'

F(T29A)-R (27 mer)

5' - gTA/gCT/gCT/Tgg/TgC/ACC/ACg/gCC/CCA - 3'

PRIMERS FOR BLO T 5-FVE FUSION PROTEIN*Bt5Fv-F (36mer)*

30 5' -/AAg/gAT/ATT/CAA/ACC/CAA/TCC/gCC/ACg/TCg/CTC/ACC/-3'

Bt5Fv-R (36mer)

5' - /ggT/gAg/CgA/CgT/ggC/ggA/TTg/ggT/TTg/AAT/ATC/CTT/-3'

PRIMERS FOR DER P 2-FVE FUSION PROTEIN*Dp2Fv-F (36mer)*

5 5' - /CAT/gCT/AAA/ATC/CgC/gAT/TCC/gCC/ACg/TCg/CTC/ACC-3'

Dp2Fv-R (36mer)

5' - /ggT/gAg/CgA/CgT/ggC/ggA/ATC/gCg/gAT/TTT/AgC/ATg-3'

PRIMERS FOR BLO T 5-DER P 2-FVE FUSION PROTEIN*Bt5Dp2-F (36mer)*

10 5' - /aag/gat/att/caa/acc/caa/gat/caa/gtc/gat/gtc/aaa/-3'

Bt5Dp2-R (36mer)

5' - /ttt/gac/atc/gac/ttg/atc/ttg/ggt/ttg/aat/atc/ctt/-3'

APPENDIX B: FVE FRAGMENTS (RGT TRIPLET HIGHLIGHTED)

Fragment Number	Residues	Sequence
1	24-28	WGRGT
2	25-29	GRGTP
3	26-30	RGTPS
4	27-31	GTPSS
5	28-32	TPSSY
6	23-28	NWGRGT
7	24-29	WGRGTP
8	25-30	GRGTPS
9	26-31	RGTPSS
10	27-32	GTPSSY
11	28-33	TPSSYI
12	22-28	PNWGRGT
13	23-29	NWGRGTP
14	24-30	WGRGTPS
15	25-31	GRGTPSS
16	26-32	RGTPSSY
17	27-33	GTPSSYI
18	28-34	TPSSYID
19	21-28	TPNWGRGT
20	22-29	PNWGRGTP
21	23-30	NWGRGTPS
22	24-31	WGRGTPSS
23	25-32	GRGTPSSY
24	26-33	RGTPSSYI
25	27-34	GTPSSYID
26	28-35	TPSSYIDN
27	20-28	YTPNWGRGT
28	21-29	TPNWGRGTP
29	22-30	PNWGRGTPS
30	23-31	NWGRGTPSS
31	24-32	WGRGTPSSY
32	25-33	GRGTPSSYI
33	26-34	RGTPSSYID
34	27-35	GTPSSYIDN
35	28-36	TPSSYIDNL
36	19-28	DYTPNWGRGT
37	20-29	YTPNWGRGTP
38	21-30	TPNWGRGTPS
39	22-31	PNWGRGTPSS
40	23-32	NWGRGTPSSY

Fragment Number	Residues	Sequence
41	24-33	WGRGTPSSYI
42	25-34	GRGTPSSYID
43	26-35	RGTPSSYIDN
44	27-36	GTPSSYIDNL
45	28-37	TPSSYIDNLT
46	18-28	FDYTPNWGRGT
47	19-29	DYTPNWGRGTP
48	20-30	YTPNWGRGTPS
49	21-31	TPNWGRGTPSS
50	22-32	PNWGRGTPSSY
51	23-33	NWGRGTPSSYI
52	24-34	WGRGTPSSYID
53	25-35	GRGTPSSYIDN
54	26-36	RGTPSSYIDNL
55	27-37	GTPSSYIDNLT
56	28-38	TPSSYIDNLTF
57	17-28	DFDYTPNWGRGT
58	18-29	FDYTPNWGRGTP
59	19-30	DYTPNWGRGTPS
60	20-31	YTPNWGRGTPSS
61	21-32	TPNWGRGTPSSY
62	22-33	PNWGRGTPSSYI
63	23-34	NWGRGTPSSYID
64	24-35	WGRGTPSSYIDN
65	25-36	GRGTPSSYIDNL
66	26-37	RGTPSSYIDNLT
67	27-38	GTPSSYIDNLTF
68	28-39	TPSSYIDNLTFP
69	16-28	IDFDYTPNWGRGT
70	17-29	DFDYTPNWGRGTP
71	18-30	FDYTPNWGRGTPS
72	19-31	DYTPNWGRGTPSS
73	20-32	YTPNWGRGTPSSY
74	21-33	TPNWGRGTPSSYI
75	22-34	PNWGRGTPSSYID
76	23-35	NWGRGTPSSYIDN
77	24-36	WGRGTPSSYIDNL
78	25-37	GRGTPSSYIDNLT
79	26-38	RGTPSSYIDNLTF
80	27-39	GTPSSYIDNLTFP
81	28-40	TPSSYIDNLTFPK
82	15-28	KIDFDYTPNWGRGT
83	16-29	IDFDYTPNWGRGTP

Fragment Number	Residues	Sequence
84	17-30	DFDYTPNWGRGTPS
85	18-31	FDYTPNWGRGTPSS
86	19-32	DYTPNWGRGTPSSY
87	20-33	YTPNWGRGTPSSYI
88	21-34	TPNWGRGTPSSYID
89	22-35	PNWGRGTPSSYIDN
90	23-36	NWGRGTPSSYIDNL
91	24-37	WGRGTPSSYIDNLT
92	25-38	GRGTPSSYIDNLTF
93	26-39	RGTPSSYIDNLTFP
94	27-40	GTPSSYIDNLTFPK
95	28-41	TPSSYIDNLTFPKV
96	14-28	KKIDFDYTPNWGRGT
97	15-29	KIDFDYTPNWGRGTP
98	16-30	IDFDYTPNWGRGTPS
99	17-31	DFDYTPNWGRGTPSS
100	18-32	FDYTPNWGRGTPSSY
101	19-33	DYTPNWGRGTPSSYI
102	20-34	YTPNWGRGTPSSYID
103	21-35	TPNWGRGTPSSYIDN
104	22-36	PNWGRGTPSSYIDNL
105	23-37	NWGRGTPSSYIDNLT
106	24-38	WGRGTPSSYIDNLTF
107	25-39	GRGTPSSYIDNLTFP
108	26-40	RGTPSSYIDNLTFPK
109	27-41	GTPSSYIDNLTFPKV
110	28-42	TPSSYIDNLTFPKVL
111	13-28	VKKIDFDYTPNWGRGT
112	14-29	KKIDFDYTPNWGRGTP
113	15-30	KIDFDYTPNWGRGTPS
114	16-31	IDFDYTPNWGRGTPSS
115	17-32	DFDYTPNWGRGTPSSY
116	18-33	FDYTPNWGRGTPSSYI
117	19-34	DYTPNWGRGTPSSYID
118	20-35	YTPNWGRGTPSSYIDN
119	21-36	TPNWGRGTPSSYIDNL
120	22-37	PNWGRGTPSSYIDNLT
121	23-38	NWGRGTPSSYIDNLTF
122	24-39	WGRGTPSSYIDNLTFP
123	25-40	GRGTPSSYIDNLTFPK
124	26-41	RGTPSSYIDNLTFPKV
125	27-42	GTPSSYIDNLTFPKVL
126	28-43	TPSSYIDNLTFPKVLT

Fragment Number	Residues	Sequence
127	12-28	LVKKIDFDYTPNWGRGT
128	13-29	VKKIDFDYTPNWGRGTP
129	14-30	KKIDFDYTPNWGRGTPS
130	15-31	KIDFDYTPNWGRGTPSS
131	16-32	IDFDYTPNWGRGTPSSY
132	17-33	DFDYTPNWGRGTPSSYI
133	18-34	FDYTPNWGRGTPSSYID
134	19-35	DYTPNWGRGTPSSYIDN
135	20-36	YTPNWGRGTPSSYIDNL
136	21-37	TPNWGRGTPSSYIDNLT
137	22-38	PNWGRGTPSSYIDNLTF
138	23-39	NWGRGTPSSYIDNLTFP
139	24-40	WGRGTPSSYIDNLTFPK
140	25-41	GRGTPSSYIDNLTFPKV
141	26-42	RGTPSSYIDNLTFPKVL
142	27-43	GTPSSYIDNLTFPKVLT
143	28-44	TPSSYIDNLTFPKVLT
144	11-28	YLVKKIDFDYTPNWGRGT
145	12-29	LVKKIDFDYTPNWGRGTP
146	13-30	VKKIDFDYTPNWGRGTPS
147	14-31	KKIDFDYTPNWGRGTPSS
148	15-32	KIDFDYTPNWGRGTPSSY
149	16-33	IDFDYTPNWGRGTPSSYI
150	17-34	DFDYTPNWGRGTPSSYID
151	18-35	FDYTPNWGRGTPSSYIDN
152	19-36	DYTPNWGRGTPSSYIDNL
153	20-37	YTPNWGRGTPSSYIDNLT
154	21-38	TPNWGRGTPSSYIDNLTF
155	22-39	PNWGRGTPSSYIDNLTFP
156	23-40	NWGRGTPSSYIDNLTFPK
157	24-41	WGRGTPSSYIDNLTFPKV
158	25-42	GRGTPSSYIDNLTFPKVL
159	26-43	RGTPSSYIDNLTFPKVLT
160	27-44	GTPSSYIDNLTFPKVLT
161	28-45	TPSSYIDNLTFPKVLT
162	10-28	AYLVKKIDFDYTPNWGRGT
163	11-29	YLVKKIDFDYTPNWGRGTP
164	12-30	LVKKIDFDYTPNWGRGTPS
165	13-31	VKKIDFDYTPNWGRGTPSS
166	14-32	KKIDFDYTPNWGRGTPSSY
167	15-33	KIDFDYTPNWGRGTPSSYI
168	16-34	IDFDYTPNWGRGTPSSYID
169	17-35	DFDYTPNWGRGTPSSYIDN

Fragment Number	Residues	Sequence
170	18-36	FDYTPNWGRGTPSSYIDNL
171	19-37	DYTPNWGRGTPSSYIDNLT
172	20-38	YTPNWGRGTPSSYIDNLTF
173	21-39	TPNWGRGTPSSYIDNLTFP
174	22-40	PNWGRGTPSSYIDNLTFPK
175	23-41	NWGRGTPSSYIDNLTFPKV
176	24-42	WGRGTPSSYIDNLTFPKVL
177	25-43	GRGTPSSYIDNLTFPKVLT
178	26-44	RGTPSSYIDNLTFPKVLT
179	27-45	GTPSSYIDNLTFPKVLT
180	28-46	TPSSYIDNLTFPKVLT
181	9-28	LAYLVKKIDFDYTPNWGRGT
182	10-29	AYLVKKIDFDYTPNWGRGTP
183	11-30	YLVKKIDFDYTPNWGRGTPS
184	12-31	LVKKIDFDYTPNWGRGTPSS
185	13-32	VKKIDFDYTPNWGRGTPSSY
186	14-33	KKIDFDYTPNWGRGTPSSYI
187	15-34	KIDFDYTPNWGRGTPSSYID
188	16-35	IDFDYTPNWGRGTPSSYIDN
189	17-36	DFDYTPNWGRGTPSSYIDNL
190	18-37	FDYTPNWGRGTPSSYIDNLT
191	19-38	DYTPNWGRGTPSSYIDNLTF
192	20-39	YTPNWGRGTPSSYIDNLTFP
193	21-40	TPNWGRGTPSSYIDNLTFPK
194	22-41	PNWGRGTPSSYIDNLTFPKV
195	23-42	NWGRGTPSSYIDNLTFPKVL
196	24-43	WGRGTPSSYIDNLTFPKVLT
197	25-44	GRGTPSSYIDNLTFPKVLT
198	26-45	RGTPSSYIDNLTFPKVLT
199	27-46	GTPSSYIDNLTFPKVLT
200	28-47	TPSSYIDNLTFPKVLT
201	8-28	QLAYLVKKIDFDYTPNWGRGT
202	9-29	LAYLVKKIDFDYTPNWGRGTP
203	10-30	AYLVKKIDFDYTPNWGRGTPS
204	11-31	YLVKKIDFDYTPNWGRGTPSS
205	12-32	LVKKIDFDYTPNWGRGTPSSY
206	13-33	VKKIDFDYTPNWGRGTPSSYI
207	14-34	KKIDFDYTPNWGRGTPSSYID
208	15-35	KIDFDYTPNWGRGTPSSYIDN
209	16-36	IDFDYTPNWGRGTPSSYIDNL
210	17-37	DFDYTPNWGRGTPSSYIDNLT
211	18-38	FDYTPNWGRGTPSSYIDNLTF
212	19-39	DYTPNWGRGTPSSYIDNLTFP

Fragment Number	Residues	Sequence
213	20-40	YTPNWGRGTPSSYIDNLTFPK
214	21-41	TPNWGRGTPSSYIDNLTFPKV
215	22-42	PNWGRGTPSSYIDNLTFPKVL
216	23-43	NWGRGTPSSYIDNLTFPKVLT
217	24-44	WGRGTPSSYIDNLTFPKVLT
218	25-45	GRGTPSSYIDNLTFPKVLT
219	26-46	RGTPSSYIDNLTFPKVLT
220	27-47	GTPSSYIDNLTFPKVLT
221	28-48	TPSSYIDNLTFPKVLT
222	7-28	FQLAYLVKKIDFDYTPNWGRGT
223	8-29	QLAYLVKKIDFDYTPNWGRGTP
224	9-30	LAYLVKKIDFDYTPNWGRGTPS
225	10-31	AYLVKKIDFDYTPNWGRGTPSS
226	11-32	YLVKKIDFDYTPNWGRGTPSSY
227	12-33	LVKKIDFDYTPNWGRGTPSSYI
228	13-34	VKKIDFDYTPNWGRGTPSSYID
229	14-35	KKIDFDYTPNWGRGTPSSYIDN
230	15-36	KIDFDYTPNWGRGTPSSYIDNL
231	16-37	IDFDYTPNWGRGTPSSYIDNL
232	17-38	DFDYTPNWGRGTPSSYIDNL
233	18-39	FDYTPNWGRGTPSSYIDNL
234	19-40	DYTPNWGRGTPSSYIDNL
235	20-41	YTPNWGRGTPSSYIDNL
236	21-42	TPNWGRGTPSSYIDNL
237	22-43	PNWGRGTPSSYIDNL
238	23-44	NWGRGTPSSYIDNL
239	24-45	WGRGTPSSYIDNL
240	25-46	GRGTPSSYIDNL
241	26-47	RGTPSSYIDNL
242	27-48	GTPSSYIDNL
243	28-49	TPSSYIDNL
244	6-28	TFQLAYLVKKIDFDYTPNWGRGT
245	7-29	FQLAYLVKKIDFDYTPNWGRGTP
246	8-30	QLAYLVKKIDFDYTPNWGRGTPS
247	9-31	LAYLVKKIDFDYTPNWGRGTPSS
248	10-32	AYLVKKIDFDYTPNWGRGTPSSY
249	11-33	YLVKKIDFDYTPNWGRGTPSSYI
250	12-34	LVKKIDFDYTPNWGRGTPSSYID
251	13-35	VKKIDFDYTPNWGRGTPSSYIDN
252	14-36	KKIDFDYTPNWGRGTPSSYIDNL
253	15-37	KIDFDYTPNWGRGTPSSYIDNL
254	16-38	IDFDYTPNWGRGTPSSYIDNL
255	17-39	DFDYTPNWGRGTPSSYIDNL

Fragment Number	Residues	Sequence
256	18-40	FDYTPNWGRGTPSSYIDNLTFPK
257	19-41	DYTPNWGRGTPSSYIDNLTFPKV
258	20-42	YTPNWGRGTPSSYIDNLTFPKVL
259	21-43	TPNWGRGTPSSYIDNLTFPKVLT
260	22-44	PNWGRGTPSSYIDNLTFPKVLT
261	23-45	NWGRGTPSSYIDNLTFPKVLT
262	24-46	WGRGTPSSYIDNLTFPKVLT
263	25-47	GRGTPSSYIDNLTFPKVLT
264	26-48	RGTPSSYIDNLTFPKVLT
265	27-49	GTPSSYIDNLTFPKVLT
266	28-50	TPSSYIDNLTFPKVLT
267	5-28	LTFLAYLVKKIDFDYTPNWGRGT
268	6-29	TFQLAYLVKKIDFDYTPNWGRGTP
269	7-30	FQLAYLVKKIDFDYTPNWGRGTPS
270	8-31	QLAYLVKKIDFDYTPNWGRGTPSS
271	9-32	LAYLVKKIDFDYTPNWGRGTPSSY
272	10-33	AYLVKKIDFDYTPNWGRGTPSSYI
273	11-34	YLVKKIDFDYTPNWGRGTPSSYID
274	12-35	LVKKIDFDYTPNWGRGTPSSYIDN
275	13-36	VKKIDFDYTPNWGRGTPSSYIDNL
276	14-37	KKIDFDYTPNWGRGTPSSYIDNLT
277	15-38	KIDFDYTPNWGRGTPSSYIDNLTF
278	16-39	IDFDYTPNWGRGTPSSYIDNLTFP
279	17-40	DFDYTPNWGRGTPSSYIDNLTFPK
280	18-41	FDYTPNWGRGTPSSYIDNLTFPKV
281	19-42	DYTPNWGRGTPSSYIDNLTFPKVL
282	20-43	YTPNWGRGTPSSYIDNLTFPKVLT
283	21-44	TPNWGRGTPSSYIDNLTFPKVLT
284	22-45	PNWGRGTPSSYIDNLTFPKVLT
285	23-46	NWGRGTPSSYIDNLTFPKVLT
286	24-47	WGRGTPSSYIDNLTFPKVLT
287	25-48	GRGTPSSYIDNLTFPKVLT
288	26-49	RGTPSSYIDNLTFPKVLT
289	27-50	GTPSSYIDNLTFPKVLT
290	28-51	TPSSYIDNLTFPKVLT
291	4-28	SLTFQLAYLVKKIDFDYTPNWGRGT
292	5-29	LTFLAYLVKKIDFDYTPNWGRGTP
293	6-30	TFQLAYLVKKIDFDYTPNWGRGTPS
294	7-31	FQLAYLVKKIDFDYTPNWGRGTPSS
295	8-32	QLAYLVKKIDFDYTPNWGRGTPSSY
296	9-33	LAYLVKKIDFDYTPNWGRGTPSSYI
297	10-34	AYLVKKIDFDYTPNWGRGTPSSYID
298	11-35	YLVKKIDFDYTPNWGRGTPSSYIDN

Fragment Number	Residues	Sequence
299	12-36	LVKKIDFDYTPNWGRGTPSSYIDNL
300	13-37	VKKIDFDYTPNWGRGTPSSYIDNLT
301	14-38	KKIDFDYTPNWGRGTPSSYIDNLTF
302	15-39	KIDFDYTPNWGRGTPSSYIDNLTFP
303	16-40	IDFDYTPNWGRGTPSSYIDNLTFPK
304	17-41	DFDYTPNWGRGTPSSYIDNLTFPKV
305	18-42	FDYTPNWGRGTPSSYIDNLTFPKVL
306	19-43	DYTPNWGRGTPSSYIDNLTFPKVLT
307	20-44	YTPNWGRGTPSSYIDNLTFPKVLT
308	21-45	TPNWGRGTPSSYIDNLTFPKVLT
309	22-46	PNWGRGTPSSYIDNLTFPKVLT
310	23-47	NWGRGTPSSYIDNLTFPKVLT
311	24-48	WGRGTPSSYIDNLTFPKVLT
312	25-49	GRGTPSSYIDNLTFPKVLT
313	26-50	RGTPSSYIDNLTFPKVLT
314	27-51	GTPSSYIDNLTFPKVLT
315	28-52	TPSSYIDNLTFPKVLT
316	3-28	TSLTFQLAYLVKKIDFDYTPNWGRGT
317	4-29	SLTFQLAYLVKKIDFDYTPNWGRGTP
318	5-30	LTFQLAYLVKKIDFDYTPNWGRGTPS
319	6-31	TFQLAYLVKKIDFDYTPNWGRGTPSS
320	7-32	FQLAYLVKKIDFDYTPNWGRGTPSSY
321	8-33	QLAYLVKKIDFDYTPNWGRGTPSSYI
322	9-34	LAYLVKKIDFDYTPNWGRGTPSSYID
323	10-35	AYLVKKIDFDYTPNWGRGTPSSYIDN
324	11-36	YLVKKIDFDYTPNWGRGTPSSYIDNL
325	12-37	LVKKIDFDYTPNWGRGTPSSYIDNLT
326	13-38	VKKIDFDYTPNWGRGTPSSYIDNLTF
327	14-39	KKIDFDYTPNWGRGTPSSYIDNLTFP
328	15-40	KIDFDYTPNWGRGTPSSYIDNLTFPK
329	16-41	IDFDYTPNWGRGTPSSYIDNLTFPKV
330	17-42	DFDYTPNWGRGTPSSYIDNLTFPKVL
331	18-43	FDYTPNWGRGTPSSYIDNLTFPKVLT
332	19-44	DYTPNWGRGTPSSYIDNLTFPKVLT
333	20-45	YTPNWGRGTPSSYIDNLTFPKVLT
334	21-46	TPNWGRGTPSSYIDNLTFPKVLT
335	22-47	PNWGRGTPSSYIDNLTFPKVLT
336	23-48	NWGRGTPSSYIDNLTFPKVLT
337	24-49	WGRGTPSSYIDNLTFPKVLT
338	25-50	GRGTPSSYIDNLTFPKVLT
339	26-51	RGTPSSYIDNLTFPKVLT
340	27-52	GTPSSYIDNLTFPKVLT
341	28-53	TPSSYIDNLTFPKVLT

Fragment Number	Residues	Sequence
342	2-28	ATSLTFQLAYLVKKIDFDYTPNWGRGT
343	3-29	TSLTFQLAYLVKKIDFDYTPNWGRGTP
344	4-30	SLTFQLAYLVKKIDFDYTPNWGRGTPS
345	5-31	LTFQLAYLVKKIDFDYTPNWGRGTPSS
346	6-32	TFQLAYLVKKIDFDYTPNWGRGTPSSY
347	7-33	FQLAYLVKKIDFDYTPNWGRGTPSSYI
348	8-34	QLAYLVKKIDFDYTPNWGRGTPSSYID
349	9-35	LAYLVKKIDFDYTPNWGRGTPSSYIDN
350	10-36	AYLVKKIDFDYTPNWGRGTPSSYIDNL
351	11-37	YLVKKIDFDYTPNWGRGTPSSYIDNLT
352	12-38	LVKKIDFDYTPNWGRGTPSSYIDNLTF
353	13-39	VKKIDFDYTPNWGRGTPSSYIDNLTFP
354	14-40	KKIDFDYTPNWGRGTPSSYIDNLTFPK
355	15-41	KIDFDYTPNWGRGTPSSYIDNLTFPKV
356	16-42	IDFDYTPNWGRGTPSSYIDNLTFPKVL
357	17-43	DFDYTPNWGRGTPSSYIDNLTFPKVLT
358	18-44	FDYTPNWGRGTPSSYIDNLTFPKVLT
359	19-45	DYTPNWGRGTPSSYIDNLTFPKVLT
360	20-46	YTPNWGRGTPSSYIDNLTFPKVLT
361	21-47	TPNWGRGTPSSYIDNLTFPKVLT
362	22-48	PNWGRGTPSSYIDNLTFPKVLT
363	23-49	NWGRGTPSSYIDNLTFPKVLT
364	24-50	WGRGTPSSYIDNLTFPKVLT
365	25-51	GRGTPSSYIDNLTFPKVLT
366	26-52	RGTPSSYIDNLTFPKVLT
367	27-53	GTPSSYIDNLTFPKVLT
368	28-54	TPSSYIDNLTFPKVLT
369	1-28	SATSLTFQLAYLVKKIDFDYTPNWGRGT
370	2-29	ATSLTFQLAYLVKKIDFDYTPNWGRGTP
371	3-30	TSLTFQLAYLVKKIDFDYTPNWGRGTPS
372	4-31	SLTFQLAYLVKKIDFDYTPNWGRGTPSS
373	5-32	LTFQLAYLVKKIDFDYTPNWGRGTPSSY
374	6-33	TFQLAYLVKKIDFDYTPNWGRGTPSSYI
375	7-34	FQLAYLVKKIDFDYTPNWGRGTPSSYID
376	8-35	QLAYLVKKIDFDYTPNWGRGTPSSYIDN
377	9-36	LAYLVKKIDFDYTPNWGRGTPSSYIDNL
378	10-37	AYLVKKIDFDYTPNWGRGTPSSYIDNLT
379	11-38	YLVKKIDFDYTPNWGRGTPSSYIDNLTF
380	12-39	LVKKIDFDYTPNWGRGTPSSYIDNLTFP
381	13-40	VKKIDFDYTPNWGRGTPSSYIDNLTFPK
382	14-41	KKIDFDYTPNWGRGTPSSYIDNLTFPKV
383	15-42	KIDFDYTPNWGRGTPSSYIDNLTFPKVL
384	16-43	IDFDYTPNWGRGTPSSYIDNLTFPKVLT

Fragment Number	Residues	Sequence
385	17-44	DFDYTPNWGRGTPSSYIDNLTFPKVLTD
386	18-45	FDYTPNWGRGTPSSYIDNLTFPKVLTDK
387	19-46	DYTPNWGRGTPSSYIDNLTFPKVLTDKK
388	20-47	YTPNWGRGTPSSYIDNLTFPKVLTDKKY
389	21-48	TPNWGRGTPSSYIDNLTFPKVLTDKKYS
390	22-49	PNWGRGTPSSYIDNLTFPKVLTDKKYSY
391	23-50	NWGRGTPSSYIDNLTFPKVLTDKKYSYR
392	24-51	WGRGTPSSYIDNLTFPKVLTDKKYSYRV
393	25-52	GRGTPSSYIDNLTFPKVLTDKKYSYRVV
394	26-53	RGTPSSYIDNLTFPKVLTDKKYSYRVVV
395	27-54	GTPSSYIDNLTFPKVLTDKKYSYRVVNN
396	28-55	TPSSYIDNLTFPKVLTDKKYSYRVVNG

APPENDIX C: CRYSTAL COORDINATES OF FVE PROTEIN

HEADER ---- XX-XXX-XX xxxxx
COMPND ---
REMARK 3
5 REMARK 3 REFINEMENT.
REMARK 3 PROGRAM : REFMAC 5.0
REMARK 3 AUTHORS : MURSHUDOV,VAGIN,DODSON
REMARK 3
REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD
10 REMARK 3
REMARK 3 DATA USED IN REFINEMENT.
REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.70
REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 30.02
REMARK 3 DATA CUTOFF (SIGMA(F)) : NONE
15 REMARK 3 COMPLETENESS FOR RANGE (%) : 98.80
REMARK 3 NUMBER OF REFLECTIONS : 30783
REMARK 3
REMARK 3 FIT TO DATA USED IN REFINEMENT.
REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT
20 REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM
REMARK 3 R VALUE (WORKING + TEST SET) : 0.18358
REMARK 3 R VALUE (WORKING SET) : 0.18218
REMARK 3 FREE R VALUE : 0.21016
REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.1
25 REMARK 3 FREE R VALUE TEST SET COUNT : 1650
REMARK 3
REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN.
REMARK 3 TOTAL NUMBER OF BINS USED : 20
REMARK 3 BIN RESOLUTION RANGE HIGH : 1.701
30 REMARK 3 BIN RESOLUTION RANGE LOW : 1.745
REMARK 3 REFLECTION IN BIN (WORKING SET) : 2183
REMARK 3 BIN R VALUE (WORKING SET) : 0.160
REMARK 3 BIN FREE R VALUE SET COUNT : 114
REMARK 3 BIN FREE R VALUE : 0.197
35 REMARK 3
REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT.
REMARK 3 ALL ATOMS : 1940
REMARK 3
REMARK 3 B VALUES.
40 REMARK 3 FROM WILSON PLOT (A**2) : NULL
REMARK 3 MEAN B VALUE (OVERALL, A**2) : 13.666
REMARK 3 OVERALL ANISOTROPIC B VALUE.
REMARK 3 B11 (A**2) : -0.02
REMARK 3 B22 (A**2) : -0.02
45 REMARK 3 B33 (A**2) : 0.03
REMARK 3 B12 (A**2) : 0.00
REMARK 3 B13 (A**2) : 0.00
REMARK 3 B23 (A**2) : 0.00
REMARK 3
50 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR.
REMARK 3 ESU BASED ON R VALUE (A) : 0.092
REMARK 3 ESU BASED ON FREE R VALUE (A) : 0.092
REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A) : 0.075
REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2) : 2.208
55 REMARK 3
REMARK 3 CORRELATION COEFFICIENTS.
REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.947
REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.933
REMARK 3
60 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT

REMARK 3 BOND LENGTHS REFINED ATOMS (A): 1830 ; 0.010 ; 0.022
REMARK 3 BOND LENGTHS OTHERS (A): 1593 ; 0.001 ; 0.020
REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 2490 ; 1.466 ; 1.941
REMARK 3 BOND ANGLES OTHERS (DEGREES): 3724 ; 0.921 ; 3.000
5 REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 224 ; 4.899 ; 3.000
REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 311 ; 16.844 ; 15.000
REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 280 ; 0.231 ; 0.200
REMARK 3 GENERAL PLANES REFINED ATOMS (A): 2026 ; 0.006 ; 0.020
REMARK 3 GENERAL PLANES OTHERS (A): 374 ; 0.003 ; 0.020
10 REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 327 ; 0.271 ; 0.300
REMARK 3 NON-BONDED CONTACTS OTHERS (A): 1447 ; 0.212 ; 0.300
REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 131 ; 0.131 ; 0.500
REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 8 ; 0.310 ; 0.300
REMARK 3 SYMMETRY VDW OTHERS (A): 17 ; 0.291 ; 0.300
15 REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 14 ; 0.144 ; 0.500
REMARK 3
REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT
REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 1124 ; 0.898 ; 1.500
REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 1827 ; 1.603 ; 2.000
20 REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 706 ; 2.292 ; 3.000
REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 663 ; 3.839 ; 4.500
REMARK 3
REMARK 3 NCS RESTRAINTS STATISTICS
REMARK 3 NUMBER OF NCS GROUPS : NULL
25 REMARK 3
REMARK 3
REMARK 3 TLS DETAILS
REMARK 3 NUMBER OF TLS GROUPS : 2
REMARK 3
30 REMARK 3 TLS GROUP : 1
REMARK 3 NUMBER OF COMPONENTS GROUP : 1
REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI
REMARK 3 RESIDUE RANGE : A 1 A 113
REMARK 3 ORIGIN FOR THE GROUP (A): 31.8380 34.4130 15.9540
35 REMARK 3 T TENSOR
REMARK 3 T11: 0.0826 T22: 0.0528
REMARK 3 T33: 0.0022 T12: 0.0085
REMARK 3 T13: 0.0118 T23: 0.0066
REMARK 3 L TENSOR
40 REMARK 3 L11: 0.3236 L22: 1.6346
REMARK 3 L33: 0.0319 L12: -0.4538
REMARK 3 L13: -0.1060 L23: -0.1134
REMARK 3 S TENSOR
REMARK 3 S11: 0.0668 S12: 0.0317 S13: 0.0266
45 REMARK 3 S21: -0.0158 S22: -0.0508 S23: -0.0656
REMARK 3 S31: -0.0111 S32: 0.0027 S33: -0.0160
REMARK 3
REMARK 3 TLS GROUP : 2
REMARK 3 NUMBER OF COMPONENTS GROUP : 1
50 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI
REMARK 3 RESIDUE RANGE : B 1 B 112
REMARK 3 ORIGIN FOR THE GROUP (A): 33.7580 2.5150 18.4210
REMARK 3 T TENSOR
REMARK 3 T11: 0.0638 T22: 0.0608
55 REMARK 3 T33: 0.0227 T12: 0.0019
REMARK 3 T13: -0.0064 T23: -0.0055
REMARK 3 L TENSOR
REMARK 3 L11: 0.0923 L22: 0.6926
REMARK 3 L33: 0.1427 L12: -0.1092
60 REMARK 3 L13: -0.1135 L23: -0.0160
REMARK 3 S TENSOR
REMARK 3 S11: 0.0096 S12: 0.0276 S13: -0.0212
REMARK 3 S21: -0.0046 S22: -0.0327 S23: 0.0279

REMARK 3 S31: -0.0061 S32: -0.0095 S33: 0.0231
REMARK 3
REMARK 3
REMARK 3 BULK SOLVENT MODELLING.
5 REMARK 3 METHOD USED : BABINET MODEL WITH MASK
REMARK 3 PARAMETERS FOR MASK CALCULATION
REMARK 3 VDW PROBE RADIUS : 1.40
REMARK 3 ION PROBE RADIUS : 0.80
REMARK 3 SHRINKAGE RADIUS : 0.80
10 REMARK 3
REMARK 3 OTHER REFINEMENT REMARKS:
REMARK 3 HYDROGENS HAVE BEEN ADDED IN THE RIDING POSITIONS
REMARK 3
CISPEP 1 THR A 28 PRO A 29 0.00
15 CISPEP 2 THR B 28 PRO B 29 0.00
CRYST1 97.118 97.118 61.413 90.00 90.00 90.00 P 43 21 2
SCALE1 0.010297 0.000000 0.000000 0.000000
SCALE2 0.000000 0.010297 0.000000 0.000000
SCALE3 0.000000 0.000000 0.016283 0.000000
20 ATOM 1 O ACE A 0 39.758 17.815 6.621 1.00 32.04 O
ATOM 2 C ACE A 0 38.470 17.959 6.297 1.00 30.44 C
ATOM 3 CA ACE A 0 37.841 19.332 5.940 1.00 30.13 C
ATOM 4 N SER A 1 37.877 16.775 5.643 1.00 19.18 N
ATOM 6 CA SER A 1 36.408 16.741 5.468 1.00 17.19 C
25 ATOM 8 CB SER A 1 35.991 15.421 4.841 1.00 17.15 C
ATOM 11 OG SER A 1 36.194 14.363 5.768 1.00 16.56 O
ATOM 13 C SER A 1 35.748 16.842 6.834 1.00 16.94 C
ATOM 14 O SER A 1 36.412 16.630 7.854 1.00 16.93 O
ATOM 17 N ALA A 2 34.500 17.297 6.850 1.00 17.11 N
30 ATOM 19 CA ALA A 2 33.637 17.247 8.031 1.00 16.12 C
ATOM 21 CB ALA A 2 32.200 17.465 7.619 1.00 16.40 C
ATOM 25 C ALA A 2 33.762 15.907 8.757 1.00 15.10 C
ATOM 26 O ALA A 2 33.901 15.848 9.975 1.00 13.93 O
ATOM 27 N THR A 3 33.680 14.823 8.009 1.00 14.66 N
35 ATOM 29 CA THR A 3 33.773 13.515 8.630 1.00 13.12 C
ATOM 31 CB THR A 3 33.497 12.440 7.599 1.00 13.38 C
ATOM 33 OG1 THR A 3 32.154 12.599 7.122 1.00 13.50 O
ATOM 35 CG2 THR A 3 33.517 11.067 8.238 1.00 14.13 C
ATOM 39 C THR A 3 35.111 13.272 9.307 1.00 12.51 C
40 ATOM 40 O THR A 3 35.141 12.780 10.440 1.00 10.83 O
ATOM 41 N SER A 4 36.216 13.578 8.632 1.00 11.39 N
ATOM 43 CA SER A 4 37.538 13.356 9.244 1.00 12.60 C
ATOM 45 CB SER A 4 38.694 13.609 8.266 1.00 13.31 C
ATOM 48 OG SER A 4 38.566 14.874 7.668 1.00 19.57 O
45 ATOM 50 C SER A 4 37.726 14.223 10.471 1.00 11.69 C
ATOM 51 O SER A 4 38.223 13.765 11.484 1.00 10.87 O
ATOM 52 N LEU A 5 37.331 15.484 10.379 1.00 11.95 N
ATOM 54 CA LEU A 5 37.478 16.382 11.515 1.00 11.00 C
ATOM 56 CB LEU A 5 37.047 17.801 11.149 1.00 11.44 C
50 ATOM 59 CG LEU A 5 37.928 18.509 10.117 1.00 13.46 C
ATOM 61 CD1 LEU A 5 37.267 19.790 9.651 1.00 15.05 C
ATOM 65 CD2 LEU A 5 39.270 18.807 10.731 1.00 15.52 C
ATOM 69 C LEU A 5 36.658 15.900 12.698 1.00 10.25 C
ATOM 70 O LEU A 5 37.114 15.947 13.852 1.00 9.79 O
55 ATOM 71 N THR A 6 35.440 15.446 12.417 1.00 9.51 N
ATOM 73 CA THR A 6 34.547 14.953 13.459 1.00 9.80 C
ATOM 75 CB THR A 6 33.250 14.425 12.840 1.00 9.84 C
ATOM 77 OG1 THR A 6 32.454 15.510 12.319 1.00 10.30 O
ATOM 79 CG2 THR A 6 32.388 13.749 13.859 1.00 9.40 C
60 ATOM 83 C THR A 6 35.186 13.816 14.236 1.00 9.72 C
ATOM 84 O THR A 6 35.215 13.845 15.451 1.00 9.30 O
ATOM 85 N PHE A 7 35.679 12.796 13.545 1.00 9.95 N
ATOM 87 CA PHE A 7 36.185 11.642 14.278 1.00 8.92 C

ATOM 89 CB PHE A 7 35.993 10.367 13.490 1.00 8.90 C
ATOM 92 CG PHE A 7 34.552 9.988 13.365 1.00 8.19 C
ATOM 93 CD1 PHE A 7 33.848 9.583 14.485 1.00 10.40 C
ATOM 95 CE1 PHE A 7 32.512 9.267 14.407 1.00 10.95 C
5 ATOM 97 CZ PHE A 7 31.848 9.370 13.217 1.00 11.35 C
ATOM 99 CE2 PHE A 7 32.532 9.791 12.080 1.00 10.55 C
ATOM 101 CD2 PHE A 7 33.872 10.127 12.165 1.00 10.65 C
ATOM 103 C PHE A 7 37.603 11.819 14.812 1.00 9.58 C
ATOM 104 O PHE A 7 37.970 11.203 15.811 1.00 9.17 O
10 ATOM 105 N GLN A 8 38.405 12.669 14.177 1.00 9.36 N
ATOM 107 CA GLN A 8 39.683 12.999 14.778 1.00 10.36 C
ATOM 109 CB GLN A 8 40.476 13.937 13.891 1.00 10.90 C
ATOM 112 CG GLN A 8 41.097 13.322 12.692 1.00 14.14 C
ATOM 115 CD GLN A 8 41.805 14.419 11.894 1.00 16.75 C
15 ATOM 116 OE1 GLN A 8 41.409 14.742 10.787 1.00 21.77 O
ATOM 117 NE2 GLN A 8 42.799 15.056 12.517 1.00 20.28 N
ATOM 120 C GLN A 8 39.409 13.716 16.116 1.00 10.53 C
ATOM 121 O GLN A 8 40.049 13.416 17.118 1.00 10.95 O
ATOM 122 N LEU A 9 38.457 14.654 16.122 1.00 9.95 N
20 ATOM 124 CA LEU A 9 38.145 15.413 17.332 1.00 9.62 C
ATOM 126 CB LEU A 9 37.162 16.537 17.057 1.00 9.66 C
ATOM 129 CG LEU A 9 36.767 17.375 18.278 1.00 9.80 C
ATOM 131 CD1 LEU A 9 37.974 18.098 18.862 1.00 10.08 C
ATOM 135 CD2 LEU A 9 35.701 18.397 17.886 1.00 12.75 C
25 ATOM 139 C LEU A 9 37.541 14.467 18.346 1.00 9.58 C
ATOM 140 O LEU A 9 37.935 14.484 19.514 1.00 9.46 O
ATOM 141 N ALA A 10 36.588 13.637 17.917 1.00 9.20 N
ATOM 143 CA ALA A 10 35.952 12.701 18.856 1.00 9.03 C
ATOM 145 CB ALA A 10 34.875 11.850 18.154 1.00 8.72 C
30 ATOM 149 C ALA A 10 36.949 11.802 19.605 1.00 8.50 C
ATOM 150 O ALA A 10 36.855 11.615 20.825 1.00 8.50 O
ATOM 151 N TYR A 11 37.918 11.242 18.899 1.00 9.18 N
ATOM 153 CA TYR A 11 38.865 10.359 19.541 1.00 8.12 C
ATOM 155 CB TYR A 11 39.716 9.664 18.491 1.00 8.30 C
35 ATOM 158 CG TYR A 11 40.642 8.638 19.075 1.00 7.61 C
ATOM 159 CD1 TYR A 11 40.156 7.495 19.699 1.00 9.07 C
ATOM 161 CE1 TYR A 11 41.008 6.560 20.229 1.00 10.41 C
ATOM 163 CZ TYR A 11 42.359 6.768 20.170 1.00 13.73 C
ATOM 164 OH TYR A 11 43.210 5.831 20.740 1.00 15.09 O
40 ATOM 166 CE2 TYR A 11 42.868 7.898 19.571 1.00 10.94 C
ATOM 168 CD2 TYR A 11 42.014 8.827 19.027 1.00 10.00 C
ATOM 170 C TYR A 11 39.752 11.139 20.530 1.00 8.66 C
ATOM 171 O TYR A 11 40.158 10.596 21.550 1.00 8.96 O
ATOM 172 N LEU A 12 40.012 12.412 20.245 1.00 8.35 N
45 ATOM 174 CA LEU A 12 40.899 13.238 21.081 1.00 9.68 C
ATOM 176 CB LEU A 12 41.501 14.374 20.257 1.00 10.19 C
ATOM 179 CG LEU A 12 42.469 13.943 19.152 1.00 15.33 C
ATOM 181 CD1 LEU A 12 43.187 15.145 18.549 1.00 18.28 C
ATOM 185 CD2 LEU A 12 43.464 12.905 19.653 1.00 18.55 C
50 ATOM 189 C LEU A 12 40.242 13.812 22.351 1.00 9.19 C
ATOM 190 O LEU A 12 40.851 13.776 23.445 1.00 10.13 O
ATOM 191 N VAL A 13 39.010 14.301 22.232 1.00 8.92 N
ATOM 193 CA VAL A 13 38.357 14.969 23.368 1.00 8.52 C
ATOM 195 CB VAL A 13 38.013 16.426 23.050 1.00 8.78 C
55 ATOM 197 CG1 VAL A 13 39.251 17.141 22.537 1.00 10.74 C
ATOM 201 CG2 VAL A 13 36.864 16.560 22.057 1.00 9.49 C
ATOM 205 C VAL A 13 37.131 14.252 23.904 1.00 8.44 C
ATOM 206 O VAL A 13 36.592 14.631 24.947 1.00 8.60 O
ATOM 207 N LYS A 14 36.709 13.218 23.178 1.00 8.48 N
60 ATOM 209 CA LYS A 14 35.583 12.339 23.536 1.00 8.98 C
ATOM 211 CB LYS A 14 35.771 11.687 24.909 1.00 8.33 C
ATOM 214 CG LYS A 14 37.127 11.029 25.118 1.00 7.66 C
ATOM 217 CD LYS A 14 37.513 10.044 23.992 1.00 8.44 C

	ATOM	220	CE	LYS	A	14	38.818	9.318	24.229	1.00	7.68	C
	ATOM	223	NZ	LYS	A	14	39.160	8.416	23.087	1.00	7.55	N
	ATOM	227	C	LYS	A	14	34.187	12.932	23.465	1.00	10.23	C
	ATOM	228	O	LYS	A	14	33.306	12.332	22.864	1.00	9.28	O
5	ATOM	229	N	LYS	A	15	33.976	14.083	24.089	1.00	10.78	N
	ATOM	231	CA	LYS	A	15	32.636	14.648	24.202	1.00	12.04	C
	ATOM	233	CB	LYS	A	15	32.058	14.428	25.615	1.00	13.87	C
	ATOM	236	CG	LYS	A	15	30.626	14.970	25.767	1.00	18.29	C
	ATOM	239	CD	LYS	A	15	30.411	15.838	26.991	1.00	25.35	C
10	ATOM	242	CE	LYS	A	15	29.648	17.144	26.648	1.00	26.80	C
	ATOM	245	NZ	LYS	A	15	30.479	18.398	26.848	1.00	28.04	N
	ATOM	249	C	LYS	A	15	32.701	16.124	23.876	1.00	11.99	C
	ATOM	250	O	LYS	A	15	33.603	16.825	24.333	1.00	12.92	O
	ATOM	251	N	ILE	A	16	31.770	16.587	23.054	1.00	11.71	N
15	ATOM	253	CA	ILE	A	16	31.631	18.011	22.795	1.00	11.45	C
	ATOM	255	CB	ILE	A	16	32.644	18.502	21.769	1.00	12.21	C
	ATOM	257	CG1	ILE	A	16	32.966	19.980	22.019	1.00	12.61	C
	ATOM	260	CD1	ILE	A	16	34.167	20.459	21.239	1.00	16.67	C
	ATOM	264	CG2	ILE	A	16	32.154	18.226	20.357	1.00	12.62	C
20	ATOM	268	C	ILE	A	16	30.193	18.273	22.375	1.00	11.19	C
	ATOM	269	O	ILE	A	16	29.515	17.396	21.835	1.00	10.05	O
	ATOM	270	N	ASP	A	17	29.729	19.495	22.614	1.00	11.77	N
	ATOM	272	CA	ASP	A	17	28.357	19.861	22.315	1.00	11.36	C
	ATOM	274	CB	ASP	A	17	27.503	19.570	23.548	1.00	12.18	C
25	ATOM	277	CG	ASP	A	17	26.019	19.854	23.363	1.00	13.83	C
	ATOM	278	OD1	ASP	A	17	25.558	20.190	22.262	1.00	14.93	O
	ATOM	279	OD2	ASP	A	17	25.207	19.726	24.327	1.00	17.34	O
	ATOM	280	C	ASP	A	17	28.354	21.342	22.018	1.00	10.94	C
	ATOM	281	O	ASP	A	17	28.505	22.158	22.930	1.00	12.08	O
30	ATOM	282	N	PHE	A	18	28.220	21.709	20.754	1.00	9.97	N
	ATOM	284	CA	PHE	A	18	28.208	23.121	20.420	1.00	9.42	C
	ATOM	286	CB	PHE	A	18	29.621	23.630	20.070	1.00	9.10	C
	ATOM	289	CG	PHE	A	18	30.262	22.990	18.849	1.00	9.30	C
	ATOM	290	CD1	PHE	A	18	31.457	22.269	18.966	1.00	11.84	C
35	ATOM	292	CE1	PHE	A	18	32.069	21.704	17.850	1.00	11.09	C
	ATOM	294	CZ	PHE	A	18	31.520	21.860	16.619	1.00	10.73	C
	ATOM	296	CE2	PHE	A	18	30.335	22.573	16.470	1.00	11.19	C
	ATOM	298	CD2	PHE	A	18	29.725	23.157	17.586	1.00	8.90	C
	ATOM	300	C	PHE	A	18	27.226	23.431	19.299	1.00	9.78	C
40	ATOM	301	O	PHE	A	18	26.794	22.537	18.568	1.00	9.84	O
	ATOM	302	N	ASP	A	19	26.899	24.711	19.156	1.00	10.97	N
	ATOM	304	CA	ASP	A	19	26.059	25.169	18.060	1.00	10.37	C
	ATOM	306	CB	ASP	A	19	24.575	25.130	18.429	1.00	10.87	C
	ATOM	309	CG	ASP	A	19	23.674	25.452	17.267	1.00	11.55	C
45	ATOM	310	OD1	ASP	A	19	24.180	25.843	16.178	1.00	11.30	O
	ATOM	311	OD2	ASP	A	19	22.418	25.322	17.350	1.00	12.10	O
	ATOM	312	C	ASP	A	19	26.497	26.590	17.705	1.00	10.71	C
	ATOM	313	O	ASP	A	19	26.136	27.575	18.388	1.00	10.19	O
	ATOM	314	N	TYR	A	20	27.297	26.678	16.646	1.00	10.10	N
50	ATOM	316	CA	TYR	A	20	27.788	27.942	16.103	1.00	9.68	C
	ATOM	318	CB	TYR	A	20	29.308	27.879	15.911	1.00	9.82	C
	ATOM	321	CG	TYR	A	20	30.089	28.043	17.181	1.00	8.36	C
	ATOM	322	CD1	TYR	A	20	30.459	26.943	17.934	1.00	9.01	C
	ATOM	324	CE1	TYR	A	20	31.175	27.087	19.115	1.00	9.44	C
55	ATOM	326	CZ	TYR	A	20	31.514	28.335	19.546	1.00	10.02	C
	ATOM	327	OH	TYR	A	20	32.228	28.469	20.703	1.00	9.07	O
	ATOM	329	CE2	TYR	A	20	31.167	29.441	18.804	1.00	10.02	C
	ATOM	331	CD2	TYR	A	20	30.451	29.303	17.648	1.00	8.62	C
	ATOM	333	C	TYR	A	20	27.054	28.282	14.786	1.00	10.92	C
60	ATOM	334	O	TYR	A	20	27.600	28.930	13.878	1.00	11.60	O
	ATOM	335	N	THR	A	21	25.800	27.857	14.694	1.00	12.18	N
	ATOM	337	CA	THR	A	21	24.980	28.261	13.567	1.00	12.37	C
	ATOM	339	CB	THR	A	21	23.584	27.692	13.676	1.00	12.82	C

ATOM 341 OG1 THR A 21 23.623 26.259 13.737 1.00 12.95 O
ATOM 343 CG2 THR A 21 22.832 27.997 12.401 1.00 13.70 C
ATOM 347 C THR A 21 24.871 29.776 13.598 1.00 12.58 C
5 ATOM 348 O THR A 21 24.445 30.332 14.595 1.00 12.57 O
ATOM 349 N PRO A 22 25.259 30.460 12.528 1.00 12.83 N
ATOM 350 CA PRO A 22 25.263 31.917 12.549 1.00 12.54 C
ATOM 352 CB PRO A 22 26.214 32.276 11.409 1.00 12.71 C
ATOM 355 CG PRO A 22 26.064 31.150 10.423 1.00 12.51 C
10 ATOM 358 CD PRO A 22 25.773 29.925 11.259 1.00 12.22 C
ATOM 361 C PRO A 22 23.890 32.509 12.337 1.00 12.87 C
ATOM 362 O PRO A 22 23.281 32.302 11.282 1.00 14.33 O
ATOM 363 N ASN A 23 23.405 33.202 13.363 1.00 12.69 N
ATOM 365 CA ASN A 23 22.145 33.920 13.285 1.00 12.96 C
ATOM 367 CB ASN A 23 21.290 33.568 14.497 1.00 13.22 C
15 ATOM 370 CG ASN A 23 20.761 32.141 14.427 1.00 16.73 C
ATOM 371 OD1 ASN A 23 19.705 31.904 13.821 1.00 22.06 O
ATOM 372 ND2 ASN A 23 21.511 31.174 14.977 1.00 18.52 N
ATOM 375 C ASN A 23 22.449 35.415 13.208 1.00 12.31 C
ATOM 376 O ASN A 23 22.904 36.007 14.185 1.00 12.34 O
20 ATOM 377 N TRP A 24 22.216 36.016 12.048 1.00 12.92 N
ATOM 379 CA TRP A 24 22.554 37.408 11.814 1.00 12.37 C
ATOM 381 CB TRP A 24 22.990 37.612 10.367 1.00 13.22 C
ATOM 384 CG TRP A 24 24.130 36.740 9.944 1.00 12.12 C
ATOM 385 CD1 TRP A 24 24.039 35.556 9.279 1.00 11.86 C
25 ATOM 387 NE1 TRP A 24 25.292 35.046 9.042 1.00 13.92 N
ATOM 389 CE2 TRP A 24 26.230 35.904 9.547 1.00 11.19 C
ATOM 390 CD2 TRP A 24 25.536 36.989 10.123 1.00 10.96 C
ATOM 391 CE3 TRP A 24 26.276 38.003 10.726 1.00 11.62 C
ATOM 393 CZ3 TRP A 24 27.660 37.925 10.707 1.00 13.20 C
30 ATOM 395 CH2 TRP A 24 28.317 36.833 10.136 1.00 11.66 C
ATOM 397 CZ2 TRP A 24 27.619 35.814 9.545 1.00 10.81 C
ATOM 399 C TRP A 24 21.343 38.268 12.120 1.00 12.73 C
ATOM 400 O TRP A 24 20.282 38.076 11.532 1.00 13.03 O
ATOM 401 N GLY A 25 21.488 39.222 13.029 1.00 12.00 N
35 ATOM 403 CA GLY A 25 20.370 40.074 13.398 1.00 11.21 C
ATOM 406 C GLY A 25 20.495 41.423 12.706 1.00 11.71 C
ATOM 407 O GLY A 25 21.592 41.969 12.603 1.00 11.26 O
ATOM 408 N ARG A 26 19.375 41.957 12.233 1.00 11.79 N
ATOM 410 CA ARG A 26 19.388 43.192 11.486 1.00 12.49 C
40 ATOM 412 CB ARG A 26 18.460 43.083 10.267 1.00 12.94 C
ATOM 415 CG ARG A 26 18.999 42.137 9.202 1.00 16.01 C
ATOM 418 CD ARG A 26 18.019 41.888 8.062 1.00 20.32 C
ATOM 421 NE ARG A 26 18.565 41.043 6.998 1.00 24.78 N
ATOM 423 CZ ARG A 26 19.426 41.460 6.071 1.00 25.04 C
45 ATOM 424 NH1 ARG A 26 19.860 40.607 5.149 1.00 29.16 N
ATOM 427 NH2 ARG A 26 19.863 42.715 6.057 1.00 19.47 N
ATOM 430 C ARG A 26 19.010 44.365 12.357 1.00 12.60 C
ATOM 431 O ARG A 26 18.369 44.206 13.398 1.00 12.88 O
ATOM 432 N GLY A 27 19.411 45.549 11.917 1.00 12.77 N
50 ATOM 434 CA GLY A 27 19.173 46.761 12.675 1.00 12.32 C
ATOM 437 C GLY A 27 18.090 47.628 12.071 1.00 13.21 C
ATOM 438 O GLY A 27 17.167 47.128 11.435 1.00 11.98 O
ATOM 439 N THR A 28 18.203 48.928 12.316 1.00 14.26 N
ATOM 441 CA THR A 28 17.261 49.925 11.819 1.00 14.60 C
55 ATOM 443 CB THR A 28 16.523 50.576 13.006 1.00 13.94 C
ATOM 445 OG1 THR A 28 15.801 49.590 13.761 1.00 12.38 O
ATOM 447 CG2 THR A 28 15.460 51.569 12.517 1.00 14.06 C
ATOM 451 C THR A 28 18.039 51.002 11.041 1.00 15.60 C
ATOM 452 O THR A 28 18.823 51.756 11.636 1.00 15.37 O
60 ATOM 453 N PRO A 29 17.874 51.082 9.718 1.00 17.62 N
ATOM 454 CA PRO A 29 17.025 50.182 8.928 1.00 17.21 C
ATOM 456 CB PRO A 29 16.956 50.887 7.570 1.00 17.70 C
ATOM 459 CG PRO A 29 18.211 51.657 7.483 1.00 17.48 C

ATOM 462 CD PRO A 29 18.513 52.109 8.878 1.00 17.56 C
ATOM 465 C PRO A 29 17.586 48.772 8.752 1.00 17.76 C
ATOM 466 O PRO A 29 18.751 48.525 9.061 1.00 16.07 O
5 ATOM 467 N SER A 30 16.742 47.873 8.242 1.00 18.81 N
ATOM 469 CA SER A 30 17.050 46.450 8.184 1.00 18.37 C
ATOM 471 CB SER A 30 15.805 45.644 7.833 1.00 18.99 C
ATOM 474 OG SER A 30 15.343 45.991 6.543 1.00 20.21 O
ATOM 476 C SER A 30 18.169 46.068 7.246 1.00 17.73 C
10 ATOM 477 O SER A 30 18.593 44.925 7.249 1.00 17.30 O
ATOM 478 N SER A 31 18.638 47.019 6.442 1.00 17.71 N
ATOM 480 CA SER A 31 19.762 46.788 5.545 1.00 16.65 C
ATOM 482 CB SER A 31 19.806 47.894 4.489 1.00 16.79 C
ATOM 485 OG SER A 31 19.921 49.171 5.094 1.00 17.30 O
ATOM 487 C SER A 31 21.098 46.709 6.297 1.00 16.11 C
15 ATOM 488 O SER A 31 22.127 46.365 5.704 1.00 15.78 O
ATOM 489 N TYR A 32 21.086 47.032 7.597 1.00 14.64 N
ATOM 491 CA TYR A 32 22.271 46.896 8.439 1.00 14.65 C
ATOM 493 CB TYR A 32 22.375 48.046 9.422 1.00 14.98 C
ATOM 496 CG TYR A 32 22.739 49.334 8.714 1.00 18.51 C
20 ATOM 497 CD1 TYR A 32 24.066 49.674 8.496 1.00 21.23 C
ATOM 499 CE1 TYR A 32 24.407 50.838 7.829 1.00 23.56 C
ATOM 501 CZ TYR A 32 23.413 51.669 7.369 1.00 24.54 C
ATOM 502 OH TYR A 32 23.739 52.830 6.706 1.00 26.67 O
ATOM 504 CE2 TYR A 32 22.087 51.341 7.555 1.00 23.37 C
25 ATOM 506 CD2 TYR A 32 21.758 50.174 8.225 1.00 21.68 C
ATOM 508 C TYR A 32 22.237 45.591 9.229 1.00 13.62 C
ATOM 509 O TYR A 32 21.188 45.198 9.725 1.00 13.16 O
ATOM 510 N ILE A 33 23.380 44.911 9.286 1.00 13.61 N
ATOM 512 CA ILE A 33 23.586 43.751 10.157 1.00 12.63 C
30 ATOM 514 CB ILE A 33 24.578 42.754 9.534 1.00 12.46 C
ATOM 516 CG1 ILE A 33 24.075 42.259 8.180 1.00 15.30 C
ATOM 519 CD1 ILE A 33 22.722 41.668 8.218 1.00 17.61 C
ATOM 523 CG2 ILE A 33 24.827 41.551 10.448 1.00 12.99 C
ATOM 527 C ILE A 33 24.190 44.290 11.450 1.00 12.11 C
35 ATOM 528 O ILE A 33 25.296 44.828 11.452 1.00 11.53 O
ATOM 529 N ASP A 34 23.471 44.131 12.551 1.00 12.39 N
ATOM 531 CA ASP A 34 23.884 44.688 13.831 1.00 11.42 C
ATOM 533 CB ASP A 34 22.658 45.171 14.607 1.00 11.00 C
ATOM 536 CG ASP A 34 22.217 46.584 14.234 1.00 12.48 C
40 ATOM 537 OD1 ASP A 34 22.658 47.096 13.183 1.00 13.04 O
ATOM 538 OD2 ASP A 34 21.399 47.223 14.951 1.00 13.34 O
ATOM 539 C ASP A 34 24.580 43.675 14.723 1.00 10.32 C
ATOM 540 O ASP A 34 25.317 44.056 15.621 1.00 10.05 O
ATOM 541 N ASN A 35 24.321 42.394 14.504 1.00 10.16 N
45 ATOM 543 CA ASN A 35 24.851 41.393 15.433 1.00 9.67 C
ATOM 545 CB ASN A 35 24.030 41.450 16.727 1.00 10.07 C
ATOM 548 CG ASN A 35 22.554 41.273 16.471 1.00 10.85 C
ATOM 549 OD1 ASN A 35 22.107 40.167 16.176 1.00 12.45 O
ATOM 550 ND2 ASN A 35 21.783 42.374 16.550 1.00 9.57 N
50 ATOM 553 C ASN A 35 24.840 39.977 14.875 1.00 9.80 C
ATOM 554 O ASN A 35 24.247 39.693 13.824 1.00 10.06 O
ATOM 555 N LEU A 36 25.504 39.087 15.604 1.00 9.45 N
ATOM 557 CA LEU A 36 25.636 37.689 15.262 1.00 9.51 C
ATOM 559 CB LEU A 36 27.042 37.442 14.753 1.00 9.66 C
55 ATOM 562 CG LEU A 36 27.470 36.000 14.536 1.00 9.35 C
ATOM 564 CD1 LEU A 36 26.605 35.300 13.482 1.00 10.39 C
ATOM 568 CD2 LEU A 36 28.951 35.986 14.161 1.00 10.50 C
ATOM 572 C LEU A 36 25.419 36.881 16.535 1.00 10.20 C
ATOM 573 O LEU A 36 26.105 37.111 17.539 1.00 10.03 O
60 ATOM 574 N THR A 37 24.482 35.941 16.502 1.00 10.24 N
ATOM 576 CA THR A 37 24.190 35.099 17.661 1.00 10.84 C
ATOM 578 CB THR A 37 22.716 35.234 18.063 1.00 11.04 C
ATOM 580 OG1 THR A 37 22.440 36.591 18.421 1.00 12.32 O

ATOM 582 CG2 THR A 37 22.397 34.382 19.308 1.00 11.78 C
ATOM 586 C THR A 37 24.484 33.647 17.365 1.00 10.36 C
ATOM 587 O THR A 37 24.103 33.128 16.314 1.00 11.69 O
5 ATOM 588 N PHE A 38 25.183 33.002 18.288 1.00 10.33 N
ATOM 590 CA PHE A 38 25.435 31.568 18.220 1.00 10.67 C
ATOM 592 CB PHE A 38 26.892 31.285 18.520 1.00 10.97 C
ATOM 595 CG PHE A 38 27.844 31.792 17.480 1.00 9.37 C
ATOM 596 CD1 PHE A 38 28.952 32.543 17.835 1.00 10.78 C
10 ATOM 598 CE1 PHE A 38 29.844 32.982 16.879 1.00 10.42 C
ATOM 600 CZ PHE A 38 29.659 32.667 15.590 1.00 12.03 C
ATOM 602 CE2 PHE A 38 28.559 31.898 15.215 1.00 10.68 C
ATOM 604 CD2 PHE A 38 27.660 31.476 16.146 1.00 10.68 C
ATOM 606 C PHE A 38 24.595 30.912 19.303 1.00 11.13 C
ATOM 607 O PHE A 38 24.678 31.328 20.444 1.00 11.20 O
15 ATOM 608 N PRO A 39 23.777 29.911 18.995 1.00 11.41 N
ATOM 609 CA PRO A 39 22.920 29.317 20.033 1.00 11.03 C
ATOM 611 CB PRO A 39 22.047 28.347 19.251 1.00 11.55 C
ATOM 614 CG PRO A 39 22.138 28.792 17.827 1.00 11.41 C
ATOM 617 CD PRO A 39 23.501 29.337 17.671 1.00 10.69 C
20 ATOM 620 C PRO A 39 23.593 28.585 21.186 1.00 10.78 C
ATOM 621 O PRO A 39 23.007 28.537 22.272 1.00 11.13 O
ATOM 622 N LYS A 40 24.756 27.986 20.961 1.00 10.03 N
ATOM 624 CA LYS A 40 25.420 27.246 22.033 1.00 11.35 C
ATOM 626 CB LYS A 40 24.930 25.808 22.100 1.00 11.81 C
25 ATOM 629 CG LYS A 40 25.329 25.153 23.413 1.00 15.47 C
ATOM 632 CD LYS A 40 25.020 23.673 23.445 1.00 21.03 C
ATOM 635 CE LYS A 40 25.654 23.024 24.665 1.00 26.85 C
ATOM 638 NZ LYS A 40 24.928 23.362 25.917 1.00 35.22 N
30 ATOM 642 C LYS A 40 26.939 27.297 21.877 1.00 11.13 C
ATOM 643 O LYS A 40 27.540 26.454 21.211 1.00 11.86 O
ATOM 644 N VAL A 41 27.549 28.310 22.479 1.00 10.84 N
ATOM 646 CA VAL A 41 28.995 28.462 22.410 1.00 10.68 C
ATOM 648 CB VAL A 41 29.449 29.903 22.641 1.00 10.07 C
ATOM 650 CG1 VAL A 41 28.907 30.826 21.533 1.00 10.33 C
35 ATOM 654 CG2 VAL A 41 29.040 30.419 24.007 1.00 10.45 C
ATOM 658 C VAL A 41 29.690 27.564 23.425 1.00 11.85 C
ATOM 659 O VAL A 41 29.093 27.111 24.425 1.00 12.38 O
ATOM 660 N LEU A 42 30.957 27.305 23.165 1.00 13.03 N
40 ATOM 662 CA LEU A 42 31.803 26.664 24.159 1.00 15.12 C
ATOM 664 CB LEU A 42 33.126 26.219 23.556 1.00 14.97 C
ATOM 667 CG LEU A 42 32.873 25.139 22.491 1.00 15.42 C
ATOM 669 CD1 LEU A 42 34.128 24.763 21.705 1.00 16.85 C
ATOM 673 CD2 LEU A 42 32.303 23.917 23.125 1.00 17.26 C
45 ATOM 677 C LEU A 42 32.012 27.709 25.245 1.00 17.87 C
ATOM 678 O LEU A 42 32.083 28.897 24.974 1.00 17.12 O
ATOM 679 N THR A 43 32.171 27.279 26.476 1.00 21.75 N
ATOM 681 CA THR A 43 32.188 28.272 27.549 1.00 24.61 C
ATOM 683 CB THR A 43 30.761 28.365 28.043 1.00 24.82 C
50 ATOM 685 OG1 THR A 43 29.883 29.292 27.424 1.00 27.15 O
ATOM 687 CG2 THR A 43 30.199 27.229 28.835 1.00 24.68 C
ATOM 691 C THR A 43 33.197 27.863 28.620 1.00 26.54 C
ATOM 692 O THR A 43 33.185 28.377 29.738 1.00 27.45 O
ATOM 693 N ASP A 44 34.103 26.963 28.249 1.00 28.93 N
55 ATOM 695 CA ASP A 44 35.103 26.469 29.179 1.00 29.14 C
ATOM 697 CB ASP A 44 35.855 25.271 28.602 1.00 28.74 C
ATOM 700 CG ASP A 44 36.401 25.521 27.217 1.00 28.34 C
ATOM 701 OD1 ASP A 44 37.572 25.172 26.990 1.00 26.28 O
ATOM 702 OD2 ASP A 44 35.734 26.028 26.286 1.00 24.46 O
60 ATOM 703 C ASP A 44 36.063 27.575 29.547 1.00 30.53 C
ATOM 704 O ASP A 44 36.513 27.663 30.699 1.00 30.19 O
ATOM 705 N LYS A 45 36.372 28.422 28.568 1.00 31.95 N
ATOM 707 CA LYS A 45 37.275 29.547 28.790 1.00 31.72 C
ATOM 709 CB LYS A 45 38.701 29.244 28.320 1.00 31.90 C

	ATOM	712	CG	LYS	A	45	38.971	29.445	26.860	1.00	32.28	C
	ATOM	715	CD	LYS	A	45	39.201	28.149	26.171	1.00	33.73	C
	ATOM	718	CE	LYS	A	45	40.448	27.462	26.609	1.00	33.84	C
	ATOM	721	NZ	LYS	A	45	40.509	26.190	25.855	1.00	36.70	N
5	ATOM	725	C	LYS	A	45	36.715	30.803	28.140	1.00	31.38	C
	ATOM	726	O	LYS	A	45	35.679	30.756	27.482	1.00	31.01	O
	ATOM	727	N	LYS	A	46	37.399	31.925	28.352	1.00	31.71	N
	ATOM	729	CA	LYS	A	46	36.910	33.224	27.903	1.00	29.44	C
10	ATOM	731	CB	LYS	A	46	37.338	34.330	28.875	1.00	30.08	C
	ATOM	734	CG	LYS	A	46	38.819	34.397	29.144	1.00	32.08	C
	ATOM	737	CD	LYS	A	46	39.083	34.836	30.591	1.00	35.03	C
	ATOM	740	CE	LYS	A	46	40.571	34.941	30.910	1.00	36.79	C
	ATOM	743	NZ	LYS	A	46	40.827	34.716	32.367	1.00	37.85	N
	ATOM	747	C	LYS	A	46	37.335	33.551	26.488	1.00	26.70	C
15	ATOM	748	O	LYS	A	46	38.347	34.201	26.240	1.00	26.57	O
	ATOM	749	N	TYR	A	47	36.542	33.083	25.544	1.00	24.74	N
	ATOM	751	CA	TYR	A	47	36.802	33.387	24.144	1.00	20.86	C
	ATOM	753	CB	TYR	A	47	35.966	32.476	23.252	1.00	19.97	C
	ATOM	756	CG	TYR	A	47	36.251	31.026	23.482	1.00	17.82	C
20	ATOM	757	CD1	TYR	A	47	35.393	30.240	24.244	1.00	17.29	C
	ATOM	759	CE1	TYR	A	47	35.654	28.910	24.468	1.00	17.53	C
	ATOM	761	CZ	TYR	A	47	36.797	28.346	23.956	1.00	16.67	C
	ATOM	762	OH	TYR	A	47	37.076	27.005	24.174	1.00	20.90	O
	ATOM	764	CE2	TYR	A	47	37.670	29.109	23.205	1.00	17.26	C
25	ATOM	766	CD2	TYR	A	47	37.395	30.446	22.984	1.00	16.93	C
	ATOM	768	C	TYR	A	47	36.482	34.836	23.806	1.00	18.65	C
	ATOM	769	O	TYR	A	47	35.575	35.432	24.361	1.00	19.20	O
	ATOM	770	N	SER	A	48	37.229	35.388	22.863	1.00	16.14	N
	ATOM	772	CA	SER	A	48	36.957	36.716	22.329	1.00	14.79	C
30	ATOM	774	CB	SER	A	48	38.168	37.624	22.472	1.00	15.65	C
	ATOM	777	OG	SER	A	48	38.434	37.890	23.830	1.00	17.92	O
	ATOM	779	C	SER	A	48	36.638	36.586	20.852	1.00	12.87	C
	ATOM	780	O	SER	A	48	36.836	35.525	20.255	1.00	11.78	O
	ATOM	781	N	TYR	A	49	36.173	37.675	20.249	1.00	10.68	N
35	ATOM	783	CA	TYR	A	49	35.870	37.671	18.822	1.00	11.65	C
	ATOM	785	CB	TYR	A	49	34.362	37.641	18.580	1.00	11.29	C
	ATOM	788	CG	TYR	A	49	33.668	36.471	19.256	1.00	10.85	C
	ATOM	789	CD1	TYR	A	49	33.098	36.593	20.510	1.00	10.38	C
	ATOM	791	CE1	TYR	A	49	32.475	35.517	21.131	1.00	10.61	C
40	ATOM	793	CZ	TYR	A	49	32.404	34.310	20.480	1.00	12.03	C
	ATOM	794	OH	TYR	A	49	31.781	33.238	21.072	1.00	13.62	O
	ATOM	796	CE2	TYR	A	49	32.980	34.163	19.239	1.00	10.96	C
	ATOM	798	CD2	TYR	A	49	33.598	35.240	18.631	1.00	11.17	C
	ATOM	800	C	TYR	A	49	36.446	38.895	18.119	1.00	11.93	C
45	ATOM	801	O	TYR	A	49	36.259	40.028	18.564	1.00	12.07	O
	ATOM	802	N	ARG	A	50	37.122	38.649	17.004	1.00	13.41	N
	ATOM	804	CA	ARG	A	50	37.603	39.714	16.134	1.00	13.03	C
	ATOM	806	CB	ARG	A	50	38.983	39.376	15.561	1.00	13.84	C
	ATOM	809	CG	ARG	A	50	39.542	40.479	14.661	1.00	15.89	C
50	ATOM	812	CD	ARG	A	50	40.799	40.094	13.892	1.00	19.76	C
	ATOM	815	NE	ARG	A	50	41.825	39.658	14.809	1.00	22.85	N
	ATOM	817	CZ	ARG	A	50	42.474	40.468	15.643	1.00	29.33	C
	ATOM	818	NH1	ARG	A	50	43.391	39.966	16.456	1.00	35.65	N
	ATOM	821	NH2	ARG	A	50	42.224	41.779	15.666	1.00	30.97	N
55	ATOM	824	C	ARG	A	50	36.632	39.865	14.982	1.00	12.87	C
	ATOM	825	O	ARG	A	50	36.175	38.857	14.420	1.00	12.78	O
	ATOM	826	N	VAL	A	51	36.338	41.108	14.605	1.00	12.80	N
	ATOM	828	CA	VAL	A	51	35.419	41.393	13.506	1.00	13.04	C
	ATOM	830	CB	VAL	A	51	34.206	42.194	13.983	1.00	12.62	C
60	ATOM	832	CG1	VAL	A	51	33.343	42.630	12.809	1.00	12.65	C
	ATOM	836	CG2	VAL	A	51	33.389	41.356	14.936	1.00	12.04	C
	ATOM	840	C	VAL	A	51	36.167	42.170	12.438	1.00	13.60	C
	ATOM	841	O	VAL	A	51	36.851	43.153	12.738	1.00	13.27	O

ATOM 842 N VAL A 52 36.074 41.685 11.206 1.00 14.90 N
ATOM 844 CA VAL A 52 36.768 42.287 10.070 1.00 14.99 C
ATOM 846 CB VAL A 52 37.834 41.307 9.534 1.00 15.36 C
ATOM 848 CG1 VAL A 52 38.577 41.908 8.360 1.00 15.94 C
5 ATOM 852 CG2 VAL A 52 38.819 40.945 10.636 1.00 15.62 C
ATOM 856 C VAL A 52 35.733 42.590 8.981 1.00 15.27 C
ATOM 857 O VAL A 52 35.001 41.691 8.577 1.00 14.98 O
ATOM 858 N VAL A 53 35.680 43.840 8.506 1.00 15.37 N
ATOM 860 CA VAL A 53 34.663 44.255 7.542 1.00 16.36 C
10 ATOM 862 CB VAL A 53 33.805 45.395 8.090 1.00 16.50 C
ATOM 864 CG1 VAL A 53 32.827 45.905 7.043 1.00 16.92 C
ATOM 868 CG2 VAL A 53 33.037 44.923 9.314 1.00 16.68 C
ATOM 872 C VAL A 53 35.366 44.712 6.284 1.00 17.90 C
ATOM 873 O VAL A 53 36.121 45.670 6.321 1.00 17.86 O
15 ATOM 874 N ASN A 54 35.099 44.024 5.182 1.00 19.87 N
ATOM 876 CA ASN A 54 35.764 44.316 3.916 1.00 20.93 C
ATOM 878 CB ASN A 54 35.225 45.606 3.324 1.00 20.73 C
ATOM 881 CG ASN A 54 33.946 45.408 2.504 1.00 20.64 C
ATOM 882 OD1 ASN A 54 33.395 46.382 1.976 1.00 22.37 O
20 ATOM 883 ND2 ASN A 54 33.474 44.168 2.388 1.00 18.46 N
ATOM 886 C ASN A 54 37.281 44.421 4.100 1.00 22.08 C
ATOM 887 O ASN A 54 37.924 45.291 3.513 1.00 22.88 O
ATOM 888 N GLY A 55 37.851 43.545 4.924 1.00 23.68 N
ATOM 890 CA GLY A 55 39.288 43.532 5.134 1.00 22.59 C
25 ATOM 893 C GLY A 55 39.767 44.478 6.212 1.00 22.03 C
ATOM 894 O GLY A 55 40.936 44.441 6.586 1.00 22.03 O
ATOM 895 N SER A 56 38.883 45.332 6.712 1.00 21.22 N
ATOM 897 CA SER A 56 39.268 46.257 7.764 1.00 20.83 C
ATOM 899 CB SER A 56 38.434 47.521 7.666 1.00 21.16 C
30 ATOM 902 OG SER A 56 38.925 48.496 8.556 1.00 24.04 O
ATOM 904 C SER A 56 39.068 45.628 9.138 1.00 19.96 C
ATOM 905 O SER A 56 37.961 45.229 9.477 1.00 18.84 O
ATOM 906 N ASP A 57 40.129 45.590 9.937 1.00 19.21 N
ATOM 908 CA ASP A 57 40.100 44.953 11.252 1.00 19.05 C
35 ATOM 910 CB ASP A 57 41.547 44.599 11.610 1.00 19.38 C
ATOM 913 CG ASP A 57 41.704 43.926 12.947 1.00 20.67 C
ATOM 914 OD1 ASP A 57 40.717 43.476 13.545 1.00 19.91 O
ATOM 915 OD2 ASP A 57 42.833 43.786 13.472 1.00 25.20 O
ATOM 916 C ASP A 57 39.483 45.908 12.263 1.00 18.66 C
40 ATOM 917 O ASP A 57 40.031 46.992 12.524 1.00 17.62 O
ATOM 918 N LEU A 58 38.337 45.517 12.823 1.00 18.14 N
ATOM 920 CA LEU A 58 37.660 46.339 13.821 1.00 17.44 C
ATOM 922 CB LEU A 58 36.140 46.283 13.638 1.00 17.54 C
ATOM 925 CG LEU A 58 35.587 46.711 12.271 1.00 18.21 C
45 ATOM 927 CD1 LEU A 58 34.067 46.915 12.314 1.00 18.79 C
ATOM 931 CD2 LEU A 58 36.271 47.970 11.777 1.00 20.33 C
ATOM 935 C LEU A 58 38.058 45.955 15.248 1.00 17.13 C
ATOM 936 O LEU A 58 37.539 46.510 16.221 1.00 17.54 O
ATOM 937 N GLY A 59 38.978 45.010 15.381 1.00 16.87 N
50 ATOM 939 CA GLY A 59 39.503 44.667 16.686 1.00 16.43 C
ATOM 942 C GLY A 59 38.781 43.524 17.361 1.00 16.14 C
ATOM 943 O GLY A 59 37.953 42.845 16.768 1.00 13.91 O
ATOM 944 N VAL A 60 39.070 43.377 18.641 1.00 16.63 N
ATOM 946 CA VAL A 60 38.664 42.216 19.409 1.00 16.80 C
55 ATOM 948 CB VAL A 60 39.909 41.452 19.859 1.00 17.07 C
ATOM 950 CG1 VAL A 60 39.536 40.267 20.694 1.00 17.82 C
ATOM 954 CG2 VAL A 60 40.719 40.997 18.636 1.00 17.98 C
ATOM 958 C VAL A 60 37.883 42.635 20.638 1.00 17.13 C
ATOM 959 O VAL A 60 38.254 43.594 21.331 1.00 17.22 O
60 ATOM 960 N GLU A 61 36.806 41.913 20.913 1.00 16.81 N
ATOM 962 CA GLU A 61 35.954 42.215 22.058 1.00 17.72 C
ATOM 964 CB GLU A 61 34.759 43.060 21.623 1.00 18.26 C
ATOM 967 CG GLU A 61 35.079 44.412 20.956 1.00 20.64 C

ATOM 970 CD GLU A 61 35.548 45.510 21.912 1.00 24.07 C
ATOM 971 OE1 GLU A 61 35.294 45.417 23.142 1.00 25.24 O
ATOM 972 OE2 GLU A 61 36.174 46.484 21.416 1.00 24.17 O
ATOM 973 C GLU A 61 35.477 40.897 22.667 1.00 18.17 C
5 ATOM 974 O GLU A 61 35.387 39.870 21.972 1.00 15.50 O
ATOM 975 N SER A 62 35.171 40.917 23.964 1.00 19.13 N
ATOM 977 CA SER A 62 34.710 39.697 24.634 1.00 20.18 C
ATOM 979 CB SER A 62 35.838 39.109 25.479 1.00 20.45 C
ATOM 982 OG SER A 62 36.229 40.016 26.499 1.00 21.81 O
10 ATOM 984 C SER A 62 33.488 39.884 25.537 1.00 20.19 C
ATOM 985 O SER A 62 32.920 38.912 26.038 1.00 20.33 O
ATOM 986 N ASN A 63 33.073 41.120 25.735 1.00 20.95 N
ATOM 988 CA ASN A 63 32.043 41.388 26.729 1.00 21.35 C
ATOM 990 CB ASN A 63 32.310 42.725 27.418 1.00 22.62 C
15 ATOM 993 CG ASN A 63 31.947 43.893 26.582 1.00 26.10 C
ATOM 994 OD1 ASN A 63 31.697 44.985 27.106 1.00 33.95 O
ATOM 995 ND2 ASN A 63 31.936 43.704 25.268 1.00 38.69 N
ATOM 998 C ASN A 63 30.655 41.248 26.135 1.00 19.66 C
ATOM 999 O ASN A 63 29.954 42.221 25.801 1.00 20.53 O
20 ATOM 1000 N PHE A 64 30.318 39.982 25.925 1.00 17.32 N
ATOM 1002 CA PHE A 64 29.024 39.592 25.437 1.00 15.47 C
ATOM 1004 CB PHE A 64 29.125 39.076 23.995 1.00 14.91 C
ATOM 1007 CG PHE A 64 29.885 40.014 23.077 1.00 13.87 C
ATOM 1008 CD1 PHE A 64 29.388 41.270 22.792 1.00 14.13 C
25 ATOM 1010 CE1 PHE A 64 30.091 42.136 21.982 1.00 14.78 C
ATOM 1012 CZ PHE A 64 31.299 41.748 21.441 1.00 12.67 C
ATOM 1014 CE2 PHE A 64 31.808 40.511 21.723 1.00 13.44 C
ATOM 1016 CD2 PHE A 64 31.108 39.644 22.529 1.00 13.11 C
ATOM 1018 C PHE A 64 28.561 38.496 26.376 1.00 14.27 C
30 ATOM 1019 O PHE A 64 29.242 37.490 26.585 1.00 12.73 O
ATOM 1020 N ALA A 65 27.382 38.708 26.928 1.00 14.30 N
ATOM 1022 CA ALA A 65 26.782 37.806 27.875 1.00 14.41 C
ATOM 1024 CB ALA A 65 25.441 38.380 28.300 1.00 14.45 C
ATOM 1028 C ALA A 65 26.581 36.424 27.282 1.00 14.66 C
35 ATOM 1029 O ALA A 65 26.244 36.311 26.098 1.00 15.01 O
ATOM 1030 N VAL A 66 26.796 35.389 28.086 1.00 15.36 N
ATOM 1032 CA VAL A 66 26.427 34.049 27.683 1.00 15.61 C
ATOM 1034 CB VAL A 66 27.484 32.994 27.972 1.00 15.66 C
ATOM 1036 CG1 VAL A 66 26.958 31.609 27.592 1.00 17.06 C
40 ATOM 1040 CG2 VAL A 66 28.754 33.275 27.215 1.00 16.50 C
ATOM 1044 C VAL A 66 25.158 33.766 28.476 1.00 15.70 C
ATOM 1045 O VAL A 66 25.098 33.936 29.705 1.00 17.12 O
ATOM 1046 N THR A 67 24.115 33.379 27.777 1.00 15.06 N
ATOM 1048 CA THR A 67 22.854 33.106 28.439 1.00 15.98 C
45 ATOM 1050 CB THR A 67 21.681 33.345 27.491 1.00 15.54 C
ATOM 1052 OG1 THR A 67 21.794 32.535 26.311 1.00 14.59 O
ATOM 1054 CG2 THR A 67 21.718 34.774 26.958 1.00 15.99 C
ATOM 1058 C THR A 67 22.910 31.687 29.016 1.00 16.78 C
ATOM 1059 O THR A 67 23.742 30.885 28.620 1.00 16.89 O
50 ATOM 1060 N PRO A 68 22.150 31.418 30.062 1.00 18.84 N
ATOM 1061 CA PRO A 68 22.093 30.058 30.617 1.00 19.21 C
ATOM 1063 CB PRO A 68 20.997 30.168 31.683 1.00 19.65 C
ATOM 1066 CG PRO A 68 21.101 31.602 32.125 1.00 18.30 C
ATOM 1069 CD PRO A 68 21.436 32.395 30.897 1.00 18.90 C
55 ATOM 1072 C PRO A 68 21.826 28.955 29.582 1.00 20.21 C
ATOM 1073 O PRO A 68 22.274 27.827 29.790 1.00 19.65 O
ATOM 1074 N SER A 69 21.145 29.278 28.485 1.00 22.19 N
ATOM 1076 CA SER A 69 20.918 28.325 27.390 1.00 21.01 C
ATOM 1078 CB SER A 69 19.822 28.847 26.463 1.00 21.48 C
60 ATOM 1081 OG SER A 69 20.198 30.084 25.869 1.00 21.75 O
ATOM 1083 C SER A 69 22.189 28.062 26.582 1.00 20.29 C
ATOM 1084 O SER A 69 22.276 27.090 25.825 1.00 20.29 O
ATOM 1085 N GLY A 70 23.185 28.926 26.742 1.00 18.45 N

ATOM 1087 CA GLY A 70 24.455 28.736 26.089 1.00 16.37 C
ATOM 1090 C GLY A 70 24.635 29.701 24.941 1.00 14.59 C
ATOM 1091 O GLY A 70 25.655 29.678 24.275 1.00 14.71 O
5 ATOM 1092 N GLY A 71 23.655 30.564 24.707 1.00 12.55 N
ATOM 1094 CA GLY A 71 23.758 31.485 23.587 1.00 11.79 C
ATOM 1097 C GLY A 71 24.646 32.689 23.872 1.00 11.04 C
ATOM 1098 O GLY A 71 24.827 33.109 25.024 1.00 11.27 O
ATOM 1099 N GLN A 72 25.209 33.247 22.807 1.00 10.97 N
10 ATOM 1101 CA GLN A 72 26.016 34.462 22.914 1.00 10.54 C
ATOM 1103 CB GLN A 72 27.497 34.125 23.115 1.00 10.98 C
ATOM 1106 CG GLN A 72 28.414 35.293 23.430 1.00 12.20 C
ATOM 1109 CD GLN A 72 29.834 34.862 23.853 1.00 15.65 C
ATOM 1110 OE1 GLN A 72 30.449 35.487 24.742 1.00 17.66 O
15 ATOM 1111 NE2 GLN A 72 30.354 33.820 23.222 1.00 10.29 N
ATOM 1114 C GLN A 72 25.807 35.312 21.675 1.00 11.06 C
ATOM 1115 O GLN A 72 25.877 34.821 20.533 1.00 11.31 O
ATOM 1116 N THR A 73 25.535 36.589 21.904 1.00 10.95 N
ATOM 1118 CA THR A 73 25.337 37.526 20.830 1.00 9.80 C
20 ATOM 1120 CB THR A 73 24.021 38.290 21.035 1.00 10.73 C
ATOM 1122 OG1 THR A 73 22.912 37.385 21.013 1.00 11.04 O
ATOM 1124 CG2 THR A 73 23.786 39.270 19.891 1.00 10.78 C
ATOM 1128 C THR A 73 26.475 38.540 20.782 1.00 9.92 C
ATOM 1129 O THR A 73 26.722 39.283 21.745 1.00 10.19 O
25 ATOM 1130 N ILE A 74 27.161 38.554 19.643 1.00 9.37 N
ATOM 1132 CA ILE A 74 28.232 39.493 19.364 1.00 10.19 C
ATOM 1134 CB ILE A 74 29.235 38.855 18.371 1.00 10.48 C
ATOM 1136 CG1 ILE A 74 29.843 37.581 18.972 1.00 12.71 C
ATOM 1139 CD1 ILE A 74 30.471 36.666 17.946 1.00 16.05 C
30 ATOM 1143 CG2 ILE A 74 30.296 39.860 17.986 1.00 10.70 C
ATOM 1147 C ILE A 74 27.609 40.733 18.756 1.00 10.18 C
ATOM 1148 O ILE A 74 27.052 40.677 17.660 1.00 11.08 O
ATOM 1149 N ASN A 75 27.674 41.851 19.489 1.00 9.17 N
ATOM 1151 CA ASN A 75 27.079 43.102 19.040 1.00 9.50 C
35 ATOM 1153 CB ASN A 75 26.600 43.849 20.274 1.00 9.51 C
ATOM 1156 CG ASN A 75 25.994 45.177 19.950 1.00 10.45 C
ATOM 1157 OD1 ASN A 75 25.558 45.424 18.827 1.00 9.62 O
ATOM 1158 ND2 ASN A 75 25.931 46.046 20.959 1.00 12.30 N
ATOM 1161 C ASN A 75 28.050 43.975 18.248 1.00 9.58 C
40 ATOM 1162 O ASN A 75 28.992 44.543 18.807 1.00 10.09 O
ATOM 1163 N PHE A 76 27.817 44.088 16.945 1.00 10.23 N
ATOM 1165 CA PHE A 76 28.751 44.809 16.087 1.00 10.31 C
ATOM 1167 CB PHE A 76 28.464 44.552 14.610 1.00 10.82 C
ATOM 1170 CG PHE A 76 28.596 43.096 14.199 1.00 11.07 C
45 ATOM 1171 CD1 PHE A 76 29.568 42.277 14.737 1.00 13.37 C
ATOM 1173 CE1 PHE A 76 29.681 40.936 14.328 1.00 10.49 C
ATOM 1175 CZ PHE A 76 28.820 40.441 13.411 1.00 10.42 C
ATOM 1177 CE2 PHE A 76 27.856 41.259 12.865 1.00 11.96 C
ATOM 1179 CD2 PHE A 76 27.746 42.568 13.258 1.00 12.00 C
50 ATOM 1181 C PHE A 76 28.780 46.301 16.409 1.00 10.53 C
ATOM 1182 O PHE A 76 29.743 46.978 16.059 1.00 10.34 O
ATOM 1183 N LEU A 77 27.746 46.826 17.073 1.00 10.19 N
ATOM 1185 CA LEU A 77 27.754 48.242 17.446 1.00 11.27 C
ATOM 1187 CB LEU A 77 26.443 48.652 18.120 1.00 11.26 C
ATOM 1190 CG LEU A 77 25.267 48.913 17.154 1.00 12.41 C
55 ATOM 1192 CD1 LEU A 77 24.989 47.774 16.232 1.00 12.55 C
ATOM 1196 CD2 LEU A 77 23.977 49.223 17.911 1.00 13.90 C
ATOM 1200 C LEU A 77 28.933 48.577 18.368 1.00 12.07 C
ATOM 1201 O LEU A 77 29.399 49.717 18.371 1.00 13.10 O
60 ATOM 1202 N GLN A 78 29.416 47.580 19.112 1.00 12.87 N
ATOM 1204 CA GLN A 78 30.562 47.741 20.011 1.00 13.30 C
ATOM 1206 CB GLN A 78 30.588 46.602 21.048 1.00 13.42 C
ATOM 1209 CG GLN A 78 29.408 46.690 22.022 1.00 14.19 C
ATOM 1212 CD GLN A 78 29.251 45.560 23.009 1.00 17.92 C

ATOM 1213 OE1 GLN A 78 28.141 45.045 23.165 1.00 20.68 O
ATOM 1214 NE2 GLN A 78 30.316 45.212 23.726 1.00 21.02 N
ATOM 1217 C GLN A 78 31.892 47.837 19.231 1.00 14.14 C
5 ATOM 1218 O GLN A 78 32.905 48.303 19.774 1.00 16.34 O
ATOM 1219 N TYR A 79 31.896 47.398 17.979 1.00 13.44 N
ATOM 1221 CA TYR A 79 33.101 47.443 17.143 1.00 13.76 C
ATOM 1223 CB TYR A 79 33.220 46.165 16.311 1.00 13.39 C
ATOM 1226 CG TYR A 79 33.402 44.856 17.041 1.00 12.44 C
10 ATOM 1227 CD1 TYR A 79 34.649 44.249 17.117 1.00 11.93 C
ATOM 1229 CE1 TYR A 79 34.816 43.040 17.755 1.00 11.71 C
ATOM 1231 CZ TYR A 79 33.712 42.414 18.310 1.00 12.16 C
ATOM 1232 OH TYR A 79 33.873 41.215 18.929 1.00 13.43 O
ATOM 1234 CE2 TYR A 79 32.463 43.002 18.239 1.00 10.82 C
ATOM 1236 CD2 TYR A 79 32.319 44.204 17.607 1.00 11.32 C
15 ATOM 1238 C TYR A 79 33.092 48.571 16.111 1.00 14.75 C
ATOM 1239 O TYR A 79 34.154 48.964 15.600 1.00 14.73 O
ATOM 1240 N ASN A 80 31.899 49.072 15.786 1.00 15.93 N
ATOM 1242 CA ASN A 80 31.702 49.928 14.614 1.00 15.93 C
ATOM 1244 CB ASN A 80 30.814 49.164 13.619 1.00 15.91 C
20 ATOM 1247 CG ASN A 80 30.884 49.703 12.203 1.00 17.60 C
ATOM 1248 OD1 ASN A 80 29.863 49.757 11.507 1.00 22.84 O
ATOM 1249 ND2 ASN A 80 32.067 50.104 11.767 1.00 16.39 N
ATOM 1252 C ASN A 80 31.101 51.293 14.941 1.00 16.30 C
ATOM 1253 O ASN A 80 30.238 51.789 14.220 1.00 16.27 O
25 ATOM 1254 N LYS A 81 31.559 51.881 16.042 1.00 16.66 N
ATOM 1256 CA LYS A 81 31.166 53.238 16.448 1.00 17.75 C
ATOM 1258 CB LYS A 81 31.753 54.274 15.485 1.00 18.72 C
ATOM 1261 CG LYS A 81 33.275 54.164 15.279 1.00 22.17 C
ATOM 1264 CD LYS A 81 34.098 53.637 16.494 1.00 28.26 C
30 ATOM 1267 CE LYS A 81 33.999 54.432 17.816 1.00 31.88 C
ATOM 1270 NZ LYS A 81 34.916 53.895 18.908 1.00 34.98 N
ATOM 1274 C LYS A 81 29.660 53.445 16.590 1.00 17.22 C
ATOM 1275 O LYS A 81 29.139 54.507 16.230 1.00 16.93 O
ATOM 1276 N GLY A 82 28.969 52.429 17.115 1.00 16.00 N
35 ATOM 1278 CA GLY A 82 27.546 52.523 17.393 1.00 16.21 C
ATOM 1281 C GLY A 82 26.612 52.249 16.232 1.00 16.87 C
ATOM 1282 O GLY A 82 25.406 52.461 16.362 1.00 16.37 O
ATOM 1283 N TYR A 83 27.152 51.772 15.111 1.00 16.99 N
ATOM 1285 CA TYR A 83 26.342 51.425 13.958 1.00 17.84 C
40 ATOM 1287 CB TYR A 83 26.751 52.240 12.735 1.00 18.95 C
ATOM 1290 CG TYR A 83 26.375 53.678 12.816 1.00 24.21 C
ATOM 1291 CD1 TYR A 83 25.138 54.103 12.373 1.00 29.21 C
ATOM 1293 CE1 TYR A 83 24.775 55.428 12.440 1.00 31.15 C
ATOM 1295 CZ TYR A 83 25.660 56.351 12.956 1.00 32.63 C
45 ATOM 1296 OH TYR A 83 25.291 57.680 13.016 1.00 35.54 O
ATOM 1298 CE2 TYR A 83 26.906 55.954 13.404 1.00 31.21 C
ATOM 1300 CD2 TYR A 83 27.258 54.618 13.327 1.00 28.33 C
ATOM 1302 C TYR A 83 26.576 49.990 13.590 1.00 16.45 C
ATOM 1303 O TYR A 83 27.652 49.438 13.854 1.00 16.18 O
50 ATOM 1304 N GLY A 84 25.570 49.372 12.982 1.00 14.45 N
ATOM 1306 CA GLY A 84 25.761 48.049 12.430 1.00 14.93 C
ATOM 1309 C GLY A 84 26.514 48.187 11.109 1.00 15.19 C
ATOM 1310 O GLY A 84 27.001 49.273 10.757 1.00 15.50 O
ATOM 1311 N VAL A 85 26.565 47.099 10.353 1.00 15.19 N
55 ATOM 1313 CA VAL A 85 27.352 47.043 9.112 1.00 15.08 C
ATOM 1315 CB VAL A 85 28.332 45.860 9.143 1.00 15.27 C
ATOM 1317 CG1 VAL A 85 29.157 45.794 7.872 1.00 15.21 C
ATOM 1321 CG2 VAL A 85 29.255 45.956 10.329 1.00 15.25 C
ATOM 1325 C VAL A 85 26.438 46.873 7.911 1.00 15.53 C
60 ATOM 1326 O VAL A 85 25.551 46.025 7.910 1.00 14.72 O
ATOM 1327 N ALA A 86 26.648 47.673 6.875 1.00 15.80 N
ATOM 1329 CA ALA A 86 25.802 47.548 5.698 1.00 16.04 C
ATOM 1331 CB ALA A 86 26.250 48.488 4.631 1.00 16.32 C

ATOM 1335 C ALA A 86 25.861 46.128 5.186 1.00 15.57 C
ATOM 1336 O ALA A 86 26.941 45.575 5.059 1.00 15.01 O
ATOM 1337 N ASP A 87 24.708 45.558 4.842 1.00 16.64 N
5 ATOM 1339 CA ASP A 87 24.658 44.160 4.402 1.00 16.37 C
ATOM 1341 CB ASP A 87 23.253 43.550 4.495 1.00 16.92 C
ATOM 1344 CG ASP A 87 22.293 44.088 3.472 1.00 17.15 C
ATOM 1345 OD1 ASP A 87 21.117 43.677 3.520 1.00 17.33 O
ATOM 1346 OD2 ASP A 87 22.615 44.920 2.605 1.00 17.89 O
10 ATOM 1347 C ASP A 87 25.316 43.899 3.046 1.00 16.95 C
ATOM 1348 O ASP A 87 25.392 42.753 2.623 1.00 16.19 O
ATOM 1349 N THR A 88 25.812 44.949 2.398 1.00 18.29 N
ATOM 1351 CA THR A 88 26.566 44.803 1.146 1.00 17.50 C
ATOM 1353 CB THR A 88 26.427 46.084 0.327 1.00 17.73 C
ATOM 1355 OG1 THR A 88 26.702 47.225 1.150 1.00 16.82 O
15 ATOM 1357 CG2 THR A 88 25.020 46.269 -0.109 1.00 18.14 C
ATOM 1361 C THR A 88 28.052 44.563 1.361 1.00 17.57 C
ATOM 1362 O THR A 88 28.820 44.404 0.409 1.00 16.74 O
ATOM 1363 N LYS A 89 28.477 44.594 2.609 1.00 17.46 N
20 ATOM 1365 CA LYS A 89 29.871 44.389 2.919 1.00 17.25 C
ATOM 1367 CB LYS A 89 30.312 45.388 3.978 1.00 17.22 C
ATOM 1370 CG LYS A 89 30.058 46.844 3.579 1.00 18.92 C
ATOM 1373 CD LYS A 89 30.818 47.788 4.471 1.00 22.27 C
ATOM 1376 CE LYS A 89 30.590 49.242 4.055 1.00 25.20 C
ATOM 1379 NZ LYS A 89 31.208 50.160 5.042 1.00 29.86 N
25 ATOM 1383 C LYS A 89 30.069 42.968 3.411 1.00 17.09 C
ATOM 1384 O LYS A 89 29.122 42.311 3.818 1.00 16.84 O
ATOM 1385 N THR A 90 31.300 42.493 3.343 1.00 17.10 N
ATOM 1387 CA THR A 90 31.662 41.181 3.842 1.00 16.27 C
30 ATOM 1389 CB THR A 90 32.860 40.644 3.086 1.00 17.13 C
ATOM 1391 OG1 THR A 90 32.533 40.515 1.704 1.00 15.79 O
ATOM 1393 CG2 THR A 90 33.199 39.226 3.543 1.00 17.35 C
ATOM 1397 C THR A 90 32.068 41.322 5.296 1.00 15.60 C
ATOM 1398 O THR A 90 32.930 42.137 5.613 1.00 14.66 O
ATOM 1399 N ILE A 91 31.451 40.543 6.170 1.00 15.11 N
35 ATOM 1401 CA ILE A 91 31.823 40.561 7.577 1.00 14.05 C
ATOM 1403 CB ILE A 91 30.596 40.777 8.475 1.00 14.05 C
ATOM 1405 CG1 ILE A 91 29.771 41.971 7.995 1.00 13.77 C
ATOM 1408 CD1 ILE A 91 28.482 42.119 8.725 1.00 15.25 C
40 ATOM 1412 CG2 ILE A 91 31.039 40.924 9.949 1.00 13.82 C
ATOM 1416 C ILE A 91 32.435 39.221 7.914 1.00 14.03 C
ATOM 1417 O ILE A 91 31.795 38.191 7.702 1.00 14.85 O
ATOM 1418 N GLN A 92 33.679 39.230 8.382 1.00 12.86 N
ATOM 1420 CA GLN A 92 34.298 38.028 8.919 1.00 13.25 C
45 ATOM 1422 CB GLN A 92 35.678 37.818 8.338 1.00 14.29 C
ATOM 1425 CG GLN A 92 35.645 37.428 6.904 1.00 16.51 C
ATOM 1428 CD GLN A 92 37.020 37.515 6.275 1.00 21.30 C
ATOM 1429 OE1 GLN A 92 37.536 36.517 5.775 1.00 25.59 O
ATOM 1430 NE2 GLN A 92 37.627 38.701 6.319 1.00 23.68 N
50 ATOM 1433 C GLN A 92 34.443 38.120 10.423 1.00 12.74 C
ATOM 1434 O GLN A 92 34.914 39.127 10.940 1.00 12.27 O
ATOM 1435 N VAL A 93 34.072 37.051 11.115 1.00 11.90 N
ATOM 1437 CA VAL A 93 34.217 36.985 12.564 1.00 11.73 C
ATOM 1439 CB VAL A 93 32.865 36.841 13.257 1.00 11.43 C
ATOM 1441 CG1 VAL A 93 33.048 36.856 14.771 1.00 12.22 C
55 ATOM 1445 CG2 VAL A 93 31.925 37.956 12.809 1.00 12.10 C
ATOM 1449 C VAL A 93 35.118 35.797 12.912 1.00 11.97 C
ATOM 1450 O VAL A 93 34.953 34.707 12.379 1.00 11.23 O
ATOM 1451 N PHE A 94 36.096 36.055 13.773 1.00 11.48 N
60 ATOM 1453 CA PHE A 94 37.069 35.064 14.188 1.00 12.22 C
ATOM 1455 CB PHE A 94 38.473 35.563 13.871 1.00 12.62 C
ATOM 1458 CG PHE A 94 38.736 35.743 12.404 1.00 12.77 C
ATOM 1459 CD1 PHE A 94 38.345 36.900 11.763 1.00 14.64 C
ATOM 1461 CE1 PHE A 94 38.598 37.083 10.420 1.00 16.13 C

ATOM 1463 CZ PHE A 94 39.255 36.106 9.711 1.00 15.54 C
ATOM 1465 CE2 PHE A 94 39.660 34.948 10.345 1.00 16.06 C
ATOM 1467 CD2 PHE A 94 39.409 34.768 11.682 1.00 13.20 C
5 ATOM 1469 C PHE A 94 36.984 34.837 15.681 1.00 12.26 C
ATOM 1470 O PHE A 94 36.882 35.794 16.458 1.00 11.72 O
ATOM 1471 N VAL A 95 36.998 33.581 16.097 1.00 12.66 N
ATOM 1473 CA VAL A 95 37.063 33.304 17.530 1.00 13.63 C
ATOM 1475 CB VAL A 95 36.390 31.976 17.924 1.00 13.74 C
10 ATOM 1477 CG1 VAL A 95 37.054 30.809 17.246 1.00 15.18 C
ATOM 1481 CG2 VAL A 95 36.397 31.814 19.473 1.00 15.16 C
ATOM 1485 C VAL A 95 38.554 33.362 17.882 1.00 13.85 C
ATOM 1486 O VAL A 95 39.399 32.777 17.203 1.00 13.33 O
ATOM 1487 N VAL A 96 38.862 34.116 18.924 1.00 14.98 N
15 ATOM 1489 CA VAL A 96 40.231 34.355 19.364 1.00 16.25 C
ATOM 1491 CB VAL A 96 40.478 35.868 19.524 1.00 16.70 C
ATOM 1493 CG1 VAL A 96 41.904 36.141 20.002 1.00 17.91 C
ATOM 1497 CG2 VAL A 96 40.202 36.576 18.209 1.00 17.10 C
ATOM 1501 C VAL A 96 40.466 33.634 20.691 1.00 17.27 C
ATOM 1502 O VAL A 96 39.695 33.788 21.641 1.00 16.34 O
20 ATOM 1503 N ILE A 97 41.522 32.830 20.726 1.00 18.96 N
ATOM 1505 CA ILE A 97 41.842 32.001 21.883 1.00 20.35 C
ATOM 1507 CB ILE A 97 42.745 30.808 21.453 1.00 20.22 C
ATOM 1509 CG1 ILE A 97 42.107 30.040 20.289 1.00 19.14 C
ATOM 1512 CD1 ILE A 97 40.750 29.510 20.588 1.00 18.75 C
25 ATOM 1516 CG2 ILE A 97 43.031 29.889 22.639 1.00 20.66 C
ATOM 1520 C ILE A 97 42.545 32.863 22.925 1.00 22.26 C
ATOM 1521 O ILE A 97 43.457 33.599 22.579 1.00 22.69 O
ATOM 1522 N PRO A 98 42.099 32.814 24.176 1.00 24.62 N
ATOM 1523 CA PRO A 98 42.733 33.599 25.240 1.00 26.52 C
30 ATOM 1525 CB PRO A 98 41.778 33.441 26.426 1.00 25.97 C
ATOM 1528 CG PRO A 98 40.990 32.213 26.153 1.00 25.73 C
ATOM 1531 CD PRO A 98 40.942 32.054 24.669 1.00 24.63 C
ATOM 1534 C PRO A 98 44.114 33.108 25.621 1.00 28.91 C
ATOM 1535 O PRO A 98 44.507 31.975 25.313 1.00 28.13 O
35 ATOM 1536 N ASP A 99 44.838 33.999 26.295 1.00 32.98 N
ATOM 1538 CA ASP A 99 46.175 33.735 26.804 1.00 34.16 C
ATOM 1540 CB ASP A 99 46.090 32.683 27.897 1.00 34.51 C
ATOM 1543 CG ASP A 99 45.238 33.162 29.064 1.00 36.30 C
ATOM 1544 OD1 ASP A 99 45.547 34.247 29.608 1.00 39.17 O
40 ATOM 1545 OD2 ASP A 99 44.222 32.559 29.481 1.00 39.73 O
ATOM 1546 C ASP A 99 47.083 33.361 25.645 1.00 35.01 C
ATOM 1547 O ASP A 99 47.925 32.468 25.733 1.00 35.21 O
ATOM 1548 N THR A 100 46.914 34.118 24.568 1.00 36.50 N
ATOM 1550 CA THR A 100 47.559 33.836 23.307 1.00 35.94 C
45 ATOM 1552 CB THR A 100 46.536 33.051 22.457 1.00 36.18 C
ATOM 1554 OG1 THR A 100 47.151 31.891 21.882 1.00 36.31 O
ATOM 1556 CG2 THR A 100 46.021 33.845 21.282 1.00 35.16 C
ATOM 1560 C THR A 100 48.034 35.115 22.606 1.00 36.08 C
ATOM 1561 O THR A 100 48.650 35.058 21.542 1.00 35.70 O
50 ATOM 1562 N GLY A 101 47.776 36.267 23.220 1.00 36.43 N
ATOM 1564 CA GLY A 101 48.151 37.550 22.636 1.00 36.52 C
ATOM 1567 C GLY A 101 47.365 37.850 21.368 1.00 36.69 C
ATOM 1568 O GLY A 101 47.842 38.551 20.467 1.00 36.66 O
ATOM 1569 N ASN A 102 46.149 37.309 21.305 1.00 37.04 N
55 ATOM 1571 CA ASN A 102 45.279 37.436 20.135 1.00 35.46 C
ATOM 1573 CB ASN A 102 44.881 38.904 19.889 1.00 35.74 C
ATOM 1576 CG ASN A 102 44.070 39.509 21.044 1.00 36.19 C
ATOM 1577 OD1 ASN A 102 43.556 38.795 21.914 1.00 36.82 O
ATOM 1578 ND2 ASN A 102 43.948 40.836 21.046 1.00 38.45 N
60 ATOM 1581 C ASN A 102 45.884 36.813 18.855 1.00 34.28 C
ATOM 1582 O ASN A 102 45.401 37.081 17.757 1.00 34.09 O
ATOM 1583 N SER A 103 46.919 35.978 18.997 1.00 32.94 N
ATOM 1585 CA SER A 103 47.608 35.359 17.852 1.00 30.99 C

ATOM 1587 CB SER A 103 49.068 35.070 18.214 1.00 31.29 C
ATOM 1590 OG SER A 103 49.175 34.552 19.532 1.00 32.26 O
ATOM 1592 C SER A 103 46.981 34.072 17.315 1.00 28.93 C
ATOM 1593 O SER A 103 47.135 33.752 16.140 1.00 29.01 O
5 ATOM 1594 N GLU A 104 46.308 33.320 18.173 1.00 26.74 N
ATOM 1596 CA GLU A 104 45.648 32.098 17.739 1.00 23.55 C
ATOM 1598 CB GLU A 104 45.821 30.969 18.759 1.00 23.10 C
ATOM 1601 CG GLU A 104 45.217 29.652 18.294 1.00 22.29 C
ATOM 1604 CD GLU A 104 45.267 28.539 19.335 1.00 20.79 C
10 ATOM 1605 OE1 GLU A 104 44.705 27.459 19.063 1.00 18.27 O
ATOM 1606 OE2 GLU A 104 45.872 28.735 20.405 1.00 19.73 O
ATOM 1607 C GLU A 104 44.166 32.431 17.527 1.00 21.26 C
ATOM 1608 O GLU A 104 43.463 32.788 18.468 1.00 20.20 O
ATOM 1609 N GLU A 105 43.706 32.342 16.286 1.00 19.27 N
15 ATOM 1611 CA GLU A 105 42.310 32.652 15.989 1.00 17.92 C
ATOM 1613 CB GLU A 105 42.119 34.141 15.658 1.00 18.34 C
ATOM 1616 CG GLU A 105 42.614 34.515 14.283 1.00 19.41 C
ATOM 1619 CD GLU A 105 42.443 35.986 13.960 1.00 21.46 C
ATOM 1620 OE1 GLU A 105 42.657 36.346 12.779 1.00 22.55 O
20 ATOM 1621 OE2 GLU A 105 42.097 36.770 14.872 1.00 19.79 O
ATOM 1622 C GLU A 105 41.807 31.788 14.851 1.00 16.31 C
ATOM 1623 O GLU A 105 42.589 31.268 14.050 1.00 16.35 O
ATOM 1624 N TYR A 106 40.489 31.642 14.779 1.00 14.92 N
ATOM 1626 CA TYR A 106 39.856 30.789 13.784 1.00 13.70 C
25 ATOM 1628 CB TYR A 106 39.466 29.416 14.400 1.00 12.91 C
ATOM 1631 CG TYR A 106 40.630 28.705 15.037 1.00 13.45 C
ATOM 1632 CD1 TYR A 106 41.441 27.863 14.296 1.00 15.31 C
ATOM 1634 CE1 TYR A 106 42.517 27.226 14.869 1.00 15.32 C
ATOM 1636 CZ TYR A 106 42.812 27.428 16.186 1.00 15.25 C
30 ATOM 1637 OH TYR A 106 43.904 26.776 16.728 1.00 16.78 O
ATOM 1639 CE2 TYR A 106 42.027 28.251 16.961 1.00 15.05 C
ATOM 1641 CD2 TYR A 106 40.934 28.890 16.379 1.00 13.75 C
ATOM 1643 C TYR A 106 38.605 31.460 13.230 1.00 13.16 C
ATOM 1644 O TYR A 106 37.789 31.993 14.001 1.00 12.90 O
35 ATOM 1645 N ILE A 107 38.432 31.416 11.911 1.00 12.87 N
ATOM 1647 CA ILE A 107 37.219 31.954 11.296 1.00 13.04 C
ATOM 1649 CB ILE A 107 37.271 31.865 9.734 1.00 13.61 C
ATOM 1651 CG1 ILE A 107 36.049 32.531 9.105 1.00 16.08 C
ATOM 1654 CD1 ILE A 107 36.054 33.996 9.131 1.00 19.25 C
40 ATOM 1658 CG2 ILE A 107 37.277 30.431 9.234 1.00 14.39 C
ATOM 1662 C ILE A 107 36.026 31.203 11.890 1.00 12.69 C
ATOM 1663 O ILE A 107 36.050 29.967 11.991 1.00 12.26 O
ATOM 1664 N ILE A 108 34.994 31.931 12.314 1.00 10.96 N
ATOM 1666 CA ILE A 108 33.831 31.283 12.892 1.00 11.58 C
45 ATOM 1668 CB ILE A 108 33.823 31.470 14.438 1.00 11.47 C
ATOM 1670 CG1 ILE A 108 32.825 30.527 15.117 1.00 12.45 C
ATOM 1673 CD1 ILE A 108 33.138 29.042 14.913 1.00 14.07 C
ATOM 1677 CG2 ILE A 108 33.541 32.903 14.825 1.00 11.20 C
ATOM 1681 C ILE A 108 32.516 31.695 12.234 1.00 11.67 C
50 ATOM 1682 O ILE A 108 31.510 31.041 12.437 1.00 13.19 O
ATOM 1683 N ALA A 109 32.512 32.756 11.438 1.00 11.35 N
ATOM 1685 CA ALA A 109 31.319 33.139 10.675 1.00 12.23 C
ATOM 1687 CB ALA A 109 30.290 33.798 11.582 1.00 12.13 C
ATOM 1691 C ALA A 109 31.699 34.113 9.557 1.00 12.08 C
55 ATOM 1692 O ALA A 109 32.648 34.879 9.714 1.00 12.05 O
ATOM 1693 N GLU A 110 30.956 34.090 8.448 1.00 13.59 N
ATOM 1695 CA GLU A 110 31.147 35.085 7.399 1.00 13.30 C
ATOM 1697 CB GLU A 110 32.149 34.594 6.336 1.00 14.11 C
ATOM 1700 CG GLU A 110 32.258 35.509 5.123 1.00 15.16 C
60 ATOM 1703 CD GLU A 110 33.187 34.947 4.059 1.00 18.76 C
ATOM 1704 OE1 GLU A 110 34.393 35.270 4.085 1.00 20.47 O
ATOM 1705 OE2 GLU A 110 32.706 34.165 3.204 1.00 21.90 O
ATOM 1706 C GLU A 110 29.814 35.470 6.762 1.00 13.12 C

ATOM 1707 O GLU A 110 29.028 34.608 6.372 1.00 13.60 O
ATOM 1708 N TRP A 111 29.559 36.772 6.709 1.00 12.93 N
ATOM 1710 CA TRP A 111 28.420 37.335 6.032 1.00 14.60 C
ATOM 1712 CB TRP A 111 27.809 38.507 6.808 1.00 15.14 C
5 ATOM 1715 CG TRP A 111 26.726 39.127 5.988 1.00 15.69 C
ATOM 1716 CD1 TRP A 111 26.858 40.164 5.110 1.00 16.10 C
ATOM 1718 NE1 TRP A 111 25.661 40.419 4.489 1.00 16.03 N
ATOM 1720 CE2 TRP A 111 24.727 39.530 4.949 1.00 18.16 C
ATOM 1721 CD2 TRP A 111 25.367 38.695 5.891 1.00 18.12 C
10 ATOM 1722 CE3 TRP A 111 24.618 37.689 6.510 1.00 19.20 C
ATOM 1724 CZ3 TRP A 111 23.277 37.560 6.189 1.00 21.05 C
ATOM 1726 CH2 TRP A 111 22.673 38.410 5.255 1.00 20.77 C
ATOM 1728 CZ2 TRP A 111 23.382 39.397 4.626 1.00 19.73 C
ATOM 1730 C TRP A 111 28.912 37.854 4.684 1.00 16.60 C
15 ATOM 1731 O TRP A 111 29.813 38.692 4.621 1.00 15.60 O
ATOM 1732 N LYS A 112 28.344 37.323 3.618 1.00 18.75 N
ATOM 1734 CA LYS A 112 28.630 37.843 2.288 1.00 21.69 C
ATOM 1736 CB LYS A 112 29.829 37.176 1.651 1.00 21.83 C
ATOM 1739 CG LYS A 112 30.317 37.972 0.444 1.00 24.07 C
20 ATOM 1742 CD LYS A 112 31.330 37.217 -0.360 1.00 26.81 C
ATOM 1745 CE LYS A 112 32.648 37.120 0.351 1.00 28.67 C
ATOM 1748 NZ LYS A 112 33.684 36.627 -0.601 1.00 31.60 N
ATOM 1752 C LYS A 112 27.394 37.622 1.452 1.00 23.68 C
ATOM 1753 O LYS A 112 27.097 36.495 1.042 1.00 24.51 O
25 ATOM 1754 N LYS A 113 26.678 38.708 1.226 1.00 26.48 N
ATOM 1756 CA LYS A 113 25.423 38.686 0.536 1.00 29.15 C
ATOM 1758 CB LYS A 113 24.840 40.091 0.501 1.00 29.56 C
ATOM 1761 CG LYS A 113 23.349 40.115 0.396 1.00 31.24 C
ATOM 1764 CD LYS A 113 22.790 41.488 0.542 1.00 33.22 C
30 ATOM 1767 CE LYS A 113 21.264 41.332 0.752 1.00 34.56 C
ATOM 1770 NZ LYS A 113 20.811 40.425 1.911 1.00 34.61 N
ATOM 1774 C LYS A 113 25.589 38.215 -0.870 1.00 30.92 C
ATOM 1775 O LYS A 113 26.581 38.511 -1.536 1.00 31.06 O
ATOM 1776 N ALA A 114 24.575 37.490 -1.308 1.00 33.51 N
35 ATOM 1778 CA ALA A 114 24.484 37.015 -2.669 1.00 34.75 C
ATOM 1780 CB ALA A 114 25.336 35.792 -2.859 1.00 35.33 C
ATOM 1784 C ALA A 114 23.016 36.693 -2.918 1.00 35.91 C
ATOM 1785 O ALA A 114 22.275 36.373 -1.973 1.00 37.33 O
ATOM 1786 O ACE B 0 45.942 19.784 14.579 1.00 39.31 O
40 ATOM 1787 C ACE B 0 45.727 19.383 15.830 1.00 38.58 C
ATOM 1788 CA ACE B 0 44.966 18.078 16.167 1.00 38.68 C
ATOM 1789 N SER B 1 45.689 20.569 16.659 1.00 19.77 N
ATOM 1791 CA SER B 1 45.431 20.583 18.122 1.00 17.98 C
ATOM 1793 CB SER B 1 45.842 21.915 18.761 1.00 18.61 C
45 ATOM 1796 OG SER B 1 44.965 22.977 18.387 1.00 16.99 O
ATOM 1798 C SER B 1 43.950 20.368 18.350 1.00 17.78 C
ATOM 1799 O SER B 1 43.169 20.531 17.414 1.00 17.20 O
ATOM 1802 N ALA B 2 43.575 19.905 19.539 1.00 16.87 N
ATOM 1804 CA ALA B 2 42.161 19.821 19.902 1.00 16.13 C
50 ATOM 1806 CB ALA B 2 41.991 19.439 21.370 1.00 16.68 C
ATOM 1810 C ALA B 2 41.405 21.112 19.611 1.00 15.41 C
ATOM 1811 O ALA B 2 40.278 21.088 19.118 1.00 14.56 O
ATOM 1812 N THR B 3 42.018 22.234 19.952 1.00 15.22 N
ATOM 1814 CA THR B 3 41.391 23.526 19.766 1.00 14.31 C
55 ATOM 1816 CB THR B 3 42.264 24.598 20.403 1.00 14.74 C
ATOM 1818 OG1 THR B 3 42.272 24.402 21.826 1.00 16.14 O
ATOM 1820 CG2 THR B 3 41.660 25.961 20.217 1.00 14.49 C
ATOM 1824 C THR B 3 41.194 23.813 18.295 1.00 13.68 C
ATOM 1825 O THR B 3 40.111 24.227 17.861 1.00 13.01 O
60 ATOM 1826 N SER B 4 42.231 23.568 17.505 1.00 12.92 N
ATOM 1828 CA SER B 4 42.114 23.823 16.074 1.00 12.63 C
ATOM 1830 CB SER B 4 43.466 23.637 15.389 1.00 13.31 C
ATOM 1833 OG SER B 4 43.349 23.779 13.980 1.00 15.34 O

ATOM 1835 C SER B 4 41.042 22.939 15.427 1.00 11.99 C
ATOM 1836 O SER B 4 40.232 23.408 14.613 1.00 11.15 O
ATOM 1837 N LEU B 5 41.045 21.652 15.755 1.00 11.62 N
5 ATOM 1839 CA LEU B 5 40.036 20.744 15.224 1.00 10.95 C
ATOM 1841 CB LEU B 5 40.253 19.326 15.755 1.00 11.58 C
ATOM 1844 CG LEU B 5 41.493 18.602 15.191 1.00 13.26 C
ATOM 1846 CD1 LEU B 5 41.671 17.274 15.878 1.00 14.30 C
ATOM 1850 CD2 LEU B 5 41.430 18.388 13.679 1.00 16.20 C
10 ATOM 1854 C LEU B 5 38.633 21.207 15.621 1.00 10.05 C
ATOM 1855 O LEU B 5 37.713 21.115 14.830 1.00 9.60 O
ATOM 1856 N THR B 6 38.482 21.669 16.858 1.00 9.83 N
ATOM 1858 CA THR B 6 37.187 22.108 17.359 1.00 10.01 C
ATOM 1860 CB THR B 6 37.300 22.622 18.794 1.00 9.92 C
ATOM 1862 OG1 THR B 6 37.622 21.536 19.681 1.00 10.43 O
15 ATOM 1864 CG2 THR B 6 35.965 23.168 19.289 1.00 9.67 C
ATOM 1868 C THR B 6 36.616 23.197 16.490 1.00 10.19 C
ATOM 1869 O THR B 6 35.478 23.121 16.047 1.00 10.13 O
ATOM 1870 N PHE B 7 37.416 24.217 16.232 1.00 10.95 N
20 ATOM 1872 CA PHE B 7 36.898 25.372 15.532 1.00 10.37 C
ATOM 1874 CB PHE B 7 37.576 26.643 16.024 1.00 10.33 C
ATOM 1877 CG PHE B 7 37.149 27.021 17.415 1.00 10.12 C
ATOM 1878 CD1 PHE B 7 35.833 27.366 17.673 1.00 10.88 C
ATOM 1880 CE1 PHE B 7 35.417 27.659 18.945 1.00 11.19 C
25 ATOM 1882 CZ PHE B 7 36.296 27.605 19.969 1.00 11.18 C
ATOM 1884 CE2 PHE B 7 37.605 27.245 19.734 1.00 12.59 C
ATOM 1886 CD2 PHE B 7 38.021 26.936 18.466 1.00 11.83 C
ATOM 1888 C PHE B 7 36.909 25.194 14.025 1.00 10.94 C
ATOM 1889 O PHE B 7 36.103 25.820 13.353 1.00 11.93 O
30 ATOM 1890 N GLN B 8 37.767 24.329 13.489 1.00 11.93 N
ATOM 1892 CA GLN B 8 37.647 24.010 12.067 1.00 11.34 C
ATOM 1894 CB GLN B 8 38.761 23.087 11.621 1.00 12.48 C
ATOM 1897 CG GLN B 8 40.113 23.720 11.528 1.00 14.22 C
ATOM 1900 CD GLN B 8 41.117 22.698 11.051 1.00 15.81 C
ATOM 1901 OE1 GLN B 8 42.036 22.331 11.781 1.00 19.91 O
35 ATOM 1902 NE2 GLN B 8 40.902 22.184 9.843 1.00 17.92 N
ATOM 1905 C GLN B 8 36.316 23.286 11.855 1.00 10.37 C
ATOM 1906 O GLN B 8 35.580 23.546 10.908 1.00 10.98 O
ATOM 1907 N LEU B 9 36.006 22.360 12.758 1.00 10.06 N
40 ATOM 1909 CA LEU B 9 34.757 21.608 12.648 1.00 9.71 C
ATOM 1911 CB LEU B 9 34.726 20.455 13.634 1.00 9.51 C
ATOM 1914 CG LEU B 9 33.493 19.574 13.606 1.00 10.41 C
ATOM 1916 CD1 LEU B 9 33.447 18.825 12.265 1.00 11.23 C
ATOM 1920 CD2 LEU B 9 33.561 18.587 14.753 1.00 9.36 C
45 ATOM 1924 C LEU B 9 33.552 22.498 12.880 1.00 9.33 C
ATOM 1925 O LEU B 9 32.566 22.409 12.160 1.00 10.21 O
ATOM 1926 N ALA B 10 33.618 23.376 13.874 1.00 9.78 N
ATOM 1928 CA ALA B 10 32.476 24.246 14.138 1.00 9.75 C
ATOM 1930 CB ALA B 10 32.727 25.091 15.353 1.00 10.03 C
50 ATOM 1934 C ALA B 10 32.145 25.126 12.919 1.00 9.57 C
ATOM 1935 O ALA B 10 30.982 25.275 12.554 1.00 8.63 O
ATOM 1936 N TYR B 11 33.155 25.688 12.269 1.00 9.75 N
ATOM 1938 CA TYR B 11 32.885 26.566 11.136 1.00 10.72 C
ATOM 1940 CB TYR B 11 34.159 27.237 10.688 1.00 10.48 C
55 ATOM 1943 CG TYR B 11 33.979 28.188 9.535 1.00 11.27 C
ATOM 1944 CD1 TYR B 11 34.664 27.988 8.352 1.00 11.30 C
ATOM 1946 CE1 TYR B 11 34.534 28.867 7.292 1.00 13.85 C
ATOM 1948 CZ TYR B 11 33.706 29.949 7.409 1.00 14.97 C
ATOM 1949 OH TYR B 11 33.579 30.827 6.350 1.00 16.32 O
60 ATOM 1951 CE2 TYR B 11 33.022 30.183 8.582 1.00 14.29 C
ATOM 1953 CD2 TYR B 11 33.159 29.300 9.640 1.00 12.05 C
ATOM 1955 C TYR B 11 32.250 25.801 9.987 1.00 11.09 C
ATOM 1956 O TYR B 11 31.380 26.310 9.272 1.00 11.19 O
ATOM 1957 N LEU B 12 32.672 24.556 9.823 1.00 12.21 N

ATOM 1959 CA LEU B 12 32.179 23.730 8.742 1.00 12.45 C
ATOM 1961 CB LEU B 12 33.187 22.614 8.470 1.00 12.95 C
ATOM 1964 CG LEU B 12 33.011 21.779 7.209 1.00 16.64 C
5 ATOM 1966 CD1 LEU B 12 32.907 22.662 5.962 1.00 17.27 C
ATOM 1970 CD2 LEU B 12 34.193 20.804 7.093 1.00 18.06 C
ATOM 1974 C LEU B 12 30.767 23.156 8.956 1.00 12.37 C
ATOM 1975 O LEU B 12 29.914 23.302 8.071 1.00 13.09 O
ATOM 1976 N VAL B 13 30.514 22.525 10.103 1.00 12.47 N
10 ATOM 1978 CA VAL B 13 29.256 21.805 10.335 1.00 12.51 C
ATOM 1980 CB VAL B 13 29.485 20.381 10.894 1.00 13.37 C
ATOM 1982 CG1 VAL B 13 30.492 19.620 10.042 1.00 15.30 C
ATOM 1986 CG2 VAL B 13 29.922 20.398 12.336 1.00 14.08 C
ATOM 1990 C VAL B 13 28.273 22.541 11.237 1.00 12.00 C
15 ATOM 1991 O VAL B 13 27.106 22.172 11.319 1.00 11.68 O
ATOM 1992 N LYS B 14 28.775 23.558 11.917 1.00 11.40 N
ATOM 1994 CA LYS B 14 27.991 24.459 12.764 1.00 11.19 C
ATOM 1996 CB LYS B 14 26.759 25.042 12.035 1.00 11.48 C
ATOM 1999 CG LYS B 14 27.039 25.761 10.731 1.00 11.14 C
20 ATOM 2002 CD LYS B 14 28.190 26.750 10.824 1.00 9.92 C
ATOM 2005 CE LYS B 14 28.422 27.540 9.526 1.00 10.31 C
ATOM 2008 NZ LYS B 14 29.602 28.448 9.653 1.00 12.24 N
ATOM 2012 C LYS B 14 27.549 23.850 14.104 1.00 10.98 C
ATOM 2013 O LYS B 14 27.795 24.432 15.165 1.00 10.55 O
25 ATOM 2014 N LYS B 15 26.914 22.684 14.069 1.00 10.86 N
ATOM 2016 CA LYS B 15 26.282 22.127 15.256 1.00 12.66 C
ATOM 2018 CB LYS B 15 24.753 22.337 15.149 1.00 13.78 C
ATOM 2021 CG LYS B 15 23.878 21.739 16.237 1.00 18.00 C
ATOM 2024 CD LYS B 15 22.382 22.146 16.068 1.00 23.19 C
30 ATOM 2027 CE LYS B 15 21.671 21.394 14.921 1.00 27.17 C
ATOM 2030 NZ LYS B 15 20.279 21.902 14.547 1.00 34.39 N
ATOM 2034 C LYS B 15 26.637 20.640 15.355 1.00 12.47 C
ATOM 2035 O LYS B 15 26.526 19.913 14.363 1.00 13.03 O
ATOM 2036 N ILE B 16 27.094 20.207 16.526 1.00 13.16 N
35 ATOM 2038 CA ILE B 16 27.368 18.784 16.760 1.00 12.11 C
ATOM 2040 CB ILE B 16 28.707 18.380 16.149 1.00 12.61 C
ATOM 2042 CG1 ILE B 16 28.660 16.894 15.756 1.00 13.09 C
ATOM 2045 CD1 ILE B 16 29.822 16.447 14.941 1.00 14.91 C
ATOM 2049 CG2 ILE B 16 29.831 18.704 17.105 1.00 12.04 C
40 ATOM 2053 C ILE B 16 27.276 18.487 18.258 1.00 12.09 C
ATOM 2054 O ILE B 16 27.516 19.360 19.098 1.00 11.30 O
ATOM 2055 N ASP B 17 26.903 17.257 18.587 1.00 11.37 N
ATOM 2057 CA ASP B 17 26.701 16.850 19.977 1.00 11.97 C
ATOM 2059 CB ASP B 17 25.238 17.060 20.347 1.00 12.19 C
45 ATOM 2062 CG ASP B 17 24.929 16.770 21.795 1.00 15.47 C
ATOM 2063 OD1 ASP B 17 25.834 16.488 22.602 1.00 15.71 O
ATOM 2064 OD2 ASP B 17 23.746 16.838 22.212 1.00 21.94 O
ATOM 2065 C ASP B 17 27.026 15.373 20.040 1.00 11.79 C
ATOM 2066 O ASP B 17 26.246 14.552 19.554 1.00 12.85 O
50 ATOM 2067 N PHE B 18 28.190 15.029 20.566 1.00 10.57 N
ATOM 2069 CA PHE B 18 28.552 13.620 20.686 1.00 10.47 C
ATOM 2071 CB PHE B 18 29.385 13.115 19.479 1.00 9.71 C
ATOM 2074 CG PHE B 18 30.728 13.797 19.316 1.00 9.88 C
ATOM 2075 CD1 PHE B 18 31.732 13.663 20.275 1.00 7.77 C
55 ATOM 2077 CE1 PHE B 18 32.936 14.318 20.131 1.00 9.85 C
ATOM 2079 CZ PHE B 18 33.172 15.094 19.013 1.00 10.47 C
ATOM 2081 CE2 PHE B 18 32.194 15.226 18.062 1.00 9.60 C
ATOM 2083 CD2 PHE B 18 30.979 14.584 18.211 1.00 9.21 C
ATOM 2085 C PHE B 18 29.281 13.324 21.983 1.00 9.72 C
60 ATOM 2086 O PHE B 18 29.760 14.220 22.691 1.00 10.09 O
ATOM 2087 N ASP B 19 29.326 12.041 22.306 1.00 9.08 N
ATOM 2089 CA ASP B 19 30.050 11.562 23.459 1.00 9.72 C
ATOM 2091 CB ASP B 19 29.193 11.549 24.716 1.00 9.54 C
ATOM 2094 CG ASP B 19 29.999 11.225 25.937 1.00 11.36 C

ATOM 2095 OD1 ASP B 19 29.498 11.408 27.093 1.00 13.80 O
ATOM 2096 OD2 ASP B 19 31.149 10.767 25.834 1.00 10.64 O
ATOM 2097 C ASP B 19 30.543 10.155 23.160 1.00 9.57 C
5 ATOM 2098 O ASP B 19 29.765 9.177 23.218 1.00 10.53 O
ATOM 2099 N TYR B 20 31.830 10.085 22.813 1.00 9.01 N
ATOM 2101 CA TYR B 20 32.505 8.831 22.518 1.00 8.11 C
ATOM 2103 CB TYR B 20 33.232 8.896 21.163 1.00 7.80 C
ATOM 2106 CG TYR B 20 32.292 8.800 19.966 1.00 7.18 C
10 ATOM 2107 CD1 TYR B 20 31.765 9.933 19.381 1.00 8.23 C
ATOM 2109 CE1 TYR B 20 30.897 9.849 18.286 1.00 8.63 C
ATOM 2111 CZ TYR B 20 30.570 8.623 17.777 1.00 8.76 C
ATOM 2112 OH TYR B 20 29.690 8.504 16.698 1.00 7.11 O
ATOM 2114 CE2 TYR B 20 31.081 7.492 18.358 1.00 7.59 C
ATOM 2116 CD2 TYR B 20 31.929 7.580 19.435 1.00 8.21 C
15 ATOM 2118 C TYR B 20 33.453 8.446 23.657 1.00 7.82 C
ATOM 2119 O TYR B 20 34.453 7.777 23.416 1.00 8.72 O
ATOM 2120 N THR B 21 33.128 8.834 24.892 1.00 8.34 N
ATOM 2122 CA THR B 21 33.897 8.365 26.046 1.00 8.81 C
ATOM 2124 CB THR B 21 33.320 8.922 27.334 1.00 9.96 C
20 ATOM 2126 OG1 THR B 21 33.372 10.363 27.299 1.00 10.43 O
ATOM 2128 CG2 THR B 21 34.222 8.512 28.491 1.00 9.86 C
ATOM 2132 C THR B 21 33.804 6.831 26.040 1.00 9.35 C
ATOM 2133 O THR B 21 32.692 6.291 26.011 1.00 9.22 O
ATOM 2134 N PRO B 22 34.922 6.111 26.025 1.00 9.19 N
25 ATOM 2135 CA PRO B 22 34.844 4.647 25.905 1.00 9.50 C
ATOM 2137 CB PRO B 22 36.209 4.280 25.352 1.00 9.82 C
ATOM 2140 CG PRO B 22 37.138 5.334 25.941 1.00 9.26 C
ATOM 2143 CD PRO B 22 36.320 6.589 26.015 1.00 9.34 C
30 ATOM 2146 C PRO B 22 34.616 3.930 27.227 1.00 10.16 C
ATOM 2147 O PRO B 22 35.520 3.898 28.070 1.00 10.91 O
ATOM 2148 N ASN B 23 33.413 3.394 27.413 1.00 10.40 N
ATOM 2150 CA ASN B 23 33.082 2.645 28.614 1.00 10.53 C
ATOM 2152 CB ASN B 23 31.680 3.014 29.089 1.00 11.14 C
ATOM 2155 CG ASN B 23 31.595 4.472 29.590 1.00 13.44 C
35 ATOM 2156 OD1 ASN B 23 31.816 4.721 30.763 1.00 19.39 O
ATOM 2157 ND2 ASN B 23 31.342 5.441 28.685 1.00 14.28 N
ATOM 2160 C ASN B 23 33.228 1.143 28.312 1.00 9.85 C
ATOM 2161 O ASN B 23 32.489 0.595 27.483 1.00 10.11 O
40 ATOM 2162 N TRP B 24 34.208 0.502 28.942 1.00 8.96 N
ATOM 2164 CA TRP B 24 34.524 -0.899 28.684 1.00 8.99 C
ATOM 2166 CB TRP B 24 36.032 -1.117 28.760 1.00 8.98 C
ATOM 2169 CG TRP B 24 36.799 -0.256 27.823 1.00 8.22 C
ATOM 2170 CD1 TRP B 24 37.375 0.965 28.116 1.00 9.52 C
ATOM 2172 NE1 TRP B 24 38.003 1.469 27.000 1.00 9.37 N
45 ATOM 2174 CE2 TRP B 24 37.860 0.574 25.967 1.00 9.60 C
ATOM 2175 CD2 TRP B 24 37.099 -0.517 26.446 1.00 9.21 C
ATOM 2176 CE3 TRP B 24 36.824 -1.577 25.560 1.00 9.09 C
ATOM 2178 CZ3 TRP B 24 37.292 -1.502 24.264 1.00 9.03 C
50 ATOM 2180 CH2 TRP B 24 38.045 -0.414 23.829 1.00 7.76 C
ATOM 2182 CZ2 TRP B 24 38.337 0.636 24.661 1.00 8.73 C
ATOM 2184 C TRP B 24 33.806 -1.771 29.715 1.00 10.09 C
ATOM 2185 O TRP B 24 34.024 -1.610 30.922 1.00 11.35 O
ATOM 2186 N GLY B 25 32.931 -2.655 29.234 1.00 10.43 N
60 ATOM 2188 CA GLY B 25 32.143 -3.516 30.098 1.00 9.95 C
ATOM 2191 C GLY B 25 32.749 -4.894 30.176 1.00 10.10 C
ATOM 2192 O GLY B 25 33.220 -5.444 29.184 1.00 10.44 O
ATOM 2193 N ARG B 26 32.721 -5.470 31.372 1.00 9.91 N
ATOM 2195 CA ARG B 26 33.393 -6.738 31.594 1.00 10.74 C
ATOM 2197 CB ARG B 26 34.185 -6.692 32.897 1.00 11.28 C
ATOM 2200 CG ARG B 26 35.418 -5.792 32.764 1.00 14.61 C
ATOM 2203 CD ARG B 26 36.168 -5.505 34.025 1.00 18.47 C
ATOM 2206 NE ARG B 26 37.353 -4.694 33.713 1.00 22.81 N
ATOM 2208 CZ ARG B 26 38.526 -5.167 33.274 1.00 20.92 C

ATOM 2209 NH1 ARG B 26 38.730 -6.471 33.093 1.00 16.47 N
ATOM 2212 NH2 ARG B 26 39.522 -4.318 33.028 1.00 21.83 N
ATOM 2215 C ARG B 26 32.431 -7.898 31.604 1.00 11.12 C
5 ATOM 2216 O ARG B 26 31.227 -7.721 31.802 1.00 11.55 O
ATOM 2217 N GLY B 27 32.990 -9.082 31.405 1.00 10.76 N
ATOM 2219 CA GLY B 27 32.203 -10.305 31.337 1.00 11.53 C
ATOM 2222 C GLY B 27 32.382 -11.170 32.553 1.00 12.49 C
ATOM 2223 O GLY B 27 32.588 -10.677 33.664 1.00 11.38 O
10 ATOM 2224 N THR B 28 32.285 -12.468 32.308 1.00 14.02 N
ATOM 2226 CA THR B 28 32.361 -13.494 33.325 1.00 14.82 C
ATOM 2228 CB THR B 28 30.965 -14.118 33.495 1.00 14.80 C
ATOM 2230 OG1 THR B 28 30.052 -13.151 34.032 1.00 15.92 O
ATOM 2232 CG2 THR B 28 30.974 -15.235 34.519 1.00 16.05 C
15 ATOM 2236 C THR B 28 33.327 -14.552 32.828 1.00 15.01 C
ATOM 2237 O THR B 28 33.037 -15.215 31.838 1.00 15.21 O
ATOM 2238 N PRO B 29 34.490 -14.700 33.454 1.00 16.30 N
ATOM 2239 CA PRO B 29 34.948 -13.877 34.569 1.00 16.04 C
ATOM 2241 CB PRO B 29 36.219 -14.575 35.028 1.00 16.47 C
20 ATOM 2244 CG PRO B 29 36.636 -15.376 33.917 1.00 16.57 C
ATOM 2247 CD PRO B 29 35.467 -15.724 33.083 1.00 16.58 C
ATOM 2250 C PRO B 29 35.286 -12.472 34.156 1.00 15.67 C
ATOM 2251 O PRO B 29 35.396 -12.161 32.977 1.00 14.52 O
ATOM 2252 N SER B 30 35.477 -11.643 35.164 1.00 15.56 N
25 ATOM 2254 CA SER B 30 35.592 -10.188 34.990 1.00 15.79 C
ATOM 2256 CB SER B 30 35.368 -9.479 36.338 1.00 16.72 C
ATOM 2259 OG SER B 30 36.454 -9.647 37.224 1.00 19.27 O
ATOM 2261 C SER B 30 36.886 -9.718 34.319 1.00 15.13 C
ATOM 2262 O SER B 30 37.028 -8.535 33.981 1.00 14.89 O
30 ATOM 2263 N SER B 31 37.813 -10.644 34.117 1.00 15.18 N
ATOM 2265 CA SER B 31 39.073 -10.365 33.451 1.00 14.92 C
ATOM 2267 CB SER B 31 40.078 -11.489 33.743 1.00 15.53 C
ATOM 2270 OG SER B 31 39.588 -12.751 33.330 1.00 16.71 O
ATOM 2272 C SER B 31 38.833 -10.220 31.958 1.00 14.13 C
35 ATOM 2273 O SER B 31 39.704 -9.755 31.247 1.00 14.11 O
ATOM 2274 N TYR B 32 37.655 -10.629 31.492 1.00 13.25 N
ATOM 2276 CA TYR B 32 37.263 -10.430 30.088 1.00 12.84 C
ATOM 2278 CB TYR B 32 36.386 -11.579 29.595 1.00 13.42 C
ATOM 2281 CG TYR B 32 37.194 -12.849 29.494 1.00 17.98 C
40 ATOM 2282 CD1 TYR B 32 37.301 -13.710 30.586 1.00 22.94 C
ATOM 2284 CE1 TYR B 32 38.065 -14.852 30.521 1.00 23.98 C
ATOM 2286 CZ TYR B 32 38.746 -15.143 29.354 1.00 25.27 C
ATOM 2287 OH TYR B 32 39.505 -16.288 29.289 1.00 27.54 O
ATOM 2289 CE2 TYR B 32 38.663 -14.298 28.266 1.00 23.63 C
45 ATOM 2291 CD2 TYR B 32 37.895 -13.159 28.344 1.00 21.29 C
ATOM 2293 C TYR B 32 36.533 -9.112 29.846 1.00 11.60 C
ATOM 2294 O TYR B 32 35.685 -8.695 30.647 1.00 10.60 O
ATOM 2295 N ILE B 33 36.880 -8.444 28.745 1.00 10.45 N
ATOM 2297 CA ILE B 33 36.165 -7.242 28.298 1.00 10.39 C
50 ATOM 2299 CB ILE B 33 37.144 -6.198 27.724 1.00 10.57 C
ATOM 2301 CG1 ILE B 33 38.031 -5.676 28.860 1.00 13.06 C
ATOM 2304 CD1 ILE B 33 39.008 -4.662 28.440 1.00 16.01 C
ATOM 2308 CG2 ILE B 33 36.395 -5.062 26.975 1.00 10.92 C
ATOM 2312 C ILE B 33 35.178 -7.715 27.237 1.00 9.65 C
55 ATOM 2313 O ILE B 33 35.595 -8.249 26.202 1.00 8.88 O
ATOM 2314 N ASP B 34 33.883 -7.580 27.498 1.00 9.91 N
ATOM 2316 CA ASP B 34 32.857 -8.063 26.583 1.00 9.11 C
ATOM 2318 CB ASP B 34 31.665 -8.615 27.367 1.00 9.19 C
ATOM 2321 CG ASP B 34 31.881 -10.030 27.892 1.00 11.22 C
60 ATOM 2322 OD1 ASP B 34 33.013 -10.576 27.882 1.00 10.96 O
ATOM 2323 OD2 ASP B 34 30.916 -10.660 28.362 1.00 11.64 O
ATOM 2324 C ASP B 34 32.306 -7.017 25.640 1.00 9.26 C
ATOM 2325 O ASP B 34 31.726 -7.362 24.616 1.00 8.27 O
ATOM 2326 N ASN B 35 32.465 -5.740 25.959 1.00 9.55 N

ATOM 2328 CA ASN B 35 31.791 -4.730 25.152 1.00 8.99 C
ATOM 2330 CB ASN B 35 30.278 -4.762 25.446 1.00 9.72 C
ATOM 2333 CG ASN B 35 29.970 -4.723 26.949 1.00 11.37 C
5 ATOM 2334 OD1 ASN B 35 29.559 -5.741 27.574 1.00 14.30 O
ATOM 2335 ND2 ASN B 35 30.186 -3.573 27.551 1.00 7.97 N
ATOM 2338 C ASN B 35 32.351 -3.341 25.400 1.00 9.17 C
ATOM 2339 O ASN B 35 33.129 -3.115 26.332 1.00 9.29 O
ATOM 2340 N LEU B 36 31.917 -2.413 24.552 1.00 9.41 N
10 ATOM 2342 CA LEU B 36 32.345 -1.026 24.581 1.00 9.12 C
ATOM 2344 CB LEU B 36 33.308 -0.779 23.414 1.00 8.17 C
ATOM 2347 CG LEU B 36 33.652 0.670 23.053 1.00 9.08 C
ATOM 2349 CD1 LEU B 36 34.294 1.387 24.199 1.00 9.44 C
ATOM 2353 CD2 LEU B 36 34.560 0.729 21.837 1.00 10.64 C
15 ATOM 2357 C LEU B 36 31.099 -0.186 24.369 1.00 9.10 C
ATOM 2358 O LEU B 36 30.382 -0.391 23.385 1.00 8.92 O
ATOM 2359 N THR B 37 30.824 0.737 25.279 1.00 9.13 N
ATOM 2361 CA THR B 37 29.653 1.596 25.151 1.00 8.93 C
ATOM 2363 CB THR B 37 28.725 1.447 26.372 1.00 9.51 C
20 ATOM 2365 OG1 THR B 37 28.238 0.095 26.458 1.00 10.29 O
ATOM 2367 CG2 THR B 37 27.474 2.316 26.234 1.00 10.22 C
ATOM 2371 C THR B 37 30.041 3.056 25.034 1.00 8.89 C
ATOM 2372 O THR B 37 30.857 3.557 25.814 1.00 8.97 O
ATOM 2373 N PHE B 38 29.450 3.724 24.042 1.00 7.97 N
ATOM 2375 CA PHE B 38 29.584 5.161 23.853 1.00 8.58 C
25 ATOM 2377 CB PHE B 38 29.827 5.456 22.386 1.00 8.85 C
ATOM 2380 CG PHE B 38 31.134 4.951 21.847 1.00 7.28 C
ATOM 2381 CD1 PHE B 38 32.340 5.237 22.482 1.00 7.91 C
ATOM 2383 CE1 PHE B 38 33.544 4.811 21.942 1.00 8.72 C
30 ATOM 2385 CZ PHE B 38 33.555 4.102 20.756 1.00 11.58 C
ATOM 2387 CE2 PHE B 38 32.366 3.817 20.120 1.00 9.53 C
ATOM 2389 CD2 PHE B 38 31.163 4.243 20.661 1.00 7.95 C
ATOM 2391 C PHE B 38 28.269 5.844 24.273 1.00 8.73 C
ATOM 2392 O PHE B 38 27.216 5.431 23.811 1.00 9.98 O
35 ATOM 2393 N PRO B 39 28.293 6.842 25.163 1.00 8.76 N
ATOM 2394 CA PRO B 39 27.036 7.460 25.636 1.00 8.86 C
ATOM 2396 CB PRO B 39 27.497 8.386 26.780 1.00 9.34 C
ATOM 2399 CG PRO B 39 28.785 7.866 27.199 1.00 9.35 C
40 ATOM 2402 CD PRO B 39 29.448 7.348 25.916 1.00 9.58 C
ATOM 2405 C PRO B 39 26.209 8.230 24.627 1.00 9.13 C
ATOM 2406 O PRO B 39 24.991 8.328 24.796 1.00 8.44 O
ATOM 2407 N LYS B 40 26.834 8.794 23.602 1.00 9.49 N
45 ATOM 2409 CA LYS B 40 26.061 9.548 22.618 1.00 9.43 C
ATOM 2411 CB LYS B 40 25.784 10.967 23.094 1.00 10.36 C
ATOM 2414 CG LYS B 40 24.760 11.685 22.232 1.00 12.43 C
ATOM 2417 CD LYS B 40 24.661 13.182 22.550 1.00 16.76 C
50 ATOM 2420 CE LYS B 40 24.030 13.456 23.916 1.00 22.56 C
ATOM 2423 NZ LYS B 40 24.148 14.904 24.336 1.00 28.45 N
ATOM 2427 C LYS B 40 26.748 9.529 21.265 1.00 9.14 C
ATOM 2428 O LYS B 40 27.597 10.355 20.962 1.00 9.57 O
55 ATOM 2429 N VAL B 41 26.393 8.544 20.458 1.00 9.12 N
ATOM 2431 CA VAL B 41 26.969 8.438 19.131 1.00 9.08 C
ATOM 2433 CB VAL B 41 26.967 6.970 18.603 1.00 9.12 C
ATOM 2435 CG1 VAL B 41 27.769 6.059 19.553 1.00 8.74 C
60 ATOM 2439 CG2 VAL B 41 25.556 6.453 18.410 1.00 8.61 C
ATOM 2443 C VAL B 41 26.243 9.323 18.136 1.00 9.87 C
ATOM 2444 O VAL B 41 25.107 9.759 18.350 1.00 9.30 O
ATOM 2445 N LEU B 42 26.907 9.582 17.022 1.00 10.23 N
ATOM 2447 CA LEU B 42 26.261 10.288 15.932 1.00 11.90 C
ATOM 2449 CB LEU B 42 27.303 10.820 14.948 1.00 11.82 C
65 ATOM 2452 CG LEU B 42 28.246 11.835 15.604 1.00 13.37 C
ATOM 2454 CD1 LEU B 42 29.484 12.076 14.765 1.00 17.49 C
ATOM 2458 CD2 LEU B 42 27.504 13.150 15.923 1.00 13.74 C
ATOM 2462 C LEU B 42 25.303 9.312 15.257 1.00 13.53 C

ATOM 2463 O LEU B 42 25.559 8.103 15.208 1.00 13.30 O
ATOM 2464 N THR B 43 24.203 9.824 14.717 1.00 16.10 N
ATOM 2466 CA THR B 43 23.223 8.949 14.082 1.00 17.45 C
ATOM 2468 CB THR B 43 21.953 8.828 14.935 1.00 17.82 C
5 ATOM 2470 OG1 THR B 43 21.431 10.123 15.252 1.00 20.64 O
ATOM 2472 CG2 THR B 43 22.241 8.193 16.296 1.00 18.56 C
ATOM 2476 C THR B 43 22.842 9.433 12.691 1.00 18.34 C
ATOM 2477 O THR B 43 21.866 8.947 12.117 1.00 18.70 O
ATOM 2478 N ASP B 44 23.614 10.367 12.148 1.00 18.36 N
10 ATOM 2480 CA ASP B 44 23.349 10.867 10.776 1.00 19.37 C
ATOM 2482 CB ASP B 44 24.158 12.130 10.514 1.00 18.75 C
ATOM 2485 CG ASP B 44 25.649 11.906 10.660 1.00 20.65 C
ATOM 2486 OD1 ASP B 44 26.435 12.599 9.975 1.00 22.24 O
ATOM 2487 OD2 ASP B 44 26.119 11.081 11.464 1.00 18.51 O
15 ATOM 2488 C ASP B 44 23.632 9.875 9.640 1.00 20.76 C
ATOM 2489 O ASP B 44 23.120 10.045 8.516 1.00 20.73 O
ATOM 2490 N LYS B 45 24.451 8.858 9.910 1.00 22.30 N
ATOM 2492 CA LYS B 45 24.845 7.850 8.930 1.00 22.65 C
ATOM 2494 CB LYS B 45 26.271 8.089 8.416 1.00 23.02 C
20 ATOM 2497 CG LYS B 45 26.515 9.467 7.807 1.00 25.19 C
ATOM 2500 CD LYS B 45 27.968 9.681 7.419 1.00 29.05 C
ATOM 2503 CE LYS B 45 28.158 10.993 6.672 1.00 32.51 C
ATOM 2506 NZ LYS B 45 29.514 11.592 6.878 1.00 36.79 N
ATOM 2510 C LYS B 45 24.790 6.500 9.640 1.00 23.32 C
25 ATOM 2511 O LYS B 45 24.775 6.441 10.878 1.00 23.05 O
ATOM 2512 N LYS B 46 24.771 5.425 8.856 1.00 24.20 N
ATOM 2514 CA LYS B 46 24.712 4.075 9.398 1.00 23.77 C
ATOM 2516 CB LYS B 46 24.033 3.132 8.406 1.00 23.95 C
ATOM 2519 CG LYS B 46 22.685 3.632 7.903 1.00 24.89 C
30 ATOM 2522 CD LYS B 46 22.803 4.957 7.139 1.00 24.88 C
ATOM 2525 CE LYS B 46 23.693 4.858 5.919 1.00 24.51 C
ATOM 2528 NZ LYS B 46 24.316 6.162 5.572 1.00 20.23 N
ATOM 2532 C LYS B 46 26.127 3.598 9.655 1.00 22.13 C
ATOM 2533 O LYS B 46 26.717 2.916 8.828 1.00 23.19 O
35 ATOM 2534 N TYR B 47 26.678 3.932 10.814 1.00 21.82 N
ATOM 2536 CA TYR B 47 28.065 3.580 11.084 1.00 17.30 C
ATOM 2538 CB TYR B 47 28.630 4.461 12.199 1.00 16.73 C
ATOM 2541 CG TYR B 47 28.584 5.926 11.880 1.00 14.44 C
ATOM 2542 CD1 TYR B 47 29.504 6.494 11.022 1.00 14.82 C
40 ATOM 2544 CE1 TYR B 47 29.475 7.842 10.736 1.00 15.44 C
ATOM 2546 CZ TYR B 47 28.502 8.629 11.305 1.00 14.96 C
ATOM 2547 OH TYR B 47 28.457 9.966 11.010 1.00 16.74 O
ATOM 2549 CE2 TYR B 47 27.572 8.078 12.165 1.00 15.51 C
ATOM 2551 CD2 TYR B 47 27.616 6.748 12.446 1.00 15.33 C
45 ATOM 2553 C TYR B 47 28.239 2.119 11.467 1.00 15.49 C
ATOM 2554 O TYR B 47 27.349 1.501 12.055 1.00 15.48 O
ATOM 2555 N SER B 48 29.376 1.550 11.086 1.00 12.97 N
ATOM 2557 CA SER B 48 29.731 0.219 11.553 1.00 12.31 C
ATOM 2559 CB SER B 48 29.852 -0.787 10.419 1.00 13.21 C
50 ATOM 2562 OG SER B 48 30.688 -0.272 9.425 1.00 17.27 O
ATOM 2564 C SER B 48 31.064 0.343 12.277 1.00 10.66 C
ATOM 2565 O SER B 48 31.687 1.401 12.295 1.00 9.38 O
ATOM 2566 N TYR B 49 31.478 -0.754 12.890 1.00 9.05 N
ATOM 2568 CA TYR B 49 32.700 -0.772 13.663 1.00 8.64 C
55 ATOM 2570 CB TYR B 49 32.345 -0.790 15.142 1.00 8.24 C
ATOM 2573 CG TYR B 49 31.547 0.419 15.574 1.00 7.93 C
ATOM 2574 CD1 TYR B 49 30.173 0.348 15.704 1.00 9.31 C
ATOM 2576 CE1 TYR B 49 29.444 1.443 16.089 1.00 10.10 C
ATOM 2578 CZ TYR B 49 30.076 2.635 16.361 1.00 9.43 C
60 ATOM 2579 OH TYR B 49 29.321 3.726 16.755 1.00 11.22 O
ATOM 2581 CE2 TYR B 49 31.442 2.741 16.222 1.00 7.22 C
ATOM 2583 CD2 TYR B 49 32.169 1.629 15.833 1.00 7.22 C
ATOM 2585 C TYR B 49 33.542 -1.997 13.338 1.00 8.84 C

ATOM 2586 O TYR B 49 33.035 -3.120 13.301 1.00 8.75 O
ATOM 2587 N ARG B 50 34.838 -1.764 13.149 1.00 8.80 N
ATOM 2589 CA ARG B 50 35.811 -2.821 12.915 1.00 8.50 C
ATOM 2591 CB ARG B 50 36.725 -2.427 11.771 1.00 8.52 C
5 ATOM 2594 CG ARG B 50 37.615 -3.545 11.308 1.00 9.29 C
ATOM 2597 CD ARG B 50 38.349 -3.220 10.048 1.00 9.53 C
ATOM 2600 NE ARG B 50 39.382 -2.205 10.191 1.00 8.80 N
ATOM 2602 CZ ARG B 50 40.631 -2.476 10.566 1.00 11.23 C
ATOM 2603 NH1 ARG B 50 40.986 -3.721 10.901 1.00 11.51 N
10 ATOM 2606 NH2 ARG B 50 41.533 -1.506 10.650 1.00 13.88 N
ATOM 2609 C ARG B 50 36.627 -2.987 14.186 1.00 8.77 C
ATOM 2610 O ARG B 50 37.063 -2.001 14.787 1.00 8.89 O
ATOM 2611 N VAL B 51 36.797 -4.230 14.609 1.00 9.25 N
ATOM 2613 CA VAL B 51 37.467 -4.543 15.860 1.00 9.05 C
15 ATOM 2615 CB VAL B 51 36.503 -5.312 16.778 1.00 9.51 C
ATOM 2617 CG1 VAL B 51 37.193 -5.808 18.029 1.00 10.94 C
ATOM 2621 CG2 VAL B 51 35.356 -4.425 17.179 1.00 9.48 C
ATOM 2625 C VAL B 51 38.729 -5.378 15.614 1.00 9.31 C
ATOM 2626 O VAL B 51 38.692 -6.344 14.865 1.00 9.58 O
20 ATOM 2627 N VAL B 52 39.827 -5.004 16.274 1.00 8.69 N
ATOM 2629 CA VAL B 52 41.136 -5.638 16.112 1.00 8.61 C
ATOM 2631 CB VAL B 52 42.132 -4.664 15.406 1.00 8.82 C
ATOM 2633 CG1 VAL B 52 43.432 -5.350 15.057 1.00 8.22 C
ATOM 2637 CG2 VAL B 52 41.503 -4.031 14.166 1.00 8.20 C
25 ATOM 2641 C VAL B 52 41.680 -6.010 17.490 1.00 8.96 C
ATOM 2642 O VAL B 52 41.759 -5.166 18.367 1.00 9.37 O
ATOM 2643 N VAL B 53 42.050 -7.276 17.677 1.00 8.28 N
ATOM 2645 CA VAL B 53 42.521 -7.758 18.973 1.00 9.11 C
ATOM 2647 CB VAL B 53 41.645 -8.918 19.482 1.00 9.88 C
30 ATOM 2649 CG1 VAL B 53 42.248 -9.531 20.746 1.00 10.11 C
ATOM 2653 CG2 VAL B 53 40.207 -8.420 19.731 1.00 10.75 C
ATOM 2657 C VAL B 53 43.965 -8.214 18.850 1.00 9.11 C
ATOM 2658 O VAL B 53 44.254 -9.170 18.105 1.00 9.06 O
ATOM 2659 N ASN B 54 44.873 -7.543 19.563 1.00 8.85 N
35 ATOM 2661 CA ASN B 54 46.310 -7.827 19.435 1.00 9.61 C
ATOM 2663 CB ASN B 54 46.676 -9.140 20.109 1.00 10.03 C
ATOM 2666 CG ASN B 54 47.031 -8.996 21.586 1.00 11.16 C
ATOM 2667 OD1 ASN B 54 47.247 -10.014 22.267 1.00 16.89 O
ATOM 2668 ND2 ASN B 54 47.126 -7.781 22.076 1.00 9.72 N
40 ATOM 2671 C ASN B 54 46.747 -7.870 17.956 1.00 10.26 C
ATOM 2672 O ASN B 54 47.522 -8.745 17.548 1.00 11.02 O
ATOM 2673 N GLY B 55 46.238 -6.928 17.168 1.00 10.54 N
ATOM 2675 CA GLY B 55 46.575 -6.793 15.760 1.00 9.95 C
ATOM 2678 C GLY B 55 45.844 -7.707 14.792 1.00 9.84 C
45 ATOM 2679 O GLY B 55 45.998 -7.522 13.579 1.00 9.89 O
ATOM 2680 N SER B 56 45.036 -8.629 15.310 1.00 9.14 N
ATOM 2682 CA SER B 56 44.226 -9.538 14.506 1.00 9.52 C
ATOM 2684 CB SER B 56 44.022 -10.867 15.235 1.00 10.16 C
ATOM 2687 OG SER B 56 43.162 -11.730 14.503 1.00 10.98 O
50 ATOM 2689 C SER B 56 42.858 -8.888 14.232 1.00 9.17 C
ATOM 2690 O SER B 56 42.065 -8.653 15.148 1.00 8.64 O
ATOM 2691 N ASP B 57 42.613 -8.558 12.976 1.00 9.04 N
ATOM 2693 CA ASP B 57 41.358 -7.950 12.530 1.00 8.46 C
ATOM 2695 CB ASP B 57 41.559 -7.526 11.067 1.00 8.57 C
55 ATOM 2698 CG ASP B 57 40.364 -6.842 10.457 1.00 9.39 C
ATOM 2699 OD1 ASP B 57 40.383 -6.708 9.193 1.00 9.52 O
ATOM 2700 OD2 ASP B 57 39.385 -6.414 11.106 1.00 9.56 O
ATOM 2701 C ASP B 57 40.201 -8.950 12.628 1.00 8.72 C
ATOM 2702 O ASP B 57 40.218 -10.003 11.966 1.00 8.92 O
60 ATOM 2703 N LEU B 58 39.217 -8.665 13.478 1.00 9.29 N
ATOM 2705 CA LEU B 58 38.021 -9.508 13.542 1.00 9.33 C
ATOM 2707 CB LEU B 58 37.508 -9.582 14.977 1.00 9.53 C
ATOM 2710 CG LEU B 58 38.564 -9.973 16.005 1.00 9.47 C

ATOM 2712 CD1 LEU B 58 37.925 -10.156 17.379 1.00 11.17 C
ATOM 2716 CD2 LEU B 58 39.325 -11.242 15.604 1.00 11.86 C
ATOM 2720 C LEU B 58 36.897 -9.037 12.608 1.00 9.41 C
ATOM 2721 O LEU B 58 35.797 -9.607 12.608 1.00 10.79 O
5 ATOM 2722 N GLY B 59 37.166 -8.006 11.826 1.00 9.53 N
ATOM 2724 CA GLY B 59 36.245 -7.517 10.815 1.00 9.73 C
ATOM 2727 C GLY B 59 35.209 -6.570 11.375 1.00 9.94 C
ATOM 2728 O GLY B 59 35.355 -6.046 12.482 1.00 9.32 O
ATOM 2729 N VAL B 60 34.133 -6.407 10.614 1.00 10.86 N
10 ATOM 2731 CA VAL B 60 33.165 -5.356 10.840 1.00 11.57 C
ATOM 2733 CB VAL B 60 33.048 -4.476 9.571 1.00 11.80 C
ATOM 2735 CG1 VAL B 60 32.330 -3.170 9.845 1.00 13.91 C
ATOM 2739 CG2 VAL B 60 32.361 -5.227 8.443 1.00 13.46 C
ATOM 2743 C VAL B 60 31.806 -5.894 11.230 1.00 11.41 C
15 ATOM 2744 O VAL B 60 31.409 -7.016 10.849 1.00 11.80 O
ATOM 2745 N GLU B 61 31.090 -5.084 11.998 1.00 10.41 N
ATOM 2747 CA GLU B 61 29.728 -5.416 12.391 1.00 11.68 C
ATOM 2749 CB GLU B 61 29.701 -6.352 13.600 1.00 11.99 C
ATOM 2752 CG GLU B 61 28.316 -6.803 14.051 1.00 16.37 C
20 ATOM 2755 CD GLU B 61 27.469 -7.353 12.931 1.00 18.62 C
ATOM 2756 OE1 GLU B 61 26.499 -6.673 12.533 1.00 19.03 O
ATOM 2757 OE2 GLU B 61 27.791 -8.452 12.418 1.00 20.11 O
ATOM 2758 C GLU B 61 28.994 -4.105 12.643 1.00 12.02 C
ATOM 2759 O GLU B 61 29.616 -3.087 12.944 1.00 10.24 O
25 ATOM 2760 N SER B 62 27.673 -4.129 12.540 1.00 13.34 N
ATOM 2762 CA SER B 62 26.908 -2.919 12.741 1.00 13.52 C
ATOM 2764 CB SER B 62 26.526 -2.289 11.407 1.00 14.00 C
ATOM 2767 OG SER B 62 25.717 -3.176 10.647 1.00 13.96 O
ATOM 2769 C SER B 62 25.631 -3.142 13.513 1.00 13.46 C
30 ATOM 2770 O SER B 62 24.940 -2.159 13.807 1.00 14.34 O
ATOM 2771 N ASN B 63 25.333 -4.389 13.869 1.00 12.74 N
ATOM 2773 CA ASN B 63 24.037 -4.692 14.474 1.00 14.23 C
ATOM 2775 CB ASN B 63 23.557 -6.123 14.156 1.00 15.00 C
ATOM 2778 CG ASN B 63 22.193 -6.441 14.798 1.00 16.84 C
35 ATOM 2779 OD1 ASN B 63 21.441 -5.531 15.129 1.00 21.06 O
ATOM 2780 ND2 ASN B 63 21.895 -7.727 15.010 1.00 21.14 N
ATOM 2783 C ASN B 63 24.089 -4.438 15.971 1.00 13.99 C
ATOM 2784 O ASN B 63 24.093 -5.385 16.770 1.00 13.96 O
ATOM 2785 N PHE B 64 24.126 -3.143 16.308 1.00 13.92 N
40 ATOM 2787 CA PHE B 64 24.126 -2.622 17.673 1.00 12.95 C
ATOM 2789 CB PHE B 64 25.518 -2.121 18.080 1.00 12.24 C
ATOM 2792 CG PHE B 64 26.621 -3.056 17.698 1.00 10.08 C
ATOM 2793 CD1 PHE B 64 26.707 -4.313 18.267 1.00 9.82 C
ATOM 2795 CE1 PHE B 64 27.717 -5.176 17.900 1.00 10.20 C
45 ATOM 2797 CZ PHE B 64 28.622 -4.784 16.947 1.00 10.37 C
ATOM 2799 CE2 PHE B 64 28.533 -3.542 16.383 1.00 10.15 C
ATOM 2801 CD2 PHE B 64 27.547 -2.689 16.752 1.00 9.91 C
ATOM 2803 C PHE B 64 23.135 -1.462 17.777 1.00 12.85 C
ATOM 2804 O PHE B 64 23.282 -0.433 17.128 1.00 12.07 O
50 ATOM 2805 N ALA B 65 22.124 -1.637 18.613 1.00 13.52 N
ATOM 2807 CA ALA B 65 21.038 -0.677 18.719 1.00 13.11 C
ATOM 2809 CB ALA B 65 19.990 -1.165 19.701 1.00 13.88 C
ATOM 2813 C ALA B 65 21.554 0.641 19.215 1.00 13.59 C
ATOM 2814 O ALA B 65 22.471 0.668 20.026 1.00 13.52 O
55 ATOM 2815 N VAL B 66 20.985 1.727 18.716 1.00 13.44 N
ATOM 2817 CA VAL B 66 21.223 3.015 19.337 1.00 13.23 C
ATOM 2819 CB VAL B 66 21.412 4.126 18.322 1.00 13.46 C
ATOM 2821 CG1 VAL B 66 21.554 5.453 19.053 1.00 14.25 C
ATOM 2825 CG2 VAL B 66 22.634 3.839 17.457 1.00 12.99 C
60 ATOM 2829 C VAL B 66 20.007 3.276 20.232 1.00 13.98 C
ATOM 2830 O VAL B 66 18.860 3.239 19.765 1.00 14.47 O
ATOM 2831 N THR B 67 20.241 3.517 21.512 1.00 13.83 N
ATOM 2833 CA THR B 67 19.134 3.762 22.438 1.00 15.29 C

ATOM 2835 CB THR B 67 19.577 3.436 23.873 1.00 15.38 C
ATOM 2837 OG1 THR B 67 20.710 4.246 24.225 1.00 13.23 O
ATOM 2839 CG2 THR B 67 20.111 2.014 23.990 1.00 15.32 C
5 ATOM 2843 C THR B 67 18.644 5.220 22.269 1.00 16.76 C
ATOM 2844 O THR B 67 19.300 6.037 21.642 1.00 16.95 O
ATOM 2845 N PRO B 68 17.459 5.547 22.766 1.00 20.60 N
ATOM 2846 CA PRO B 68 16.921 6.907 22.635 1.00 20.58 C
ATOM 2848 CB PRO B 68 15.605 6.822 23.400 1.00 21.01 C
ATOM 2851 CG PRO B 68 15.218 5.414 23.278 1.00 21.24 C
10 ATOM 2854 CD PRO B 68 16.507 4.646 23.423 1.00 19.89 C
ATOM 2857 C PRO B 68 17.814 8.029 23.188 1.00 21.33 C
ATOM 2858 O PRO B 68 17.759 9.162 22.687 1.00 21.25 O
ATOM 2859 N SER B 69 18.616 7.701 24.199 1.00 22.75 N
ATOM 2861 CA SER B 69 19.587 8.608 24.826 1.00 21.20 C
15 ATOM 2863 CB SER B 69 20.082 7.995 26.138 1.00 21.30 C
ATOM 2866 OG SER B 69 20.644 6.705 25.953 1.00 22.43 O
ATOM 2868 C SER B 69 20.769 8.877 23.909 1.00 20.23 C
ATOM 2869 O SER B 69 21.553 9.820 24.111 1.00 20.71 O
ATOM 2870 N GLY B 70 20.897 8.016 22.908 1.00 18.48 N
20 ATOM 2872 CA GLY B 70 21.923 8.132 21.904 1.00 15.60 C
ATOM 2875 C GLY B 70 23.049 7.151 22.179 1.00 13.15 C
ATOM 2876 O GLY B 70 24.061 7.186 21.524 1.00 12.69 O
ATOM 2877 N GLY B 71 22.876 6.276 23.162 1.00 10.24 N
ATOM 2879 CA GLY B 71 23.942 5.354 23.525 1.00 10.32 C
25 ATOM 2882 C GLY B 71 24.044 4.180 22.570 1.00 10.01 C
ATOM 2883 O GLY B 71 23.067 3.830 21.893 1.00 9.06 O
ATOM 2884 N GLN B 72 25.221 3.567 22.513 1.00 9.21 N
ATOM 2886 CA GLN B 72 25.427 2.402 21.654 1.00 9.07 C
ATOM 2888 CB GLN B 72 25.841 2.818 20.242 1.00 9.26 C
30 ATOM 2891 CG GLN B 72 25.762 1.671 19.241 1.00 10.65 C
ATOM 2894 CD GLN B 72 25.989 2.078 17.779 1.00 11.82 C
ATOM 2895 OE1 GLN B 72 25.420 1.465 16.838 1.00 14.64 O
ATOM 2896 NE2 GLN B 72 26.832 3.043 17.578 1.00 8.39 N
ATOM 2899 C GLN B 72 26.482 1.500 22.251 1.00 8.92 C
35 ATOM 2900 O GLN B 72 27.562 1.958 22.606 1.00 9.57 O
ATOM 2901 N THR B 73 26.154 0.216 22.363 1.00 8.86 N
ATOM 2903 CA THR B 73 27.059 -0.781 22.906 1.00 9.09 C
ATOM 2905 CB THR B 73 26.344 -1.572 24.005 1.00 9.39 C
ATOM 2907 OG1 THR B 73 25.995 -0.692 25.072 1.00 9.52 O
40 ATOM 2909 CG2 THR B 73 27.270 -2.612 24.627 1.00 10.72 C
ATOM 2913 C THR B 73 27.509 -1.748 21.809 1.00 9.41 C
ATOM 2914 O THR B 73 26.680 -2.437 21.200 1.00 10.31 O
ATOM 2915 N ILE B 74 28.812 -1.757 21.563 1.00 9.66 N
ATOM 2917 CA ILE B 74 29.458 -2.662 20.630 1.00 9.26 C
45 ATOM 2919 CB ILE B 74 30.716 -2.000 20.065 1.00 9.30 C
ATOM 2921 CG1 ILE B 74 30.322 -0.764 19.234 1.00 10.63 C
ATOM 2924 CD1 ILE B 74 31.405 0.279 19.094 1.00 13.52 C
ATOM 2928 CG2 ILE B 74 31.494 -2.996 19.212 1.00 9.71 C
ATOM 2932 C ILE B 74 29.779 -3.915 21.441 1.00 8.04 C
50 ATOM 2933 O ILE B 74 30.553 -3.873 22.389 1.00 8.84 O
ATOM 2934 N ASN B 75 29.117 -5.012 21.103 1.00 8.10 N
ATOM 2936 CA ASN B 75 29.257 -6.266 21.819 1.00 7.89 C
ATOM 2938 CB ASN B 75 27.908 -6.975 21.781 1.00 8.13 C
ATOM 2941 CG ASN B 75 27.942 -8.323 22.426 1.00 8.20 C
55 ATOM 2942 OD1 ASN B 75 28.856 -8.662 23.195 1.00 7.74 O
ATOM 2943 ND2 ASN B 75 26.946 -9.120 22.108 1.00 11.67 N
ATOM 2946 C ASN B 75 30.324 -7.129 21.149 1.00 8.35 C
ATOM 2947 O ASN B 75 30.128 -7.635 20.029 1.00 7.57 O
ATOM 2948 N PHE B 76 31.449 -7.309 21.831 1.00 8.93 N
60 ATOM 2950 CA PHE B 76 32.572 -8.022 21.228 1.00 9.24 C
ATOM 2952 CB PHE B 76 33.846 -7.826 22.054 1.00 9.38 C
ATOM 2955 CG PHE B 76 34.319 -6.391 22.076 1.00 9.36 C
ATOM 2956 CD1 PHE B 76 34.307 -5.628 20.921 1.00 10.05 C

ATOM 2958 CE1 PHE B 76 34.715 -4.318 20.939 1.00 9.26 C
ATOM 2960 CZ PHE B 76 35.131 -3.763 22.112 1.00 8.99 C
ATOM 2962 CE2 PHE B 76 35.143 -4.500 23.259 1.00 10.57 C
ATOM 2964 CD2 PHE B 76 34.745 -5.806 23.246 1.00 10.62 C
5 ATOM 2966 C PHE B 76 32.260 -9.502 20.999 1.00 9.01 C
ATOM 2967 O PHE B 76 32.893 -10.149 20.169 1.00 9.14 O
ATOM 2968 N LEU B 77 31.268 -10.038 21.708 1.00 9.74 N
ATOM 2970 CA LEU B 77 30.894 -11.444 21.525 1.00 9.62 C
ATOM 2972 CB LEU B 77 29.844 -11.840 22.565 1.00 9.60 C
10 ATOM 2975 CG LEU B 77 30.361 -12.157 23.981 1.00 11.85 C
ATOM 2977 CD1 LEU B 77 31.102 -11.029 24.640 1.00 13.22 C
ATOM 2981 CD2 LEU B 77 29.174 -12.593 24.854 1.00 12.68 C
ATOM 2985 C LEU B 77 30.400 -11.713 20.077 1.00 9.32 C
ATOM 2986 O LEU B 77 30.481 -12.843 19.574 1.00 10.46 O
15 ATOM 2987 N GLN B 78 29.907 -10.671 19.415 1.00 9.10 N
ATOM 2989 CA GLN B 78 29.450 -10.748 18.032 1.00 10.10 C
ATOM 2991 CB GLN B 78 28.517 -9.569 17.697 1.00 10.43 C
ATOM 2994 CG GLN B 78 27.143 -9.734 18.379 1.00 9.66 C
ATOM 2997 CD GLN B 78 26.224 -8.538 18.295 1.00 11.71 C
20 ATOM 2998 OE1 GLN B 78 25.803 -8.019 19.329 1.00 11.16 O
ATOM 2999 NE2 GLN B 78 25.871 -8.113 17.071 1.00 13.17 N
ATOM 3002 C GLN B 78 30.612 -10.816 17.042 1.00 11.05 C
ATOM 3003 O GLN B 78 30.379 -11.128 15.859 1.00 13.23 O
ATOM 3004 N TYR B 79 31.826 -10.506 17.500 1.00 10.96 N
25 ATOM 3006 CA TYR B 79 33.026 -10.570 16.654 1.00 12.02 C
ATOM 3008 CB TYR B 79 33.915 -9.339 16.842 1.00 11.81 C
ATOM 3011 CG TYR B 79 33.345 -8.005 16.481 1.00 10.03 C
ATOM 3012 CD1 TYR B 79 33.681 -7.372 15.280 1.00 8.25 C
ATOM 3014 CE1 TYR B 79 33.169 -6.116 14.965 1.00 8.39 C
30 ATOM 3016 CZ TYR B 79 32.322 -5.483 15.842 1.00 8.21 C
ATOM 3017 OH TYR B 79 31.827 -4.250 15.505 1.00 8.87 O
ATOM 3019 CE2 TYR B 79 31.972 -6.104 17.033 1.00 10.02 C
ATOM 3021 CD2 TYR B 79 32.487 -7.347 17.345 1.00 9.93 C
ATOM 3023 C TYR B 79 33.940 -11.728 16.985 1.00 13.56 C
35 ATOM 3024 O TYR B 79 34.689 -12.190 16.120 1.00 13.49 O
ATOM 3025 N ASN B 80 33.919 -12.162 18.242 1.00 15.17 N
ATOM 3027 CA ASN B 80 34.925 -13.076 18.751 1.00 14.48 C
ATOM 3029 CB ASN B 80 35.582 -12.444 19.978 1.00 14.14 C
ATOM 3032 CG ASN B 80 36.890 -13.105 20.361 1.00 14.62 C
40 ATOM 3033 OD1 ASN B 80 37.651 -13.558 19.509 1.00 16.67 O
ATOM 3034 ND2 ASN B 80 37.153 -13.163 21.664 1.00 13.88 N
ATOM 3037 C ASN B 80 34.352 -14.437 19.084 1.00 14.66 C
ATOM 3038 O ASN B 80 34.712 -15.056 20.083 1.00 13.88 O
ATOM 3039 N LYS B 81 33.412 -14.879 18.257 1.00 15.51 N
45 ATOM 3041 CA LYS B 81 32.859 -16.233 18.368 1.00 16.46 C
ATOM 3043 CB LYS B 81 33.943 -17.263 17.992 1.00 16.91 C
ATOM 3046 CG LYS B 81 34.644 -16.962 16.663 1.00 20.41 C
ATOM 3049 CD LYS B 81 35.616 -18.076 16.175 1.00 26.52 C
ATOM 3052 CE LYS B 81 36.392 -18.798 17.293 1.00 31.18 C
50 ATOM 3055 NZ LYS B 81 37.525 -19.720 16.822 1.00 38.55 N
ATOM 3059 C LYS B 81 32.216 -16.559 19.735 1.00 15.91 C
ATOM 3060 O LYS B 81 32.322 -17.678 20.227 1.00 16.16 O
ATOM 3061 N GLY B 82 31.522 -15.575 20.307 1.00 15.03 N
ATOM 3063 CA GLY B 82 30.735 -15.736 21.512 1.00 15.26 C
55 ATOM 3066 C GLY B 82 31.492 -15.553 22.800 1.00 15.69 C
ATOM 3067 O GLY B 82 30.960 -15.833 23.857 1.00 15.34 O
ATOM 3068 N TYR B 83 32.721 -15.052 22.708 1.00 16.90 N
ATOM 3070 CA TYR B 83 33.550 -14.806 23.873 1.00 17.19 C
ATOM 3072 CB TYR B 83 34.815 -15.667 23.808 1.00 18.20 C
60 ATOM 3075 CG TYR B 83 34.583 -17.155 23.934 1.00 23.38 C
ATOM 3076 CD1 TYR B 83 34.448 -17.745 25.181 1.00 28.89 C
ATOM 3078 CE1 TYR B 83 34.239 -19.105 25.310 1.00 31.05 C
ATOM 3080 CZ TYR B 83 34.170 -19.896 24.184 1.00 32.68 C

ATOM 3081 OH TYR B 83 33.962 -21.259 24.329 1.00 36.36 O
ATOM 3083 CE2 TYR B 83 34.305 -19.340 22.930 1.00 30.78 C
ATOM 3085 CD2 TYR B 83 34.506 -17.972 22.810 1.00 28.62 C
5 ATOM 3087 C TYR B 83 34.006 -13.355 23.925 1.00 16.15 C
ATOM 3088 O TYR B 83 34.169 -12.715 22.894 1.00 15.94 O
ATOM 3089 N GLY B 84 34.190 -12.828 25.134 1.00 15.91 N
ATOM 3091 CA GLY B 84 34.842 -11.539 25.278 1.00 14.80 C
ATOM 3094 C GLY B 84 36.359 -11.675 25.047 1.00 13.96 C
ATOM 3095 O GLY B 84 36.882 -12.737 24.675 1.00 14.24 O
10 ATOM 3096 N VAL B 85 37.071 -10.586 25.311 1.00 11.64 N
ATOM 3098 CA VAL B 85 38.497 -10.478 25.027 1.00 12.19 C
ATOM 3100 CB VAL B 85 38.761 -9.214 24.159 1.00 11.76 C
ATOM 3102 CG1 VAL B 85 40.254 -9.019 23.892 1.00 12.27 C
ATOM 3106 CG2 VAL B 85 37.970 -9.236 22.852 1.00 12.61 C
15 ATOM 3110 C VAL B 85 39.258 -10.315 26.329 1.00 12.06 C
ATOM 3111 O VAL B 85 38.954 -9.435 27.133 1.00 11.39 O
ATOM 3112 N ALA B 86 40.263 -11.154 26.554 1.00 11.94 N
ATOM 3114 CA ALA B 86 41.077 -11.026 27.752 1.00 12.43 C
ATOM 3116 CB ALA B 86 42.221 -12.031 27.709 1.00 12.46 C
20 ATOM 3120 C ALA B 86 41.630 -9.606 27.895 1.00 12.58 C
ATOM 3121 O ALA B 86 42.145 -9.034 26.921 1.00 11.12 O
ATOM 3122 N ASP B 87 41.542 -9.046 29.101 1.00 12.96 N
ATOM 3124 CA ASP B 87 41.977 -7.664 29.319 1.00 13.26 C
ATOM 3126 CB ASP B 87 41.413 -7.038 30.599 1.00 12.94 C
25 ATOM 3129 CG ASP B 87 41.973 -7.621 31.863 1.00 15.55 C
ATOM 3130 OD1 ASP B 87 42.925 -8.435 31.811 1.00 16.54 O
ATOM 3131 OD2 ASP B 87 41.478 -7.304 32.971 1.00 17.64 O
ATOM 3132 C ASP B 87 43.473 -7.446 29.177 1.00 13.14 C
ATOM 3133 O ASP B 87 43.923 -6.303 29.211 1.00 13.88 O
30 ATOM 3134 N THR B 88 44.222 -8.529 28.986 1.00 13.35 N
ATOM 3136 CA THR B 88 45.648 -8.426 28.770 1.00 13.89 C
ATOM 3138 CB THR B 88 46.376 -9.702 29.223 1.00 13.97 C
ATOM 3140 OG1 THR B 88 45.720 -10.853 28.692 1.00 14.23 O
ATOM 3142 CG2 THR B 88 46.312 -9.865 30.728 1.00 15.70 C
35 ATOM 3146 C THR B 88 45.972 -8.179 27.308 1.00 14.14 C
ATOM 3147 O THR B 88 47.138 -7.960 26.978 1.00 16.23 O
ATOM 3148 N LYS B 89 44.961 -8.217 26.444 1.00 13.28 N
ATOM 3150 CA LYS B 89 45.163 -7.962 25.021 1.00 13.04 C
ATOM 3152 CB LYS B 89 44.317 -8.922 24.185 1.00 13.74 C
40 ATOM 3155 CG LYS B 89 44.531 -10.371 24.562 1.00 15.15 C
ATOM 3158 CD LYS B 89 43.821 -11.309 23.612 1.00 18.37 C
ATOM 3161 CE LYS B 89 43.980 -12.771 24.006 1.00 20.95 C
ATOM 3164 NZ LYS B 89 43.412 -13.640 22.933 1.00 24.82 N
ATOM 3168 C LYS B 89 44.798 -6.531 24.667 1.00 12.47 C
45 ATOM 3169 O LYS B 89 44.022 -5.884 25.369 1.00 12.82 O
ATOM 3170 N THR B 90 45.377 -6.023 23.589 1.00 11.85 N
ATOM 3172 CA THR B 90 45.017 -4.714 23.072 1.00 11.57 C
ATOM 3174 CB THR B 90 46.177 -4.184 22.273 1.00 11.83 C
ATOM 3176 OG1 THR B 90 47.280 -3.912 23.164 1.00 14.04 O
50 ATOM 3178 CG2 THR B 90 45.838 -2.872 21.626 1.00 13.14 C
ATOM 3182 C THR B 90 43.780 -4.827 22.180 1.00 11.03 C
ATOM 3183 O THR B 90 43.684 -5.748 21.355 1.00 10.60 O
ATOM 3184 N ILE B 91 42.839 -3.893 22.344 1.00 10.28 N
ATOM 3186 CA ILE B 91 41.640 -3.871 21.530 1.00 10.28 C
55 ATOM 3188 CB ILE B 91 40.361 -4.011 22.361 1.00 10.29 C
ATOM 3190 CG1 ILE B 91 40.407 -5.261 23.238 1.00 11.66 C
ATOM 3193 CD1 ILE B 91 39.298 -5.354 24.285 1.00 13.60 C
ATOM 3197 CG2 ILE B 91 39.141 -4.060 21.408 1.00 10.59 C
ATOM 3201 C ILE B 91 41.597 -2.536 20.815 1.00 10.62 C
60 ATOM 3202 O ILE B 91 41.700 -1.489 21.442 1.00 10.66 O
ATOM 3203 N GLN B 92 41.490 -2.563 19.497 1.00 10.49 N
ATOM 3205 CA GLN B 92 41.313 -1.326 18.764 1.00 10.71 C
ATOM 3207 CB GLN B 92 42.410 -1.146 17.719 1.00 11.65 C

ATOM 3210 CG GLN B 92 43.778 -0.942 18.282 1.00 15.30 C
ATOM 3213 CD GLN B 92 44.809 -1.227 17.215 1.00 21.75 C
ATOM 3214 OE1 GLN B 92 45.030 -2.382 16.855 1.00 23.06 O
ATOM 3215 NE2 GLN B 92 45.388 -0.176 16.654 1.00 29.53 N
5 ATOM 3218 C GLN B 92 39.964 -1.384 18.063 1.00 9.76 C
ATOM 3219 O GLN B 92 39.599 -2.416 17.499 1.00 9.52 O
ATOM 3220 N VAL B 93 39.225 -0.286 18.109 1.00 8.49 N
ATOM 3222 CA VAL B 93 37.922 -0.204 17.447 1.00 8.46 C
ATOM 3224 CB VAL B 93 36.754 -0.031 18.452 1.00 8.40 C
10 ATOM 3226 CG1 VAL B 93 35.408 -0.068 17.715 1.00 8.33 C
ATOM 3230 CG2 VAL B 93 36.818 -1.110 19.565 1.00 9.21 C
ATOM 3234 C VAL B 93 37.954 0.979 16.498 1.00 8.80 C
ATOM 3235 O VAL B 93 38.313 2.100 16.913 1.00 9.38 O
ATOM 3236 N PHE B 94 37.585 0.735 15.235 1.00 7.89 N
15 ATOM 3238 CA PHE B 94 37.514 1.756 14.207 1.00 8.32 C
ATOM 3240 CB PHE B 94 38.303 1.336 12.954 1.00 8.53 C
ATOM 3243 CG PHE B 94 39.774 1.165 13.207 1.00 8.61 C
ATOM 3244 CD1 PHE B 94 40.658 2.188 12.898 1.00 10.93 C
ATOM 3246 CE1 PHE B 94 42.001 2.046 13.153 1.00 11.25 C
20 ATOM 3248 CZ PHE B 94 42.482 0.899 13.732 1.00 10.46 C
ATOM 3250 CE2 PHE B 94 41.644 -0.131 14.027 1.00 10.75 C
ATOM 3252 CD2 PHE B 94 40.273 0.003 13.776 1.00 10.71 C
ATOM 3254 C PHE B 94 36.070 1.974 13.819 1.00 8.61 C
ATOM 3255 O PHE B 94 35.314 1.013 13.648 1.00 9.56 O
25 ATOM 3256 N VAL B 95 35.687 3.231 13.647 1.00 8.45 N
ATOM 3258 CA VAL B 95 34.370 3.546 13.104 1.00 9.19 C
ATOM 3260 CB VAL B 95 33.767 4.834 13.699 1.00 9.11 C
ATOM 3262 CG1 VAL B 95 34.614 6.052 13.439 1.00 11.33 C
ATOM 3266 CG2 VAL B 95 32.342 5.013 13.203 1.00 10.43 C
30 ATOM 3270 C VAL B 95 34.535 3.607 11.594 1.00 9.06 C
ATOM 3271 O VAL B 95 35.480 4.251 11.094 1.00 9.36 O
ATOM 3272 N VAL B 96 33.660 2.896 10.888 1.00 10.07 N
ATOM 3274 CA VAL B 96 33.731 2.760 9.435 1.00 10.75 C
ATOM 3276 CB VAL B 96 33.633 1.287 9.027 1.00 11.31 C
35 ATOM 3278 CG1 VAL B 96 33.699 1.117 7.507 1.00 12.23 C
ATOM 3282 CG2 VAL B 96 34.726 0.475 9.716 1.00 11.29 C
ATOM 3286 C VAL B 96 32.598 3.544 8.811 1.00 11.08 C
ATOM 3287 O VAL B 96 31.425 3.388 9.170 1.00 11.36 O
ATOM 3288 N ILE B 97 32.948 4.403 7.866 1.00 11.39 N
40 ATOM 3290 CA ILE B 97 31.959 5.265 7.236 1.00 12.42 C
ATOM 3292 CB ILE B 97 32.677 6.496 6.644 1.00 12.48 C
ATOM 3294 CG1 ILE B 97 33.614 7.145 7.677 1.00 12.52 C
ATOM 3297 CD1 ILE B 97 32.936 7.612 8.958 1.00 14.19 C
ATOM 3301 CG2 ILE B 97 31.669 7.488 6.082 1.00 12.90 C
45 ATOM 3305 C ILE B 97 31.234 4.501 6.130 1.00 13.56 C
ATOM 3306 O ILE B 97 31.898 3.883 5.308 1.00 13.06 O
ATOM 3307 N PRO B 98 29.898 4.524 6.113 1.00 15.09 N
ATOM 3308 CA PRO B 98 29.132 3.809 5.086 1.00 16.07 C
ATOM 3310 CB PRO B 98 27.696 3.899 5.600 1.00 15.86 C
50 ATOM 3313 CG PRO B 98 27.661 5.122 6.370 1.00 16.80 C
ATOM 3316 CD PRO B 98 29.007 5.184 7.076 1.00 14.97 C
ATOM 3319 C PRO B 98 29.267 4.451 3.718 1.00 17.70 C
ATOM 3320 O PRO B 98 29.605 5.631 3.592 1.00 17.04 O
ATOM 3321 N ASP B 99 29.014 3.649 2.696 1.00 20.10 N
55 ATOM 3323 CA ASP B 99 29.082 4.091 1.303 1.00 20.04 C
ATOM 3325 CB ASP B 99 28.029 5.172 1.061 1.00 21.12 C
ATOM 3328 CG ASP B 99 26.612 4.657 1.337 1.00 23.44 C
ATOM 3329 OD1 ASP B 99 26.291 3.537 0.874 1.00 27.92 O
ATOM 3330 OD2 ASP B 99 25.761 5.269 2.020 1.00 28.30 O
60 ATOM 3331 C ASP B 99 30.494 4.496 0.860 1.00 19.38 C
ATOM 3332 O ASP B 99 30.646 5.358 -0.015 1.00 19.12 O
ATOM 3333 N THR B 100 31.521 3.879 1.460 1.00 17.96 N
ATOM 3335 CA THR B 100 32.917 4.061 1.030 1.00 18.27 C

ATOM 3337 CB THR B 100 33.757 4.812 2.091 1.00 18.29 C
ATOM 3339 OG1 THR B 100 33.964 3.969 3.249 1.00 16.21 O
ATOM 3341 CG2 THR B 100 33.041 6.065 2.595 1.00 18.22 C
5 ATOM 3345 C THR B 100 33.606 2.725 0.744 1.00 18.55 C
ATOM 3346 O THR B 100 34.839 2.644 0.724 1.00 18.17 O
ATOM 3347 N GLY B 101 32.813 1.676 0.537 1.00 19.93 N
ATOM 3349 CA GLY B 101 33.346 0.341 0.306 1.00 19.59 C
ATOM 3352 C GLY B 101 34.217 -0.119 1.467 1.00 19.66 C
ATOM 3353 O GLY B 101 35.181 -0.861 1.285 1.00 19.57 O
10 ATOM 3354 N ASN B 102 33.856 0.343 2.661 1.00 19.84 N
ATOM 3356 CA ASN B 102 34.580 0.071 3.906 1.00 19.99 C
ATOM 3358 CB ASN B 102 34.517 -1.406 4.266 1.00 20.27 C
ATOM 3361 CG ASN B 102 33.148 -1.823 4.683 1.00 22.54 C
ATOM 3362 OD1 ASN B 102 32.856 -1.970 5.871 1.00 26.86 O
15 ATOM 3363 ND2 ASN B 102 32.293 -2.035 3.709 1.00 25.85 N
ATOM 3366 C ASN B 102 36.016 0.557 3.943 1.00 19.98 C
ATOM 3367 O ASN B 102 36.805 0.124 4.782 1.00 19.09 O
ATOM 3368 N SER B 103 36.343 1.504 3.076 1.00 20.60 N
ATOM 3370 CA SER B 103 37.707 1.990 2.986 1.00 19.63 C
20 ATOM 3372 CB SER B 103 38.016 2.353 1.541 1.00 20.16 C
ATOM 3375 OG SER B 103 37.253 3.481 1.156 1.00 22.36 O
ATOM 3377 C SER B 103 37.979 3.214 3.870 1.00 18.01 C
ATOM 3378 O SER B 103 39.137 3.525 4.144 1.00 18.98 O
ATOM 3379 N GLU B 104 36.936 3.918 4.294 1.00 15.67 N
25 ATOM 3381 CA GLU B 104 37.135 5.116 5.120 1.00 13.43 C
ATOM 3383 CB GLU B 104 36.265 6.297 4.656 1.00 12.81 C
ATOM 3386 CG GLU B 104 36.679 7.618 5.313 1.00 13.27 C
ATOM 3389 CD GLU B 104 35.732 8.776 5.029 1.00 14.64 C
ATOM 3390 OE1 GLU B 104 34.919 8.679 4.069 1.00 15.08 O
30 ATOM 3391 OE2 GLU B 104 35.814 9.803 5.742 1.00 14.12 O
ATOM 3392 C GLU B 104 36.797 4.780 6.558 1.00 12.23 C
ATOM 3393 O GLU B 104 35.659 4.435 6.855 1.00 11.79 O
ATOM 3394 N GLU B 105 37.793 4.856 7.439 1.00 11.65 N
ATOM 3396 CA GLU B 105 37.573 4.534 8.845 1.00 10.60 C
35 ATOM 3398 CB GLU B 105 37.830 3.047 9.102 1.00 10.23 C
ATOM 3401 CG GLU B 105 39.288 2.653 8.998 1.00 11.51 C
ATOM 3404 CD GLU B 105 39.569 1.177 9.250 1.00 13.25 C
ATOM 3405 OE1 GLU B 105 40.772 0.827 9.367 1.00 14.63 O
ATOM 3406 OE2 GLU B 105 38.617 0.366 9.341 1.00 11.87 O
40 ATOM 3407 C GLU B 105 38.476 5.381 9.732 1.00 9.65 C
ATOM 3408 O GLU B 105 39.492 5.931 9.272 1.00 10.58 O
ATOM 3409 N TYR B 106 38.112 5.465 11.014 1.00 9.46 N
ATOM 3411 CA TYR B 106 38.842 6.260 12.004 1.00 9.17 C
ATOM 3413 CB TYR B 106 38.119 7.593 12.258 1.00 9.00 C
45 ATOM 3416 CG TYR B 106 37.989 8.388 10.990 1.00 9.70 C
ATOM 3417 CD1 TYR B 106 39.000 9.227 10.565 1.00 10.02 C
ATOM 3419 CE1 TYR B 106 38.900 9.908 9.378 1.00 11.83 C
ATOM 3421 CZ TYR B 106 37.797 9.755 8.584 1.00 10.67 C
ATOM 3422 OH TYR B 106 37.719 10.438 7.368 1.00 13.02 O
50 ATOM 3424 CE2 TYR B 106 36.784 8.909 8.958 1.00 10.26 C
ATOM 3426 CD2 TYR B 106 36.887 8.224 10.166 1.00 9.29 C
ATOM 3428 C TYR B 106 38.949 5.516 13.318 1.00 9.17 C
ATOM 3429 O TYR B 106 37.963 4.945 13.774 1.00 8.39 O
ATOM 3430 N ILE B 107 40.116 5.546 13.955 1.00 8.89 N
55 ATOM 3432 CA ILE B 107 40.211 4.966 15.288 1.00 8.90 C
ATOM 3434 CB ILE B 107 41.652 5.037 15.848 1.00 9.24 C
ATOM 3436 CG1 ILE B 107 41.770 4.245 17.155 1.00 10.76 C
ATOM 3439 CD1 ILE B 107 41.571 2.765 16.979 1.00 12.64 C
ATOM 3443 CG2 ILE B 107 42.088 6.484 16.051 1.00 9.73 C
60 ATOM 3447 C ILE B 107 39.211 5.679 16.194 1.00 9.06 C
ATOM 3448 O ILE B 107 39.102 6.912 16.171 1.00 9.11 O
ATOM 3449 N ILE B 108 38.448 4.908 16.958 1.00 8.10 N
ATOM 3451 CA ILE B 108 37.466 5.505 17.858 1.00 8.46 C

ATOM 3453 CB ILE B 108 36.038 5.362 17.263 1.00 7.92 C
ATOM 3455 CG1 ILE B 108 35.058 6.318 17.933 1.00 8.44 C
ATOM 3458 CD1 ILE B 108 35.451 7.735 17.791 1.00 10.51 C
ATOM 3462 CG2 ILE B 108 35.548 3.943 17.367 1.00 7.73 C
5 ATOM 3466 C ILE B 108 37.577 5.032 19.315 1.00 9.21 C
ATOM 3467 O ILE B 108 37.028 5.675 20.206 1.00 9.94 O
ATOM 3468 N ALA B 109 38.295 3.939 19.566 1.00 8.98 N
ATOM 3470 CA ALA B 109 38.565 3.467 20.929 1.00 8.87 C
ATOM 3472 CB ALA B 109 37.358 2.771 21.525 1.00 9.01 C
10 ATOM 3476 C ALA B 109 39.744 2.507 20.935 1.00 8.73 C
ATOM 3477 O ALA B 109 39.957 1.757 19.994 1.00 9.76 O
ATOM 3478 N GLU B 110 40.533 2.576 21.998 1.00 9.54 N
ATOM 3480 CA GLU B 110 41.607 1.634 22.215 1.00 9.46 C
ATOM 3482 CB GLU B 110 42.946 2.257 21.824 1.00 10.74 C
15 ATOM 3485 CG GLU B 110 44.120 1.290 21.888 1.00 14.55 C
ATOM 3488 CD GLU B 110 45.414 1.938 21.419 1.00 21.68 C
ATOM 3489 OE1 GLU B 110 45.950 2.812 22.134 1.00 25.49 O
ATOM 3490 OE2 GLU B 110 45.877 1.587 20.321 1.00 27.22 O
ATOM 3491 C GLU B 110 41.678 1.209 23.680 1.00 9.73 C
20 ATOM 3492 O GLU B 110 41.720 2.056 24.582 1.00 10.15 O
ATOM 3493 N TRP B 111 41.703 -0.098 23.894 1.00 9.39 N
ATOM 3495 CA TRP B 111 41.990 -0.671 25.187 1.00 10.20 C
ATOM 3497 CB TRP B 111 41.076 -1.840 25.491 1.00 9.67 C
ATOM 3500 CG TRP B 111 41.470 -2.528 26.787 1.00 8.52 C
25 ATOM 3501 CD1 TRP B 111 42.308 -3.581 26.928 1.00 9.95 C
ATOM 3503 NE1 TRP B 111 42.456 -3.906 28.256 1.00 13.10 N
ATOM 3505 CE2 TRP B 111 41.728 -3.017 29.010 1.00 10.98 C
ATOM 3506 CD2 TRP B 111 41.102 -2.128 28.116 1.00 9.50 C
ATOM 3507 CE3 TRP B 111 40.282 -1.123 28.636 1.00 10.62 C
30 ATOM 3509 CZ3 TRP B 111 40.114 -1.040 30.002 1.00 12.26 C
ATOM 3511 CH2 TRP B 111 40.756 -1.929 30.857 1.00 9.96 C
ATOM 3513 CZ2 TRP B 111 41.561 -2.926 30.385 1.00 12.41 C
ATOM 3515 C TRP B 111 43.423 -1.193 25.169 1.00 13.35 C
ATOM 3516 O TRP B 111 43.775 -2.031 24.344 1.00 11.63 O
35 ATOM 3517 N LYS B 112 44.263 -0.666 26.056 1.00 16.48 N
ATOM 3519 CA LYS B 112 45.593 -1.223 26.244 1.00 20.35 C
ATOM 3521 CB LYS B 112 46.627 -0.459 25.436 1.00 22.00 C
ATOM 3524 CG LYS B 112 47.926 -1.228 25.265 1.00 26.13 C
ATOM 3527 CD LYS B 112 49.024 -0.337 24.701 1.00 31.80 C
40 ATOM 3530 CE LYS B 112 48.724 0.098 23.278 1.00 34.89 C
ATOM 3533 NZ LYS B 112 49.811 0.945 22.716 1.00 40.47 N
ATOM 3537 C LYS B 112 45.946 -1.177 27.725 1.00 22.27 C
ATOM 3538 O LYS B 112 46.204 -0.081 28.253 1.00 23.96 O
ATOM 3539 BR BR1 C 1 32.421 56.008 18.617 1.00 7.69 B
45 ATOM 3540 BR BR1 C 2 29.535 49.785 7.652 1.00 7.89 B
ATOM 3541 BR BR1 C 3 14.888 42.517 9.414 1.00 6.57 B
ATOM 3542 BR BR1 C 4 25.062 15.958 16.407 1.00 10.90 B
ATOM 3543 BR BR1 C 5 33.144 18.262 4.026 1.00 20.03 B
ATOM 3544 BR BR1 C 6 40.800 30.559 10.185 1.00 12.36 B
50 ATOM 3545 BR BR1 C 7 30.248 54.190 19.852 1.00 14.74 B
ATOM 3546 BR BR1 C 8 38.772 41.003 24.687 1.00 22.37 B
ATOM 3547 BR BR1 C 9 26.990 5.115 28.326 1.00 15.47 B
ATOM 3548 BR BR1 C 10 40.148 5.267 23.548 1.00 2.00 B
ATOM 3549 BR BR1 C 11 40.494 -13.035 23.333 1.00 14.97 B
55 ATOM 3550 BR BR1 C 12 26.318 -12.293 15.448 1.00 14.38 B
ATOM 3551 BR BR1 C 13 31.199 -18.188 15.135 1.00 9.41 B
ATOM 3552 BR BR1 C 14 32.035 -14.040 15.742 1.00 12.63 B
ATOM 3553 BR BR1 C 15 29.171 31.139 8.101 1.00 2.00 B
ATOM 3554 BR BR1 C 16 28.318 -4.326 9.061 1.00 2.00 B
60 ATOM 3555 O HOH D 1 45.016 -8.481 11.093 1.00 14.02 O
ATOM 3558 O HOH D 2 39.945 9.187 15.069 1.00 13.06 O
ATOM 3561 O HOH D 3 37.478 27.672 11.707 1.00 16.80 O
ATOM 3564 O HOH D 4 44.772 -4.577 18.363 1.00 14.26 O

ATOM 3567 O HOH D 5 28.336 -7.855 25.862 1.00 13.43 O
ATOM 3570 O HOH D 6 23.544 0.467 24.663 1.00 16.56 O
ATOM 3573 O HOH D 7 29.531 -5.991 30.538 1.00 15.82 O
ATOM 3576 O HOH D 8 24.673 37.622 24.477 1.00 15.51 O
5 ATOM 3579 O HOH D 9 33.907 51.248 18.235 1.00 18.02 O
ATOM 3582 O HOH D 10 29.468 6.207 15.500 1.00 14.54 O
ATOM 3585 O HOH D 11 33.083 30.830 21.409 1.00 17.28 O
ATOM 3588 O HOH D 12 22.901 44.556 18.335 1.00 14.73 O
ATOM 3591 O HOH D 13 31.027 20.428 25.544 1.00 16.68 O
10 ATOM 3594 O HOH D 14 30.995 8.205 30.208 1.00 19.66 O
ATOM 3597 O HOH D 15 28.108 -13.792 35.951 1.00 20.73 O
ATOM 3600 O HOH D 16 42.527 6.434 12.302 1.00 18.94 O
ATOM 3603 O HOH D 17 32.508 14.749 4.982 1.00 23.91 O
ATOM 3606 O HOH D 18 23.468 6.955 26.616 1.00 18.06 O
15 ATOM 3609 O HOH D 19 22.712 2.972 25.766 1.00 20.00 O
ATOM 3612 O HOH D 20 13.244 50.277 14.738 1.00 18.37 O
ATOM 3615 O HOH D 21 36.790 15.994 26.963 1.00 17.85 O
ATOM 3618 O HOH D 22 22.367 36.375 23.529 1.00 17.11 O
ATOM 3621 O HOH D 23 18.911 31.260 28.272 1.00 26.39 O
20 ATOM 3624 O HOH D 24 31.505 1.688 3.641 1.00 20.97 O
ATOM 3627 O HOH D 25 21.210 33.851 24.000 1.00 21.28 O
ATOM 3630 O HOH D 26 23.386 -0.715 22.103 1.00 15.14 O
ATOM 3633 O HOH D 27 29.074 -11.945 31.532 1.00 24.32 O
ATOM 3636 O HOH D 28 25.268 40.455 23.574 1.00 23.95 O
25 ATOM 3639 O HOH D 29 33.156 -9.344 11.616 1.00 20.79 O
ATOM 3642 O HOH D 30 38.478 -5.911 7.639 1.00 21.26 O
ATOM 3645 O HOH D 31 24.308 53.095 18.780 1.00 19.70 O
ATOM 3648 O HOH D 32 17.754 48.477 15.499 1.00 20.76 O
ATOM 3651 O HOH D 33 42.790 5.854 23.394 1.00 23.30 O
30 ATOM 3654 O HOH D 34 27.861 15.691 24.120 1.00 23.40 O
ATOM 3657 O HOH D 35 35.797 12.184 4.416 1.00 21.31 O
ATOM 3660 O HOH D 36 30.360 -0.992 28.013 1.00 16.72 O
ATOM 3663 O HOH D 37 28.276 -16.367 24.146 1.00 20.65 O
ATOM 3666 O HOH D 38 32.226 24.366 27.005 1.00 23.68 O
35 ATOM 3669 O HOH D 39 20.858 29.760 23.162 1.00 21.99 O
ATOM 3672 O HOH D 40 49.235 18.819 15.583 1.00 25.35 O
ATOM 3675 O HOH D 41 24.467 -3.793 21.863 1.00 22.04 O
ATOM 3678 O HOH D 42 26.332 -5.940 25.774 1.00 16.62 O
ATOM 3681 O HOH D 43 40.578 4.994 6.108 1.00 25.58 O
40 ATOM 3684 O HOH D 44 20.863 46.163 17.522 1.00 25.28 O
ATOM 3687 O HOH D 45 42.794 2.619 9.388 1.00 23.00 O
ATOM 3690 O HOH D 46 20.611 25.977 15.514 1.00 25.08 O
ATOM 3693 O HOH D 47 24.778 21.030 19.875 1.00 21.37 O
ATOM 3696 O HOH D 48 24.759 -5.920 23.503 1.00 16.11 O
45 ATOM 3699 O HOH D 49 36.889 24.475 8.631 1.00 23.03 O
ATOM 3702 O HOH D 50 20.215 49.361 14.399 1.00 22.50 O
ATOM 3705 O HOH D 51 47.164 -5.215 12.615 1.00 22.87 O
ATOM 3708 O HOH D 52 46.004 25.078 19.448 1.00 25.71 O
ATOM 3711 O HOH D 53 20.097 31.594 19.238 1.00 27.29 O
50 ATOM 3714 O HOH D 54 19.046 1.435 16.404 1.00 27.34 O
ATOM 3717 O HOH D 55 39.089 23.057 7.816 1.00 28.18 O
ATOM 3720 O HOH D 56 22.799 49.789 12.926 1.00 27.76 O
ATOM 3723 O HOH D 57 21.681 37.631 15.807 1.00 23.46 O
ATOM 3726 O HOH D 58 44.307 22.404 22.181 1.00 23.37 O
55 ATOM 3729 O HOH D 59 46.170 -13.085 20.941 1.00 17.48 O
ATOM 3732 O HOH D 60 36.365 41.071 5.729 1.00 27.02 O
ATOM 3735 O HOH D 61 36.990 7.023 22.512 1.00 22.71 O
ATOM 3738 O HOH D 62 19.169 -8.584 16.372 1.00 23.92 O
ATOM 3741 O HOH D 63 20.055 28.469 14.698 1.00 26.12 O
60 ATOM 3744 O HOH D 64 30.998 -12.907 29.623 1.00 25.28 O
ATOM 3747 O HOH D 65 37.347 -1.150 7.121 1.00 22.93 O
ATOM 3750 O HOH D 66 33.031 -13.258 27.775 1.00 32.50 O
ATOM 3753 O HOH D 67 22.945 -4.003 11.274 1.00 30.88 O

	ATOM	3756	O	HOH	D	68	27.701	41.270	1.720	1.00	29.57	O
	ATOM	3759	O	HOH	D	69	25.980	-9.896	14.868	1.00	27.31	O
	ATOM	3762	O	HOH	D	70	23.821	12.814	14.658	1.00	24.54	O
	ATOM	3765	O	HOH	D	71	35.006	43.534	25.083	1.00	28.85	O
5	ATOM	3768	O	HOH	D	72	35.312	36.253	1.522	1.00	29.21	O
	ATOM	3771	O	HOH	D	73	48.598	-9.901	24.935	1.00	25.55	O
	ATOM	3774	O	HOH	D	74	42.294	-13.685	16.218	1.00	25.18	O
	ATOM	3777	O	HOH	D	75	42.607	12.387	16.515	1.00	31.10	O
	ATOM	3780	O	HOH	D	76	26.330	35.006	4.050	1.00	31.74	O
10	ATOM	3783	O	HOH	D	77	32.850	10.209	3.504	1.00	27.19	O
	ATOM	3786	O	HOH	D	78	30.508	10.747	29.512	1.00	25.87	O
	ATOM	3789	O	HOH	D	79	45.693	19.098	22.237	1.00	30.36	O
	ATOM	3792	O	HOH	D	80	15.634	44.761	11.710	1.00	26.02	O
	ATOM	3795	O	HOH	D	81	18.085	50.959	3.872	1.00	35.51	O
15	ATOM	3798	O	HOH	D	82	29.549	1.503	7.572	1.00	29.19	O
	ATOM	3801	O	HOH	D	83	39.725	31.841	30.695	1.00	40.77	O
	ATOM	3804	O	HOH	D	84	20.283	36.188	-4.205	1.00	39.38	O
	ATOM	3807	O	HOH	D	85	34.763	-11.883	13.146	1.00	21.47	O
	ATOM	3810	O	HOH	D	86	26.410	32.901	7.289	1.00	24.64	O
20	ATOM	3813	O	HOH	D	87	44.314	-2.758	11.932	1.00	23.95	O
	ATOM	3816	O	HOH	D	88	30.034	-14.313	17.413	1.00	29.20	O
	ATOM	3819	O	HOH	D	89	26.961	12.263	27.391	1.00	30.17	O
	ATOM	3822	O	HOH	D	90	28.249	0.678	3.312	1.00	28.11	O
	ATOM	3825	O	HOH	D	91	45.718	32.030	14.220	1.00	34.46	O
25	ATOM	3828	O	HOH	D	92	28.299	-9.696	27.995	1.00	24.79	O
	ATOM	3831	O	HOH	D	93	13.832	48.982	7.768	1.00	33.46	O
	ATOM	3834	O	HOH	D	94	43.000	-11.174	31.241	1.00	28.43	O
	ATOM	3837	O	HOH	D	95	35.944	8.335	1.385	1.00	29.40	O
	ATOM	3840	O	HOH	D	96	29.165	29.895	11.877	1.00	24.28	O
30	ATOM	3843	O	HOH	D	97	32.349	31.864	24.473	1.00	30.09	O
	ATOM	3846	O	HOH	D	98	22.954	24.601	11.686	1.00	28.72	O
	ATOM	3849	O	HOH	D	99	31.154	51.462	19.574	1.00	25.81	O
	ATOM	3852	O	HOH	D	100	43.443	12.360	23.615	1.00	24.55	O
	ATOM	3855	O	HOH	D	101	15.670	52.252	4.362	1.00	34.13	O
35	ATOM	3858	O	HOH	D	102	25.701	41.081	26.231	1.00	27.56	O
	ATOM	3861	O	HOH	D	103	37.527	21.694	22.195	1.00	32.29	O
	ATOM	3864	O	HOH	D	104	33.325	-12.660	37.738	1.00	35.18	O
	ATOM	3867	O	HOH	D	105	26.319	5.217	15.262	1.00	26.13	O
	ATOM	3870	O	HOH	D	106	33.848	22.140	26.173	1.00	31.07	O
40	ATOM	3873	O	HOH	D	107	35.489	18.857	24.618	1.00	27.43	O
	ATOM	3876	O	HOH	D	108	42.855	46.462	8.947	1.00	33.41	O
	ATOM	3879	O	HOH	D	109	42.188	5.317	9.853	1.00	30.90	O
	ATOM	3882	O	HOH	D	110	41.401	45.084	19.630	1.00	35.22	O
	ATOM	3885	O	HOH	D	111	45.990	-4.685	27.447	1.00	36.33	O
45	ATOM	3888	O	HOH	D	112	44.969	4.979	13.641	1.00	30.89	O
	ATOM	3891	O	HOH	D	113	21.231	24.488	19.771	1.00	29.91	O
	ATOM	3894	O	HOH	D	114	28.991	22.460	25.768	1.00	32.28	O
	ATOM	3897	O	HOH	D	115	30.182	42.704	28.664	1.00	34.73	O
	ATOM	3900	O	HOH	D	116	38.457	26.788	9.301	1.00	28.25	O
50	ATOM	3903	O	HOH	D	117	33.010	8.247	32.080	1.00	30.38	O
	ATOM	3906	O	HOH	D	118	40.296	-12.388	19.763	1.00	29.43	O
	ATOM	3909	O	HOH	D	119	26.522	44.371	25.621	1.00	29.51	O
	ATOM	3912	O	HOH	D	120	43.804	-4.826	10.570	1.00	33.46	O
	ATOM	3915	O	HOH	D	121	47.448	-11.680	26.748	1.00	37.40	O
55	ATOM	3918	O	HOH	D	122	40.716	-13.572	24.920	1.00	24.40	O
	ATOM	3921	O	HOH	D	123	41.998	-1.274	34.849	1.00	32.74	O
	ATOM	3924	O	HOH	D	124	45.154	42.318	18.028	1.00	36.95	O
	ATOM	3927	O	HOH	D	125	30.324	-11.134	10.862	1.00	29.46	O
	ATOM	3930	O	HOH	D	126	42.517	10.179	15.159	1.00	30.78	O
60	ATOM	3933	O	HOH	D	127	48.214	-11.222	16.932	1.00	31.45	O
	ATOM	3936	O	HOH	D	128	23.815	-9.373	14.042	1.00	33.96	O
	ATOM	3939	O	HOH	D	129	31.988	24.965	29.884	1.00	32.47	O
	ATOM	3942	O	HOH	D	130	35.266	30.662	4.339	1.00	37.13	O

5 ATOM 3945 O HOH D 131 42.057 38.530 10.976 1.00 38.75 O
ATOM 3948 O HOH D 132 24.900 3.888 13.671 1.00 41.30 O
ATOM 3951 O HOH D 133 44.797 -11.819 18.372 1.00 31.27 O
ATOM 3954 O HOH D 134 31.380 27.561 6.462 1.00 38.93 O
ATOM 3957 O HOH D 135 24.585 -2.131 6.886 1.00 36.52 O
ATOM 3960 O HOH D 136 44.178 14.598 21.666 1.00 49.82 O

CLAIMS

1. An Fve polypeptide comprising at least one biological activity of native Fve protein, and being a fragment, homologue, variant or derivative thereof.
2. An Fve polypeptide according to Claim 1, which comprises an immunomodulatory
5 activity.
3. An Fve polypeptide according to Claim 1 or 2, which comprises a biological activity selected from the group consisting of: up-regulation of expression of Th1/Tc1 cytokines, preferably IFN- γ and TNF- α , down-regulation of expression of Th2/Tc2 cytokines, preferably IL-4 and IL-13, up-regulation of expression of T regulatory (Tr)
10 cytokines IL-10 and TGF- β , hemagglutination activity, cell aggregation activity, lymphocyte aggregation activity, lymphoproliferation activity, up-regulation of expression of IL-2, IFN- γ , TNF- α , but not IL-4 in CD3⁺ T cells, interaction with T and NK cells, adjuvant activity, stimulation of CD3⁺ CD16⁺ CD56⁺ natural killer (NK) T cells and CD3⁺ CD8⁺ CD18⁺ bright T cells, and up-regulation of allergen specific Th1 immune responses.
- 15 4. An Fve polypeptide according to Claim 1, 2 or 3, in which the polypeptide comprises between 2 to 20 residues of amino acid sequence flanking the glycine residue corresponding to position 28 of Fve.
5. An Fve polypeptide according to any preceding claim, in which the polypeptide comprises the sequence RGT or the sequence RGD.
- 20 6. An Fve polypeptide according to any preceding claim, in which the polypeptide has a sequence as set out in **Appendix A** or **Appendix B**.

7. An Fve polypeptide comprising an sequence selected from the group consisting of: Fve R27A, Fve T29A, GST-Fve (wild type), GST-Fve R27A, and GST-Fve T29A, and fragments, homologues, variants and derivatives thereof.
8. A polypeptide comprising a first portion comprising at least a fragment of native Fve, or an Fve polypeptide according to any preceding claim, and a second portion comprising at least a fragment of an allergen.
9. A polypeptide according to Claim 8, in which the allergen comprises an allergen from a mite, preferably from Family *Glycyphagidae* or Family *Pyroglyphidae*, preferably a group 1 allergen (Der p 1, Der f 1, Blo t 1, Eur m1, Lep d 1), a group 2 allergen (Der p 2, Der f 2, Blo t 2, Eur m 2, Lep d 2), a group 5 allergen (Blo t 5, Der p 5, Der f 5, Eur m 5, Lep d 5) a group 15 allergen (Der p 15, Der f 15, Blot 15, Eur m 15, Lep d 15).
10. A Fve polypeptide or a polypeptide according to Claim 8 or 9, which is selected from the group consisting of: Blo t 5-Fve, Blo t 5-FveR27A, Blo t 5-FveT29A, Der p 2-FveT29A, GST-Der p 2-FveR27A, GST-Der p 2-FveT29A, Blo t 5-Der p 2-FveR27A and Blo t 5-Der p 2-FveT29A.
11. A polypeptide according to Claim 8, in which the allergen is selected from the group consisting of: tree pollen allergen, Bet v 1 and Bet v 2 from birch tree; grass pollen allergen, Phl p 1 and Phl p 2 from timothy grass; weed pollen allergen, antigen E from ragweed; major feline antigen, Fel d; major fungal allergen, Asp f1, Asp f2, and Asp f3 from *Aspergillus fumigatus*.
12. A polypeptide comprising a first portion comprising at least a fragment of native Fve, or an Fve polypeptide according to any of Claims 1 to 7, and a second portion comprising at least a fragment of a viral antigen selected from the group consisting of: E6 and E7 from HPV; core Ag and E2 from HCV; core and surface antigens from HBV; LMP-1, LMP-2, EBNA-2, EBNA-3 from EBV; and Tax from HTLV-1.

13. A polypeptide according to Claim 12, which comprises HCV Core23-FveT29A, or HPV E7-FveT29A.
14. A polypeptide comprising a first portion comprising at least a fragment of native Fve, or an Fve polypeptide according to any of Claims 1 to 7, and a second portion
5 comprising at least a fragment of a tumour-associated antigen selected from the group consisting of: MAGE-1, MAGE-2, MAGE-3, preferably a sequence, BAGE, GAGE, PRAME, SSX-2, Tyrosinase, MART-1, NY-ESO-1, gp100, TRP-1, TRP-2, A2 melanotope, BCR/ABL, Proteinase-3/Myeloblastin, HER2/neu, CEA, P1A, HK2, PAPA, PSA, PSCA, PSMA, pg75, MUM-1, MUC-1, BTA, GnT-V, β -catenin, CDK4, and P15.
- 10 15. A polypeptide according to Claim 14, which comprises MAGE3-FveT29A, MART1-FveT29A or CEA-FveT29A.
16. A nucleic acid encoding a Fve polypeptide or a polypeptide according to any preceding claim.
17. A nucleic acid according to Claim 16, in which the nucleic acid comprises CGT
15 GGT ACC, or a sequence which differs from the above by virtue of the degeneracy of the genetic code and which encodes a sequence RGT.
18. A nucleic acid comprising a first sequence encoding at least a fragment of native Fve, or an Fve polypeptide according to any of Claims 1 to 7, and a second sequence encoding at least a fragment of an allergen.
- 20 19. A nucleic acid according to Claim 18, which comprises Blo t 5-Fve, Blo t 5-FveR27A, Blo t 5-FveT29A, Der p 2-FveT29A, GST-Der p 2-FveR27A, GST-Der p 2-FveT29A, Blo t 5-Der p 2-FveR27A or Blo t 5-Der p 2-FveT29A.

20. A nucleic acid comprising a first sequence encoding at least a fragment of native Fve, or an Fve polypeptide according to any of Claims 1 to 7, and a second sequence encoding at least a fragment of a viral antigen selected from the group consisting of: E6 and E7 from HPV; core Ag and E2 from HCV; core and surface antigens from HBV; LMP-1, LMP-2, EBNA-2, EBNA-3 from EBV; and Tax from HTLV-1.
21. A nucleic acid according to Claim 20, which comprises HCV Core23-FveT29A, or HPV E7-FveT29A.
22. A nucleic acid comprising a first sequence encoding at least a fragment of native Fve, or an Fve polypeptide according to any of Claims 1 to 7, and a second sequence encoding at least a fragment of a tumour associated antigen selected from the group consisting of: MAGE-1, MAGE-2, MAGE-3, BAGE, GAGE, PRAME, SSX-2, Tyrosinase, MART-1, NY-ESO-1, gp100, TRP-1, TRP-2, A2 melanotope, BCR/ABL, Proteinase-3/Myeloblastin, HER2/neu, CEA, P1A, HK2, PAPA, PSA, PSCA, PSMA, pg75, MUM-1, MUC-1, BTA, GnT-V, β -catenin, CDK4, and P15.
23. A nucleic acid according to Claim 22, which comprises MAGE3-FveT29A, MART1-FveT29A or CEA-FveT29A.
24. A nucleic acid selected from the group consisting of: Fve R27A, Fve T29A, GST-Fve (wild type), GST-Fve R27A, GST-Fve T29A, Blo t 5-Fve, Blo t 5-FveR27A, Blo t 5-FveT29A, GST-Der p 2-FveR27A, GST-Der p 2-FveT29A, Blo t 5-Der p 2-FveR27A, Blo t 5-Der p 2-FveT29A, and fragments, homologues, variants and derivatives thereof.
25. A vector, preferably an expression vector, comprising a nucleic acid sequence according to any of Claims 16 to 24.
26. A DNA vaccine comprising a nucleic acid encoding Fve, a nucleic acid according to any of Claims 16 to 24, or a vector according to Claim 25.

27. A host cell comprising a nucleic acid encoding Fve, a nucleic acid according to any of Claims 16 to 24, or a vector according to Claim 25.
28. A transgenic non-human organism comprising a nucleic acid encoding Fve, a nucleic acid according to any of Claims 16 to 24, or a vector according to Claim 25.
- 5 29. A transgenic non-human organism according to Claim 28 which is a bacterium, a yeast, a fungus, a plant or an animal, preferably a mouse.
30. A pharmaceutical composition comprising a polypeptide according to any of Claims 1 to 15, a nucleic acid according to any of Claims 16 to 24, a vector according to Claim 25, a DNA vaccine according to Claim 26, or a host cell according to Claim 27,
10 together with a pharmaceutically acceptable carrier or diluent.
31. Use of a native Fve polypeptide, or an Fve polypeptide, nucleic acid, vector, DNA vaccine, host cell, transgenic organism, or a pharmaceutical composition according to any of Claims 1 to 30 as an immunomodulator.
32. Use of a native Fve polypeptide, or an Fve polypeptide, nucleic acid, vector, DNA
15 vaccine, host cell, transgenic organism, or a pharmaceutical composition according to any of Claims 1 to 30 to enhance an immune response in a mammal.
33. Use of a native Fve polypeptide, or an Fve polypeptide, nucleic acid, vector, DNA vaccine, host cell, transgenic organism, or a pharmaceutical composition according to any of Claims 1 to 30 to stimulate proliferation of CD3⁺ CD8⁺ CD18⁺ bright T cells.
- 20 34. Use of a native Fve polypeptide, or an Fve polypeptide, nucleic acid, vector, DNA vaccine, host cell, transgenic organism, or a pharmaceutical composition according to any of Claims 1 to 30 to stimulate proliferation of CD3⁺ CD16⁺ CD56⁺ natural killer (NK) T cells.

35. Use of a native Fve polypeptide, or an Fve polypeptide, nucleic acid, vector, DNA vaccine, host cell, transgenic organism, or a pharmaceutical composition according to any of Claims 1 to 30 to stimulate production of IL-2, IL-10, TGF- β , IFN- γ or TNF- α in CD3⁺ cells.
- 5 36. Use according to Claim 35, in which production of IL-4 is not stimulated in the CD3⁺ cells.
37. Use of a native Fve polypeptide, or an Fve polypeptide, nucleic acid, vector, DNA vaccine, host cell, transgenic organism, or a pharmaceutical composition according to any of Claims 1 to 30 as an adjuvant for a vaccine.
- 10 38. Use of a native Fve polypeptide, or an Fve polypeptide, nucleic acid, vector, DNA vaccine, host cell, transgenic organism, or a pharmaceutical composition according to any of Claims 1 to 30 in a method of treatment or prophylaxis of a disease.
39. Use of a native Fve polypeptide, or an Fve polypeptide, nucleic acid, vector or host cell according to any of Claims 1 to 30 for the preparation of a pharmaceutical
15 composition for the treatment of a disease.
40. A method of treating an individual suffering from a disease or preventing the occurrence of a disease in an individual, the method comprising administering to the individual a therapeutically or prophylactically effective amount of a native Fve polypeptide, or an Fve polypeptide, nucleic acid, vector, DNA vaccine, host cell,
20 transgenic organism, or a pharmaceutical composition according to any of Claims 1 to 30.
41. A use or method according to any of Claims 38, 39 or 40, in which the disease comprises an atopic disease or allergy.

42. Use of a DNA vaccine according to Claim 26, preferably as dependent on Claim 18 or 19, in a method of treatment or prevention of an allergy.
43. A use or method according to Claim 41 or 42, in which the allergy is selected from the group consisting of: allergic asthma, a seasonal respiratory allergy, a perennial
5 respiratory allergy, allergic rhinitis, hayfever, nonallergic rhinitis, vasomotor rhinitis, irritant rhinitis, an allergy against grass pollen, weed pollen, tree pollen or animal danders, an allergy associated with allergic asthma and a food allergy.
44. A use or method according to Claim 41, 42 or 43, in which the allergy is to a house
10 dust mite from Family Glyphagidae, preferably *Blomia tropicalis* or from Family Pyroglyphidae, preferably *Dermatophagoides pteronyssinus* or *Dermatophagoides farinae*, or to fungi or fungal spores, preferably *Aspergillus fumigatus*, or to tree pollen allergens, preferably from birch tree, or grass pollen allergens, preferably from timothy grass, or weed allergens, preferably ragweed.
45. A use or method according to any of Claims 38, 39 or 40, in which the disease
15 comprises a cancer.
46. Use of a DNA vaccine according to Claim 26, preferably as dependent on Claim 20 or 21, in a method of treatment or prevention of a cancer, or in a method of suppressing tumour progression.
47. Use of a DNA vaccine according to Claim 26, preferably as dependent on Claim
20 22, in a method of treatment or prevention of a cancer, or in a method of suppressing tumour progression.
48. A use or method according to Claim 45, 46 or 47, in which the cancer comprises a T cell lymphoma, melanoma, lung cancer, colon cancer, breast cancer or prostate cancer.

49. A method of identifying a molecule capable of binding to Fve, the method comprising exposing a native Fve polypeptide, or an Fve polypeptide or nucleic acid, vector, host cell or transgenic organism according to any of Claims 1 to 25, 27 and 28 to a candidate molecule and detecting whether the candidate molecule binds to the native Fve polypeptide, or an Fve polypeptide or nucleic acid, vector, host cell or transgenic organism.
50. A method of identifying an agonist or antagonist of an Fve polypeptide, the method comprising: (a) providing a cell or organism; (b) exposing the cell or organism to a native Fve polypeptide, or an Fve polypeptide or nucleic acid, vector, host cell or transgenic organism according to any of Claims 1 to 25, 27 and 28; (c) exposing the cell to a candidate molecule; and (d) detecting an Fve mediated effect.
51. A method according to Claim 50, in which the Fve mediated effect is selected from the biological activities set out in Claim 2.
52. A method according to Claim 49, 50 or 51, in which the method further comprises isolating or synthesising a selected or identified molecule.
53. A molecule identified or selected using a method according to any of Claims 49 to 52.
54. A native Fve polypeptide, or an Fve polypeptide in crystalline form.
55. A native Fve polypeptide, or an Fve polypeptide in crystalline form according to Claim 54, which has the structural coordinates shown in **Appendix C**.
56. A model for at least part of Fve made using a crystal according to Claim 54 or 55.

57. A method of screening for a receptor capable of binding to Fve, or designing a ligand capable of modulating the interaction between Fve and an Fve receptor, comprising the use of a model according to Claim 56.
58. A computer readable medium having stored thereon the structure of a crystal
5 according to Claim 54 or 55, or a model according to Claim 56.
59. A ligand identified by the method according to Claim 57.
60. Use of a molecule according to Claim 53 or a ligand according to Claim 59 for the treatment or prevention of a disease in an individual.
61. A pharmaceutical composition comprising a molecule according to Claim 53 or a
10 ligand according to Claim 59 and optionally a pharmaceutically acceptable carrier, diluent, excipient or adjuvant or any combination thereof.
62. A method of treating and/or preventing a disease comprising administering a molecule according to Claim 53 or a ligand according to Claim 59 and/or a pharmaceutical composition according to Claim 61 to an individual in need of such treatment.
- 15 63. A method of amplifying a sub-population of cells, the method comprising: (a) obtaining a population of cells from an individual; (b) amplifying $CD3^{+} CD8^{+}$ and $CD18^{+}$ ^{bright} T cells by exposing the population of cells to a native Fve polypeptide, or an Fve polypeptide or nucleic acid, vector, host cell or transgenic organism according to any of Claims 1 to 25, 27 and 28.
- 20 64. A method according to Claim 63, further comprising the step of: (c) isolating the $CD3^{+} CD8^{+}$ and $CD18^{+}$ ^{bright} T cells.

65. A method of treating an individual suffering from a disease or preventing the occurrence of a disease in an individual, the method comprising amplifying a CD3⁺ CD8⁺ and CD18⁺ ^{bright} T cell by a method according to Claim 63 or 64, and administering the amplified CD3⁺ CD8⁺ and CD18⁺ ^{bright} T cell to an individual.
- 5 66. An amplified population of CD3⁺ CD8⁺ and CD18⁺ ^{bright} T cells obtainable by a method according to Claim 63 or 64.
67. A pharmaceutical composition comprising an amplified population of CD3⁺ CD8⁺ and CD18⁺ ^{bright} T cells according to Claim 66, together with a pharmaceutically acceptable excipient or carrier.
- 10 68. A combination comprising a first component comprising an immunomodulator and a second component comprising at least a fragment of an allergen, a viral antigen or a tumour associated antigen.
69. A combination according to Claim 68 in which the first component is separate from the second component.
- 15 70. A combination according to Claim 68 in which the first component is associated with the second component.
71. A combination according to Claim 68 which is a fusion protein.
72. A combination according to Claim 68, in which the first component comprises a native Fve polypeptide, or a polypeptide according to any of Claims 1 to 15.
- 20 73. A combination according to any of Claims 68 to 72, in which the second component comprises an allergen selected from the group consisting of: a mite allergen, an mite allergen from Family *Glycyphagidae* or Family *Pyroglyphidae*, a group 1 allergen

(Der p 1, Der f 1, Blo t 1, Eur m1, Lep d 1), a group 2 allergen (Der p 2, Der f 2, Blo t 2, Eur m 2, Lep d 2), a group 5 allergen (Blo t 5, Der p 5, Der f 5, Eur m 5, Lep d 5), a group 15 allergen (Der p 15, Der f 15, Blo t 15, Eur m 15, Lep d 15), a tree pollen allergen, Bet v 1 and Bet v 2 from birch tree; grass pollen allergen, Phl p 1 and Phl p 2 from timothy grass; weed pollen allergen, antigen E from ragweed; major feline antigen, Fel d; major fungal allergen, Asp f1, Asp f2, and Asp f3 from *Aspergillus fumigatus*.

74. A combination according to any of Claims 68 to 72, in which the second component comprises a viral antigen selected from the group consisting of: E6 and E7 from HPV; core Ag and E2 from HCV; core and surface antigens from HBV; LMP-1, LMP-2, EBNA-2, EBNA-3 from EBV; and Tax from HTLV-1.


75. A combination according to any of Claims 68 to 72, in which the second component comprises a tumour-associated antigen selected from the group consisting of: MAGE-1, MAGE-2, MAGE-3, BAGE, GAGE, PRAME, SSX-2, Tyrosinase, MART-1, NY-ESO-1, gp100, TRP-1, TRP-2, A2 melanotope, BCR/ABL, Proteinase-3/Myeloblastin, HER2/neu, CEA, P1A, HK2, PAPA, PSA, PSCA, PSMA, pg75, MUM-1, MUC-1, BTA, GnT-V, β -catenin, CDK4, and P15.

76. An immunomodulator-antigen conjugate, preferably an immunomodulator-allergen conjugate, an immunomodulator-tumour associated antigen conjugate or a immunomodulator-viral antigen conjugate, in which the immunomodulator preferably comprises an Fve polypeptide.


77. A polypeptide comprising a first portion comprising at least a fragment of native Fve, or an Fve polypeptide according to any of Claims 1 to 7, and a second portion comprising at least a fragment of a viral antigen selected from the group consisting of an antigen from from Adenovirus, Parainfluenza 3 virus, Human Immunodeficiency Virus (HIV), Herpes simplex virus, HSV, Respiratory syncytial virus, RSV, or Influenza A, Flu A.

78. A nucleic acid comprising a first sequence encoding at least a fragment of native Fve, or an Fve polypeptide according to any of Claims 1 to 7, and a second sequence encoding at least a fragment of a viral antigen selected from the group consisting of an antigen from from Adenovirus, Parainfluenza 3 virus, Human Immunodeficiency Virus (HIV), Herpes simplex virus, HSV, Respiratory syncytial virus, RSV, or Influenza A, Flu A.
79. A combination according to any of Claims 68 to 72, in which the second component comprises a tumour-associated antigen selected from the group consisting of antigen from from Adenovirus, Parainfluenza 3 virus, Human Immunodeficiency Virus (HIV), Herpes simplex virus, HSV, Respiratory syncytial virus, RSV, or Influenza A, Flu A.
80. A nucleic acid sequence, including an Fve nucleic acid sequence, a polypeptide sequence, including a Fve polypeptide sequence, a method of treatment, a method of diagnosis, a host cell, vector, transgenic animal, a transgenic plant, a genetically-modified lactose bacilli, assay, vaccine, pharmaceutical composition or agent substantially as hereinbefore described with reference to and as shown in the accompanying drawings.


1/57


**FIGURE 1**

2/57

**FIGURE 2**

3/57

**FIGURE 3**

**FIGURE 4**






FIGURE 5


6/57

**FIGURE 6**

7/57


**FIGURE 7**

8/57


**FIGURE 8**

9/57


(A).




(C).



(B).




(D).


**FIGURE 9**

10/57


(A).




(B).



(C).




(D).

**FIGURE 10**


11/57

IFN- γ production at day 3

(1a).




(1b).




GST

0.8%

(2a).




(2b).




GST-FveWT

12.3%

(3a).



(3b).




GST-FveR27A

14.3%


FIGURE 11

12/57


(4a).




(4b).



(5a).




(5b).

**FIGURE 11 (CONTINUED)**


13/57

TNF- α production at day 3


(1a).




(1b).




(2a).




(2b).



(3a).



(3b).


**FIGURE 12**

WO 2004/092210


PCT/SG2004/000098

14/57


(4a).




(4b).



(5a).




(5b).

**FIGURE 12 (CONTINUED)**

WO 2004/092210

PCT/SG2004/000098

15/57

**(group A)**



ip(10ug of Derp2+Alum) ip(10ug of Derp2+Alum) sc(50ug of Derp2 alone)
6 injections over 12 days ip(10ug of Derp2+Alum)

(group B)


ip(10ug of Derp2+Alum) ip(10ug of Derp2+Alum) sc(50ug of Derp2+40ug of Fve)
6 injections over 12 days ip(10ug of Derp2+Alum)

FIGURE 13


16/57

**FIGURE 14**

17/57


FIGURE 14B

18/57


**FIGURE 14C**

Mice received subcutaneous injection of a mixture of 10 ug of major mite allergen Der p 1 and 10 ug of Fve at days 0 and 14. Results showed that Der p 1+ Fve induced higher Der p 1-specific IgG2a (pink) than Der p 1 alone (Blue).


(A)

**FIGURE 15A**

(B)

**FIGURE 15B**

20/57


FIGURE 15C

21/57

Blo t 5	Fve	Bt5-Fve	
Blo t 5	FveR27A	Bt5-FveR27A	
Blo t 5	FveT29A	Bt5-FveT29A	
Der p 2	FveR27A	Dp2-FveR27A	
Der p 2	FveT29A	Dp2-FveT29A	
Blo t 5	Der p 2	FveR27A	Bt5-Dp2-FveR27A
Blo t 5	Der p 2	FveT29A	Bt5-Dp2-FveT29A

FIGURE 16


22/57

**FIGURE 17**

23/57


(1a)

Control: Non-stimulated (10x10 magnification)




(1b)

Control : Non-stimulated (40x10 magnification)




(2a)

20ug of GST 10x10




(2b)

20ug of GST 40x10




(3a)

20ug of Blo t 5 10x10



(3b)

20ug of Blo t 5 40x10

**FIGURE 18**


WO 2004/092210

PCT/SG2004/000098

24/57

(4a)

20ug of native FIP-Fve 10x10




(4b)

20ug of native FIP-Fve 40x10



(5a)

20ug of Bt5-Fve 10x10




(5b)

20ug of Bt5-Fve 40x10




(6a)

40ug of Bt5-Fve 10x10



(6b)

40ug of Bt5-Fve 40x10

**FIGURE 18 (CONTINUED)**


WO 2004/092210

PCT/SG2004/000098

25/57


(7a)

40ug of Bt5-FveR27A 10x10




(7b)

40ug of Bt5-FveR27A 40x10




(8a)

20ug of Der p 2 10x10




(8b)

20ug of Der p 2 40x10




(9a)

40ug of GST-Dp2-FveR27A 10x10




(9b)

40ug of GST-Dp2-FveR27A 40x10


**FIGURE 18 (CONTINUED)**

26/57


(A)




(B)

**FIGURE 19**

27/57

**FIGURE 20**

28/57

FIGURE 21

29/57

FIGURE 22A





FIGURE 22B



30/57


**FIGURE 23**




FIGURE 23B


FIGURE 23C

33/57


(a).




(d).




(b).



(e).



(c).


**FIGURE 24**

WO 2004/092210


PCT/SG2004/000098

34/57


(a).




(d).




(b).



(e).




(c).


**FIGURE 25**

35/57


(a).




(b).



(c).




(d).


**FIGURE 26**

36/57


(a).




(b).




(c).




(d).

**FIGURE 27**


37/57

**FIGURE 28**


38/57


**FIGURE 29**


39/57

**FIGURE 30**

40/57

**FIGURE 31**

**FIGURE 32**

**FIGURE 33**






FIGURE 34


44/57

**FIGURE 35**

WO 2004/092210

PCT/SG2004/000098


45/57

**FIGURE 36**


WO 2004/092210

PCT/SG2004/000098


46/57

**FIGURE 37**

47/57

**FIGURE 38**

48/57

**FIGURE 39**

49/57


**FIGURE 40**


FIGURE 40B


FIGURE 40C

FIGURE 41


**FIGURE 42**

FIGURE 43

FIGURE 44A




FIGURE 44B





FIGURE 44C

WO 2004/092210

PCT/SG2004/000098

57/57




FIGURE 45A

FIGURE 45B